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NOVEL NUCLEOTIDE ANALOGUES FOR FORMING STABLE DNA TRIPLE 
HELICES
by Simon Richard Gerrard
DNA triple helices are an important tool in a variety of medicinal and biotechnological 
applications, such as gene therapy and chemotherapeutics.   DNA triple helices are 
formed by binding of a triplex-forming oligonucleotide (TFO) to a DNA duplex, via 
specific recognition of the individual base pairs in the target sequence.
   Mixed-sequence recognition of duplex DNA by TFOs is therefore an essential 
requirement for successful targeting.  However, achieving strong, yet specific binding to 
the pyrimidine.purine (Py.Pu) base pairs CG and TA, by TFOs is a greater challenge 
than to the purine.pyrimidine (Pu.Py) base pairs (GC, AT), as fewer hydrogen bonds are 
presented for binding in the major groove of the double helix.
   Selective recognition of CG, could be achieved by utilising additional interactions 
across the CG base pair, via amino-modified nucleosides, to form more stable, selective 
triplets than those which can be formed by the natural base T.   Four modified 
phosphoramidite monomers,  meta-aminophenyl-modified analogues of the bicyclic 
nucleosides,   (2,3H)-furano[2,3-d]pyrimidin-2(7H)-one  and  N-methyl-(2,3H)-pyrrolo-
[2,3-d]pyrimidin-2(7H)-one,   were   synthesised   to   address   this   potential   hydrogen-
bonding motif.
  Biophysical studies demonstrate selective recognition of the CG base pair.  Results 
indicate selectivity for CG and binding affinity are much improved on previous 
modifications.  Their fluorescence properties and general oligonucleotide deprotection 
conditions were also studied.
   In addition, the synthesis of a  bis-amine modified 6-oxocytidine phosphoramidite 
monomer for GC recognition was re-investigated.
  This research shows significant advances in the field of triplexes for therapeutic use.Contents
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xivChapter 1
Base Pair Recognition within DNA 
Triple Helices – Introduction
11. Base Pair Recognition within DNA Triple Helices: Introduction
1.1 Structure of DNA
1-3
1.1.1 Primary Structure
Deoxyribonucleic   acid   (DNA)   and   ribonucleic   acid   (RNA)   are   macromolecular 
structures   comprised   of   nucleotides   (monomeric   subunits).     Each   nucleotide   is 
composed of a heterocyclic nucleobase, a furanose sugar and a phosphate moiety. 
Human genomic DNA is approximately 3.9´10
9 nucleotides, or 1.33 m in length, and 
each cell carries two copies.
In DNA, there are two purine bases, adenine  1  (A) and guanine  2  (G); and two 
pyrimidine bases, cytosine 3 (C) and thymine 4 (T).  Nucleobases combine with a 2’-
deoxy-ribofuranose sugar (dR) to give the nucleosides, 2’-deoxyadenosine 5 (dA), 2’-
deoxyguanosine  6  (dG), 2’-deoxycytidine  7  (dC)  and  2’-deoxythymidine  8  (dT) 
respectively.  The bases are covalently bonded to C
1’ of the sugar moiety by a glycosidic 
bond; for pyrimidine bases  via  the  N
1-atom, and for purine bases, via the N
9-atom 
(Figure 1.1).
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Figure 1.1.  DNA nucleobases and corresponding 2’-deoxyribonucleosides.
RNA differs from DNA in two ways.  The sugar moiety is ribofuranose, namely it has a 
hydroxyl group in the 2’-position, and thymine is replaced by uracil 9, which lacks a 
methyl group at the 5-position (Figure 1.2).
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O N
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HO NH
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O N
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OH
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OH
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Figure 1.2.  Uracil 9 and corresponding ribonucleoside, uridine 10 (U or rU).
Phosphodiesters link the nucleosides together to form the nucleic acid polymer.  The 
sugar-phosphate backbone of this polymer is directional and chiral, by nature of the 
furanose ring structure.  Nucleic acid sequences are therefore by definition, quoted as 5’ 
to 3’; the tetramer ACGT therefore is not the same as TGCA (Figure 1.3).
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Figure 1.3.  Nucleic acid primary structure and examples of simple nucleotides 11,12.
Geometry of nucleotides within the macromolecule or polymer, and of the nucleosides, 
is governed by sugar and sugar-base conformations.  The furanose sugar ring can adopt 
two energy-minimised conformations or puckers, the C
2’-endo (S-type) and C
3’-endo (N-
type) (Figure 1.4).
3O
O3'
C5'
R B
O
R
B
O3' C5'
C2'-endo C3'-endo
B = nucleobase
R = H, OH
Figure 1.4.  C
2’-endo and C
3’-endo sugar puckers.
The nucleobase lies almost perpendicular to the plane of the sugar allowing for different 
conformations.  The nucleoside may adopt one of two principal orientations, either syn- 
or anti-conformations, by rotation around the C
1’-N glycosidic bond (Figure 1.5).
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Figure 1.5.  Syn- and anti- conformations of pyrimidine/purine nucleosides.
Pyrimidine nucleobases always occupy the anti-conformation due to repulsion between 
the base carbonyl oxygen and furanose ether oxygen.  Purine nucleobases, however, are 
also   able   to   occupy   the  syn-conformation.     Guanine   occupies   this   orientation 
preferentially   in   mono-nucleotides,   Z-DNA   and   some   other   oligomers,   where 
favourable interactions are possible between the NH2 and 5’-phosphate.
1.1.2 Secondary Structure
The secondary structure of B-DNA was published in 1953 by Watson and Crick,
4 
following   extensive   X-ray   diffraction   studies   by   their   associates,   Franklin   and 
Gosling,
5,6 and Wilkins et al.
7
Two   DNA   strands   are   bound   in   an   anti-parallel,   double-helical   structure   by 
intramolecular hydrogen-bonding between bases.  The four bases form Watson-Crick 
base pairs;
8 G pairs with C via three intramolecular hydrogen bonds, and A pairs with T 
via two hydrogen-bonds.
4Figure 1.6. B-DNA double helix (schematic/model) and Watson-Crick base pairing (red arrow 
– major groove, blue arrow – minor groove).
Due to the antiparallel orientation of the two strands within the DNA duplex and non-
symmetrical structure of deoxyribofuranose, GC is non-equivalent to CG, and AT is 
non-equivalent to TA.  Therefore four orientation-specific Watson-Crick base pairs GC, 
CG, AT and TA can be described.
In the DNA double-helix or duplex, the sugar-phosphate backbones form the highly 
charged (poly-anionic), hydrophilic exterior of the structure, while the base pairs stack 
on top of each other within the hydrophobic core of the duplex, via p-p interactions. 
There are also two grooves running the entire length of the duplex, a major and a minor 
groove (Figure 1.6).
RNA exists in both single-stranded (within cell nucleii) and double-stranded forms 
(viral genome). It can form DNA.RNA hybrids, for example during transcription of 
genetic code from an unwound, single-strand of DNA to mRNA.
There are two principle conformations for the DNA double helix, A and B, both of 
which have been characterised by X-ray crystallography.  B-DNA, which occurs in 
conditions of high humidity/low salt (e.g. in solution, intracellular), is a right-handed 
duplex.  It has a periodicity of 10 base pairs; a pitch of 34 Å; a major groove 12 Å wide 
and 9 Å deep; and a minor groove 6 Å wide and 8 Å deep.  The sugar pucker is C
2’-
endo and nucleosides adopt the anti-conformation.
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5A-DNA occurs under conditions of low humidity/high salt.  This form is also adopted 
by RNA duplexes and DNA.RNA hybrid duplexes.  It is a right-handed duplex like B-
DNA but is wider; it has a periodicity of 11 base pairs; and the base pairs are tilted 20° 
from the helical axis.  The major groove is now much narrower (3 Å) but very deep
(14 Å), and the reverse is true for the minor groove.  The sugars adopt the C
3’-endo 
pucker and the glycosidic bond has the anti conformation.
There are also a number of variants on A- and B-forms, some with synthetically-
modified   bases   (methylated,   brominated);   all   are   right-handed,   with   different 
periodicities, dimensions and sugar conformations.
Z-DNA, a left-handed duplex, was first discovered by Rich et al. in 1979 during studies 
on the DNA hexamer d(CGCGCG).
9  Other sequences of alternating pyrimidine-purine 
such as d(CG)n have also been found to adopt this form.  Z-DNA has a periodicity of 12 
base pairs, a very narrow, deep minor groove, lacks a formal major groove, and is stable 
in conditions of high salt.  Interestingly, for the left-handed duplex d(CG)n, although all 
nucleosides should now adopt the syn-conformation, the pyrimidine nucleoside dC is 
unable to, hence adopts the anti.  The sugar pucker is C
2’-endo for dC and C
3’-endo for 
dG.  Due to these conformations, the backbone zigzags around the helical axis.
1.2 DNA Triplexes
1,2,10-13
The major and minor grooves of the DNA duplex are lined with potential hydrogen-
bonding acceptors and donors.  The major groove of B-DNA is accessible to DNA 
binding regions of various proteins and large drug molecules.   The minor groove, 
although smaller, may also host a number of small molecules such as the pyrrole-
amidine antibiotics distamycin and netropsin, which have a preference for AT-rich 
regions.
1,14  Importantly, it is possible for a third strand of DNA (or RNA) to bind inside 
the major groove to form a local triple-helix or triplex (Figure 1.7).
DNA triple helices were discovered by Felsenfeld and Rich in 1957.
15  In experiments 
using polyuridylic acid (polyU) and polyadenylic acid (polyA), they found a relatively 
weak complex (compared with the duplex An.Un) was formed in a 2:1 ratio when these 
were mixed in aqueous solution.  Stabilised by Na
+/Mg
2+ cations, binding was specific 
6to polyU.  No complexation was observed with polyC or other oligonucleotides.  A 
decade later, the same observation was made for d(CT)n binding to d(GA)n.d(CT)n, and 
dGn binding to dGn.dCn.
1
Figure 1.7.  Schematic model (TFO in blue) and space-filling molecular model (TFO in red) of 
a parallel triple helix.  Molecular model derived from NMR data on a triplex-duplex 
junction.
16
It is only in recent years, however, that the potential applications have been recognised. 
Triplexes could have important uses in gene therapy (antigene strategy),
17-22 site-directed 
cleavage
17,23-25  and repair,
17,26-28  or as a tool in molecular biology and biotechnology 
applications.
17,29,30   Binding of the third strand, or triplex-forming oligonucleotide 
(TFO), to a specific region of the genome blocks unwinding of the duplex by helicases. 
Importantly,   this   prevents   transcription   thereby   inhibiting   gene   expression   (gene 
knockout),   and   prevents   DNA   replication   hence   interrupts   cell   division 
(chemotherapeutics).  TFOs for human therapeutic use should statistically be ca. 16-17 
nucleotides long for the recognised duplex sequence to be unique, thus preventing 
undesired inhibition.  In genomic DNA however, the base pairs are not statistically-
distributed, hence TFOs may vary in length from 18 to 30 nucleotides or more, to 
account for local variation and repeating motifs.
31
In a DNA triplex, the TFO binds in a helical manor around the duplex via “Hoogsteen” 
hydrogen-bonds
32 to exposed hydrogen-bond donors and acceptors in the major groove 
(Figures 1.7, 1.8).
← TFO →
FRONT BACK
5’ 5’
3’
5’
7N
N
N O
N
N
H
H
H
N
N
N
O
H
H
O
RO
RO
O
OR
OR
GC
N
N
N
O
H
H
N
N
N O
N
N
H
H
H
O
RO
RO
O
OR
OR
CG
O
RO
RO
O
OR
OR
O
OR
OR
O
RO
RO
N
N
N
N N
N
N
O
O
CH3
H
H
H
AT TA
N
N
O
O
H3C
H N
N
N
N N
H
H
H H
aa dd dd aa
ad a a da
( = non-bonding methyl group, R = sugar-phosphate backbone)
 
 




Figure 1.8.   Four Watson-Crick base pairs and hydrogen-bond acceptors (a) and donors (d) 
exposed in major groove.
If the H-bond donors and acceptors on a nucleotide are correctly placed, it can bind to a 
base pair forming a triplet.  Such triplets, written in the form X.YZ, can be formed from 
the natural bases.
There are two possible triplex configurations, which differ in the orientation of the third 
strand (Figure 1.9).   In the parallel triplex, the third strand (TFO) is orientated in 
parallel with the strand to which it binds.  In antiparallel triplexes, the reverse is true. 
Antiparallel triplexes are inherently less stable than parallel triplexes, hence most work 
in this area has involved parallel triple helices.   DNA triplexes are structurally-
characterised predominantly by NMR studies and circular dichroism (CD).  Although 
the structure of DNA duplexes can be studied by X-ray crystallography (Section 1.1.2), 
DNA triplexes remain very difficult to crystallise.
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5
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Figure 1.9.  TFO orientation in a Parallel and Antiparallel Triplexes.
The most stable, natural parallel triplets are C
+.GC, T.AT, T.CG and G.TA.
33  With all 
natural triplets, binding can only occur to the nearest base in the pair, hence GC and AT, 
the purine-pyrimidine base pairs with two available purine H-bond acceptors/donors 
form the strongest triplets (Figure 1.10).
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Figure 1.10.   Structures of natural parallel triplets C
+.GC, T.CG, T.AT and G.TA (dR  = 
deoxyribofuranose).
Antiparallel triplets include G.GC, T.CG, A.AT and T.AT (Figure 1.11).  No natural 
base is capable of specifically recognising a TA base pair in an antiparallel triplex, 
although C.TA is probably the least unfavourable.
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Figure   1.11.    Structures   of   natural   “reverse   Hoogsteen”   antiparallel   triplets   (dR  = 
deoxyribofuranose).
The strongest and most selective natural base triplets, C
+.GC and T.AT (parallel), have 
been the subject of much research.  However, there are intrinsic problems with both of 
these when used in triplex base pair recognition.
Triplexes are inherently less stable than DNA duplexes due to electrostatic repulsion 
associated with the close proximity of the three polyanionic strands; Hoogsteen 
hydrogen-bonds are therefore longer and weaker.  Protonation of cytosine at the N
3-
position is required for the C
+.GC triplet to form.  However, due to the low pKa of this 
protonated N
3 atom (pKaH 4.5, as free nucleobase, cytosine), a low pH (<6.0) is required 
for partial protonation.  At low pH, the triplet is very stable as the positive charge aids 
stabilisation of the negative charges on the phosphate groups, and there may be extra 
stabilisation from favourable p-stacking of the positively-charged cytosine ring in the 
complex.  At physiological pH, however, few cytosines are protonated.  Triplex stability 
9is then greatly reduced, such that TFOs containing many C bases or contiguous C bases 
will not form triplexes above pH 6.0.  C.GC triplets are much less stable, lacking a 
second hydrogen-bond and favourable positive charge.  The charge is the dominating 
factor governing stability.  The triplet T.AT is less stable than C
+.GC as it lacks a 
stabilising positive charge, but the stability is not dependent on pH as protonation is not 
required for its formation.
1.2.1 Purine Recognition
Recognition of purine-pyrimidine base pairs, AT and GC, is potentially easiest because 
two hydrogen-bonds are possible between the third base and the purine, giving greater 
selectivity over other base pairs.   Pyrimidine bases are more difficult to recognise 
selectively as only one formal H-bond is possible.  Indeed, both purine and pyrimidine 
recognition have been subject to much research.  DNA sequence recognition is still, 
however,   mainly   restricted   to   tracts   of   contiguous   purine-pyrimidine 
(homopurine.homopyrimidine, Pu.Py) base pairs (AT, GC), as these form the most 
stable   and   selective   triplexes.     Achieving   four-base  mixed-sequence   recognition, 
however, is essential to be able to target any gene or genetic code of choice.  The 
number of target Pu.Py genomic sequences is limited, and many contain one or several 
pyrimidine interruptions, or Py.Pu inversions, which must be accommodated.
1.2.1.1 AT Base Pair Recognition
Recognition of the AT base pair was achieved by Sollogoub and Osborne et al.,
35-37 with 
a bis-amino-modified analogue of T, 2’-O-aminoethyl-5-(3-aminoprop-1-ynyl)-uridine 
or bis-amino-U (
BAU) 15 (Figure 1.12).
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Figure 1.12.  Analogues of T and nucleosides for AT recognition; 2’-O-aminoethyl-dT (
AET) 
13,
38 5-(3-aminoprop-1-ynyl)-dU (pdU) 14
39 and bis-amino-U (
BAU) 15.
37
10Cuenoud et al.
38 demonstrated that addition of a 2’-aminoethoxy group to dT enhances 
triplex stability.  The amine group is protonated at physiological pH (pH 7.0) hence 
imparts partial charge-stabilisation of the anionic sugar-phosphate backbone.   The 
replacement of the methyl group of dT, with an aminopropynyl group at the 5-position, 
significantly   enhances   stability   of   the   triplex  via  partial   charge-stabilisation
39  as 
described above, and through increased p-p stacking interactions.
40  Combining these 
modifications afforded 
BAU, which whilst retaining the hydrogen-bonding pattern of T, 
binds to AT more strongly and with much better selectivity.
Guanidinium-based groups have also been assessed as moieties with potential for 
charge-stabilisation.  The guanidinium moiety remains protonated over a large pH range 
(pKa ~12.5) and can form multiple hydrogen-bonds.  Prakash et al.
41 reported that a
2’-O-guanidinylethyl group had significant benefits over a 2’-O-aminoethyl group. 
TFOs containing this modification showed high affinity for duplex DNA and RNA, and 
when in isolated positions, increased the triplex/third strand melting temperature (Tm) by 
~3.2 °C per modification.   A novel protecting group,  N-(2-cyanoethoxycarbonyl)- 
(CEOC) was also used, which is compatible with oligonucleotide synthesis conditions.
42 
Sensitivity to base, however, even aqueous sodium bicarbonate or triethylamine, is an 
issue during synthesis.   The guanidinyl group is often added post-synthetically, for 
example by heating the oligonucleotide with  O-methylisourea chloride in aqueous 
ammonia.
43    This   is   not   selective,   however,   as   all   exposed   amines   will   be 
guanidinylated.
Roig et al.
44 also reported triplex formation using 2’-deoxyuridine with modification at 
the 5-position by a range of alkynyl linkers terminating in one or two guanidinium 
groups.  These linkers gave an increase in triplex stability through charge-stabilisation. 
Incorporation of two non-contiguous monomers gave a small increase in Tm over just 
one (1.5-2.0 °C).   The  bis-guanidinyl version of  
BAU (synthesised  in-house) was 
discovered to be as effective as the mono-guanidinylated version.  This was thought to 
be due to steric hindrance factors.  Both guanidinyl monomers were an improvement on 
BAU and these studies are continuing.
111.2.1.2 GC Base Pair Recognition using Pyrimidine Bases
Many modifications could be made to cytosine to give potential nucleotides for GC 
recognition, and there have also been a variety of other strategies.  The first logical 
analogue was 5-methylcytosine
45-47 (
5-MeC) (Figure 1.13).  Combining properties of T 
and C, N
3 has a slightly increased pKaH and triplexes containing a 
5-MeC
+.GC triplet were 
stable at a higher pH than C, although still not at physiological pH.  Thermodynamic 
studies indicated the enhanced stability was entropic in origin (methyl groups displacing 
water molecules from hydrophobic core), however, the methyl groups may also improve 
base-stacking.
46,48 
Stable triplex formation has also been achieved using 
5-MedC modified at the 4N-position 
with spermine
49-51 or tetraethyleneoxyamine.
51  4-Guanidino analogues of C
52 were also 
synthesised and assessed against GC.
53,54   However, although the predicted alignment 
was good, triplexes could not be formed (Figure 1.13).
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Figure 1.13.  Cytosine analogues for GC recognition.  R = furanose sugar
Pseudoisocytosine (y
isoC)
55,56 was successfully incorporated into TFOs for recognition 
of GC.  The 2’-O-methyl-derivative of y
isoC formed pH-independent triplets, via two 
permanent N–H bonds.  It could also be protonated at the N
1-position thereby increasing 
stability of  y
isoC.GC triplets by charge-stabilisation.   These triplets were also more 
stable than  C
+.GC, at sites containing  several contiguous  GC pairs.    This was 
presumably due to reduced charge repulsion, as is present between contiguous C
+.GC 
triplets.
Recently, y
isoC was incorporated into a peptidic analogue of DNA, aminoethylglycyl 
peptide nucleic acid (aegPNA) for use in PNA/DNA triplex systems.
57  In PNA
58,59, the 
12DNA sugar-phosphate backbone is replaced by a flexible, pseudo-polypeptide, to which 
the nucleobases (B) are attached (Figure 1.14).
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Figure 1.14.  Example PNA structures, aegPNA and aepPNA.
1-Deazacytosine
60,61  (
1-deazaC),   similar   in   structure   to  y
isoC,   was   investigated   by 
Sollogoub,   Powers  et   al.   as   a   non-protonated,  C-nucleoside   analogue   of   C. 
Unfortunately, due to the challenging synthesis of the monomer although finally 
successful,   and   problems   in   deprotection   of   subsequent  
1-deazaC   containing 
oligonucleotides, biophysical studies were abandoned.   There were also potential 
problems with GC selectivity due to tautomeric ambiguity of the endocyclic amide 
(Figure 1.15).
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Figure 1.15.  Tautomerism in 1-deazacytosine.
61
2-Aminopyridine
62-66 (
2-AP) was successfully employed for recognition of GC.  Triplexes 
containing this C analogue, as the 2’-deoxy-derivative, were found to be far more stable 
than C or 
5-MeC at high pH.  This is due to the much higher basicity of N
1 (pKaH 5.93), 
although it was still pH-dependent.  This stability was demonstrated when a triplex 
containing six contiguous 
2-AP.GC triplets formed at pH 7.0.  In addition, it had greater 
stability at lower pH as well.  Surprisingly, Bates et al.
62 found the a-anomer more 
effective in stabilisation of the parallel triplex than the b-anomer, although Cassidy et 
al.
63 report otherwise.  Cassidy does report, however, that the a-anomer can bind in an 
otherwise b-anomeric triplex with minimal structural perturbation.
3-Methyl-2-aminopyridine (
MAP)
61,65 also exhibits excellent triplex stability to higher pH 
than 
5-MeC.  The methyl group, however, does not appear to exact a noticeable difference 
in   properties,   hence   the   hydrophobic/entropic   effects   associated   with
5-MeC cannot be a factor in this circumstance.   
MAP also demonstrated excellent 
13selectivity for GC in a mixed four-base sequence,
67 and forms very stable triplexes, 
together with 
BAU, for alternating GC/AT base pairs.
61
A lesser known pyrazine-based C analogue (pyDDA)
68, demonstrated pH-independent 
binding between pH 6.3 and 8.0, to GC base pairs.  PyDDA was also analysed recently 
in epimerisation studies as a new base for incorporation into duplex DNA
69.
1.2.1.3 6-Oxocytosine in GC recognition
6-Oxocytosine (
6-oxoC) and derivatives were used successfully as non-protonated C-
analogues, for pH-independent GC recognition (Figure 1.16).
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Figure 1.16.  Example 6-oxocytidine (
6-oxoC) derivatives for GC recognition
Berressem and Engels
70  examined  
6-oxoC and 5-methyl-6-oxo-C (
moxC), as the 2’-O-
methyl derivatives (16,17), for efficacy in triplex formation.  Both bases formed stable 
triplets with a GC inversion in a tract of contiguous AT base pairs.  This binding was 
nearly pH independent with a small loss of stability in basic conditions around pH 8.0; 
the 5’-methyl group proving slightly destabilising.  They also reported that at conditions 
of low pH, C
+.GC formed the more stable triplet.  This was proposed to be due to 
enhanced base-stacking by the positively-charged cytosine ring, although 
6-oxoC forms 
stronger hydrogen bonds to guanine, due to the electron-withdrawing C
6-carbonyl 
group.  Cytosine therefore has a greater binding affinity at low pH due to the positive 
charge, but forms a much less stable triplet than 
6-oxoC and 
moxC from pH 6.0-8.0.  Parsch 
and Engels
71 later reported results of a number of 
6-oxoC and 5-allyl-
6-oxo-C derivatives 
designed   for   guanine   recognition.     UV   melting   studies   showed   that
5-allyl-
6-oxoC derivatives (inc. 19) destabilised the triplex.  They gave a lower triplex 
melting temperature (Tm), than 
6-oxoC; hence, favourable hydrophobic/entropic properties 
that the 5-methyl group gave to C, also could not play a role in this case (c.f. 
MAP).  An 
14RNA TFO containing RNA monomers of  
6-oxoC (inc.  20), however, did not form 
triplexes with duplex DNA.
Xiang et al.
72,73 reported that 2’-deoxy-
moxC (
moxdC) had the highest Tm of all analogues 
tried, and demonstrated pH-independent binding from pH 6.4 to 8.5.  However, triplex-
formation was weaker over five contiguous GC base pairs.   If this base was used 
alternatively with 
5-MeC or in presence of the DNA binding agent, spermine, several 
contiguous GC pairs could be recognised.
Following this work, Xiang and McLaughlin
74  reported use of a simple acyclic 
carbohydrate linker in place of 2’-deoxyribofuranose (dR) on  
moxC.   The  Tm  was 
increased for this compound at an isolated GC base pair, the linker flexibility aiding 
orientation for hydrogen-bonding, which may be compromised due to steric repulsions. 
Over several contiguous GC pairs, however, the Tm was reduced.  The triplex may be 
entropically destabilised by several contiguous flexible linkers.
6-Oxocytosine was even reported to be effective as a sequence-specific HIV-1 integrase 
competitive inhibitor in vitro, in duplex DNA.
75  Integrase is responsible for integrating 
viral DNA into DNA of the host, thus enabling virus replication.
Studies conducted by Wang, Powers and Osborne
11,37,76 on 2’-O-aminoethyl derivatives 
of  
6-oxoC and  
moxC indicated this base proved ineffective at GC recognition, because 
triplexes were weak or did not form; the 2’-O-aminoethyl group proving non-effective 
in triplex stabilisation.   It was rationalised that a steric clash between the furanose 
oxygen and C
6-carbonyl oxygen caused the base to twist around the glycosidic bond 
(Figure 1.17).  This makes the triplet non-planar, thereby misaligning the Hoogsteen 
hydrogen-bonding motif.   This repulsion may also have induced a change in sugar 
pucker.
Figure 1.17.  Space-filling representation of steric clash and repulsion in 2’-O-aminoethyl-6-
oxocytidine.
151.2.1.4 GC Base Pair Recognition using Purine Bases
The natural purine base G forms triplets with GC, in both parallel (anti-conformer) and 
antiparallel (syn-conformer) triplexes.
33  Another logical approach therefore to analogue 
development, involved the use of purines as bases for guanine recognition (Figure 1.18).
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Figure 1.18.  Purines as C analogues for GC recognition.
The G-related compounds, N
7-G
77-80 and P1,
81-83 form triplets with GC, independent of 
pH.  Their stability as isolated X.GC triplets is similar to 
5-MeC
+.GC, but have much 
greater stability over  
5-MeC, in triplexes with contiguous GC base pairs.   They also 
demonstrate selectivity for GC over other base pairs, as was detected by DNase I 
footprinting studies.  D’Costa et al.
84 have also incorporated N
7-G into two types of 
PNA (aegPNA, aepPNA) as a C
+ analogue for PNA/DNA triplex formation.
Marfurt et al.
85 researched N
7-inosine (N
7-I) as a base for guanine recognition.  This 
structure would form only one hydrogen bond, most likely between N
1H of N
7-inosine 
and N
7 of guanine, but obtain selectivity over other base pairs by disfavoured steric 
interactions.  The a-anomer was shown to significantly reduce binding affinity relative 
to a triplex containing a 
5-MeC base at this position.  The 2’-O-methyl- b-anomer slightly 
destabilised the triplex but the 2’-deoxy- b-anomer gave a ~10-fold increase in binding 
affinity on 
5-MeC as determined by quantitative DNAse I footprinting analysis.  Very 
high selectivity was also observed over the other base pairs.   Further molecular 
modelling studies also suggested that H-bonding between N
1H and C
2H, with O
6 of 
guanine cannot be ruled out, as these favourable electrostatic interactions may help 
stabilise the triplet.
168-Oxoadenine   (
8-oxoA)   and  N
6-methyl-8-oxoadenine
86-90  were   synthesised   for   GC 
recognition and again formed pH-independent triplets (syn-conformer).  These triplets 
were almost as stable at a range of pHs, as C
+.GC is at low pH, and could form triplets 
in DNA tracts containing several contiguous GC pairs.  Selectivity for GC was achieved 
by a combination of steric and electronic factors.
1.2.1.5 Other Novel Base designs
Other heterocyclic bases have been designed, which aim to mimic cytosine in binding to 
the GC base pair.  Christensen et al.
57 used a novel 1,8-naphthyridine-2,7(1,8H)-dione 
moiety   (as   a   replacement   for   C
+)   in   Hoogsteen-like   triplex   formation,   in   a 
PNA.DNA/PNA system for recognition of a single-strand of DNA (Figure 1.19).
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Figure 1.19.  Bi- and tricyclic analogues of C; 1,8-naphthyridine-2,7(1,8H)-dione, 1,3-diaza-2-
oxophenothiazine (tC) and 1,3-diaza-2-oxophenoxazine (tC
O), and the tCG base pair.
Capable of binding with two permanent NH bonds (major tautomer), the larger aromatic 
system was proposed to improve base-stacking in the triplex, hence impart extra 
stability.  In isolated positions on the PNA it performed comparably with C
+ at pH 5.0, 
and better by 6.7 °C/modification with C
+ and by 1.5 °C with y
isoC, at pH 7.0.  In 
adjacent positions, although both C and y
isoC displayed slightly reduced stability over 
isolated positions, the naphthyridindione performed significantly better than in isolated 
positions at pH 7 and 9.  This was attributed to the increase in base-stacking over C and 
y
isoC.   Adjacent C
+  and protonated  y
isoC suffer some electrostatic repulsion due to 
positive charges.  This modified base has been used in triplex recognition studies.
91,92
Related structures, 1,3-diaza-2-oxo-phenothiazine (tC) and –phenoxazine (tC
O), have 
also been used in various DNA systems (DNA and DNA.PNA duplexes), as their non-
protonated form, as C-substitutes in base pairing,
93-95  Tricyclic base tC has also been 
studied for its fluorescence properties.
96,97
171.2.2 Pyrimidine Recognition
Pyrimidine.purine   base   pairs   TA   and   CG   are   more   difficult   to   target   than 
purine.pyrimidine base pairs GC and AT, as only one formal hydrogen-bonding residue 
is offered for binding in the major groove.   It may be possible to achieve either 
selectivity or strong binding affinity, but achieving both in combination is a challenge.
1.2.2.1 TA Base Pair Recognition
The natural base G is capable of recognising TA with only limited affinity and 
selectivity, hence alternative monomers have been designed to utilise the full hydrogen-
bonding pattern of the TA base pair.  The most selective nucleoside for recognition of 
TA base pairs is the S nucleoside  21  (Figure 1.20).
98,99   This non-natural, novel 
monomer was partly derived from the TA/CG recognition monomer D3 22,
100 which was 
actually demonstrated to intercalate selectively between a TA-AT step.
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Figure 1.20.  TA recognition monomers; D3 22,
100 S 21
98,99 and 2’-aminoethoxy-S 23 (
2-AES),
76 
and the S.TA triplet.
2’-O-Aminoethyl-S (
2-AES) 23, evaluated by Wang et al.,
76 showed increased binding 
affinity to a TA interruption over S.  The increase in triplex stability by introduction of a 
2’-O-aminoethyl group is well-studied,
37,38,103 and clustering of several 2’-O-aminoethyl-
modified nucleosides affords significant triplex stabilisation and faster rates of triplex 
formation in vivo.
104  The drawback with D3, S and 
2-AES is a significant affinity for CG, 
although selectivity for TA is increased for S and  
2-AES at higher pH.
76   Despite 
selectivity issues, a TFO containing the recognition monomers, 
BAU, 
MAP, 
APP (Section 
1.2.2.2) and S, was used successfully to target mixed-sequence duplex DNA at pH 7.
67
18TA recognition has also been achieved using 2’-O-aminoethyl-derivatives of G and 2-
aminopurine,
105 although the 2’-O-aminoethyl group in this case proved detrimental to 
selectivity and binding affinity.  This may be due to the C
3’-endo sugar pucker of these 
RNA-derived nucleosides.
1.2.2.2 CG Base Pair Recognition using modified Pyrimidine bases
The natural base T can recognise CG with a moderate affinity, but also forms triplets 
with AT.   Thymine therefore cannot be used for CG recognition, but was a useful 
starting point for a series of modified pyrimidine-derived nucleosides, which aimed to 
utilise the full hydrogen-bonding pattern of the CG base pair.
The C
2-carbonyl group is important in recognition of CG within a parallel triplex.  This 
is demonstrated by the moderate affinity of C, at lower pH, for CG.
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Figure 1.21.  2’,4’-BNA-pyridinone nucleosides for CG recognition; 2-pyridone 24 (P
B),
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methyl-2-pyridone 25 (
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108 and 1-isoquinolone 26 (Q
B).
109
The simple, non-natural bases 2-pyridone  24  (P
B)
107,108  and 5-methyl-2-pyridone  25 
(
mP
B)
108 efficiently recognise CG, as the conformationally-locked 2’-O,4’-C-methylene 
bridged nucleic acid (2’,4’-BNA) nucleosides (Figure 1.21).  The sugar is locked in the 
C
3’-endo conformation, which also affords a generalised increase in triplex stability, 
presumably through favourable alignment of the third strand base.
110 
Hari  et al.
109  investigated a benzo-derivative of P
B, the 1-isoquinolone-2’,4’-BNA 
nucleoside, Q
B 26.  P
B was shown to have a slight affinity for AT, thereby reducing 
selectivity for CG.  The analogue Q
B demonstrated a marked reduction in affinity for 
AT at pH 7.0, appearing no more selective for AT as an abasic site (a sugar with no 
19base at the 1’-position).  They proposed that a steric clash between the isoquinolone 
C
7H and 5-methyl group of T, when placed against an AT base pair, inhibited binding.
Prévot-Halter and Leumann
111 realised the importance of the N
3-atom in addition to the 
C
2-carbonyl, in recognition of cytosine.   Comparing  
5-MeC,  
2-AP, and  
4HT  27  (4-oxo-
deletion mutant of T), the 4-amino group was shown to play no critical role in CG 
recognition.  In UV melting experiments, 
4HT in fact showed much greater selectivity 
for CG over GC and AT, although binding affinity was reduced.
Later studies, which tested recognition of a homopurine strand with a single C 
interruption, suggested a weak C–H
¼O interaction between H
5 of C and O=C
2 of 
4HT 
was key to the recognition properties.
112  This was partly based on observation that the 
7H.GC triplet is as stable as the C
+.GC triplet at pH 7.0, despite forming only one formal 
H-bond; the two weak C–H
…O interactions providing additional stability (Figure 1.22).
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Although the proposed interaction (pictured above) has not been confirmed by NMR 
studies, replacement of C (of the CG base pair) for 5-fluorocytosine destabilised the 
triplex by 8.3 °C, suggesting this interaction is highly significant.
Buchini and Leumann
105,113,114 subsequently attempted to improve the binding affinity of 
4HT for CG and triplex stability, by replacing the deoxyribofuranose (dR) sugar with that 
of 2’-O-aminoethyl-ribofuranose.   Targeting a homopurine.homopyrimidine duplex 
containing a single CG inversion, the 2’-O-aminoethyl (2’-AE) group increased the 
triplex stability by 1.3 °C at pH 7.0, whilst retaining selectivity against the other base 
pairs.  Triplexes were formed using a 15mer TFO, (using 
AET 13 and 2’-O-aminoethyl- 
5-MeC), with up to five CG interruptions in the duplex; selectivity dramatically increasing 
20with increasing number of CG interruptions, as the Tm of the other triplexes fell sharply. 
When using dT and 
5-MedC in the TFO under the same conditions, however, general 
triplex stability was poor, and with five interruptions, the Tm could not be determined.
Recognition of CG inversions using a fully 2’-AE-modified TFO produced interesting 
results.  Three and five consecutive CG inversions were tolerated using 2’-AE-
4HT (x), 
and position did not affect triplex stability.  Neighbouring nucleosides, however, played 
an important role; 2’-O-aminoethyl-
5-MeC (c) proving especially destabilising compared 
to 
AET 13 (t).  Changing part of the TFO, from ‘ttxtxtxtc’ to ‘cxccxccxc’, (and the 
corresponding duplex sequence accordingly), reduced the triplex  Tm  from 67  °C to
20  °C.   This is likely to be due to electrostatic repulsion between neighbouring 
protonated cytosine nucleobases.   Once the binding motif of  
4HT was established, 
alternative nucleosides were sought, which would increase triplex stability, and binding 
affinity and selectivity for CG.
The cyclisation reaction, (occurring via a 5-endo-dig mechanism),
115 which leads to the 
bicyclic   nucleoside  3H-furano[2,3-d]pyrimidin-2(7H)-one   (furano-dT)   was   first 
published by Robins,
116 then Cruickshank et al.,
117 as a minor fluorescent side-product of 
the Sonogashira reaction on 5-iodo-2’-deoxyuridine nucleosides.  The 6-unsubstituted 
furano-dT nucleoside, dF* 28 found use by Woo et al.
118 as a fluorescent C analogue, 
when converted to the 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one (pyrrolo-dC) nucleoside 
dP  29,   during   oligonucleotide   deprotection/resin   cleavage,   using   conc.   aqueous 
ammonia.  Although dP could not be directly incorporated into oligonucleotides due to 
instability during the oxidation step, the conversion of dF* to dP was quantitative. 
Nucleoside dP retains the hydrogen-bonding pattern of C and forms a stable base pair 
with G, also acting as a fluorescent marker (Figure 1.23).
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Figure   1.23.    Bicyclic   furano-dT/pyrrolo-dC   nucleosides;   dF*  28  and   dP  29,
118
6-methyl-furano-dT 30 (
MFP) and 6-methyl-pyrrolo-dC 31 (
MNHP).
119
21The 6-methyl- (
MNHP, 31) and 6-phenyl analogues also found use as fluorescent markers; 
the fluorescence being sensitive to base-pairing with G.
119,120  These could be directly 
incorporated into oligonucleotides as the pyrrolo-dC derivatives, or via post-synthetic 
conversion of the furano-dT nucleoside with conc. aqueous ammonia, as previously 
described.  
MNHP and other 6-alkyl derivatives were also tested by McGuigan et al. for 
anti-viral activity.
121
This core bicyclic structure was modified by Ranasinghe  et al.,
122  for use as a CG 
recognition  monomer (Figure 1.24).   Post-synthetic conversion of the furano-dT 
nucleotide to the N-methyl-pyrrolo-dC derivative using aqueous methylamine, instead 
of ammonia, alters the hydrogen-bonding pattern.  The N-methyl group prevents the 
nucleoside acting as a C-analogue, blocking any recognition of the GC base pair whilst 
retaining the C
2 carbonyl and N
3, essential for selective binding to CG.
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Figure 1.24.  N-Methylpyrrolo-dC nucleosides for CG recognition; 6-methyl-N-methyl-pyrrolo-
dC  32  (
MP),   6-(aminoethyl)-N-methylpyrrolo-dC  33  (
AEP)   and   6-(aminopropyl)-N-
methylpyrrolo-dC 34 (
APP).
122
Utilising   the   Sonogashira   cross-coupling
123  conditions   of   Hobbs   Jr.
124  and   the 
documented cyclisation reaction under reaction conditions published by McGuigan et 
al.,
121 two 6-aminoalkyl-furano-dT nucleosides were synthesised.  After incorporation 
into oligonucleotides, these, and the commercially-available 6-methyl-furano-dT  30 
(
MFP), were post-synthetically converted to the corresponding  N-methylpyrrolo-dC 
analogues 32-34 during deprotection with aque ous methylamine.
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Figure 1.25.  Proposed triplet motifs; 
MP.CG and 
APP.CG.
The purpose of using this structure was three-fold; firstly, the bicyclic-nucleobase 
should enhance triplex stability by additional base-stacking; secondly, the amino group 
would be protonated at pH 7 thus providing stability through charge-stabilisation, and 
thirdly, it could form extra hydrogen-bonds to guanine.  Using the extended hydrogen-
bonding motif of the CG base pair could enhance selectivity and binding affinity 
(Figure 1.25).
Melting studies (fluorescence and UV) compared binding affinity and selectivity of the 
core structure 
MP 32 and nucleosides 
AEP 33 and 
APP 34 with the natural base T, against a 
single CG inversion.  At pH 5.5, an increase in Tm for 
MP, 
AEP and 
APP, of 1.9 °C,
1.1  °C and 2.6  °C respectively, confirmed the aminopropyl linker performed best, 
although the results are close in value.   Quantitative DNase I footprinting studies 
confirmed selectivity for the duplex target for all three monomers.
In order to compare with 
4HT, UV melting was conducted using the same sequence and 
conditions as used by Buchini and Leumann.
113  At pH 7.0, 
MP and 
APP were shown to be 
comparable with 
4HT, and 
AEP comparable with T.  Therefore, although an improvement 
on T, and whilst selective for CG, the aminoalkyl moieties did not significantly increase 
triplex stability.  The pendant amino groups most likely did not form hydrogen-bonds 
with G as originally hoped but contributed some charge-stabilisation.  However, this did 
set precedent for future analogues, which will be discussed in Section 3, and 
APP was 
used successfully as a CG recognition monomer in a modified TFO against a mixed-
sequence DNA target.
67
231.2.2.3 Novel Pyrimidine-derived Monomers for CG Base Pair Recognition
Modification of cytosine and use of non-natural heterocyclic compounds have been 
assessed in CG recognition, in parallel and antiparallel triplexes, and in NMR studies in 
organic solution.  This significantly widens the scope for achieving CG recognition, 
despite very variable binding affinities.  Reduction in predicted stability was observed 
when moving from NMR studies of isolated triplets to melting studies on triplex 
systems.
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Figure 1.26.   Modified C analogues  35-43  for CG recognition in parallel triplex,
125-131  and 
proposed 4N-6-aminopyrid-2-yl-dC.CG (
apyC.CG) triplet.
131
Modification with pendant groups at the 4N-position of dC (Figure 1.26) was used to 
take advantage of the extended hydrogen-bonding motif of CG, and to afford extra 
stability   through   increased   base-stacking.     The   4N-carbamoyl-  35  and   4N-
ureidocarbamoyl-dC 36 nucleosides of Guzzo-Pernell et al.
128 were designed to form 
extra hydrogen-bonds with CG, and could be fitted into reasonable triplets with CG. 
However, no triplex could be observed, perhaps due to hydrophilicity of the pendant 
groups preventing binding within the hydrophobic groove.  An anthraniloyl-derivative 
37 was also evaluated, introducing a hydrophobic benzene ring, but with no triplex 
formation.  A 4N-phenyl-carbamoyl derivative did form triplexes at pH 6.0, albeit very 
weakly, with CG and GC base pairs, but the triplex was too unstable to be of practical 
use.
132
4N-Aminopropyl-  38  and 4N-acetamidopropyl-dC  39 nucleosides of Huang et al.,
130 
demonstrated selectivity for CG, but relatively weak binding affinity in UV melting 
studies against a single CG inversion.  It was a surprise to the author that the flexible 
chain could support triplex formation, and more rigid modifications were considered.
24Huang et al. later investigated a 4N-(6-aminopyrid-2-yl)-dC analogue 40 (
apyC),
129,131 
which forms a triplex with a target containing a single CG inversion.  NMR and DMS 
alkylation studies indicated this base binds as the imino-tautomer, which is also capable 
of recognising AT.  UV melting experiments indicated 
apyC had a much stronger binding 
affinity to CG than their previous modifications.  Selectivity against GC and TA was 
maintained, although it also recognised AT to a lesser extent.   A biphasic melting 
profile against CG was also observed, which indicated other triplex structures, such as 
intercalation rather than Hoogsteen hydrogen-bonding.  Notably, removing the 6-amino 
group (41) essentially eliminated triplex formation, and replacing the pyridyl for a 
phenyl ring (42) had only a minor reduction on triplex stability.
Chin  et al.
125,126  also evaluated this monomer’s CG recognition properties, in an 
intermolecular (‘linear’) triplex and an intramolecular (‘paper-clip’) triplex, against a 
single CG inversion.  The 
apyC.CG triplet was shown to be as stable as a C
+.GC triplet, at 
pH 6.0, and gave pH-independent triplex binding when located internally.  The more 
flexible ‘linear’ triplex could also tolerate the alternating sequence 
apyCT
apyCT
apyC.
A novel 
5-MedC derivative, tethered at the 4N-position with an N,N-dimethylaminoethyl-
modified naphthalenediimide 43, achieves CG recognition through one hydrogen-bond 
(from N
3 to N
4H of C), and intercalation.
127   UV melting studies demonstrated good 
selectivity from pH 6.4-7.5, predominantly due to hydrogen-bonding; intercalation was 
responsible for a general increase in stability compared with C.   Melting studies, 
monitoring at 383 nm (lmax – napthalenediimide), suggested a ‘cooperative’ un-stacking 
of the intercalator on third strand dissociation.
1.2.2.4 Novel Non-natural Heterocyclic Monomers for CG Base Pair Recognition
Several non-natural heterocyclic bases for CG recognition have also been studied in 
organic solution, by NMR of the isolated triplet.  Although only an approximation of 
their behaviour in the aqueous environment, these studies presented some interesting 
potential candidates for future triplex studies.   Some have also been progressed to 
triplex melting studies.
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Figure 1.27.  Novel heterocyclic CG recognition monomers; ureido-naphthimidazole 44 (
UNI),
133 
amino-  45,   amido-  46,47,   and   ureido-phthalimides  49-50,
134-136  ureido-isoindolin-1-one 
51,52,
135,137 urocanamide 53,54 and imidazole derivatives 55,56.
138-140
A butylureido-naphthimidazole  44  (
UNI)
133  was assessed in NMR binding studies in 
forming a triplet with CG, with hydrogen bonds to 4-NH of C and C=O
6 and N
7 of G. 
Although incorporated into DNA, biophysical studies were not published.
Several modified phthalimide structures were also evaluated in NMR binding studies 
with CG.
134-136   Whereas amino- 45, acetamido- 46 and benzamido- 47 modifications 
gave relatively weak binding, ureido- 48 and N-alkylureido- groups 49,50 demonstrated 
strong binding via three hydrogen-bonds from the phthalimide C=O to 4-NH of C, and 
from the urea to C=O
6 and N
7 of G.
A hexylureido-isoindolin-1-one structure 51,
135 analogous to the above monomer, also 
effectively   bound   to   CG   with   an   association   constant   (Kassoc)   ten-times   that   of 
Zimmerman’s naphthimidazole  44.
133   This was also progressed into triplex melting 
studies as the ethylureido-isoindolin-1-one-methylene  monomer  52,
137  however, it 
proved no more effective at CG recognition than an abasic site, with a stability of 
approximately 1.8-5.0 kcal/mol lower than the natural T.AT and C
+.GC triplets.
Derivatives of urocanamide 53,54 and related imidazole structures 55,56 were evaluated 
by   Purwanto  et   al.
138-140  in   NMR   studies   and   UV   melting   experiments.     NOE 
experiments indicated binding to CG occurred through two hydrogen-bonds, one to C
7 
and one to C=O
6 of G.  NMR binding studies of the primary amide 53, N-propylamide 
54, alkyl- 55 and phenyl- 56 derivatives indicated strongest binding from the primary 
amide (urocanamide).  Reduced affinity for the other three were attributed to rotation 
around the amide bond hindering binding for the N-ethylamide, too much flexibility for 
alkyl derivatives, and too little flexibility for phenyl derivatives.
26The N-propyl urocanamide 54 was progressed to triplex melting studies, targeting a 
single CG inversion in an AT rich duplex.  Despite showing a sharp third strand melting 
transition, a broad melt transition against TA of a similar Tm was also detected, possibly 
due to binding to A through protonation of the imidazole ring.   An increase in 
selectivity for CG over TA was observed on increasing pH to 6.5, confirming this pH 
dependence of TA binding.  Triplex stability, however, was approximately 10 °C lower 
than for the C
+.GC triplet, at pH 6.0, due in part to lack of  p-p  stacking area and 
hydrophilicity of the amide moiety.   These observations once again highlighted the 
importance of base-stacking, hydrophobic interactions and conformation within the 
triplex, which cannot be well approximated in NMR studies of isolated triplets.
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Figure 1.28.  Novel carbohydrate and antiparallel CG recognition monomers/triplets.
Recognition of the CG base pair within antiparallel triplexes has also been employed 
despite issues of stability.  The azole monomers 57-60 of Durland et al.
141 generally 
bound to two or more base pairs with moderate affinity, and the purine nucleoside 2’-
deoxynebularine 61 (dN) demonstrated equal binding affinity to CG and AT at pH 7.4 
via one hydrogen bond.  The conformationally-locked WNA-bC nucleoside of Sasaki et 
al.
142 effectively recognised CG, whilst the G and T b-anomers, WNA-bG and WNA-
bT, bound selectively to TA within an antiparallel triplex, as determined by gel-shift 
assays.  A novel abasic carbohydrate was also assessed in NMR studies as a CG binding 
agent.
143  Recognition occurs via two hydrogen-bonds, although it is doubtful this could 
be in useful in a triplex context.
Although some success has been afforded within the antiparallel triplex, CG recognition 
is still most likely to be achieved through the parallel motif.  Despite some degree of 
pH-dependence   parallel   triplexes   are  more   stable   and   easier   to   work   with,   but 
antiparallel recognition is still of interest.
271.3 Conclusion
Genomic DNA is a promising target for many small-molecule and oligonucleotide-
based therapeutics, aimed at treating a wide variety of genetic diseases and cancers.
The sequence-specificity of DNA allows for oligotherapeutics to be synthesised that 
target only specific sequences, to block a particular gene function, target cancer cells, 
and for a range of site-specific DNA strand modifications.  It is for these reasons that 
extensive research has been carried out over a number of years, to achieve selective 
recognition of each of the four base pairs, whilst understanding the effect of interaction 
of   neighbouring   modified   nucleosides   on   the  efficacy   of  triplex   formation,   and 
enhancing resistance to in vivo degradation.
The therapeutic use of DNA triplexes is an expanding, exciting field, which continues to 
produce promising results in biophysical studies and against real targets in some 
biological systems.
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292. Modified 6-Oxocytidine Nucleosides for GC Recognition
2.1. Introduction
Recognition of GC base pairs using the natural base C is both selective and strong 
below pH 6.0.  Due to the low pKaH of N
3 of cytosine, protonation of which is required 
for Hoogsteen hydrogen-bonding, the C
+.GC or C.GC triplet is not stable, however, at 
physiological pH (7.0).   This severely limits the number of biological applications 
where this can be used, especially against targets containing contiguous GC base pairs, 
where repulsion between positive charges destabilises the triplex further.
A variety of pyrimidine- and purine-based monomers for GC recognition have been 
evaluated as described in Section 1.2.1.2.  These include the pyrimidine nucleosides, 5-
methylcytosine (
5-MeC)
45-47  and the  C-nucleoside 3-methyl-2-aminopyridine (
MAP),
61,65 
providing stability through a higher pKaH  and hydrophobic methyl group; and  N
6-
methyl-
8-oxoA
87  and pyDDA,
68  which form pH-independent triplets with permanent 
hydrogen-bonds.
The non-natural base 6-oxocytosine (
6-oxoC, 62)
70-74 also found use as a GC recognition 
monomer, which forms triplets independent of pH.  Unlike some other GC recognition 
monomers, 
6-oxoC could potentially be modified at the 5-position on the nucleobase (and 
2’-position of the sugar), with pendant amino groups, such as for bis-amino-U (
BAU). 
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Figure 2.1.   Structures of 6-oxocytosine  62, 2’-O-(2-aminoethyl)-5-(3-aminoprop-1-ynyl)-6-
oxocytidine 63 (
BAoxC), and proposed hydrogen-bonding and electrostatic interactions within the 
putative 
BAoxC.GC triplet.
30In the above diagram (Figure 2.1), charge-stabilising interactions are shown between the 
protonated   2’-amine   moiety   and   guanidine   5’-phosphate,   and   also   between   the 
protonated 5’-amine moiety and 
BAoxC phosphates.  Hoogsteen hydrogen-bonds are also 
shown between 
BAoxC and G.
The initial project aim therefore, was synthesis of a direct analogue of 
BAU, a bis-amino-
modified derivative of 6-oxocytidine, 2’-O-(2-aminoethyl)-5-(3-aminoprop-1-ynyl)-6-
oxocytidine 63 (
BAoxC) (Figure 2.1).  This would combine the triplex-stabilising effect of 
the   amine   groups   as   exemplified   by  
BAU   and   potentially   enhanced  p-stacking 
interactions from the alkynyl moiety.  GC recognition would be achieved, as previously 
described, via two permanent hydrogen bonds between N
3H and N
4H of the base and N
7 
and C
6=O of guanine, giving pH-independent triplex binding.  Although poor binding 
affinity was observed when using 2’-O-aminoethyl-modified 
6-oxoC and 
moxC compared 
to 2’-O-methyl- or 2’-deoxy- derivatives (Section 1.2.1.3), combining both amine 
modifications was proposed to enhance alignment with the GC base pair in addition to 
the properties described above.
2.2. Bis-amino-6-oxocytidine: Synthesis
The key steps in synthesis of a functionalised 6-oxocytidine monomer are coupling of 
the persilylated  6-oxocytosine (6-aminouracil) base to the modified sugar; sugar 
deprotection   and   reprotection   of   the   5’-position;   halogenation   at   the   5-position; 
protection of the 4-NH2 group; and subsequent base modification.  The order in which 
these are to be carried is open to variation.  The final compound is then converted into a 
3’-O-phosphoramidite
144 for incorporation into triplex-forming oligonucleotides (TFOs).
Dr. Osborne conducted much work in house, into synthesis of a 
BAoxC monomer 64, for 
incorporation   into   TFOs.     After   the   sugar-base   coupling   using   the   2’-O-
phthalimidoethyl-modified sugar 65, and three protection/deprotection steps, problems 
were encountered in two key steps in the synthesis (Scheme 2.1).
Iodination under the above conditions required excess NIS and several days to effect the 
transformation.  The subsequent Sonogashira reaction under Hobbs’ conditions
124 was 
31unsuccessful, thought at the time to be affected by neighbouring functionality rather 
than electronic factors, and the route was abandoned for re-evaluation.
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Scheme 2.1:  Final three steps in original synthetic route to 
BAoxC monomer 64.
2.2.1 Synthesis of 5-Halo-6-oxocytidine nucleosides
It had been observed by Prof. T. Brown that during automated oligonucleotide 
synthesis, approximately 60% of unmodified 
6-oxoC nucleosides were iodinated at the 5-
position in the emerging oligonucleotide, during the oxidation of P
III to P
V.  Following 
this observation, Osborne successfully used the iodine/THF/pyridine solution, employed 
in this oxidation step, to iodinate an acetylated 2’-O-phthalimido-
6-oxoC derivative.  Once 
reaction feasibility was established, Osbourne reacted a 5’-O-(4,4’-dimethoxytrityl)-
protected 
6-oxoC derivative 66 with N-iodosuccinimide (NIS) (Scheme 2.1).  It was later 
established that the aqueous workup of 5-iodo-
6-oxoC derivatives with sat. aq sodium 
thiosulfate to remove excess iodine, as used by Dr. Osborne, caused significant 
deiodination of the product, perhaps a reason for the moderate 56% yield.
Iodine, NIS
145-147 and iodine monochloride,
148,149 are well-known as iodinating agents for 
nucleosides, although ICl has potential for chlorination
150  and is more difficult to 
handle.  For optimisation of yield/reaction time, an alternative iodinating reagent was 
sought.  Bromination at this point was considered unnecessary as iodinated substrates 
are more reactive to Pd-catalysed cross-coupling conditions.
32Benzyltriethylammonium dichloroiodate (BTEA-ICl2)  71  (Figure 2.2), was used by 
Harrowven et al.
151 to iodinate a substituted anisole intermediate in synthesis of a target 
macrocycle, in 99% yield over 5 hours.  A co-catalyst ZnCl2 was used, which also 
helped to solubilise BTEA-ICl2 in the solvent acetic acid.
N Cl I Cl
71
Figure 2.2.  Benzyltriethylammonium dichloroiodate (BTEA-ICl2) 71.
Most ammonium polyhalide-derived reactions such as this, in the literature, have 
utilised the benzyltrimethylammonium (BTMA) salt, which is commercially available, 
for halogenation reactions; for example,  the dichloroiodate,  tetrachloroiodate and 
tribromide or chlorobromate for iodination, chlorination and bromination respectively. 
The preferred solvents for halogenation, using BTMA dichloroiodate (BTMA-ICl2), 
were methanol or CH2Cl2/methanol and several inorganic co-catalysts, CaCO3,
152,153 
NaHCO3,
152,154  and ZnCl2
151,155  have been used.   Although the BTEA ion has been 
exploited as a range of salts, it has rarely been used as the dichloroiodate salt. Mitra et 
al.
156-159  however,   published   several   papers   discussing   halogenation   using   solid-
supported BTEA-polyhalide salts.  The BTEA-based reagent was used in preference to 
BTMA-ICl2 by the Harrowven group, as it was believed to afford improved yield and 
selectivity.
2.2.1.1 Synthesis and Reaction of Benzyltriethylammonium dichloroiodate
Literature methods for synthesising BTMA-ICl2, include reacting BTMA-chloride with 
iodine monochloride in 86% yield,
152 or with iodine and silver trifluoroacetate.
160  The 
first of these methods was attempted using BTEA-Cl 72 instead, however, only a gum 
containing a mixture of salts was isolated.  Attention was subsequently turned to a 
cleaner route, published by Kosynkin and Tour,
154 which used standard-grade reagents 
(bleach, NaI, HCl) in aqueous medium.  This was tested on a 10 g scale, affording 
BTEA-ICl2 71 in 96% yield.
The solution phase iodination conditions of Kosynkin  et al.
154  and the solvent-free 
conditions of Hajipour et al.
161 (in which the reagent Me4N
+ ICl2
– was ground to a fine 
33powder with the substrate), were both tested in TLC-scale reactions using BTEA-ICl2 
71, although the latter method proved inefficient for the BTEA salt.  When scaled up on 
a TIPDS-protected 
6-oxoC derivative 73, synthesised by Dr. Osbourne, despite a clean 
conversion, only the chlorinated nucleoside 74 was afforded in 46% yield.
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Scheme 2.2. Halogenation of 6-oxocytidine derivative 73 using BTEA-ICl2 71.
This could be rationalised by dissociation of the dichloroiodate anion forming ICl 
(brown colouration observed) in situ, which then acted as a chlorinating agent.  Boden 
et al.
150 published the ability of ICl to chlorinate very electron-rich or sterically hindered 
substrates, via a single electron transfer from substrate to ICl.
2.2.1.2 Other Methods of Halogenation of 6-Oxocytidine derivatives
Pan et al.
162 published the halogenation of TIPDS-protected 6-amino-dU derivatives, 
(structural isomers of 6-oxocytidine) using bromine/iodine in moderate to good yields. 
Reporting higher yields for bromination, this method was tested on acetylated  
6-oxoC 
derivatives.  The bromine solution was added dropwise via a steel syringe needle, and 
became darker with a black precipitate of FeBr3, which was thought to catalyse the 
reaction.  Concurrently, Dr. Y. Wang attempted to brominate 6-oxocytosine 62 with no 
success or very long reaction time by adding the bromine solution via glass pipette. 
Addition of a small quantity of FeBr3  significantly accelerated the reaction, thus 
supporting   this   hypothesis.     An   anomeric   mixture   of   furanose/pyranose  
6-oxoC 
nucleosides 75-78 was reacted with bromine, catalysed by 1.0 mol% FeBr3, to afford the 
brominated products 79-82 in 51% total yield.
After obtaining the anomerically pure 6-oxocytosinyl-b-ribofuranoside  75  (Section 
2.2.3), a cleaner and higher yielding halogenation reaction was sought, to produce a 
large quantity of brominated/iodinated  
6-oxoC.   Despite the moderate yield and long 
34reaction time necessary for iodination of 
6-oxoC using NIS, attention was turned back to 
N-halosuccinimides using the alternative conditions of Hirota et al..
163
Hirota  et   al.  brominated   several   4N-alkyl-1,3-dimethyl-6-oxocytosine   derivatives 
(Figure   2.3)   using  N-bromosuccinimide   (NBS),   with   the  radical   initiator   AIBN, 
suspended in THF, in 80-95% yield.   6-Oxocytidine derivative  75  was transformed 
cleanly under these conditions, using only 2.0 mol% AIBN in 30 minutes, to afford the 
product 79 in 95% yield.
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Figure   2.3.    4N-Alkyl-1,3-dimethyl-6-oxocytosine   derivatives,   acetylated  
6-oxoC  75  and 
halogenated 
6-oxoC nucleosides 79,83.
Iodination using  N-iodosuccinimide (NIS) under the same conditions resulted in a 
brown colouration.  Presumed to be due to decomposition of NIS in storage, a large 
quantity was recrystallised (dioxane/chloroform)
164  and the reaction was repeated. 
Despite the same brown colouration whether conducted at rt or 0 °C, on a 5 g scale the 
reaction was complete within 15 minutes.  Partial or almost complete deiodination of 
product   occurred   after   aqueous   workup,   using   dilute   aq   Na2S2O3  or   Na2S2O5 
respectively, as previously observed (Section 2.2.1).  The sodium thiosulfate (Na2S2O3) 
workup, however, was used successfully on a 0.5 g quantity of the reaction mixture, 
separating the layers as soon as decolourisation occurred.  Suspension of the remainder 
in ethyl acetate and soaking over 2 days, however, removed all excess iodine and 
succinimide by-product, affording the product 83 in 82% combined yield.
2.2.2 Synthesis of 2’-O-Phthalimidoethyl-modified Ribofuranose Sugar
The 2’-O-phthalimidoethyl-modified ribofuranose sugar 65, synthesised and used by 
Osborne et al.
37 in preparation of the AT-recognition monomer 
BAU, was prepared for 
coupling to 6-oxocytosine 62 (Scheme 2.2), as part of the synthetic route to the 
BAoxC 
monomer 64.
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Scheme 2.2.  Synthesis of 2’-modified ribofuranose sugar 65 (lit.
37 yields in parentheses).
The sugar synthesis starts with formation of the 1’-O-methyl acetal of  D-ribose 85, 
followed   by   protection   of   the   3’-   and   5’-OH   groups   with   the   bidentate   tetra-
isopropylsiloxane-1,3-diyl (TIPDS) group, using Markiewicz Reagent.
165  The reaction 
proceeded well over two steps, with minor impurities and solvent traces, which were 
removed during the following steps (Scheme 2.3).
Alkylation   of   the   2’-OH   with   methyl   bromoacetate   gave   the   product   2’-O-
methylethanoyl   sugar  87  in   a   moderate   yield,   containing   a   significant   methyl 
bromoacetate impurity which co-eluted with the product.  Subsequent reduction of the 
ester moiety using LiBH4 therefore, afforded a lower yield of 88 than in the literature. 
Phthalimide substitution via Mitsunobu conditions
166 gave the TIPDS-protected sugar 
89 (a-anomer only) and subsequent acetolysis gave the final 2’-modified ribofuranose 
sugar 65 in good yield.
This would then be coupled with 6-oxocytosine 62 (Scheme 2.3), once halogenation and 
Sonogashira reactions were optimised.
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Scheme 2.3.  Sugar-base coupling under Vorbrüggen’s
167 conditions (in house). 
362.2.3 6-Oxocytidine Synthesis
Due to the expensive nature of Markiewicz reagent (£100/g, now ~£25/g), an alternative 
sugar moiety was needed for synthesis of a 6-oxocytidine nucleoside, on which 
halogenation and Sonogashira reactions could be evaluated.  1’,2’,3’,5’-Tetra-O-acetyl-
D-ribose 91 was chosen, as the synthesis is straightforward and the reagents are cheap.
The first stage was acetylation of D-ribose 84, which was first effected using acetic 
anhydride in pyridine, with a catalytic amount of DMAP (from in house method). 
Following purification, this afforded a 97% yield, of a 1:1.6 ratio of ribofuranose (a:b 
ca. 1:7) to ribopyranose (a:b ca. 1:6.5).  Persilylation of 6-oxocytosine 62 by refluxing 
in HMDS, followed by coupling to the sugar mixture 91-94 with trimethylsilyl triflate 
in   DCE   at   rt,   afforded   an   inseparable   mixture   of  b-ribofuranoside  75  and  b-
ribopyranoside 77 in a 49% yield.  Only trace amounts of the a-anomers 76,78 were 
were isolated due to neighbouring group participation from the 2’-acetato group 
(Scheme 2.4).
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Scheme 2.4.  Synthesis of 2’,3’,5’-tri-O-acetyl-6-oxocytosinyl-ribosides 75-78.
This b-riboside mixture 75,77 was subsequently brominated, as described in Section 
2.2.1.2, for Sonogashira cross-coupling.
The desired b-ribofuranoside 75 was synthesised selectively by converting D-ribose 84 
into the 1’-O-methylribofuranoside 85, used in synthesis of the 2’-O-phthalimidoethyl-
b-ribofuranose sugar 65 in Section 2.2.2, followed by acetolysis/acetylation to give the 
b-anomer of the product sugar 91, in 39% yield.  After crystallisation, the remaining 
syrup, containing  ca.  65:35 ratio of  a:b-anomers, was not repurified, and further 
crystallisation of the b-anomer could not be induced by ice-cold ethanol or by seeding.
37The sugar-base condensation was conducted under Vorbrüggen’s conditions
167  as 
described in Scheme 2.2.  No chromatography was required, as the product nucleoside 
75 crystallised out of solution during workup, in 70% yield (16.9 g).  The nucleoside 
was brominated/iodinated using NBS/NIS, as described Section 2.2.1.2.
2.2.4 Sonogashira Cross-Coupling
123
There   has   been   much   research   on   palladium-catalysed   alkynylation   reactions. 
Modifying   Sonogashira’s
123  original   conditions   (CuI,   (Ph3P)2PdCl2,   Et2NH)   for 
nucleosides, Robins and Barr’s
116,168 use of warm triethylamine and Hobbs’ conditions 
for alkynylation of nucleosides
124 are two popular methods employed in synthesis of 
modified nucleosides.  
Prior to carrying out Sonogashira reactions, the stability of the iodinated  83  and 
brominated nucleosides 79 to heat, light and base (Et3N, piperidine) in THF, DMF and 
methanol was tested.  TLC and MS analysis indicated no decomposition of any kind 
(deacetylation,   dehalogenation),   hence   suggesting   they   should   be   stable   under 
Sonogashira conditions.
A range of conditions and reagents for the Sonogashira
123 cross-coupling of a protected 
aminoalkyne, were tested on the brominated derivatives of the b-riboside mixture 79,81, 
brominated nucleoside 79 and iodinated nucleoside 83.
The   brominated  b-riboside   mixture  79,81  was   treated   with  N-trifluoroacetyl 
propargylamine 68 (2 eq) under Hobbs’ conditions;
124 Pd(PPh3)4 (10 mol%), CuI (20 
mol%) and Et3N (2 eq) in DMF (Scheme 2.5).
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Scheme 2.5. Sonogashira cross-coupling reaction between N-trifluoroacetyl propargylamine 68 
and brominated 6-oxocytosinyl b-ribosides 79,81.
38TLC analysis indicated a complex mixture and only starting material and debrominated 
starting material were isolated after purification (analysed by MS).  It is unusual, yet 
possible that debromination occurred via hydride-insertion after Pd-insertion into the C-
Br bond.
Triethylamine was the base of choice, because it is non-nucleophilic and there is no 
possibility   of   substitution   of   bromine.     It   was   shown   by   Wang  et   al.,
169  that 
triethylamine also inhibits alkyne dimerisation/homo-coupling and promotes the desired 
cross-coupling reaction.  Diethylamine, as used by Kenkichi Sonogashira, was shown to 
promote homo-coupling under the right conditions.
Using a large excess of Et3N (20 eq) or as a solvent, on 50 mg and 500 mg scale, 
resulted only in partial debromination, deacetylation, and triphenylphosphine oxide.  A 
similar observation was made for the iodinated nucleoside 83.
The last reactions on the brominated b-riboside mixture 79,81 were carried out under 
microwave heating.  The cross-coupling reactions were conducted in DMF or THF at 60 
°C for 10 mins, and in DMF at 100 °C for 10 mins.  Once again, only complex mixtures 
were formed.
A   fresh   quantity   of  N-trifluoroacetyl   propargylamine
117,170  68  (Scheme   2.6)   was 
synthesised for subsequent Sonogashira reactions; the quality of which was confirmed 
by standard characterisation methods and in a test Sonogashira reaction using 5’-O-
(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine   (DMT-IdU)  97  under   Hobbs’ 
conditions.
124    However,  subsequent  test  reactions  using  the brominated  79  and 
iodinated 83 
6-oxoC derivatives, were unsuccessful.  Only partial de-iodination of starting 
material 83, and formation of triphenylphosphine oxide (in both cases) were observed.
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Scheme 2.6.  Synthesis of N-trifluoroacetyl propargylamine 68, (lit.
117 yield in parentheses).
It was proposed that the above problems might be exacerbated by the presence of acetyl 
groups hence a suitable method for deacetylation was sought.  The brominated 79 and 
iodinated  83 
6-oxoC nucleosides were deacetylated by heating in 0.4 M K2CO3  in 
39methanol/water   (4:1,   v/v)   (mild   reagent   occasionally   used   in   oligonucleotide 
deprotection) until fully dissolved.   Treatment with DOWEX 50WX8 ion exchange 
resin (200/400 mesh, pyridinium form) monitoring the pH until <7, soaking the 
resulting solid (after filtration and concentration) in cold ethanol or isopropanol and 
drying, afforded the ‘free’ bromo- 99 and iodo-nucleosides 100 in good to high yield.  If 
too little DOWEX resin was used, this resulted in a hygroscopic potassium salt of the 
nucleoside, which required further treatment.
A 0.5 g scale Sonogashira reaction was executed using the deacetylated iodinated 
nucleoside  100  and alkyne  68, under the same conditions.   However, complete 
deiodination was observed over 2 hours, to give the deiodinated starting material, 6-
oxocytidine 101 in 44% yield (Figure 2.4).
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Figure 2.4.  Starting material 100, desired Sonogashira product 102 and 6-oxocytidine 101.
As little success had been achieved using modifications of Hobbs’ conditions, other 
catalysts and conditions were assessed.   Recently, Alami  et al.
171  published cross-
coupling reactions effected  by the strongly active (bis-benzonitrile)palladium (II) 
dichloride – copper (I) iodide catalyst system.  Using this system they were able to 
conduct cross-couplings of vinyl chlorides with a variety of alkynes, in dry piperidine. 
The weakly-coordinated PhCN ligands, allow for much faster oxidative insertion of Pd 
into the C–X bond (even less reactive C–Cl bonds, at room temperature), and with 
excellent yields (62-97%) and reaction times (~30 minutes).
The above reaction conditions ((PhCN)2PdCl2 – 5 mol%, CuI – 10 mol%, alkyne 68 – 2 
eq, dry piperidine, rt, argon atmosphere), however proved ineffective on 6-oxocytidine 
substrates.  TLC analysis of the reaction with iodinated nucleoside 100, indicated only 
deiodination.  TLC and MS analysis of the reaction with 5-bromo-6-oxocytidine 99, 
indicated   nothing   had   occurred,   with   or   without   DMF   as   a  co-solvent   (to   aid 
dissolution).  The reactions could not be left longer than 90 minutes or heated due to 
catalyst sensitivity.
40The bis-(triphenylphosphine)palladium (II) dichloride (10 mol%) – copper (I) iodide 
(30 mol%) catalyst system, as used by Robins and Barr
116,168 for cross-coupling reactions 
with 5-iodo-2’-deoxyuridines in warm triethylamine (50 °C) was also assessed.  Even 
when using 4 equivalents of alkyne, only deiodination and alkyne dimerisation were 
detected for substrate 100 and nothing was observed for the brominated substrate 99.
Alternatively, instead of conducting cross-couplings in absence of water, the reaction 
was conducted in hot water, using 0.5 mol% (Ph3P)4Pd, as published by Bhattacharya 
and Sengupta.
172  The authors’ principal idea was to utilise the hydrophobic effect, and 
although the 6-oxocytidine substrates are (partially) water-soluble, it was hoped these 
conditions might be beneficial.  However, again only deiodination of 100 was observed.
These reactions, using various catalysts, solvents, temperatures and ratios of reagents 
were all unsuccessful.  Brominated 
6-oxoC nucleosides (b-anomers) did not react, and 
iodinated 
6-oxoC nucleosides were deiodinated.  This illustrates the surprising strength of 
the C–Br bond and susceptibility of the R–Pd(PPh3)2–I intermediate to decomposition. 
There may also be other steric and electronic factors preventing this transformation, 
such as the neighbouring C
6-carbonyl and C
4-amino groups.  Although other alkynes 
were   not   tested,  N-trifluoroacetyl   propargylamine  68  couples   to   protected   and 
unprotected 5-iodo-2’-deoxyuridine nucleosides in excellent yield.
117,170
Sonogashira-like   palladium-catalysed   cross-coupling   reactions   were   subsequently 
abandoned.  It is still possible, however, that results could be obtained using a triflato-
nucleoside,
59  alkynylzinc reagents
173,174  or even Stille coupling,
175  which have been 
successfully used to alkynylate other nucleosides.
2.3 Alternative Modifications at 5-position
Attempts to enhance base-stacking by attachment of an alkynyl  group failed as 
described   above.     It   was   also   found   that   the   5-allyl-group   of  
6-oxodC   caused 
destabilisation of the triplex, relative to 
6-oxodC alone.  An alternative method was sought 
therefore for attachment of a pendant amine group at the 5-position of 
6-oxoC, with or 
without additional base-stacking enhancement, which would increase triplex-stability by 
charge-stabilisation.
412.3.1 Halide-Amine Exchange
Halide-amine exchange was proposed as an alternative method for introduction of 
amine   functionality   to   the   base.     There   is   much   literature   precedent   for   this 
transformation on aromatic compounds, uridine nucleosides, uracils and aminouracils, 
using primary and secondary amines and even ammonia.   In 1951, Arthur Phillips 
published a series of substitution reactions on 5-bromouracil, using amines such as 
methylamine,   butylamine,   cyclohexylamine,   piperidine   and   benzylmethylamine   in 
typically good to quantitative yields.
176  Benzylmethylamine was used for introduction 
of a methylamino group (following hydrogenolysis of the benzyl group), as reaction of 
similar   heterocycles   with   methylamine   and   ammonia   often   requires   elevated 
temperatures
177 or high pressure,
178,179 with long reaction times.
5-Bromo-6-oxocytidine 99 was heated at 85 °C in a sealed tube with four different 
amines (piperidine, benzylamine, propargylamine, TAEA 103) for 3.5 hours (Figure 
2.5).  TLC analysis indicated loss of starting material, most likely through degradation, 
and no positive identification of desired products was made by MS analysis.  A tan-
coloured   solid   was   isolated   from   the   last   reaction   with   the   polyamine  tris(2-
aminoethyl)amine, TAEA 103, which was confirmed by NMR, however, to be a salt of 
TAEA.
O
OH OH
HO N
NH
NH2
O O
N
O
OH OH
HO N
NH
NH2
O O
H
N
O
OH OH
HO N
NH
NH2
O O
H
N
O
OH OH
HO N
NH
NH2
O O
H
N
N
NH2
H2N
104 105 106 107
O
OH OH
HO N
NH
NH2
O O
Br
99
Figure 2.5.  5-Bromo-6-oxocytidine 99 and amine-halide exchange products 104-107.
Azam  et al.
180  attached the polyamine TAEA  103  to an anthraquinone intercalator-
modified chimeric TFO, by a simple chloride-amine exchange reaction.  The polyamine 
moiety demonstrated increased triplex stability without altering selectivity, and has 
since been used, in house, by Dr. Z. Zhao, for synthesising simple polyamine-
anthraquinone intercalators for non-specific triplex stabilisation.
181
42Initially, test reactions were performed on 2’,3’,5’-O-triacetyl-5-bromo-6-oxocytidine 
79, heating the nucleoside at 80 °C in a sealed tube, for 2.5 hours in piperidine or 
benzylamine.  Following treatment with DOWEX 50WX8-400 (pyridinium form) and 
diethyl ether, a white gum containing some deacetylated piperidinyl compound 104, and 
deacetylated starting material 101 were obtained respectively.  Following this, to avoid 
complex   mixtures   due   to   partial   deacetylation,   the   free   nucleoside   5-bromo-6-
oxocytidine  99  was used.   This was treated with propargylamine, benzylamine and 
TAEA 103.
Varying   the   reaction   conditions   for   bromide-TAEA   exchange   was   unsuccessful. 
Heating 5-bromo-6-oxocytidine 98 with TAEA 103 at 180 °C for 20 minutes, heating at
75 °C in a 30% aq solution of the amine overnight, and refluxing in distilled pyridine 
with 5 eq of TAEA 103 produced similar results as obtained previously and isolation of 
amine salts.
In order to confirm that exchange had occurred successfully originally, when using 
piperidine, nucleoside 99 was heated in the amine alone, or with pyridine, water or 
DMF as co-solvent at 70 °C for 17 hours.  This proved partially successful, with an 
estimated 20-30% conversion (TLC analysis) for all reactions, except in water.  These 
results were also confirmed by MS analysis.
The amine-halide exchange was proposed to occur via an SNAr mechanism, which if 
true would suggest a faster, more efficient reaction with chloro- and fluoro-, rather than 
bromo- or iodo-groups.   To take advantage of this, and to avoid problems due to 
cleavage of acetyl protecting groups, a large quantity of unprotected 5-chloro-6-
oxocytidine 108 was synthesised for comparison with the other 5-halo-
6-oxoC derivatives. 
2’,3’,5’-Tri-O-acetyl-6-oxocytidine  75  was treated with  N-chloro-succinimide (NCS) 
based on the method published by Hirota  et al.
163  as described in Section 2.2.1.2 
(Scheme 2.7).  The product was purified by column chromatography, not soaked in 
ethyl acetate to remove the succinimide by-product, as it is partially soluble in ths 
solvent.
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Scheme 2.7.  Synthesis of 5-chloro-6-oxocytidine 108.
The product 109 was deacetylated as previously described to afford the desired free 
nucleoside 108 in 81% yield over two steps, containing 1.8 mol % succinimide from the 
previous step and 35.6 mol % KOAc, not observed for previous deacetylations by this 
method.
In the next series of test exchange reactions, chlorinated 74,108 and iodinated 100 
6-oxoC 
nucleosides were treated with piperidine, and brominated nucleoside 99 with five 1,n-
diaminoalkanes (n = 2, 6, 8, 10, 12), at 70 °C for 18-20 hours (Figure 2.6).
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Figure 2.6.  Substrates for amine-halide substitution reactions 74,99,100,108.
5-Iodo-6-oxocytidine  100  reacted partially with piperidine but less cleanly than 5-
bromo-6-oxocytidine 99, suggesting an SNAr mechanism might apply.  The protected 
chlorinated  
6-oxoC   derivative  74,  however,   underwent   deprotection   of   the   4N-
dimethylformamidine protecting group, with no desired reaction, and none of the 1,n-
diaminoalkanes reacted with 5-bromo-6-oxocytidine 99.
Chloro-
6-oxoC derivative 74 was treated with ethylene diamine (42 eq) and TAEA 103 
(18 eq) at 75  °C for 90 minutes and also for 18-20 hours.   Only formamidine 
deprotection and amine degradation were observed, and trifluoroacetylation of the latter 
reaction mixture yielded only trifluoroacetylated amine.
So far, successful amine-halide exchange had been limited to the secondary amine 
piperidine, which is probably not beneficial to triplex formation.  Attempts to couple 
44with primary amines, and in particular, polyamines, although unsuccessful thus far, 
were continued using 5-chloro-6-oxocytidine 108.  It was thought, that protection of 
two of the primary amine moieties of tris(2-aminoethyl)amine 103, could potentially aid 
the reaction by presenting only one centre for reaction, although the  bis-protected 
product was finally not used.   Asseline  et al.
182  published the synthesis of the  bis-
trifluoroacetylated polyamine 110 via alkylation of the trifluoroacetic acid salt of bis-
trifluoroacetylated diethylene triamine 111 with bromoethanol, followed by Mitsunobu 
reaction with LiN3 and hydrogenation over Pd/C, in 23% overall yield.
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Scheme 2.8.  First route to N-(2-aminoethyl)-bis-N,N-[2-(trifluoroacetamido)ethyl]amine 110.
The first synthetic procedure attempted (Scheme 2.8) began with mono-protection with 
a 4,4’-dimethoxytrityl (DMT) group, by addition of a solution of DMTCl  112  in 
distilled pyridine, dropwise over 20 minutes, to a stirred, ice-cold solution of TAEA 103 
(6 eq) in distilled CH2Cl2.  After aqueous workup, an off-white foam was afforded, 
which unfortunately contained only bis- and tris-tritylated products.
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Scheme 2.9.  Other routes to N-(2-aminoethyl)-bis-N,N-[2-(trifluoroacetamido)ethyl]amine 110.
The reaction was repeated using MMTCl 115 due to issues of stability with DMT, using 
7 eq of polyamine 103 and dropwise addition of the MMTCl/pyridine solution over a 
5½ hour period.  This afforded, after workup, a green syrup/resin.  Trifluoroacetylation 
using ethyl trifluoroacetate (10 eq), with excess Et3N to prevent detritylation, afforded 
the fully-protected compound 116 in a low 20% overall yield.  The detritylation step 
was carried out on a test scale, using acetic acid (30 eq) in methanol with heating to 
afford a white oil, which could not be identified by MS analysis (Scheme 2.9).
45Free amine 103 was also trifluoroacetylated directly using only 2 equivalents of ethyl 
trifluoroacetate, which selectively protected only two amines in 37% yield.  Indeed, the 
selectivity obtained using ethyl trifluoroacetate is known, as published by Yang et al.,
183 
who described the selective protection of two and three chemically-equivalent amines in 
1,4,7-triazacyclonane and cyclen respectively, despite using excess reagent.
Finally, after testing the substrate’s stability to DMF and pyridine, at 100 °C overnight, 
a number of test amine-substitution reactions on 5-chloro-6-oxocytidine  108  were 
carried out.  The substrate was heated, under argon as described previously, at 100 °C in 
DMF, with TAEA 103 (10 eq), diethylene triamine (10 eq) and piperidine (60 eq) for 21 
hours; and with piperidine (30 eq), piperidine (30 eq) with KF (2.5 eq), TAEA 103 (30 
eq) and 6-aminocaproic acid (30 eq) for up to 2½ days.  Once again, only piperidine 
proved suitably nucleophilic to react.  It was difficult to determine if KF had any effect 
on this reaction.
These studies indicated only the strongly nucleophilic amine piperidine was able to 
displace a halogen at the 5-position of 6-oxocytidine.
There   is   literature   precedent   for   reaction   of   primary   amines   with   5-bromo-6-
oxocytosine   (5-bromo-6-aminouracil)   derivatives   (e.g.   5-bromo-1,3-dimethyl-6-
aminouracil, 117).  Brederick et al.
184 achieved efficient reaction with benzylamine, n-
butylamine   and   ethanolamine   and   Searle   &   Co.
185  with   2-(N,N-
dimethylamino)ethylamine, by heating in ethanolic solution.   Rybar  et al.
186  report 
yields   of   50-80%,   using   simple   amines   such   as   propylamine,   allylamine   and 
benzylamine,   but   encountered   further   reaction   with   the   product   to   form  bis-6-
oxocytosinylamine compounds, even when using vast excess of the amine.  Zhang and 
Zhang
187  also reported efficient reaction at 120  °C, under microwave irradiation, to 
afford yields of 70-95% for several arylethylamines (Scheme 2.10).
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184-187
46Based on the literature evidence, it was thought possible to attach a polyamine or 
similar amine moiety to the base then couple to the sugar to form the modified 
nucleoside.  However, reaction with the desired amine TAEA 103 may give multiple 
additions, hence a protecting group strategy or methylated-analogue of TAEA  118 
would be needed, synthesis of which could be envisaged to proceed via a tetramethyl 
diethylene triamine 119.
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Scheme 2.11.  Proposed synthetic route to N,N,N’,N’-tetramethyl-tris-(2-aminoethyl)amine 118.
It is also unknown whether such a group would affect the sugar-base coupling and this 
route would require much optimisation.  It may also be possible therefore to exchange 
Br with NH3, for further base-modification (4N,5N-cyclisation reactions to increase 
base-stacking), however, the products (5,6-diaminouracils or 5-amino-6-oxocytosines) 
are unstable due to oxidative self-condensation.
189
2.3.2 Halide-Thiol Exchange
Amine-modified alkanethiols were chosen as the next candidate for nucleophilic 
substitution of chloride.  Being more nucleophilic than amines and with evidence of 
chloride-thiol exchange in the literature,
190 this was considered the logical next route. 
Attachment of a mercaptocarboxylic acid was considered for coupling of various 
amines, including TAEA 103 or its bis-trifluoroacetyl derivative 110.  The amine could 
be coupled to the acid, before or after halide-thiol exchange (Scheme 2.12).
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475-Chloro-6-oxocytidine 108 was treated with mercaptoacetic acid (10 eq) in DMF at 
100  °C for 18 hours, resulting in formation of a new product and near complete 
consumption of starting material.  A hygroscopic powder was obtained on precipitation 
with methanol and diethyl ether, and a second powder was obtained on ether-induced 
precipitation from the filtrate, the coupled product could not be detected by MS.
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The second proposal was synthesis of mercapto-analogues of TAEA  125,126, the 
attempted synthesis of which is described below (Scheme 2.13).   The seven-step 
synthesis of the non-acetylated analogue 126 was published by Cheng et al.
193 in 13% 
overall yield.   Either thiol could then be reacted with the desired 5-chloro-
6-oxoC 
derivative.
Selective trifluoroacetylation of the primary amine groups of diethylene triamine, 
DETA 127 was first achieved by trifluoroacetylation in presence of water to give the 
trifluoroacetate salt
182,192 111.  The large quantity of salt 111 could not be converted to 
the free amine using Et3N/heat or polyamine-modified Amberlite IRA-96 resin, hence 
the free amine 128 was synthesised.
194  This was achieved by reaction of DETA 127 
with a slight excess of ethyl trifluoroacetate, under anhydrous conditions.  Neither the 
salt 111 nor free amine 128, however, reacted with ethylene sulphide (ES) to introduce 
the 2-mercaptoethyl side-chain, despite strong literature precedent for alkylation of 
secondary amines with ES,
195,196  and of the salt  111  with alkyl bromides such as 
bromoethanol.
182 . The alternative route would proceed via alkylation using S-acetyl-2-
bromoethane thiol 129, synthesised from ES and AcBr (lit. 67% yield),
191 followed by 
selective cleavage of the S-acetyl group, using borohydride-functionalised Amberlite 
IRA-400 resin and Pd(OAc)2.
197  The resin is prepared by stirring the wet chloride-form 
with an aqueous solution of NaBH4.  The deprotection of octyl thioacetate was reported 
48to proceed cleanly in 98% yield.  Alternatively, full deprotection using 3M aq NaOH in 
acetone
198 should afford the free mercapto-polyamine 126.
5-Chloro-6-oxocytidine 108 was also treated with cysteamine (2-aminoethane thiol) (10 
eq) to assess whether a free amine moiety would affect this transformation.  The starting 
material was consumed over 16 hours and low yields of a white powder and a very 
hygroscopic tan-coloured powder were obtained by recrystallisation from methanol and 
precipitation of the filtrate with methanol/diethyl ether respectively.  No components 
could be identified by MS, but this does not disprove possible reaction, which, however, 
would need substantial optimisation.
Further work was halted at this stage, as attention was transferred to the CG recognition 
project (Chapters 3-7), which was running alongside this research, and obtaining 
positive results synthetically and in biophysical studies.
2.4 Alternative Sugar Modification at the 2’-Position
As an alternative sugar moiety, synthesis of a 2’-O-methyl-
6-oxoC derivative was also 
investigated, for comparison with published biophysical studies, by a different route to 
that already published.
70,71    Whilst lacking the charge-stabilising properties of the 2’-O-
aminoethyl   group,   the   2’-O-methyl   moiety   still   increases   stability   to   enzymic 
degradation in vivo.
199
492.4.1 2’-Modification via Tricyclic Anhydronucleosides
The 2’-O-phthalimidoethyl moiety of the monomer 
BAU was introduced onto the sugar 
via a six-step synthesis, before coupling to the base.
37   There is scope, however, for 
introducing 2’-O-aminoalkyl modifications on the nucleoside itself,  via  a tricyclic 
nucleoside intermediate.
There has been much published into cyclisation reactions of uridine derivatives to form 
their tricyclic anhydrouridine intermediates.   In most cases, HMPA is the chosen 
solvent,  however,  due  to  issues  of carcinogenicity,  DMA  and  DMF have been 
successfully employed, although in varying yields.
In work reported by Reese  et al.,
200,201  when uridine  131  is heated with diphenyl 
carbonate (1.1 eq) and a catalytic amount of NaHCO3 (5 mol%) in dry DMF or DMA at 
100 °C, for 4-5 hours, the tricyclic compound 2,2’-anhydrouridine 132 can be formed in 
quantitative yield (Scheme 2.14).   The reaction was executed successfully using
5-iodouridine by Dr. L. Brennan, in house, and a methyl group at the 5-position can also 
be tolerated.
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Scheme 2.14.  Cyclisation of uridine 131 to form 2,2’-anhydrouridine 132.
200,201
Manoharan et al.
42 and Ross et al..
203 describe introduction of a 2’-O-phthalimidoethyl 
group   by   the   following   method.     2-(Phthalimido)ethanol   is   converted   into   the 
trialkoxyborane, by slowly dissolving in a solution of diborane in THF, then reacted 
with 2,2’-anhydro-5-methyluridine  133  or 2,2’-anhydrouridine  132  in presence of 
NaHCO3  (cat.) in a steel bomb, at 150  °C for 24 hours or 175  °C for 72 hours. 
Following purification by column chromatography,  only ~20% yield  is achieved 
(Scheme 2.15).
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42,203
Blommers et al.
103 also reported the same coupling using Ti(O
iPr)4 instead of diborane, 
to form the titanium alkoxide in situ, forming an isotopically-labelled version of 134 in 
32% yield.
Reese  et al.
200,201  have also reported the reaction of 2-methoxyethanol with 2,2’-
anhydrouridine  132,  via  the   aluminium   alkoxide.     Refluxing   coarsely   divided 
aluminium foil in dry 2-methoxyethanol until dissolution, then reaction with the 2,2’-
anhydronucleoside 132, afforded the 2’-O-modified nucleoside after 48 hours in 91% 
yield.   This simpler, yet more effective reaction was executed in house, by Dr. L 
Brennan, to insert an N,N-dimethylaminoethoxy group in ~95% crude yield.
After testing the Ti(O
iPr)4  coupling (mentioned above), 2-(phthalimido)ethanol was 
successfully  coupled   to  DMT-protected   anhydro-5-methyl-uridine   in   ~45%  yield,
in house, via formation of the aluminium alkoxide, by heating aluminium foil in molten
2-(phthalimido)ethanol.  This, however, has yet to be repeated.
Cyclisation   of   cytidine  136  can   be   achieved  via  the   inexpensive   reagent,
2-acetoxybenzoyl chloride  137, and 2,2’-anhydrocytidine (cyclocytidine)  138  is also 
commercially available.   Reichman  et al.
204  report a 65% yield of 3’-O-acetyl-2,2’-
anhydrocytidine 139 after refluxing for 25 minutes in acetonitrile.  Deacetylation then 
afforded the desired product 138.  This method can also be applied to uridine.  Heating 
at 50 °C for 3 minutes affords the cyclised product 132.  Refluxing for 30 minutes 
affords the 2’-deoxy-2’-chloro- derivative 140 (Scheme 2.16).
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204
51It was possible that both methods of cyclisation could be employed for 6-oxocytidine 
101 and derivatives, as two carbonyl groups are available for reaction.  It was also 
feasible that two products 141,142 are possible through either reaction, although either 
product  could be used for subsequent 2’-modification.
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Scheme 2.17.  Cyclisation reaction of 6-oxocytidine 101.
The cyclisation reaction was carried out twice (Scheme 2.17), using diphenyl carbonate, 
to afford each time a 1:1 mixture of 2,2’- 141 and 6,2’-anhydro-6-oxocytidine 142 in 
quantitative yield.  The 
1H-NMR spectrum was complicated, but the sugar protons could 
be assigned and the spectrum contained two 1’-H signals corresponding to the two 
isomers.
2’-O-Methyl modification could then have been achieved by a similar method to 
Reese,
200,201 reacting 4 equivalents of Mg(OMe)2 in methanol,
205 with DMT-protected 
derivatives of 2,2’- 141 and 6,2’-anhydro-6-oxocytidine 142.  The anhydro-nucleosides 
141,142 were, however, not modified any further at this point.
2.5 Conclusion
Several synthetic investigations have been carried out, in order to assess reaction 
feasibility and subsequently to synthesise a bis-amino-modified 6-oxocytidine monomer 
64, for GC base pair recognition studies within DNA triple helices.   Palladium-
catalysed alkynylation was ruled out as a method of introduction of amine functionality 
at the 5-position due to substrate inactivity or degradation.  Instead, modification by 
amine- or thiol-halide exchange was investigated with some success.  Feasibility of 2’-
modification was also investigated, although this requires further work.
Synthesis of a bis-amino-modified 6-oxocytidine monomer is reliant on several key 
factors.  Attachment of an amine moiety to the 5-position must be achieved, either via a 
52thiol on the nucleoside or an amine on the base.  This functionality must then also be 
tolerated by sugar-base coupling, cyclisation and methoxide insertion reactions.  Due to 
the large number of steps involved, and extensive optimisation needed, unless large 
quantities of the initial intermediates can be synthesised, poor-moderate yields cannot 
be tolerated.
It is now unlikely that synthetic work on 
6-oxoC will continue.  However, should this not 
be the case, the 2’-O-methyl group is the most feasible 2’-modification.  Whichever 
route would be chosen, large quantities of some intermediates can be synthesised in 
good yield.
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543. Amino-Modified Furano-dT Nucleosides for CG Recognition
3.1 Introduction
The pyrimidine.purine base pairs CG and TA remain most difficult to target, as only 
one formal hydrogen-bond is presented for binding in the major groove.  Thymine is the 
only natural base that can effectively recognise CG, but it cannot be used for CG 
recognition due to lack of selectivity.  This discovery lead to a variety of monomers, 
including a series of modified pyrimidine-based nucleosides, designed to target the CG 
base pair, utilising new and extended Hoogsteen hydrogen-bonding patterns.
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Figure 3.1.  Pyrimidine-based CG recognition monomers.
The first generation pyrimidine-based nucleosides P
B  24  (and  
mP
B  25)
107,108  and  
4HT 
27,
105,111-114 demonstrated the importance of the C
2 carbonyl group and N
3 for effective 
binding to C of the CG base pair via a formal hydrogen-bond and a weaker C–H
…O 
interaction.
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Figure 3.2.  Proposed binding motifs for 
mP
B.CG, 
4HT.CG, 
MP.CG and 
APP.CG triplets.
The second generation nucleosides used the fluorescent bicyclic N-methylpyrrolo-dC 
core of 
MP 32, which retains the C
2 carbonyl and N
3 for binding.  An aminoalkyl group 
was introduced at the 6-position to target C
6=O and N
7 of guanine.
122  Combining the 
extended aromatic system and amine moiety was proposed to enhance binding affinity 
55by increased base-stacking and charge-stabilisation due to protonation of the amine 
group, and also selectivity due to extra hydrogen-bonding to G.  A small increase in Tm 
was obtained for 
APP 34 over T and 
MP 32, against a single CG inversion, indicating the 
pendant amino group may only contribute stability via charge-stabilisation, rather than 
through additional binding to G.
Modification of 
APP with a 2’-O-aminoalkyl-group did not enhance CG binding affinity 
as expected (through charge-stabilisation), but demonstrated some affinity for AT, 
presumed to be due to binding of an imino-isomer of the base.
61
A third generation of monomers was then developed; replacing the flexible alkyl linker 
with   a  meta-phenylene   group,   which   could   increase   the   potential   base-stacking 
interaction.
206  The new rigid linker may also have entropic benefits, and may place the 
amino group in the correct position for binding.   The new monomer  
APP  143 
(aminophenyl-) (Figure 3.1) showed a small increase in Tm over 
APP 34 (aminopropyl-) 
in UV melting studies at pH 5.8,
206 to give the following order of stability:
APP > 
APP > 
MP > T
Other modifications were also considered (
XPP), and these and alternative methods of 
synthesis/incorporation of these monomers are discussed below.
3.1.1 Monomer Nomenclature
Furano-dT monomers have been subsequently described by the abbreviation  
XPPf.
‘X’ describes the aryl functional group (-C6H4NH2  – A, -C6H4NHCOCH3  – Ac,
-C6H4NHCONH2 – U) and the subscript ‘f’, that these monomers were incorporated into 
TFOs as the furano-dT analogue and post-synthetically modified.  The 6-methyl-furano-
dT derivative 144 also carries the notation, 
MPf (Figure 3.4).
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Figure 3.3.  Commercially available 6-methyl-furano-dT (
MPf) phosphoramidite monomer 144.
The subscript ‘p’ denotes  N-methylpyrrolo-dC monomers (
XPPp), which require no 
further modification after incorporation into TFOs.   In addition to the three aryl 
moieties described by X above, it also describes the guanidinylphenyl moiety (-
C6H4NHC(N)NH2 – G).  The synthesis and biophysical studies of these are discussed in 
Chapters 5 and 6.
3.2 Synthesis of Furano-dT Monomers for CG Recognition
The first synthetic targets were modified furano-dT nucleosides.  In previous work by 
Ranasinghe et al.,
122 the modification was synthesised as the furano-dT phosphoramidite 
monomer.  
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Figure 3.4.  Furano-dT monomer structure (145-147) and 
XPP.CG triplet.
Following incorporation  into oligonucleotides, the nucleotide is post-synthetically 
modified during deprotection and cleavage from the solid support, as described in 
Section 3.3.
573.2.1 Synthesis of 6-(3-Trifluoroacetamidophenyl)-furano-dT monomer 145
206,207
The first aim was to repeat the synthesis of the  meta-trifluoroacetamido-furano-dT 
monomer  145,  first  synthesised,   in   house,   by  Sunil  Vadhia,
206  from  5’-O-(4,4’-
dimethoxytrityl)-5-iodo-2’-deoxyuridine (DMT-IdU)  97  (DMT-on method)   The key 
steps in the synthetic route to all the furano-dT monomers, are a Sonogashira cross-
coupling of an arylalkyne with DMT-IdU  97  or the ‘free’ nucleoside, 5-iodo-2’-
deoxyuridine 148, followed by a copper (I)-catalysed cyclisation reaction to form the 
furanopyrimidin-2-one nucleobase core.
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NH2
I
OH (2.5 eq), CuI (1 mol%)
distilled Et3N, 50 oC-reflux
PPh3 (3 mol%), (Ph3P)2PdCl2 (3 mol%)
151 149
150 KOH (2.0 eq), dry iPrOH
4Å molecular sieves, reflux
NH2
152
53% (61%)
39% (55%)
Scheme 3.1.   Synthesis of 3-ethynylaniline/3-aminophenyl acetylene  152, (lit.
206  yields in 
parentheses).
The arylalkyne, 3-ethynylaniline (3-aminophenyl acetylene, 3-EA) 152 was synthesised 
(Scheme 3.1), by the same route as used by Vadhia,
206 which follows a revised version 
of a method published by Melissaris et al..
208  3-Iodoaniline 149 was reacted with 2-
methyl-but-3-yn-2-ol 150 via a Sonogashira cross-coupling reaction, using the catalyst 
system, Pd(PPh3)2Cl2–PPh3–CuI (3.0:3.0:1.0 mol %), in triethylamine at 50 °C/reflux.
Triethylammonium iodide was removed during a lengthy workup with diethyl ether. 
Stirring in glacial acetic acid, concentration then addition of water, however, did not 
induce crystallisation or precipitation as described by Melissaris, and aqueous workup 
with 2M aq HCl did not remove residual starting material.  Upon repeating this reaction 
triethylammonium iodide was removed by trituration/precipitation using diethyl ether, 
and the protected alkyne 151 was isolated, following purification, in a moderate 53% 
yield.
Alkyne 151 was deprotected by refluxing in a dry solution of KOH in isopropanol for 
3.5 hours, to afford 3-EA 152 in 39% yield.  Following this work, a much cheaper 
commercial supply of 3-ethynylaniline 152 became available, and this compound was 
subsequently purchased instead.
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Scheme 3.2.   Synthetic route to 6-(3-trifluoroacetamidophenyl)-furano-dT phosphoramidite 
monomer 145, (lit.
206 yield in parentheses).
Sonogashira cross-coupling of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine  96 
(Section 3.2.2) with 3-ethynylaniline 152 was carried out under Hobbs’ conditions
124 for 
alkynylation of nucleosides (Scheme 3.2).  Larger quantities of CuI (0.4 eq) and alkyne 
(3.0 eq) were necessary for successful reaction.   Trituration with diethyl ether, to 
remove unreacted  alkyne,  and  column  chromatography  afforded the Sonogashira 
product  153  in   76%   yield.     Vadhia   conducted   this   cross-coupling   using   the 
trifluoroacetyl-protected alkyne followed by deacetylation to give the same product 153. 
The NH2 group was subsequently discovered not to affect this Sonogashira reaction and 
therefore did not need prior protection, although a slightly higher yield was obtained 
when protected.
206
Cyclisation was effected by heating at 50 °C overnight with CuI (1.0 eq) in methanolic 
triethylamine in absence of light.
121  The reaction could not be monitored by TLC, as the 
starting material 153 and product 154 had the same Rf, and on isolation, the product 
contained 3.5 mol % uncyclised material, as determined by 
1H-NMR analysis.
The aniline moiety of 154 was protected with a trifluoroacetyl group, by refluxing with 
ethyl trifluoroacetate (4 ´ 2.0 eq) and DMAP (4 ´ 1.0 eq) in THF with Et3N for greater 
than 2 days.  Despite adding triethylamine to protect against detritylation, the necessary 
prolonged heating lead to general degradation and a 35% yield.  This demonstrates the 
low reactivity of this aniline and instability to prolonged heating.  Vadhia achieved a 
moderate yield of 62% using a larger excess of ethyl trifluoroacetate.  The alkyne amine 
could have been trifluoroacetylated using trifluoroacetic anhydride, before Sonogashira 
59cross-coupling, thus avoiding selectivity/reactivity issues later on. However, it is 
doubtful that this protecting group would survive reflux in methanol/triethylamine, 
hence necessitating protection after cyclisation.
Finally, the protected, cyclised nucleoside 155 was phosphitylated at the 3’-position 
using 2-O-cyanoethyl-N,N-diisopropyl chlorophosphoramidite 70 (1.2 eq) with DIPEA 
in THF,
144  strictly under an argon atmosphere and anhydrous conditions, and using 
argon-degassed or distilled solvents at every stage of preparation thereafter (standard 
procedure for phosphitylation reactions).  The air- and acid-sensitive phosphoramidite 
monomer  155  was obtained in 64% yield after separation of a small amount of 
uncyclised phosphitylated material carried through from the cyclisation reaction.
3.2.2 Synthesis of 6-(3-Ureidophenyl)-furano-dT Monomer 146
207
The anilino-NH2  of  
APP is only able to form one hydrogen-bond to G (via  C
6=O). 
Formation of two hydrogen-bonds with G would not only increase binding affinity, but 
also selectivity for the CG base pair via this extended Hoogsteen binding.  A primary 
urea moiety was proposed as a suitable candidate for this binding motif.  Urea moieties 
have also been used to target G in NMR binding studies of isolated X.CG triplets, using 
various heterocyclic monomers (Section 1.2.2.4).
133-137  Vadhia had previously attempted 
the synthesis of the 3-ureidophenyl monomer  146  (Figure 3.3), using the DMT-off 
synthetic route, where the nucleoside is tritylated after Sonogashira cross-coupling and 
cyclisation, which proved difficult.
The arylalkyne for synthesis of this monomer, 3-ureidophenyl acetylene  156  was 
originally   synthesised   by   Vadhia,   by   heating   3-ethynylaniline  152  with   phenyl 
carbamate 157 (10.6 eq) in DMF.
206  The large quantity of phenyl carbamate used made 
purification   difficult,   hence   the   alkyne/carbamate   mixture   was   used   directly   in 
Sonogashira   cross-coupling   with   the   free   nucleoside   5-iodo-2’-deoxyuridine  148 
followed by cyclisation.  The phenyl carbamate was removed after cyclisation to give a 
43% yield over two steps.   Tritylation of the free nucleoside, however, proved 
problematic affording only a 12% yield.
206  This poor yield could be rationalised by the 
very high polarity/low solubility of the free, cyclised ureidophenyl nucleoside in the 
reaction solvent (pyridine).
60H2N
152
N
H
H2N
O NH2
O (1.1 eq)
dim light, 100 oC, dry
156
O
H2N
152
O NH2
O (10.6 eq)
anh. DMF, heat
69%
157 157
Scheme 3.3.  Syntheses of 3-ureidophenyl acetylene 156.
Conducting the carbamidation in a sealed tube, excluding moisture, without solvent, 
allowed for use of only a slight excess of phenyl carbamate, and the pure product 156 
could be isolated by column chromatography (Scheme 3.3).  The reaction was carried 
out several times at 80-100 °C, using no more than 1.1 eq of phenyl carbamate to ensure 
adequate mixing of components, however, the yield was limited to a maximum of ~70% 
due to oxidation of the starting material during the reaction.
Alternatively, reaction with benzoyl isocyanate and deprotection may have afforded the 
product 156 in higher yield (Section 5.2.5).  Using the benzoyl-protected urea in the 
Sonogashira cross-coupling would be a further improvement.  The benzoyl group would 
not only reduce the polarity of the subsequent products thus aiding purification, but 
would also block phosphitylation of the urea thereby increasing the potential yield for 
this reaction.  Additionally, the benzoyl group can be removed during oligonucleotide 
deprotection using ammonia, as was demonstrated, in house, by Dr. Edrees-Abdou in 
synthesis of the 3-thioureidophenyl-N-methylpyrrolo-dC analogue 158 (Section 5.2.5).
Prior to Sonogashira cross-coupling, a large quantity of 5’-O-(4,4’-dimethoxytrityl)-5-
iodo-2’-deoxyuridine
209  97  was synthesised by reaction of a slight excess of 4,4’-
dimethoxytrityl chloride (DMTCl) 112 with 5-iodo-2’-deoxyuridine 148 (25 g) in 76% 
yield (Scheme 3.4).   Yields varied from 95-75% on a 5-25 g scale, and some  bis-
tritylated compound was usually formed as the reaction is not fully regioselective.  The 
alkyne 156 was coupled to 97 (DMT-on method) in 80% yield, an 89% yield being 
obtained on a smaller scale, when triethylammonium iodide could be removed by 
soaking in acetonitrile.
Initially, the product was cyclised by heating at 60 °C overnight.  Only 50% conversion 
was observed, but extra CuI and raising the temperature to 80 °C pushed the reaction to 
completion, affording only a 39% yield due to significant degradation.  A higher yield 
may also have been attained using column chromatography instead of recrystallisation. 
Heating at 80 °C under argon pressure for only 2-3½ hours afforded a 69% yield.
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Scheme 3.4.  Synthetic route to 6-(3-ureidophenyl)-furano-dT phosphoramidite monomer 146.
Phosphitylation was pushed to ~90% completion using 2  ´  1.2 eq of the chloro-
phosphitylating agent  70.   Some of the phosphoramidite co-eluted with the starting 
material thus reducing the yield slightly further, and some material was lost during 
precipitation.  The phosphoramidite was precipitated after chromatography from CH2Cl2 
into hexane, to remove remaining hydrolysed reagent (difficult to visualise by TLC), 
and triethylamine, which would adversely affect subsequent DNA synthesis.  A minor 
nucleoside-based impurity was also detected after reaction, which was removed during 
purification, presumed later to be due to further phosphitylation of the primary urea in 
presence of excess reagent.  Product 146 was finally afforded in 69% yield, containing 
negligible impurities.
3.2.3 Synthesis of 6-(3-Acetamidophenyl)-furano-dT Monomer 147
207
The third target, a 3-acetamidophenyl-modified furano-dT phosphoramidite  147 was 
proposed as an alternative to the urea.  Although the acetamide can form only one 
hydrogen-bond with G (c.f. 
APP), the amide NH is more acidic than the aniline NH, and 
may potentially form a stronger H-bond thereby increasing binding affinity.
The arylalkyne for this synthesis, 3-acetamidophenyl acetylene 161, was synthesised in 
94% yield from 3-ethynylaniline 152 following a similar method to that published by 
Kabalka  et al.
210  for synthesis of  o-iodoacetanilide.   The product was purified by 
trituration with water as described by Arnold et al.,
211 (who prepared 161 using acetic 
anhydride and acetic acid), followed by aqueous extraction.  Using only 0.15 eq Et3N on 
62a 1.8 mmol scale, reduced the yield by 11%, and when repeated on an 18 mmol scale, 
un-neutralised HCl caused degradation to afford a 43% yield, reduced to 38% after 
recrystallisation (chloroform/hexane) (Scheme 3.5).
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Scheme 3.5.  Synthesis of 3-acetamidophenyl acetylene 161.
Sonogashira cross-coupling proceeded to completion using alkyne 161, but the product 
162 proved difficult to separate from a close-running unknown impurity, affording a 
final yield of 75%.   Cyclisation and phosphitylation under the same conditions as 
previously   described   afforded   the   cyclised   nucleoside  163  then   phosphoramidite 
monomer 147 in 89% and 69% yields respectively.  The phosphitylation was not pushed 
to completion with extra reagent beyond ~80%, as the hydrolysed reagent can prove 
difficult to fully remove after purification (Scheme 3.6).
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Scheme 3.6.  Synthetic route to 6-(3-acetamidophenyl)-furano-dT phosphoramidite monomer 
147.
3.3 Post-Synthetic Conversion of Furano-dT to N-Methylpyrrolo-dC
The three furano-dT phosphoramidite monomers  145-147  were incorporated into 
triplex-forming oligonucleotides (TFOs) for triplex melting studies, by the automated 
DNA synthesis method on solid-support (CPG), as detailed in Section 9.2.
63Following DNA synthesis, the oligonucleotides were deprotected and cleaved from the 
solid-support using 30 wt % aqueous methylamine at room temperature for 6-24 hours 
(Scheme 3.7).
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Scheme 3.7.  General deprotection/cleavage of oligonucleotides highlighting key groups.
Methylamine, in addition to deprotection and resin-cleavage, ring-opens the furano-dT 
nucleobase   to   form   a   5-aroylmethyl-N-methyl-dC   derivative.     The   methylamine 
insertion reaction occurred quantitatively in 6 hours, although some TFOs were allowed 
to deprotect overnight or longer to ensure complete reaction (Scheme 3.8).
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Scheme 3.8.  Post-synthetic conversion of furano-dT to N-methylpyrrolo-dC in oligonucleotide.
After   removal   and   washing   of   the   resin,   the   remaining   aqueous   solution   was 
concentrated in vacuo at 50-60 °C and the residue was re-dissolved in distilled water (1 
mL).  The oligonucleotide was then treated with DOWEX 50WX8 sulfonic acid resin 
(200/400 mesh, H
+-form), at room temperature for 18-36 hours, to recyclise the keto-N-
methyl-dC nucleotide to form the desired N-methylpyrrolo-dC derivative (Scheme 3.8).
Initially, oligonucleotides were HPLC-purified before acid-catalysed (DOWEX 50) 
cyclisation and analysed by MALDI-TOF to check extent of reaction (acidic matrix for 
MALDI can cause limited additional cyclisation).   Once the methylamine insertion 
reaction was determined to be quantitative, oligonucleotides were treated with DOWEX 
resin straightaway after deprotection/insertion as described above.
64After treatment with DOWEX, the resin was removed by filtration, washed with water 
and the oligonucleotide solution was concentrated  in vacuo  and desalted (Sephadex 
NAP™ column).  The post-synthetically modified oligonucleotides were analysed by 
analytical HPLC, capillary gel electrophoresis (CE) (Section 7.3.1), MALDI-TOF and 
electrospray MS (negative mode).  Unfortunately, the acid-catalysed re-cyclisation was 
not quantitative, only proceeding to 50-80% completion.
The desired cyclised TFO could be isolated by HPLC for oligonucleotides to be used in 
UV melting studies (Section 4.1).  However, HPLC could not resolve TFOs used for 
fluorescence melting studies.  These TFOs are labelled with a large, lipophilic quencher 
molecule (DABCYL), which dominates in the HPLC chromatogram thus reducing 
resolution.  The two components were resolved by CE, but cannot be purified by this 
method   hence   were   used   in   fluorescence   melting   studies   as   a   mixture.     The 
uncyclised/ring-opened modification, as a C analogue, could potentially bind to GC not 
CG as desired.
The standard method for deprotection/cleavage of oligonucleotides is treatment with 
conc. aqueous ammonia at room temperature or 55 °C for several hours.  If these TFOs 
were treated in this way, ammonia would ring-open the furano-dT modification.  The 
ammonia-insertion   product   spontaneously   recyclises   to   form   the   NH-pyrrolo-dC 
derivative, which as a C analogue, could bind preferentially with GC.  The N-methyl 
group, however, prevents the methylamine ring-opened nucleotide from cyclising 
spontaneously, necessitating acid catalysis.  This is presumably due in part to steric bulk 
of the methyl group.
The post-synthetic conversion of these modifications,  although not ideal due to 
incomplete   cyclisation,   afforded   TFOs   that   were   successfully   used   in   UV   and 
fluorescence melting studies.   The results from these are discussed in Chapter 4. 
Further discussion of oligonucleotide deprotection conditions are given in the study, 
detailed in Chapter 7.
653.4 Synthesis of 5-(3-aminoprop-1-ynyl)-dU (pdU) monomer 164
39,117
Prior to melting studies, approximately 5 g of 5-(3-aminoprop-1-ynyl)-dU (pdU) 
phosphoramidite monomer 164 was synthesised.  5’-O-(4,4’-Dimethoxytrityl)-5-iodo-
2’-deoxyuridine  97  and  N-trifluoroacetyl  propargylamine  68  were coupled   under 
Sonogashira Pd-catalysed cross-coupling conditions in two 10 g scale reactions, to 
afford, after combined purification, the alkynyl-nucleoside product 165 in 80% yield 
(16.6 g).  Following phosphitylation of 5 g of 165 using the chloro-phosphitylating 
reagent 70, under standard conditions, the phosphoramidite monomer 164 was afforded 
in 84% yield (43 bottles for oligonucleotide synthesis).
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Scheme 3.9.  Synthesis of 5-(3-aminoprop-1-ynyl)-dU (pdU) phosphoramidite monomer 164.
This phosphoramidite monomer 164 was used for synthesis of TFOs for melting studies 
(Chapter 4).
3.5 Conclusion
Three furano-dT phosphoramidite monomers 145-147 were synthesised for assessment 
as monomers for recognition of the CG base pair within a DNA triple helix motif.  The 
common synthetic route (Sonogashira cross-coupling, Cu(I)-catalysed cyclisation and 
phosphitylation) was successful for each monomer, affording moderate to very good 
yields for almost every step.
Two main issues were encountered during synthesis.   The high polarity of the 
substrates, once cyclised, introduced problems in purification, even when tritylated. 
Removal   of   close-running   impurities   and   starting   material   also   presented   minor 
difficulties.  In addition, the cyclised nucleosides demonstrated significantly reduced 
66reactivity at the 3’-OH and aniline NH2.  This presented problems in trifluoroacetylation 
and necessitated forcing the phosphitylation to completion with extra reagent, which is 
not ideal.  However, all monomers were synthesised in high purity and incorporated into 
TFOs with high coupling efficiency (as determined by trityl cation conductivity 
monitoring – see Section 9.2.1) for triplex melting studies (Chapter 4).
67Chapter 4
Biophysical Studies of Furano-dT 
Modified TFOs for CG Recognition
684. Biophysical Studies of Furano-dT Modified TFOs for CG Recognition
The three modified furano-dT phosphoramidite monomers (
APPf 145, 
AcPPf 146, 
UPPf 
147)   and   commercially   available   6-methyl-furano-dT  
MPf  monomer  144  were 
incorporated into unlabelled/labelled TFOs for UV and fluorescence melting studies. 
These studies were designed to test binding affinity for CG and selectivity against the 
other base pairs (GC, AT, TA) at several pHs.   These properties are assessed by 
determining triplex melting temperatures from graphs of, change in UV absorption or 
fluorescence emission of fluorophore label respectively, on triplex melting, for different 
sequences, in several buffer conditions.  After incorporation, the modification was post-
synthetically converted in the oligonucleotide from a furano-dT to an N-methylpyrrolo-
dC nucleotide.  The procedure for this transformation is described in Section 3.3.
4.1 UV Melting Studies
Methyl- (144, 
MPf), trifluoroacetamidophenyl- (145, 
APPf) and ureidophenyl- (147, 
UPPf) 
furano-dT phosphoramidite monomers were incorporated into TFOs (OL3-5) to assess 
binding affinity for a single CG inversion in a homopurine tract, in the parallel motif.  A 
schematic representation of the UV melting triplex, used originally by Leumann et al.
111 
is shown in Figure 4.1.
         5’-TTT TTM TXT MTM TMT
     5’-GCT AAA AAG ACA GAG AGA TCG
        CGA TTT TTC TGT CTC TCT AGC-5’
Figure 4.1.  UV triplex melting experiment.  TFO shown in bold.  M = 
5-MedC, X = 
MP (OL3), 
APP (OL4), 
UPP (OL5), purine duplex strand (C, OL1), pyrimidine duplex strand (G, OL2).
UV melting experiments were performed, (as described in detail in Section 9.2), on a 
Varian Cary 400 Scan UV-Vis spectrophotometer monitoring at 260 nm.  A 5:1 ratio of 
TFO:duplex (5:1 mM) was used.  Experiments were conducted at pH 6.07 and pH 6.40 
(10 mM sodium phosphate, 200 mM NaCl, 1 mM Na2EDTA).   A standard melt 
programme was used (Programmes 1/2: 10-50-80  °C at 0.5  °C/min) with 3 or 4 
heat/anneal cycles in total (Section 9.2).  Condensation was not a major problem at low 
temperature, affecting only the first heat/anneal cycle, hence purging the sample 
69chamber with argon was not necessary.  Disodium EDTA is used to scavenge divalent 
cations (e.g. Mg
2+), which cause general triplex stabilisation.
The results (obtained over six experiments) indicated  
APP demonstrates  enhanced 
binding affinity to CG compared to 
MP (DTm +4.0 °C/+4.5 °C at pH 6.07/6.40) (Table 
4.1).     This   represents   a   significant   improvement   over  
MP,   which   Ranasinghe
et al.
122 demonstrated to perform better than T, using the same triplex motif, at pH 7.0 in 
10 mM sodium cacodylate buffer (with 200 mM NaCl, 0.25 mM spermine) (Table 4.1).
pH
Tm / °C, melt/anneal
MP (6 runs)
APP (4 runs)
UPP (1 run)
6.07 31.6/23.1, (62.7) 35.6/29.3, (63.5) 32.2/23.0, (62.3)
6.40 24.5/n.d., (63.0) 29.0/23.6, (63.7) 25.6/19.3, (62.7)
Table 4.1.   UV triplex melting experiment: 
XPPf against CG at pH 6.07 and 6.40 (10 mM 
sodium phosphate, 200 mM NaCl, 1 mM Na2EDTA) using UV melting programme No. 1 
(Section 9.2).   Average  Tm  values given in  °C for TFO melt/anneal and for duplex in 
parentheses (average of melt and anneal Tm).  n.d. = not determined (Tm < 17 °C).
The 
UPP TFO (OL5), however, demonstrated reduced affinity compared to 
APP, yet 
performed better than the control 
MP, by +0.6 °C and +1.1 °C, at pH 6.07 and pH 6.40 
respectively.  The MALDI-TOF analysis of OL5 showed the molecular ion to be 42 Da 
higher than expected, indicating the oligonucleotide may have acetylated during the 
capping step of oligonucleotide synthesis (found m/z 4697.2, expected 4656.2 [M + H]
+).  It was presumed that acetylation had occurred on the primary urea, thereby reducing 
the Tm due to increased steric bulk directed into the side of the major groove.  The urea 
was expected to perform better than the aniline, as it has the potential to form two 
hydrogen-bonds with G instead of one; the NHs would also be more acidic lending to 
formation of stronger hydrogen-bonds.
In further UV melting studies (Section 6.1), in which TFOs were synthesised without 
capping, the same order of binding affinity and similar  DTms were observed.   It is 
unlikely therefore that the urea was acetylated, although when synthesised without 
capping, no peak for [M + 43]
+ was observed.  Acetylation may have occurred on the
4-N position of one of the 5-methyl-dC nucleotides, but this cannot be confirmed.
70Significant hysteresis  was observed for the melting  temperature using this melt 
programme, with DTm values between 5.4 and 9.2 °C.  This could be decreased by 
reducing the rate of heating/cooling.  The duplex hysteresis was within experimental 
error, at less than 0.5 °C.
A graph displaying melting curves and their derivatives for 
APP (OL4) at pH 6.07, is 
shown in Figure 4.2 below.  The hysteresis between melting and annealing curves is 
clearly visible.
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These initial studies indicated that the 3-aminophenyl moiety significantly enhanced 
binding affinity over a methyl group.  The urea moiety, unexpectedly demonstrated 
poorer binding than the amine.  This result necessitated further UV melting and other 
studies for confirmation and to test other analogues.  
4.2. Fluorescence Melting Studies
Fluorescence melting studies were conducted to assess binding affinity and selectivity, 
and the sequence-dependency of these recognition properties.   Fluorescence melting 
71measures change in fluorescence due separation of fluorophore and fluorescence 
quencher moieties on duplex and TFO respectively, on triplex melting.
4.2.1 Binding Affinity/Selectivity study
Methyl- (144, 
MPf), trifluoroacetamidophenyl- (145, 
APPf), acetamidophenyl (147, 
AcPPf) 
and ureidophenyl- (146, 
UPPf) furano-dT phosphoramidite monomers were incorporated 
into labelled TFOs for initial fluorescence melting studies.  The target was a single CG 
inversion in a homopurine tract of a hairpin duplex, in the parallel motif.  The initial 
triplex motif is represented below in Figure 4.3.  
                 5’-Q-PMM TPM TXP TPT PTM PT
          5’-F-GT GTT AGG AAG AYA AAA AAG AAC TGG T-H
               CA CAA TCC TTC TZT TTT TTC TTG ACC A-H
Figure 4.3.   Fluorescence triplex melting experiment.   TFO shown in bold. (M  =  
5-MedC,
P  = 5-(3-aminoprop-1-ynyl)-dU (pdU),   X  =  
MP  (OL10),  
APP (OL11),  
AcPP (OL12),  
UPP 
(OL13), Q = DABCYL (quencher), F = FAM (fluorophore), H = HEG (hexaethylene glycol), 
hairpin duplex YZ = CG (OL6), GC (OL7), AT (OL8), TA (OL9).
Fluorescence melting studies were conducted (as described in detail in Section 9.2), on 
a Roche LightCycler
®.  Initial experiments were performed at pH 6.0 (20 mM NaOAc, 
200 mM NaCl), and a 10:1 ratio of TFO:duplex (5:0.5 mM) was used.  Runs in these 
experiments were performed up to three times in duplicate, using LC Programme 1 (95-
30-95 °C at 0.2 °C/min, see Section 9.2) (Table 4.2).  These sequences were used for 
fluorescence melting only.
There is a stark contrast between some of these results and the previous UV melting 
study.  Whereas 
APP previously demonstrated a significantly higher Tm than 
MP against 
CG (DTm +4.0-4.5 °C), these results place the Tm of 
APP, 1.2 °C lower than 
MP.  This 
observation could not be easily explained, although the buffer and sequence had been 
changed.   Despite these observations, the urea (
UPP) showed the strongest binding 
affinity towards CG as originally expected and the order of stability (
UPP>
AcPP»
APP), 
excluding 
MP, correlates with the predicted hydrogen-bonding motif.
72X
bp
Tm / °C, melt/anneal
MP
APP
AcPP
UPP
CG 53.1/50.6 51.9/47.9 52.0/47.0 53.9/50.0
GC 40.7/40.3, (67.0) 38.0/36.3, (51.3) 38.8/n.d., (52.5) 39.8/38.1, (53.0)
AT 40.4/38.2 40.3/38.0 40.6/38.0 42.4/40.1
TA 40.1/38.7 42.3/39.7 44.7/40.6 44.6/41.4
Table 4.2.  Fluorescence triplex melting experiment: 
XPPf against all four base pairs at pH 6.0 
(20 mM NaOAc, 200 mM NaCl) using LC Programme 1 (Section 9.2).  Average Tm values 
given in °C for TFO melt/anneal and for secondary melt transition in parentheses.  n.d. = not 
determined (Tm < 36 °C), bp = base pair target.
All monomers demonstrated good selectivity for CG over GC, AT and TA.  
UPP was 
most selective against GC (DTm +14.2 °C) and 
MP proved most selective against AT and 
TA (DTm +12.7 °C, +13.0 °C).  Selectivity for CG over TA is most difficult to achieve 
as both present only one formal hydrogen-bond for binding.   Therefore, achieving 
selectivity against TA is an important criterion in choosing a monomer for CG 
recognition.  However, even the poorest selectivity (
AcPP vs TA, DTm +7.3 °C) is still 
satisfactory.
Hysteresis of 0.42-4.97 °C was observed (average 2.66 °C), despite using a low heating/
cooling rate of 0.2 °C/min (total run time - 12.5 hours).  Hysteresis could once more 
have been reduced by reducing the rate further.  However, this would necessitate a run 
time in excess of 20 hours, which might cause problems due to degradation/evaporation 
of sample.  Tms differed by no more than 1.2 °C.
The  
APPf  modification   was   evaluated   previously   by   Dr.   Powers   in   a   different 
fluorescence melting triplex motif, at lower pH and a higher buffer concentration.  It 
was shown to be selective for CG, although the order of selectivity over the other base 
pairs was different from that detected here.
61  
A biphasic melting profile was also observed, against GC, but not the other base pairs or 
indeed in annealing against any base pair.   The presence of the weaker, secondary 
transition can be rationalised by the proportion of monomer (20-40%), which was not 
re-cyclised during treatment of TFO with DOWEX-H
+ resin.  This C-analogue could, as 
73previously mentioned (Section 3.3) form a triplet with GC, affording a higher Tm than 
expected, for a triplex that should contain a disfavourable X.GC triplet (Figure 4.4).
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The observed secondary  Tm  value against GC should be similar to that against CG
(~52 °C) as was observed for 
APP, 
AcPP and 
UPP.  However, the value is significantly 
higher for 
MP (67.0 °C), which is difficult to rationalise.  Replacing the aryl group for a 
methyl group should reduce the potential for beneficial interactions within the triple 
helix,   unless   the   aryl   group   in   fact   confers   disfavourable   steric/hydrophobic 
interactions.  Furthermore, comparing with the many modifications that have been made 
to the 5-position of C-derivatives for achieving GC recognition (Section 1.2.1.2), it is 
highly unlikely that the 5-(acetylmethyl)- group of uncyclised/ring-opened  
MPf  is 
stabilising enough to account for this Tm.  Other secondary structures and interactions 
may also be contributing factors.
4.2.2 Sequence study
The two possible explanations for reversal in the order of stability of  
MP and  
APP 
between the initial UV and fluorescence melting studies were a change in buffer/pH, 
and changing the sequence.   It was hypothesised, that altering the neighbouring 
nucleosides to the modification under examination within the TFO may affect binding 
affinities and selectivity.
New TFOs were therefore synthesised, containing the central trimers, TXT (OL14), 
PXT (OL15) and PXP (OL16) (X = 
APPf, P = pdU) to compare with the TXP-containing 
TFO (OL11) already investigated.  It was thought that presence of pdU next to the 
XPP 
74modification   may   change   binding   affinity/selectivity   or   mask   the   effects   of   the 
modification, and may account for the differences between the two methods.
                 5’-Q-PMM TPM VXW TPT PTM PT
          5’-F-GT GTT AGG AAG ACA AAA AAG AAC TGG T-H
               CA CAA TCC TTC TGT TTT TTC TTG ACC A-H
Figure 4.5.   Fluorescence triplex melting experiment.   TFO shown in bold. (M  =  
5-MedC,
P = 5-(3-aminoprop-1-ynyl)-dU (pdU), X = 
APP & VXW = TXT (OL14), PXT (OL15), TXP 
(OL11), PXP (OL16);  VXW  = TXP &  X  =  
MP (OL10),  
AcPP (OL12),  
UPP (OL13),  Q  = 
DABCYL (quencher); F = FAM (fluorophore), H = HEG (hexaethylene glycol), hairpin duplex 
(CG, OL6).
The initial fluorescence melting experiments (Figure 4.5) were repeated using LC 
Programmes 1 and 2 (95-30-95 °C at 0.2 °C/min) at pH 6.2 (10 mM sodium phosphate, 
200 mM NaCl).  Experiments were run once or twice in triplicate and a 10:1 ratio of 
TFO:duplex (5:0.5 mM) was used as before.  The aims of these experiments were not 
only to obtain confirmation of previous results, but to investigate how the change of 
sequence described above affects binding, and for comparison between analogous 
furano-dT (
XPPf) and N-methylpyrrolo-dC (
XPPp) modified TFOs (see Section 6.1 for 
results from 
XPPp-modified TFOs).
X
Seq.
Tm / °C, melt/anneal
MP
APP
AcPP
UPP
TXT – 43.2/39.1 * *
PXT – 49.3/43.1 * *
TXP 49.7/43.7 49.9/43.0 48.4/43.0 51.0/45.0
PXP – 53.6/49.0 * *
Table 4.3.   Fluorescence triplex melting experiment: 
XPPf against CG in four TFOs (OL14, 
OL15, OL11, OL16) at pH 6.2 (10 mM sodium phosphate, 200 mM NaCl) using LC 
Programme 1 and 2 (Section 9.2).   Average  Tm  values given in  °C for TFO melt/anneal.
* Data obtained for 
XPPp-modified TFOs is not shown (Section 6.2).
Hysteresis was much greater than previously observed (4.08-6.91 °C, average 5.61 °C) 
and annealing data was of poorer quality than in previous experiments.  However, the 
melting data was clear and Tm values differed by no more than 1.0 °C.
75These experiments confirm that the urea (
UPP) has the highest binding affinity in the 
TXP-containing TFO.  
MP and 
APP appear as effective as each other and slightly better 
than the acetamide (
AcPP), although experimental error may account for variation as the 
difference in Tm values is small.
When T is replaced by pdU, the Tm increases because pdU forms additional charge-
stabilising interactions with the sugar-phosphate backbone (Section 1.2.1.1).   In the 
APP-modified series of TFOs, as for any modification, for each substitution the  Tm 
would be expected to increase by the same amount, and Tm should be equal for the TXP- 
and PXT-containing TFOs (OL11, OL15) as only the order is changed.  However, the 
Tm for TXP (OL11) is 0.6 °C higher than PXT (OL15).  Also the increase in Tm from 
TXT to TXP is greater than for PXT to PXP.  
These observations  indicate  that placing  pdU on the 5’-side of  
XPP is slightly 
destabilising compared to the 3’-side.  It is reasonable therefore, to suggest there may be 
interaction between the 3-aminoprop-1-ynyl group of pdU and the anilino group of 
APP, 
slightly affecting recognition of CG.   This difference was most significant for  
UPP 
(
XPPp-modified TFO, see Section 6.2) with a DTm value of 3.0 °C.  It is also reasonable 
to suggest that due to this destabilisation, replacing the second T with pdU has less 
stabilising effect than expected.
Finally,   data   for  
AcPP   and  
UPP   confirmed   that   the  Tms   for   furano-dT   and  N-
methylpyrrolo-dC modified TFOs were approximately the same, only differing by 0.7 
and 0.1 °C respectively.  These results led into a large study, using N-methylpyrrolo-dC 
monomers, the results of which are discussed in Chapter 6.
4.3 Fluorescence Melting Mismatch Experiment
Experiments were conducted to test if triplex-mediated recognition of a base pair 
mismatch can occur using the 
XPPf modifications tested above.  This may also provide 
information on binding motif of the X.CG triplet.  All four modifications were assessed 
against a hairpin duplex containing a CC mismatch.   Fluorescence melting was 
conducted using LC Programme 4 (95-30-95 °C at 0.25 and 0.2 °C/min) at pH 6.0 (20 
76mM NaOAc, 200 mM NaCl).  Experiments were run once in duplicate and a 10:1 ratio 
of TFO:duplex (5:0.5 mM) was used as before (Table 4.4).
                 5’-Q-PMM TPM TXP TPT PTM PT
          5’-F-GT GTT AGG AAG ACA AAA AAG AAC TGG T-H
               CA CAA TCC TTC TCT TTT TTC TTG ACC A-H
Figure 4.6.   Fluorescence triplex melting mismatch experiment.  TFO shown in bold. (M =
5-MedC, P = 5-(3-aminoprop-1-ynyl)-dU (pdU), X = 
MP (OL10), 
APP (OL11), 
AcPP (OL12), 
UPP 
(OL13), Q = DABCYL (quencher), F = FAM (fluorophore), H = HEG (hexaethylene glycol), 
mismatched hairpin duplex (CC, OL17).
These results show a drop in  Tm  of 4.5  °C for  
MP when CG is replaced by a CC 
mismatch.  This is expected as even though 
MP is proposed to hydrogen-bond only to 
one C of the CC base pair as is the case for CG, distortions due to the CC mismatch 
would cause destabilisation of the triplex as well.
Tm / °C, melt/anneal
MP.CG
MP.CC
APP.CC
AcPP.CC
UPP.CC
53.1/50.8 48.6/47.1 48.9/45.9 49.3/46.2 50.0/48.4
Table 4.4.   Fluorescence triplex melting mismatch experiment:  
XPPf  against CC mismatch 
hairpin duplex (OL17) at pH 6.0 (20 mM NaOAc, 200 mM NaCl) using LC Programme 4 
(Section 9.2).  Average  Tm values given in  °C for TFO melt/anneal. 
MP.CG data from this 
experiment is shown for comparison.
The CC mismatch also reduces the duplex melting temperature by ~8 °C compared to 
that of the CG hairpin duplex.  In addition, the derivative curve is markedly different to 
the duplexes containing matched base pairs, as it curves towards an apparent melting 
transition (~74 °C) just below duplex melting.  It is possible that other structures may be 
present, or that this is an unexplained feature of the melting profile of a mismatch-
containing hairpin duplex, the latter of which appears more likely.
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Melting temperatures for all modifications were very similar; the urea performing 
marginally better than the rest.  This is consistent with the proposed binding model, in 
which differentiation between modifications is achieved through additional hydrogen-
bonds to G of the CG base pair.  Altering the hydrogen-bond pattern, in conjunction 
with triplex distortion due to the mismatch, reduces these differences.
4.4 Conclusion
All   melting   studies   demonstrated   the   effectiveness   of   the  
XPP   modifications   at 
recognising CG with similar or better binding affinity/selectivity than 
MP, which itself is 
a large improvement on T.
122  Although it was unknown why order of stability differed 
between UV and fluorescence melting studies, this was investigated in further studies 
(Chapter 6).   At this stage it was presumed to be caused by change in sequence 
(particularly of neighbouring nucleotides), buffer and pH, but this was/could not be 
confirmed.
The significant effect of neighbouring groups on the modification under investigation, 
was also identified.  Results indicated that the modified nucleoside 5-(3-aminoprop-1-
ynyl)-dU  14  (pdU, P), interacts differently with  
XPP depending on which side it is 
located, giving rise to a difference in  Tm.   This neighbouring group interaction 
introduces   important   implications   for   design   of   TFOs,   particularly   for   use   as 
78oligotherapeutics.   Understanding the interactions between modified nucleosides is 
vital, so that negative interactions can be minimised.
Melting experiments were also conducted against a CC mismatch in the same hairpin 
duplex motif.  It was demonstrated that differences in Tms between TFOs is reduced as 
key hydrogen-bonding residues are removed when G is replaced with C.  The reduction 
in overall duplex and triplex Tm is expected, due to the CC mismatch.
It would also be useful to test the CT and CA mismatches to identify if any 
differentiation could be made between modifications.   Both CT and CA contain 
potential hydrogen-bonding acceptors on T and A, therefore some differentiation or 
stabilisation may be observed.
Assessing recognition of common base pair mismatches/mutations could also provide 
valuable information when designing TFOs for therapeutic use.  Depending on location 
of mismatches and on which strand the mutation is located, it may be possible to bind to 
both desired and undesired sequences.  As binding primarily occurs to one side of the 
base pair, only mutations to the other base should be tolerated.
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805. Amine-Modified N-Methylpyrrolo-dC Nucleosides for CG Recognition
5.1 Introduction
In previous studies (Sections 3-4), N-methylpyrrolo-dC modifications were incorporated 
into TFOs as the furano-dT analogues then post-synthetically converted.  Although the 
methylamine-insertion reaction was quantitative for each oligonucleotide, the acid-
catalysed cyclisation reaction using acidic DOWEX 50WX8 ion-exchange resin, to 
reform the bicyclic core, did not proceed to completion.  The major problem with this 
method, in addition to reduced yield of TFO, is difficulty in purification when labeled 
with DABCYL.  For this reason, TFOs for fluorescence melting studies were used as 
the inseparable mixture containing approx. 20-40% uncyclised modification.  This did 
not affect recognition of the CG base pair, although the concentration of correct TFO 
was lowered as a result.  However, in fluorescence melting studies against GC, a second 
minor melting transition was observed at a similar or substantially higher temperature 
than against CG.  This was proposed to be due to the small proportion of the uncyclised 
modification, which, as a C-analogue, exhibits GC recognition properties (also Sections 
4.2 and 6.2).   The very high temperature of one of these transitions could not be 
rationalised, however, unless the ring-opened modification is exceptionally strong at 
binding, which is very unlikely.
To overcome this problem, it was proposed, in house, to synthesise monomers as the N-
methylpyrrolo-dC   derivatives.     Assuming   this   bicyclic   structure   was   stable   to 
deprotection conditions (i.e. could not be ring-opened by NH3 or MeNH2, in aqueous 
solution), no post-synthetic modification would be required.  Ranasinghe synthesised, in 
house, the protected 6-aminoethyl and 6-aminopropyl- monomers  166,167  as the
N-methylpyrrolo-dC derivatives (
AEPp and 
APPp), via methylamine insertion and acid-
catalysed cyclisation, on the untritylated furano-dT nucleosides (c.f.  post-synthetic 
modification of TFO – Section 3.3) (Scheme 5.1).  
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Scheme 5.1.  Synthesis of 
AEPp and 
APPp N-methylpyrrolo-dC monomers 166,167 via furano-dT 
intermediates (in house).
Vadhia also applied this method for synthesis of the 6-(3-trifluoroacetamidophenyl)- 
178  and 6-(3-ureidophenyl)-N-methylpyrrolo-dC monomers  179  (
APPp,  
UPPp).   The 
trifluoroacetamido monomer 
APPp, was synthesised with two low yielding steps, but the 
ureido monomer 
UPPp could not be synthesised.  Poor substrate solubility was the most 
likely cause.
Although this route was successful for one monomer, the route needed to be robust; 
applicable to synthesis of all derivatives required for biophysical studies.  The method 
therefore, went through optimisation to afford a general synthetic route applicable to all 
desired analogues (Section 5.2).
5.1.1 Synthesis of 6-(3-Ureidophenyl)-N-methylpyrrolo-dC monomer 179
The first target was the ureido-modified monomer 179, which should exhibit favourable 
hydrogen-bonding interaction with G of the CG base pair, in addition to the binding 
motif previously described.   The urea moiety increases substrate polarity, which 
affected purification of the corresponding furano-dT monomer 146 and intermediates, 
therefore this modification was deemed ideal for testing this synthetic route.
825.1.1.1    Synthesis via untritylated furano-dT derivative
The first method closely followed the synthetic routes used by Ranasinghe
122  and 
Vadhia.
206  This route proceeds via the ‘free’ (unprotected) furano-dT nucleoside 180, 
which was synthesised  via  the Sonogashira and cyclisation reactions discussed in 
Section 3.2.2.
Following Cu(I)-catalysed cyclisation, Ranasinghe and Vadhia ring-opened the ‘free’ 
nucleoside 180 with 33% ethanolic methylamine, before acid-catalysed re-cyclisation. 
Ranasinghe   also,   successfully   ring-closed   a   6-butyl-derivative,   by   refluxing   in 
acetonitrile with 1 mol% toluene-sulfonic acid, to obtain an 88% yield over these two 
steps.  Vadhia used 80% aqueous acetic acid, at 80 °C to afford the re-cyclised aniline-
derivative 143 in 21% yield.  Subsequent tritylation proceeded with difficulty in 9% 
yield.  In both methods the acid was difficult to remove, and for the latter case, acetic 
acid may have also affected column purification and certainly tritylation, although poor 
to moderate solubility of the product 143 may also have played a role.  Vadhia could not 
re-cyclise the ureido-derivative using acetic acid, most likely due to poor solubility.
In an attempt optimise this route, the above synthesis was first repeated (Scheme 5.2). 
5-Iodo-2’-deoxyuridine 148 was coupled three times with 3-ureidophenyl acetylene 156 
via the previously described Sonogashira reaction, finally yielding a ~1:1 mixture of 
cyclised 180 and uncyclised nucleoside 181, containing some alkyne dimer.
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Scheme 5.2.  First route to 
UPPp monomer 179.
83The   product   mixture  180,181  was   refluxed   with   CuI   in   dry   methanol   and 
triethylamine.
121  However, the mixture was poorly soluble, even at 80 °C under argon 
pressure, and NMR analysis of the crude material confirmed no change had occurred 
from the 1:1 mixture.
Addition of DMF solubilised the substrate, but failed to illicit cyclisation, even at 90 °C. 
Tritylation of the nucleoside mixture was also problematic due to poor solubility in 
pyridine.  Excess DMTCl and some heating were necessary to afford some reaction, but 
a mixture of mono- and bis-DMT nucleosides was afforded.
It was noted that leaving the Sonogashira cross-coupling reaction for longer may have 
resulted in complete cyclisation.   However, due to solubility issues, an alternative 
synthetic route was sought.
5.1.1.2    Synthesis via tritylated furano-dT derivative
In   order   to   overcome   problems   with   solubility,   the   DMT-protected   furano-dT 
nucleoside 160 was used, synthesised as described in Section 3.2.2.
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Scheme 5.3.  Second revised route to 
UPPp monomer 179.
Alternative sources of acid to  p-TsOH and acetic acid were sought, to prevent 
detritylation if possible, but mainly for ease of removal after reaction.   Cyclised 
nucleoside 160 was dissolved in 33 wt% methylamine/ethanol at rt, to afford the ring-
84opened product 183 in near quantitative conversion.  The crude material was dissolved 
in anhydrous DMF, divided into two, and agitated  with DOWEX-50WX8 resin 
(pyridinium form) or silica gel/Et3N, at 30 °C for 1 day, then 50 °C for 1 day and 70 °C 
for 12 hours.  No change was observed using silica gel, and the DOWEX caused some 
detritylation, despite release of pyridine from the resin.  The ring-opened compound 183 
was also isolated (61% yield) in a larger-scale reaction.
In order to avoid detritylation by exposure to acid, heat alone was assessed as a method 
of cyclisation.  After quantitative ring-opening with methylamine, strong heating of the 
resulting solution caused significant degradation.   Refluxing the crude material in 
acetonitrile and triethylamine at 90  °C under argon pressure overnight afforded an 
unidentified product, less polar than the starting material, plus some degradation.  This 
was  non-fluorescent  on  TLC   and  was  presumed   to  be the  4N-methyl-imino-dC 
derivative.   Heating the mixture in ethanolic methylamine at 70  °C overnight also 
afforded ~50% conversion to the same unidentified, and undesired product, in one step.
Successful cyclisation was achieved using DOWEX 50WX8 resin, in the protonated 
form.  Following ring-opening, the residue was heated at 60 °C overnight in DMF/H2O 
(2:1 v/v) with DOWEX 50 (H
+-form) affording the cyclised, detritylated nucleoside 
182.  Clearly, protonated DOWEX resin is a suitable, easily removable source of acid, 
however, it was decided this route was not practical for synthesis of this monomer.  The 
high polarity/poor solubility would cause problems for subsequent purification and 
tritylation, as observed by Vadhia.  Removal then replacement of the DMT protecting 
group is also not atom-efficient.
5.1.1.3    Synthesis via derivatisation of 5-iodo-4N-methyl-dC 185
The third revision to the original route involved initial conversion of tritylated 5-iodo-
2’-deoxyuridine   substrate  97  to   the   4N-methyl-2’-deoxycytidine   derivative  185. 
Although   5-iodo-2’-deoxycytidine   is   commercially   available,   the   4N-methylated 
analogue is not, but several methods of uridine to cytidine conversion are presented in 
the literature.
85The 4-carbonyl group is first activated and converted into a good leaving group by a 
variety of reagents, before reaction with a suitable nucleophile (e.g. NH3, MeNH2).  This 
conversion was conducted using  N-methylimidazole (NMI) in presence of POCl3, 
conditions published by Herdewijn  et al..
212   The reaction proceeds  via  the 4-N-
methylimidazoloyl-dC intermediate  186,  which   is not  isolated   from the reaction 
(Scheme 5.4).
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Scheme 5.4.  Third revised route to 
UPPp monomer 179.
After acetylation of the 3’-OH group in 91% yield (Scheme 5.4), the protected 
nucleoside 187 was treated with phosphorous oxychloride and NMI in pyridine to form 
the yellow intermediate  186  over 30-60 minutes.   Treatment with 40 wt% aqueous 
methylamine   for   several   hours   afforded   the   partially   deacetylated   4N-methyl-dC 
nucleoside.   Further treatment with 33 wt% methylamine/ethanol, before or after 
aqueous workup completed the deacetylation.
On a 1.4 g scale, the product  185  was obtained in a 90% yield, after column 
chromatography using CH2Cl2/CH3OH as eluent.  Reaction on a 6.8 g scale afforded the 
compound in 80% yield after difficult removal of a significant quantity of NMI.  This 
was removed by 4 columns (different eluents) and recrystallisation from toluene.  On an 
8.3 g scale, NMI was removed with difficulty by 2 columns and successive extraction 
with diethyl ether, followed by recrystallisation from ethyl acetate (46% yield).
86When later resynthesised in house, by Dr. Mastoura Edrees-Abdou, stirring the reaction 
at rt overnight after addition of 40 wt% aqueous methylamine was sufficient to 
completely   deacetylated,   therefore   no   further   treatment   with   33   wt%   ethanolic 
methylamine was required.   Also, careful column chromatography using methanol/ 
CH2Cl2 as eluent afforded the product in 84% yield.
Commonly, conversion via the 4-(1,2,4-triazol-1-yl)- intermediate is used, using a large 
excess of 1,2,4-triazole in presence of excess POCl3.
213-215  The intermediate was often 
isolated, although Sanghvi et al.
213 reported an increased yield if this intermediate was 
not isolated, and have conducted this reaction up to kilo scale, in yields of 65-85%.
Other reagent systems used for this conversion include 3-nitro-1,2,4-triazole/diphenyl 
phosphorochloridate,
216  l-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-1H-triazole   (MSNT)/ 
cat. Ph2PO4 (forms the 3-nitro-1,2,4-triazolyl- intermediate),
216 2,4,6-mesitylenesulfonyl 
chloride/DMAP,
95  2,4,6-triisopropylbenzenesulfonyl   chloride/DMAP,
217,218  triiso-
propylsilyl chloride/DMAP,
219 and 2- and 4-nitrophenol/POCl3.
216,220,221
Sonogashira cross-coupling with 3-ureidophenyl acetylene 156 gave the desired alkynyl 
product 188, with a large quantity of the alkyne dimer impurity, and a minor unknown 
impurity.  The alkyne dimer was partially removed by recrystallisation from methanol. 
Following cross-coupling, the nucleoside/alkyne dimer mixture was treated with copper 
iodide in dry, refluxing CH3OH/Et3N at 80 °C under McGuigan’s conditions,
121 but only 
partial cyclisation was observed over 2 hours.
One of few literature examples of cyclisation of 5-alkynyl-dC derivatives was published 
by Inoue et al..
222,223  A protected 4N-acetyl-5-ethynyl-dC nucleoside was cyclised by 
heating at 125 °C in DMF for 10 minutes, in presence of CuI (0.55 eq).
The ureido-modified Sonogashira product 188, containing the alkyne dimer impurity, 
was successfully cyclised under similar conditions, to give the desired product in 55% 
then 79% yield, over two steps, finally using a slight excess of CuI (1.1 eq) and longer 
reaction time (40 minutes).  The alkyne dimer impurity from the previous reaction was 
then easily removed by column chromatography.
87The cyclised nucleoside 184 was subsequently phosphitylated to afford the desired 
UPPp 
monomer 179 for incorporation into TFOs.  During the first small-scale attempt, using 
the chloro-phosphitylating reagent 70, a larger quantity was added in error affording 
41% yield of the bis-phosphoramidite (reaction on primary urea) plus 19% yield of 
desired phosphoramidite 179.  Once the reactivity of the urea NH2 was highlighted, the 
less reactive bis-aminophosphitylating reagent 189 (Figure 5.1) was used, in order to 
minimise secondary reaction.  This necessitated 2.6 eq of reagent, 1.0 eq of activator 
diisopropylamine hydrotetrazolide (DIHT) 190 and very long reaction time.  During this 
time, significant degradation occurred, with formation of a viscous yellow syrup, from 
which the product was extracted in 29% yield.  No bis-phosphitylation was observed.
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Figure 5.1.  Bis-amino phosphitylating reagent 189 and activator, DIHT 190.
DIHT 190 is used in preference to tetrazole due to greater stability and solubility, and 
lower acidity and hygroscopicity.
224
Phosphitylation using the chloro-reagent 70 (1.1 eq) was, however, chosen finally, and 
the product was obtained in 51% yield after column chromatography and precipitation. 
The reaction was stopped after 2 hrs due to appearance of some  bis-phosphitylated 
material.  In all phosphitylation reactions, anhydrous DMF was added to solubilise the 
polar starting material.  In total, 6 bottles of monomer (100-120 mg each) were obtained 
for DNA synthesis.
5.1.2 Synthesis of 6-(3-Acetamidophenyl)-N-methylpyrrolo-dC monomer 191
The acetamide-modified monomer 191 was synthesised by the same route as described 
above.  After Sonogashira cross-coupling of 3-acetamidophenyl acetylene 161 and 5-
iodo-4N-methyl-dC nucleoside 185, the resultant product 192/alkyne-dimer mixture was 
treated under Inoue’s conditions
222,223 and the cyclised acetamido nucleoside 193 was 
isolated in excellent 84% yield over the two steps (Scheme 5.5).
88O
O
DMTO N
N
O
N
HN
O
P
O
N
CN
191
O
OH
DMTO N
N
O
HN
I
185
O
OH
DMTO N
N
O
HN
N
H
O
192
O
OH
DMTO N
N
O
N
HN
O
193
70
NPO
Cl
CN
(1.1 eq)
dist. DIPEA (2.5 eq)
86%
84% (over two steps)
CuI (1.1 eq), dist. Et3N (10.0 eq)
anh. DMF, argon, dark, 125 oC
N
H
O
(3.0 eq)
Pd(PPh3)4 (0.1 eq), CuI (0.4 eq)
dist. Et3N (5.0 eq), anh. DMF
argon, dark, rt
161
anh. DMF, dist. THF, argon, rt
+ alkyne dimer impurity
Scheme 5.5.  Synthesis of 
AcPPp monomer 191.
Phosphitylation was carried out using the chloro-reagent 70 in anhydrous THF/DMF to 
afford the phosphoramidite  191  in excellent 86% yield.   This substrate had no 
competing reaction sites and the reaction proceeded to completion.  Despite the high 
polarity once cyclised, purification proved easier than for the ureido nucleoside 179.  In 
total, 13 bottles of monomer (70-120 mg each) were obtained for DNA synthesis.
5.1.3 Synthesis of 6-(3-Trifluoroacetamidophenyl)-N-methylpyrrolo-dC monomer 178
Synthesis of the trifluoroacetamido-modified monomer 178 was achieved via a slightly 
altered route.   Following Sonogashira coupling of 3-ethynylaniline (3-aminophenyl 
acetylene) 152 with 5-iodo-4N-methyl-dC nucleoside 185 (93-95% yield), cyclisation 
was carried out under Inoue’s conditions.
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Scheme 5.6.  Synthesis of 
APPp monomer 178.
89The first cyclisation attempt afforded only 32% yield of product 195, plus 12% yield of 
a  bis-tritylated product  196  and some untritylated (free) nucleoside  143.   During 
workup, addition of acetone, methanol or dichloromethane (to precipitate impurities) 
had caused precipitation of what was thought at that stage to be a mixture of product 
and copper salts.  The mixture was therefore re-dissolved in DMF and filtered, which 
unfortunately proved unsuccessful in removing significant impurities.  After removing 
the resulting large volume of DMF under high vacuum at elevated temperature (40-50 
°C), the dark brown residue was dissolved/suspended in dichloromethane and filtered, 
successfully removing impurities as originally intended.  It was discovered, however, 
that   during   DMF   removal,   some   detritylation   (through   prolonged   heating)   and 
retritylation of the product was observed.  Retritylation was shown by NMR analysis to 
have occurred on the less hindered, though less reactive aniline NH2, not the 3’-OH 
group.  This is possible as the DMT
+ cation is capable of reacting further in absence of 
water (removed under heat/high vacuum).  On repeating this reaction, DCM was used to 
precipitate impurities, and a yield of 80% was achieved with no DMT migration.
The aniline-NH2  of  195  was trifluoroacetylated using trifluoroacetic anhydride with 
transient protection of the 3’-OH with a trimethylsilyl group.  This method was used in 
house, by Dr. Hong Li, to protect the 4-NH2  group of the  C-nucleoside and GC 
recognition monomer, 3-methyl-4-aminopyridine (
MAP), during an attempt to optimise 
the original synthesis.
65  In previously described synthesis (Section 3.2.1), the aniline-
NH2 of the furano-dT analogue 154 was reacted with ethyl trifluoroacetate in only 35% 
yield with significant degradation due to essential prolonged heating (Section 3.2.1). 
This alternative method obviated this poor yield but introduced other problems.
During the procedure, the 3’-OH group is protected using trimethylsilyl chloride 
(TMSCl) in pyridine.  Upon completion, trifluoroacetic anhydride is added, followed by 
water.  Addition of water, in presence of pyridine/trifluoroacetic acid/HCl cleaves the 
TMS group affording the product.   On the first attempt, despite adding further 
equivalents of TMSCl (upto 3.5 eq), some trifluoroacetylation at the 3’-position had 
occurred; this bis-trifluoroacetylated compound 198 proving very difficult to separate 
by column chromatography.  Although the conversion to products was very good, only 
a 32% yield of the desired product 197 could be obtained pure.  Some triethylamine was 
added after reaction, before removal of solvent, to prevent detritylation.
90In the second attempt, in efforts to prevent further reaction, a larger excess of TMSCl 
(5.0 eq) was added at the start.  Although the 3’-protection occurred more quickly than 
before, after addition of trifluoroacetic anhydride, white fumes were observed and the 
reaction mixture darkened slightly due to partial detritylation from HCl exposure. 
Triethylamine was added immediately to prevent further degradation, however, this 
subsequently prevented complete TMS cleavage by addition of water, as the solution 
was now too basic.  Aqueous workup with 15% aq NH3 removed excess HCl, affording 
a 1:1 mixture of TMS-protected product and unprotected nucleoside 197.  Conveniently, 
the TMS group was cleaved during column chromatography on silica, and the product 
was afforded in 53% yield.  Little bis-trifluoroacetylated compound 198 was observed, 
but the yield was compromised due to detritylation.
Dr.   Edrees-Abdou   later   repeated   this   reaction,   in   house,   using   20   eq   of   ethyl 
trifluoroacetate, 22 eq of Et3N and 1 eq of DMAP in CH2Cl2 at 50 °C overnight.  The 
product  197  was afforded in a maximum yield of 65%, despite some degradation. 
These conditions again highlight the low reactivity of this aniline due in part, to 
extended conjugation with the N-methylpyrrolopyrimidin-2-one bicycle.
For   phosphitylation,   the  bis-amino   phosphitylating   reagent  189  was   tested   first. 
However, poor conversion to products combined with significant degradation on the 
column led to only a 24% yield of desired monomer  178.   This material was 
incorporated into an oligoT DNA strand for deprotection tests (Section 7), however, the 
monomer coupled very poorly (~20%) due to the small quantity obtained (39 mg).
Phosphitylation was most successful using the chloro-phosphitylating reagent  70  in 
70% yield.  Despite an extended reaction time (4¾ hours), excess reagent (2.6 eq) and 
prolonged purification time, little degradation was observed and all hydrolysed excess 
reagent was removed.  Two bottles (90 mg each) were obtained for incorporation into 
TFOs.  The monomer contained a significant quantity of Et3N.HCl, which did not affect 
coupling efficiency during oligonucleotide synthesis.  Presence of the free amine would 
have inhibited coupling (hinders acid-catalysed detritylation step).
915.1.4 Synthesis of 6-(3-Guanidinylphenyl)-N-methylpyrrolo-dC monomer 199
The guanidinium moiety was expected to exhibit the same binding pattern as the urea, 
yet contribute additional stability by charge-stabilisation; the guanidine is protonated at 
physiological  pH.   The guanidinyl-modified  monomer  (
GPPp) proved difficult  to 
synthesise, however, possessing both acid- and base-sensitive groups, necessitating 
careful manipulation, especially during phosphitylation.
Several methods have been employed for introduction of guanidinyl groups into DNA, 
both during synthesis
41,225  or post-synthetically on the oligonucleotide.
43,44   Although 
much easier to introduce post-synthetically, this method is not selective as all exposed 
primary amines capable of reacting, can react.  The main issue with the former approach 
lies in compatibility with DNA synthesis.  Protecting groups must be stable to the acidic 
(TCA or DCA) and oxidising (iodine) conditions encountered during oligonucleotide 
synthesis (excludes using BOC and Cbz for example).   Using the free-guanidinium 
moiety significantly reduces the monomer’s solubility and therefore the coupling 
efficiency.  The protecting group 2-cyanoethoxycarbonyl- (CEOC) is used as it is stable 
to oligonucleotide synthesis.  However, the groups are base-labile, and removal of just 
one of these groups from the guanidinyl moiety (most labile on C=N) compromises 
oligonucleotide synthesis (investigated in house).
5.1.4.1 Improved Synthesis of Guanidinylating Reagent 200
The first step was synthesis of the base-sensitive guanidinylating reagent, N,N’-bis-[(2-
cyanoethoxy)carbonyl]-S-methyl-isothiourea 200.
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Scheme 5.7.  Synthesis of guanidinylating reagent 200. (lit.
42,225,226 yield in parentheses).
92The first step in the route to this reagent 200 was synthesis of the NHS-carbonate, (2-
cyanoethyl)-N-succinimidyl carbonate (CEOC-succinimide) 201, using di-succinimidyl 
carbonate (DSC) 202 under anhydrous conditions.  The literature protocol
42,226 requires 
that   DSC   is   added,   followed   by   pyridine,   to   a   solution   of   2-cyanoethanol   (3-
hydroxypropionitrile, 3-HPN) 203 upon which the suspension solubilises and a final 
yield of 94%, or 87% after further purification (column chromatography) is obtained. 
In order to reduce reaction time (7 hours), the concentration was increased almost three-
fold, however, DSC did not dissolve after 1 hour as expected although the reaction 
proceeded to completion after 4 hours.  After isolation (93%), NMR analysis in d6-
DMSO   (much   greater   solubility   than   in   CDCl3)   indicated   a   large   degree   of 
decomposition had occurred.  It was hypothesised that the initially high concentration of 
3-HPN 203 in the reaction had caused further reaction with the product, due to poor 
solubility of DSC  202.   The corresponding by-product  204  could decarboxylate in 
presence of base, producing acrylonitrile and re-forming 3-HPN  203  (Scheme 5.8). 
This appeared substantiated by significant gas evolution during aqueous workup with aq 
NaHCO3 (sat. soln:water, 1:1 v/v), and signals for NHS and acrylonitrile in the NMR 
spectrum.  Following later recrystallisation and column chromatography, the compound 
was isolated in 75% yield, despite fears over loss due to degradation.
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Scheme 5.8.  Hypothesised mechanism for by-product 204 formation.
The reaction was repeated on a smaller scale at a similar concentration to the literature, 
and the order of addition was reversed.  DSC was stirred in anhydrous CH3CN for 10 
minutes, pyridine was added, followed by 3-HPN 203 dropwise 10 minutes later.  The 
suspension dissolved after 20 minutes and the reaction was complete after 1 hour. 
Following column chromatography, even after 3 weeks in storage, the pure compound 
201  was afforded in 86% yield.   MS analysis of both reaction products indicated 
formation of the correct product with a small quantity of NHS present.  NMR analysis 
in CDCl3 confirmed this also.  CEOC-succinimide 201 was discovered to be unstable in 
93DMSO due in part to presence of water.   Also, changing the order of addition of 
reagents increased the yield by 11% on the previous attempt.  On scaling up the reaction 
to 200 mmol, at twice the concentration in the literature, the reaction was complete 
within 1.5 hours and a 94% yield was obtained.
The literature protocol
41,225,226  for formation of the guanidinylating reagent is a two-
phase reaction (CH2Cl2:conc. aq NaHCO3, 1:1 v/v), coupling the organic-soluble NHS-
carbonate 201 with water-soluble S-methylisothiourea hemisulfate 205.  The literature 
yield of 35% is poor and not cost-effective on a large-scale due to the price of DSC.
Due to base-sensitivity of the product and in order to increase the yield, the reaction was 
tested in CH2Cl2:H2O and THF:H2O (4:1 v/v), with only 6 equivalents of NaHCO3, 2.5 
eq of CEOC-succinimide 201, and using argon-degassed solvents.  After workup, TLC 
indicated a ~3:2 mixture of mono- 206 to bis-modified 200 isothiourea (Figure 5.1). 
The sp
2 nitrogen is more difficult to functionalise due to higher protecting group lability 
under basic conditions.  To push the reaction to completion, each reaction was dried, 
dissolved in CH2Cl2  or THF, split into two and treated with 1.5 eq of CEOC-
succinimide with or without 1 eq of pyridine.   Only reaction in CH2Cl2, especially 
without pyridine, achieved significant further reaction over 26 hours even under non-
anhydrous conditions.
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Figure 5.2.  Mono- 206 and bis-modified 200 S-methylisothioureas.
Using this knowledge, the reaction was scaled up (87 mmol), at a higher concentration 
than in the literature under the best conditions from the tests.  The two-step procedure 
worked very efficiently, benefitted by using argon-degassed/distilled solvents, 2 eq then 
1 eq of CEOC-succinimide and only 3 eq of NaHCO3 in the first step.  A yield of 89% 
was achieved, a significant improvement on the literature method, and could be 
optimised further, using less CEOC-succinimide in the second step.  A yield greater 
than 35% appears extremely difficult to achieve without modifying the literature 
protocol.
945.1.4.2 Final Steps towards 
GPPp Monomer 199
The anilino-N-methylpyrrolo-dC intermediate 195 (synthesised following the synthetic 
route   for   the   trifluoroacetamidophenyl   monomer  178,   see   Section   5.1.3)  was 
guanidinylated using guanidinylating reagent 200 under slightly different conditions to 
the literature, based on experiments in house.
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Scheme 5.9.  Synthesis of 
GPPp monomer 199.
The   reaction   was   conducted   in   CH2Cl2  with   pyridine   (instead   of   DMF   with 
triethylamine) at 35 °C instead of room temperature due to the previously demonstrated 
low reactivity of the aniline NH2.  Only 1.1 eq of guanidinylating reagent 200 was 
added initially, using only 0.5 eq of pyridine due to base-sensitivity.  Guanidinylation of 
a primary alkylamine-modified nucleoside, in house, required only 0.5 eq of pyridine. 
Over more than 1½ days, further reagent and pyridine were added (upto 2.5 eq and 5.2 
eq respectively) and the temperature was increased to 50  °C.   Although prolonged 
reaction time and temperature caused some degradation/cleavage of CEOC-groups, 
these conditions were necessary to ensure adequate reaction occurred.  The product was 
purified by column chromatography, on pyridine-neutralised silica gel, using eluent 
containing no base, affording a 42% yield.  Neutralising the silica gel is important to 
prevent cleavage of the acid-sensitive DMT group, yet excess base is washed from the 
column and base is omitted from the eluent to prevent base-mediated cleavage of the 
CEOC protecting groups from the product 207.
Phosphitylation was not straight-forward as during storage, some CEOC-cleavage was 
observed, likely to be caused due to presence of byproduct CH3SH.  The reaction was 
tested on this material, using 1.1 eq and 1.5 eq of the chloro-phosphitylating reagent 70 
and 1.5 eq and 2.0 eq of DIPEA.  Literature methods
41,225,226 use the bis-amino reagent 
95189  as DIPEA can cause CEOC-cleavage.   However, the low aniline reactivity 
necessitated these conditions, and less DIPEA was used.  The products of both reactions 
(better  conversion  for the latter)  were combined  and  purified  twice by column 
chromatography and precipitation.   However, due to phosphitylation of the single 
unprotected guanidinyl nitrogen, the product (208) of which eluted similarly to the 
desired product 199, the monomer could not be obtained pure.   
31P-NMR indicated 
peaks for both phosphoramidites at ~150 ppm, and signals at ~ 71 ppm corresponding to 
the N-phosphoramidyl group (Figure 5.2).
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Figure 5.3.  Expansions of 
31P-NMR of 
GPPp phosphoramidite mixture 199,208, and structure of 
bis-phosphoramidite 208.  Bis-phosphoramidyl peaks labelled with an asterisk.
Although the  
1H-NMR spectrum was too complicated to assign, both the desired 
phosphoramidite 199 and bis-phosphoramidite 208 were also detected by MS.
When the monomer was re-synthesised in house, by Dr. Edrees-Abdou, guanidinylation 
was achieved using 2.5 eq of GR 200, 5 eq of pyridine in refluxing CH2Cl2 under argon 
pressure (50 °C) for 2 days, in 44% yield.  Phosphitylation using 1.8 eq of chloro-
phosphitylating reagent 70 with 2 eq of DIPEA at rt afforded the desired 
GPPp monomer 
after 2 hours reaction time, in 58% yield.  The monomer precursor 207 was precipitated 
from   DCM   into   hexane   to   remove   residual   pyridine   and   methanethiol   and   no 
degradation was encountered during storage.
965.1.5 Synthesis of 6-(3-Thioureidophenyl)-N-methylpyrrolo-dC monomer 158
The final modification investigated was a thioureido moiety.  The greater acidity of 
thiourea N-H bonds compared to the analogous urea, should result in strengthening of 
the proposed hydrogen-bonds with G of the CG base pair.
The initial synthetic route to the thiourea-modified monomer (
TUPPp)  158  closely 
followed the procedure for the 
UPPp monomer 179 (Scheme 5.10).  After synthesis of 
the modified alkyne 208, Sonogashira cross-coupling, cyclisation and phosphitylation 
were expected to afford the desired monomer 158.
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Scheme 5.10.  Initial synthetic route to 
TUPPp monomer 158.
Synthesis of the alkyne for Sonogashira cross-coupling, 3-thioureidophenyl acetylene 
209, was first attempted using one of two methods published by Saxena et al.
227 for 
synthesis of  N-arylthioureas.   Refluxing 3-ethynylaniline  152  in 15% aq HCl with 
ammonium thiocyanate, however, afforded only 6% yield of product 209 with some 
recovery of starting material.  Poor solubility despite strong heat and vigorous stirring 
may have hindered the reaction (Scheme 5.11).
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Scheme 5.11.  Synthetic routes to 3-thioureidophenyl acetylene 209.
97After noting that isothiocyanates could be used for formation of aryl-thioureas,
227,228
3-EA 152 was treated with trimethylsilyl isothiocyanate (TMS-NCS) in dry Et2O, with 
and without base (DIPEA).  No desired thiourea could be observed; only thiocyanic 
acid salts of DIPEA or 3-EA were formed, which were broken down during workup. 
Although potentially a very convenient route to primary ureas due to facile deprotection 
of the TMS-thiourea product, TMS-NCS appears to hydrolyse before the poorly 
reactive aniline can react.
The other method published by Saxena
227 was used successfully to afford the desired 
alkyne 209 in 59% yield over two steps.  3-Ethynylaniline 152 was reacted with benzoyl 
isothiocyanate 210 cleanly in 75% yield.  Cleavage of the benzoyl group of 211 was 
achieved by heating at 90 °C in 5% aq NaOH for 15 minutes in 79% yield.  Neither step 
required chromatography and little benzamide byproduct 212 was produced (removed 
by filtration) (Scheme 5.11).
Sonogashira cross-coupling reactions throughout this work have used the catalyst, 
Pd(PPh3)4.  This posed a problem for this step, as due to the high affinity of sulphur for 
palladium, it was likely that the thiourea moiety may bind to palladium, either poisoning 
or consuming the catalyst.
Small-scale test reactions demonstrated that much higher quantities of Pd catalyst and 
CuI were required to elicit any reaction other than minimal alkyne dimerisation.  Two 
other products were also detected by TLC, which appeared to correspond to Pd-thiourea 
complexes of the alkynylated product 213 and alkyne 209.
This reaction was subsequently conducted on a 1.3 g and 0.3 g scale using 0.5-0.7 eq of 
Pd(PPh3)4, 1.1 eq of CuI and 2.0-2.5 eq of alkyne, during which, both starting material 
and alkyne were consumed.  After column chromatography, the product from the larger-
scale reaction was divided.   Aqueous workup was unsuccessful removing inorganic 
impurities, however, passing through a benzyl-thiol StratoSpheres™ SPE cartridge (PL-
BnSH MP Resin) successfully cleaved the residual thiourea complexed-Pd and removed 
excess Pd from the mixture.
After combining all batches, a portion of the Sonogashira product 213 was treated under 
Inoue’s conditions for cyclisation.
222,223.  Unexpectedly, after 40 minutes, nothing had 
98occurred except precipitation of a black solid.  The mixture was filtered, concentrated in 
vacuo, dried and treated again under the same conditions, after confirming the starting 
material had remained unchanged.   The starting material was mostly consumed, as 
determined by TLC analysis using several solvent systems, over 1½ hours hence the 
reaction was worked up and purified twice by column chromatography.  TLC analysis 
of the resulting seven fractions indicated  a complex  mixture of products, some 
fluorescent and all UV active.  The desired cyclised product 214 could not be detected 
by MS; only the analogous ureido compound 184 was identified.  It was subsequently 
discovered that in recent work by Shibahara  et al.,
229  a variety of thiocarbonyl 
compounds were oxidatively desulfurised in presence of copper (I) chloride (20 mol%), 
oxygen and heat (80  °C) in excellent yield under the right conditions.   Under the 
conditions of Inoue, it is possible that traces of oxygen, combined with strong heating 
(125  °C) and CuI (1.1 eq), may have induced oxidative desulfurisation and other 
degradation products.  This explains the presence of the urea “oxidation product” 183 in 
the mixture.  
The  remaining  uncyclised  starting  material  was  treated,  without  CuI,  under  the 
otherwise same conditions affording only complete detritylation of the starting material. 
This was recovered and treated under Inoue’s conditions, at 50 °C this time, but no 
change was observed after 24 hours.  It was decided to abandon this synthetic route and 
a new route was proposed.
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Scheme 5.12.  Revised route to 
TUPPp monomer 158.
99The new proposed route proceeds via modification of the cyclised anilino-nucleoside 
195, with benzoyl isothiocyanate  210, following suitable protection of the 3’-OH 
(Scheme 5.12).   This synthesis was subsequently investigated by Dr. Edrees-Abdou 
with success after some further modifications to the route.  The phosphoramidite 158, 
however, coupled very poorly when incorporated into DNA and MS analysis proved 
inconclusive for the desired oligonucleotides.   The thiourea-derivative (
TUPPp) was 
therefore put on hold.  It was proposed that deprotection conditions and/or the iodine 
oxidation step during oligonucleotide synthesis may have caused degradation/oxidation 
but this could not be confirmed.
5.2 Future Work
Following this work, other modifications were suggested, which could enhance binding 
and recognition.  The first was substituting the 3-aminophenyl- modification for a 3,5-
diaminophenyl- moiety.  Due to free rotation around the aryl-bicycle bond, it is possible 
that the 3-amino group may not always be correctly aligned for binding to G. 
Employing two groups should present the correct hydrogen-bonding for both rotamers. 
Any one of the bis-acetamide, bis-urea, bis-trifluoroacetamide or bis-guanidinium could 
be synthesised.  However, the bis-acetamide and bis-urea are likely to be too polar to 
handle, and the bis-guanidinium might be difficult to form, due both to low reactivity 
and steric hindrance.
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Figure 5.4.  Alternative CG recognition monomer synthetic targets 217-224 and binding motif.
100It may also be beneficial to change the aromatic ring to a heterocycle such as pyridine, 
triazine, pyrrole or imidazole.  Altering hydrophilicity and electronic properties may 
have beneficial effects on binding affinity.
The first target, however, is 6-phenyl-N-methylpyrrolo-dC phosphoramidite 220.  It is 
important   to   confirm  what  role  the   aromatic   ring   plays   in   triplex   binding   and 
recognition, and whether the modifications do benefit binding or could even be omitted. 
In addition, it would be necessary therefore to investigate how changing the ring, 
whether aromatic (phenyl, napthyl), heteroaromatic (pyridine, triazine, pyrrole, thiazole) 
or non-aromatic (cyclohexyl, cyclopentyl), affects binding, before further derivatisation. 
The phenyl monomer 221 has been synthesised in house, in excellent overall yield by 
Dr. Edrees-Abdou, and biophysical studies are in progress.
5.3 Conclusion
Three  N-methylpyrrolo-dC   monomers   (
APPp  178,  
AcPPp  191,  
UPPp  179),   were 
synthesised for incorporation into TFOs for biophysical studies.  All were synthesised 
from   the   key   intermediate,   5’-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxy-
cytidine 185, made from the 2’-deoxyuridine analogue 97 in two steps.  Sonogashira 
cross-coupling
124 and a modified copper (I)-catalysed cyclisation
222,223 were used to form 
the derivatised bicyclic base in typically good to excellent yield.
Problems were again encountered with the low reactivity of the aniline NH2 (c.f. Section 
3),   necessitating   prolonged   reaction   times,   a   higher   reagent   excess,   and   raised 
temperature (e.g. trifluoroacetylation, guanidinylation).  Care was also taken for the 
guanidinium monomer (
GPPp) and precursor, to avoid cleavage of the base-labile 
protecting groups, whilst preventing cleavage/activation of the acid-sensitive DMT and 
phosphoramidite moieties.   A revised method for synthesis of the guanidinylating 
reagent 200 from CEOC-succinimide 201 was also evaluated, affording a final semi-
optimised yield of 89%, compared to the literature yield of 35%.
41,225,226  This allows for 
a much more accessible synthesis, owing to cost of DSC.
The fourth  monomer,  
GPPp  199,  was  synthesised   later  in  house, after   synthetic 
investigation   (see above),  and  a  fifth  monomer,  
TUPPp  158,  although  eventually 
101synthesised later in house, could not be incorporated and studied as desired.  Although 
the thiourea moiety should have imparted extra stability over the urea in the triplex, it is 
unlikely   this   modification   will   be   continued.     Instability   during   oligonucleotide 
synthesis and/or deprotection introduced too many problems.   However, there are 
several new directions for future work, and the syntheses and biophysical studies 
(Section 6) already undertaken are promising.
The precursors to the four monomers that were incorporated into TFOs, were also 
deprotected and fluorescence measurements were taken.  This is discussed in detail in 
Section 6.3.
102Chapter 6
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1036. Biophysical   Studies   of  N-Methylpyrrolo-dC   Modified   TFOs   for   CG 
Recognition
Four modified N-methylpyrrolo-dC phosphoramidite monomers (
APPp 178, 
AcPPp 191, 
UPPp  179,  
GPPp  199) were incorporated into unlabelled/labelled TFOs for UV and 
fluorescence melting studies.  The initial study (from Section 4.2.2) was designed to 
compare   both   post-synthetically   modified   furano-dT,   and  N-methylpyrrolo-dC 
nucleosides at CG recognition in the four sequences introduced in Chapter 4.  Following 
this work, the main biophysical studies were carried out.  These were again designed to 
test binding affinity for CG and selectivity against the other base pairs (GC, AT, TA) at 
several pHs.  In addition to determination of the best modification for CG recognition, 
the other aim was to compare UV and fluorescence melting data (collected using the 
same buffer conditions), which appeared not to correlate in previous studies.
6.1 Initial Fluorescence Melting Study
This section discusses the  N-methylpyrrolo-dC results from the ‘Sequence Study’ 
introduced in Section 4.2.2.  
                 5’-Q-PMM TPM VXW TPT PTM PT
          5’-F-GT GTT AGG AAG ACA AAA AAG AAC TGG T-H
               CA CAA TCC TTC TGT TTT TTC TTG ACC A-H
Figure 6.1.   Fluorescence triplex melting experiment.   TFO shown in bold.  M  =  
5-MedC,
P = 5-(3-aminoprop-1-ynyl)-dU (pdU), X = 
AcPP & VXW = TXT (OL18), PXT (OL19), TXP 
(OL20), PXP (OL21), or X = 
UPP & VXW = TXT (OL22), PXT (OL23), TXP (OL24), PXP 
(OL25), Q = DABCYL (quencher), F = FAM (fluorophore), H = HEG (hexaethylene glycol), 
hairpin duplex (CG, OL6).
As previously described, these fluorescence melting experiments (Figure 6.1) were 
conducted using LC Programmes 1 and 2 (95-30-95  °C at 0.2  °C/min) at pH 6.2
(10 mM sodium phosphate, 200 mM NaCl).  Experiments were run once in triplicate 
and a 10:1 ratio of TFO:duplex (5:0.5 mM) was used.  
104X
Seq.
Tm / °C, melt/anneal
AcPP
UPP
TXT 42.1/38.0 44.0/42.0
PXT 49.0/44.0 48.1/45.1
TXP 49.1/44.0
(48.4/43.0)
51.1/47.1
(51.0/45.0)
PXP 54.0/49.0 54.5/50.0
Table 6.1.  Fluorescence triplex melting experiment: 
AcPPp and 
UPPp against CG, each in four 
TFOs (
AcPP – OL18-OL21 & 
UPP – OL22-OL25) at pH 6.2 (10 mM sodium phosphate, 200 
mM NaCl) using LC Programme 1 and 2 (Section 9.2).  Average Tm values for TFO melt/anneal 
given in °C.  Data obtained for 
XPPf-modified TFOs is shown for comparison, in parentheses 
(Section 4.2.2).
These results confirm the previous findings, that placing pdU (P) on the 5’-side of the 
modification X (
XPP) has a slightly destabilising effect compared to the 3’-side, notably 
for the urea (
UPP).  The results for the TXP TFOs for both furano-dT (in parentheses) 
and N-methylpyrrolo-dC modifications were similar (within experimental error), hence 
previous furano-dT experimental data can be corroborated.
The trends identified when examining the combined 
XPPf and 
XPPp results, correlate 
with those in the main fluorescence melting studies, despite differences in buffer 
composition and pH.
In addition, hysteresis was on average 1.5 °C lower for 
XPPp than for 
XPPf modifications. 
This may rise from the higher TFO purity when no post-synthetic modification is 
required (Sections 3.3, 5.1).
6.2 Primary UV Melting Study
A comprehensive UV melting study was conducted in cooperation with Dr. Edrees-
Abdou, to examine the binding affinity/selectivity of the four monomers, in comparison 
also with the natural base T.  Data was collected at pH 6.2, 6.6 and 7.0, and at pH 7.0 
with 2 mM spermine added.  Spermine is a general/non-specific DNA stabilising agent 
and component in all eukaryotic cells, which is used in this context, to increase the 
stability of a duplex/triplex if the Tm is too low to be easily measured.  Prior to this 
105work, large quantities of the pdU phosphoramidite monomer 164 were synthesised by 
Dr. Edrees-Abdou and Dr. Imenne Bouamaied for synthesis of the TFOs used in this 
both studies.
         5’-TTT TTM VXW MTM TMT
     5’-GCT AAA AAG AYA GAG AGA TCG
        CGA TTT TTC TZT CTC TCT AGC-5’
Figure 6.2.   UV triplex melting experiment.  TFO shown in bold.   M = 
5-MedC, P = 5-(3-
aminoprop-1-ynyl)-dU (pdU), VXW = TTT (OL32), TTP (OL33), PTT (OL34), PTP (OL35); 
X = 
APP & VXW = TXT (OL36), TXP (OL37), PXT (OL38), PXP (OL39); X = 
AcPP & VXW 
= TXT (OL40), TXP (OL41), PXT (OL42), PXP (OL43); X = 
UPP & VXW = TXT (OL44), 
TXP (OL45), PXT (OL46), PXP (OL47); X = 
GPP & VXW = TXT (OL48), TXP (OL49), PXT 
(OL50), PXP (OL51); purine strand Y = C (OL1), G (OL26), A (OL27), T (OL28), pyrimidine 
strand Z = G (OL2), C (OL23), T (OL30), A (OL31).
UV melting experiments were performed (as described previously, and in detail in 
Section 9.2), using a 5:1 ratio of TFO:duplex (5:1 mM).  Experiments were conducted at 
pH 6.2, 6.6, 7.0 and pH 7.0 + 2 mM spermine (10 mM sodium phosphate, 200 mM 
NaCl, 1 mM Na2EDTA).  All oligonucleotides for this study were synthesised without 
capping to avoid undesired acetylation of TFOs.
Standard melt programme No. 3 was used (15-50-80 °C at 0.25-0.5 °C/min) with 5 heat/
anneal cycles  in total  (Section  9.2).   Condensation was not a problem at low 
temperature (15 °C).
There are several trends, which can be drawn from the data given below in Table 6.2. 
Firstly, at pH 6.2, against CG in sequence TXT, (Table 6.2, Lines 1, 6, 19, 28, 37) the 
aniline/amine (
APP, OL36) outperforms all other monomers, and the poorest monomer 
(
AcPP, OL40) gives a Tm that is 1.7 °C greater than T.  This result appears to contradict 
the original order of stability as derived from the proposed hydrogen-bonding triplet 
motif.  The proposed motif places the urea (
UPP) and guanidinium (
GPP) as the strongest 
binders, as they can form two hydrogen-bonds and the latter also contributes additional 
charge-stabilisation.  However, these results suggest steric or electronic factors may 
play a role, where such groups cause destabilisation relative to the sterically non-
hindering amino group.
106X Sequence Base Pair Buffer Tm / °C Hysteresis
Buffer
Duplex 6.2 6.6 7.0 7.0 SP
T
TXT CG 6.2 25.6/22.9 2.7 1 CG 61.3 62.8 61.6 63.6
TXT
CG 6.6
19.4/n.d. n.d. 2 GC 60.5 - - 63.4
TXP n.d. n.d. 3 AT 58.4 - - 61.8
PXT 23.2/20.1 3.1 4 TA 58.6 - - 61.7
PXP 22.4/18.8 3.6 5
APPp
TXT
CG
6.2
30.0/26.3 3.7 6
GC 21.1/18.1 3.0 7 Hysteresis 1.1 – 5.9 °C
AT 21.4/18.4 3.0 8
TA n.d. n.d. 9 Average Hysteresis 3.7 °C
TXT
CG 6.6
22.7/18.5 4.2 10
TXP 24.0/19.8 4.2 11 Average duplex DTm 
due to spermine + 2.9 °C
PXT 25.7/21.2 4.5 12
PXP 26.8/21.9 4.9 13
TXT CG 7.0 n.d. n.d. 14
TXT
CG
7.0 SP
30.4/29.4 1.0 15
GC 20.2/n.d. n.d. 16
AT 17.5/n.d. n.d. 17
TA n.d. n.d. 18
AcPPp
TXT
CG
6.2
27.3/23.1 4.2 19
GC 20.4/n.d. n.d. 20
AT 20.4/n.d. n.d. 21
TA 20.3/n.d. n.d. 22
TXT
CG 6.6
21.0/16.8 4.2 23
TXP 21.1/n.d. n.d. 24
PXT 22.6/19.4 3.2 25
PXP 22.7/18.3 4.4 26
TXT CG 7.0 n.d. n.d. 27
UPPp
TXT
CG
6.2
29.2/24.4 4.8 28
GC 20.1/n.d. n.d. 29
AT 21.5/18.5 3.0 30
TA 21.6/19.5 2.1 31
TXT
CG 6.6
22.7/18.5 4.2 32
TXP 23.4/18.3 5.1 33
PXT 24.1/18.3 5.8 34
PXP 24.9/19.0 5.9 35
TXT CG 7.0 n.d. n.d. 36
GPPp
TXT
CG
6.2
27.9/25.0 2.9 37
GC 19.5/n.d. n.d. 38
AT 20.7/n.d. n.d. 39
TA 17.8/n.d. n.d. 40
TXT
CG 6.6
21.4/18.0 3.4 41
TXP 21.1/18.0 3.1 42
PXT 21.6/18.6 3.0 43
PXP 22.5/20.3 2.2 44
TXT CG 7.0 n.d. n.d. 45
Table 6.2.  UV triplex melting experiment: X against YZ at pH 6.2, 6.6, 7.0 and 7.0 + 2 mM 
spermine (10 mM sodium phosphate, 200 mM NaCl, 1 mM Na2EDTA) using UV melting 
programme No. 3 (Section 9.2).  Average Tm values for TFO melt/anneal and duplex (average of 
melt and anneal Tm), and hysteresis given in °C.  n.d. = not determined (Tm < 17 °C).
107At pH 6.6 (Lines 2, 10, 23, 32, 41), the urea and aniline (
APP) show similar binding 
affinity, greater than the guanidinium, which should be the strongest binder.
At pH 6.6, against CG for all the pdU-containing TFOs, the aniline is again the 
strongest binder, followed by the urea.  The order of stability for the other modifications 
varies, such that for PXT (OL50) and PXP (OL51), the guanidinium is of equal or lower 
stability than T.   This may is attributed to disfavourable steric interaction and also 
charge-repulsion with the pdU on the 5’-side as previously discussed.
All monomers demonstrated a very high selectivity for CG at pH 6.2, over the other 
base pairs, by 6.9-8.6 °C.  For all monomers except 
UPP, the second highest affinity was 
for AT not TA, the latter of which has often been observed for CG recognition 
monomers (Section 1.2.2).   A putative X.AT triplet can be drawn to support this 
observation, with hydrogen bonds between N
3 and anilino NH of 
XPP and the NH2 of A 
and C
4=O of T. Only 
UPP and 
GPP show significant differences (> 1 °C) between the Tms 
against the other base pairs.  In addition, the aniline demonstrates very high selectivity 
for CG, by 10.2 °C at pH 7.0 with 2 mM spermine, where the second highest affinity 
was for GC (Lines 15-18).
Examination of the data for the pdU-containing TFO series, obtained at pH 6.6, 
identifies significant differences from the initial fluorescence melting data discussed in 
Sections 4.2 and 6.1.  The main difference is order of stability, where higher Tms are 
observed for PXT- rather than TXP-oligonucleotides.  It was deduced from previous 
fluorescence melting data, that disfavourable interaction between the pdU and  
XPP 
amino-modified side-chains occurred when pdU was located on the 5’-side.  However, 
the reverse is observed here, and the difference between TXP and PXT is pronounced 
for the aniline (1.7 °C) and acetamide (1.4 °C).  Otherwise increase in Tm with each T-
pdU substitution varies from 0.1 to 1.3 °C.  Interestingly, the TXT TFO (X = 
GPP, 
OL48) is 0.2 °C more stable than the corresponding TXP oligonucleotide (OL49), but 
this may simply be due to experimental error.  The results for T at pH 6.6, appear 
spurious, where the order of stability (TXP < TXT < PXP < PXT) cannot be easily 
explained.
In summary, this study highlights the high selectivity of all monomers for CG over the 
other base pairs.  The order of binding affinity, however, contradicts the proposed triplet 
108binding motif, although the urea remains a strong binder.  These observations suggest 
the aniline or urea would be highly suitable candidates for CG recognition, the latter 
perhaps particularly at higher pH.  Selectivity at pH 7.0 with 2 mM spermine should be 
carried out for the urea to confirm whether the urea does indeed outperform the aniline 
at higher pH.  Without spermine, no Tm could be measured for any monomer at pH 7.0. 
The acetamide and guanidinium should also be assessed against CG at pH 7.0 + 2 mM 
spermine to determine whether the effect of the positive-charge of the guanidinium is 
beneficial   to   binding   at   higher   pH,   where   little   protonation   of   other   amine 
functionalities should occur.   The acetamide performed poorest throughout and the 
guanidinium proved less effective than expected.
6.3. Primary Fluorescence Melting Study
The main fluorescence melting study was conducted in cooperation with Dr. Edrees-
Abdou, to confirm the previous results and make more accurate comparisons between 
monomer recognition capabilities.  Data was collected using the same buffer systems as 
for the UV melting study so that direct comparisons between the studies could be made.
                 5’-Q-PMM TPM VXW TPT PTM PT
          5’-F-GT GTT AGG AAG AYA AAA AAG AAC TGG T-H
               CA CAA TCC TTC TZT TTT TTC TTG ACC A-H
Figure 6.3.   Fluorescence triplex melting experiment.   TFO shown in bold.  M  =  
5-MedC,
P = 5-(3-aminoprop-1-ynyl)-dU (pdU), VXW = TTT (OL60), PTT (OL61), TTP (OL62), PTP 
(OL63); X = 
APP & VXW = TXT (OL52), PXT (OL53), TXP (OL54), PXP (OL55); X = 
AcPP 
& VXW = TXT (OL18), PXT (OL19), TXP (OL20), PXP (OL21); X = 
UPP & VXW = TXT 
(OL22), PXT (OL23), TXP (OL24), PXP (OL25); X = 
GPP & VXW = TXT (OL56), PXT 
(OL57), TXP (OL58), PXP (OL59);. Q = DABCYL (quencher), F = FAM (fluorophore), H = 
HEG (hexaethylene glycol), hairpin duplex YZ = CG (OL6), GC (OL7), AT (OL8), TA (OL9).
109X Sequence Base Pair Buffer Tm / °C Hysteresis
T
TXT
CG 6.2
44.3/41.0 3.3 1
TXP 47.5/45.9 1.6 2
PXT 48.4/47.8 0.7 3
PXP 51.1/48.7 2.4 4
APPp
TXT
CG
6.2
44.1/40.9 3.2 5
GC 36.7/32.9 3.8 6
AT 33.9/n.d. n.d. 7
TA 36.7/33.8 2.9 8
PXP
CG
6.2
56.8/52.9 3.9 9
GC 45.8/42.9 2.9 10
AT 43.3/40.9 2.4 11
TA 47.2/43.9 3.3 12
TXT
CG
6.6
37.5/32.9 4.6 13
GC n.d. n.d. 14
AT n.d. n.d. 15
TA n.d. n.d. 16
TXP
CG 6.6
43.2/35.9 7.3 17
PXT 42.2/35.4 6.8 18
PXP 48.5/41.4 7.1 19
TXT
CG 7.0
n.d. n.d. 20
PXP 40.6/n.d. n.d. 21
TXT CG 7.0 SP 36.0/33.5 2.5 22
AcPPp
TXT
CG
6.2
43.9/40.8 3.1 23
GC 38.8/35.9 2.9 24
AT 35.0/32.7 2.3 25
TA 41.9/38.0 3.9 26
PXP
CG
6.2
55.2/50.2 5.0 27
GC 46.9/43.8 3.1 28
AT 45.0/39.9 5.1 29
TA 50.4/47.0 3.4 30
TXP
CG 6.2
50.3/46.1 4.2 31
PXT 51.0/46.0 5.0 32
TXT
CG
6.6
36.2/32.8 3.4 33
GC n.d. n.d. 34
AT n.d. n.d. 35
TA 33.9/n.d. n.d. 36
TXP
CG 6.6
43.8/35.7 8.1 37
PXT 43.8/35.7 8.1 38
PXP 46.5/37.8 8.7 39
TXT
CG 7.0
n.d. n.d. 40
PXP 39.9/n.d. n.d. 41
TXT CG 7.0 SP 36.0/34.2 1.8 42
Table 6.3.  Fluorescence triplex melting experiment: X against YZ at pH 6.2, 6.6, 7.0 and 7.0 
+ 2 mM spermine (10 mM sodium phosphate, 200 mM NaCl, 1 mM Na2EDTA) using LC 
Programme 3 (Section 9.2).  Average Tm values for TFO melt/anneal and values for hysteresis 
given in °C.  n.d. = not determined (Tm < 33 °C).  Hysteresis: 0.7–9.3 °C, average hysteresis: 4.0 
°C.  Continued on following page.
110X Sequence Base Pair Buffer Tm / °C Hysteresis
UPPp
TXT
CG
6.2
44.3/40.9 3.4 43
GC 39.9/34.4 5.5 44
AT 35.1/32.8 2.3 45
TA 40.7/36.9 3.8 46
PXP
CG
6.2
58.1/53.5 4.6 47
GC 46.0/45.0 1.0 48
AT 43.8/40.8 3.0 49
TA 49.7/45.1 4.6 50
TXP
CG 6.2
52.0/48.9 3.1 51
PXT 50.8/45.8 5.0 52
TXT
CG
6.6
38.0/n.d. n.d. 53
GC n.d. n.d. 54
AT n.d. n.d. 55
TA 33.5/n.d. n.d. 56
TXP
CG 6.6
44.2/38.8 5.4 57
PXT 43.0/37.7 5.3 58
PXP 48.2/43.9 4.3 59
TXT
CG 7.0
n.d. n.d. 60
PXP 39.9/32.8 7.1 61
TXT CG 7.0 SP 37.4/34.8 2.6 62
GPPp
TXT
CG
6.2
47.2/45.8 1.4 63
GC 36.9/35.9 1.0 64
AT 37.0/35.9 1.1 65
TA 39.7/38.5 1.2 67
PXP
CG
6.2
56.0/51.4 4.6 68
GC 45.0/40.9 4.1 69
AT 47.0/44.5 2.5 70
TA 51.0/47.2 3.8 71
TXT
CG
6.6
40.3/35.0 5.3 72
GC n.d. n.d. 73
AT 30.9/n.d. n.d. 74
TA 33.0/n.d. n.d. 75
TXP
CG 6.6
46.2/36.9 9.3 76
PXT 43.7/36.8 6.9 78
PXP 47.2/41.9 5.3 79
TXT
CG 7.0
32.7/n.d. n.d. 80
PXP 38.5/n.d. n.d. 81
TXT CG 7.0 SP 39.0/37.9 1.1 82
Table 6.3 cont.  Fluorescence triplex melting experiment.  Continued from previous page.
Fluorescence melting studies were performed (as described previously, and in detail in 
Section 9.2), on a Roche LightCycler
®.  Experiments were performed at pH 6.2, 6.6 and 
7.0, and at pH 7.0 + 2 mM spermine (10 mM sodium phosphate, 200 mM NaCl, 1 mM 
Na2EDTA), and a 10:1 ratio of TFO:duplex  (5:0.5  mM) was used.   Runs in these 
experiments were performed up to three times in triplicate, using LC Programme 3 (95-
27-95 °C at 0.2 °C/min, see Section 9.2).
111At pH 6.2, against CG in sequence TXT, (Table 6.3, Lines 1, 5, 23, 43, 63),  
GPP 
outperforms the other monomers by 2.9 °C, however, the Tm of the poorest monomer 
(
AcPP) is 0.4 °C below T.  The aniline, urea and T have similar Tms.  At pH 6.6 also 
(Lines 13, 33, 53, 72), the guanidinium monomer has the strongest binding affinity by 
2.3 °C, followed by the urea, aniline then acetamide.  In the PXP sequence at pH 6.2 
(Lines 9, 27, 47, 68), the urea has the highest Tm by 1.3 °C, followed surprisingly by the 
aniline then guanidinium and acetamide, which is 4.1 °C above T.  A similar pattern 
was observed for TXT and PXP at pH 7.0 and 7.0 with spermine.
The guanidinium monomer performed best, as expected, in the TXT sequence but not 
for PXP.  It is possible that the presence of a protonated amine species either side of the 
positively-charged guanidinium may have destabilised it significantly, below that of the 
aniline as observed.  Otherwise, apart from the acetamide performing slightly worse 
than the aniline, the order of stability can be rationalised.
A different situation was encountered for the PXT and TXP sequences.  At pH 6.6, for 
TXP (Lines 17, 37, 57, 76), the guanidinium and urea performed best, whereas for PXT 
(Lines 18, 38, 58, 77), these appear destabilised such that the acetamide has a similar Tm 
to 
GPP.  This indicates that both the guanidinium and urea have a negative interaction 
with pdU when they are located on the 5’-side (PXT) as originally noted (Section 4.2.2). 
It is also perhaps surprising, that changing from PXT to PXP has a significant effect on 
the order of binding affinity,  whereas changing from TXT to TXP makes little 
difference.  It was originally thought that the proposed negative interaction was due to 
steric hindrance between the aminopropynyl group of pdU and modified phenyl group 
of the monomer.  However, charge-repulsion may also play an important role.
All monomers demonstrate good to high selectivity for CG over the other base pairs, at 
all pHs tested in both TXT and PXP sequences.  In all cases, the second most stable 
binding is to TA as originally expected.  The least stable binding occurs to GC then AT, 
or to AT then GC for 
GPP.  For TXT at pH 6.2, the guanidinium and aniline demonstrate 
the highest selectivity, by 7.5 °C, and the acetamide the least, by 2.0 °C.  For TXT at pH 
6.6, the guanidinium is most selective (DTm 7.4 °C) and the acetamide the least (DTm 2.4 
°C), and for PXP at pH 6.2, the aniline is most selective (DTm 9.6 °C), followed by the 
urea (DTm 8.4 °C), the guanidinium (DTm 5.0 °C) then the acetamide (DTm 4.7 °C).
112The high selectivity of 
GPP and 
UPP compared to 
AcPP can be rationalised by the extra 
potential hydrogen-bond, which can effect differentiation between the binding motifs of 
CG and the other base pairs more effectively.  It does not explain the good selectivity 
for the aniline possessing only one potential hydrogen-bond donor, although in the PXP 
sequence, general destabilisation of 
GPP and 
UPP, due to neighbouring pdU nucleotides, 
may reduce their selectivity relative to the aniline.
Data for the pdU-containing TFOs demonstrates greater stability for TXP over PXT for 
aniline, urea and guanidinium, and the reverse for the acetamide, in all cases (not tested 
at pH 6.2 for 
APP and 
GPP).  The greatest difference between TXP and PXT occurs for 
GPP (DTm 2.5 °C), is moderate for 
UPP (DTm 1.2 °C) and 
APP (DTm 1.1 °C) and small for 
AcPP (av. DTm 0.4 °C).
Charge-repulsion may explain this difference for the guanidinium monomer, and steric 
hindrance for the urea, but there must be alternative reasons for the observed differences 
for the aniline and acetamide.
The fluorescence melting study results suggest the aniline, urea or guanidinium would 
prove suitable candidates.  The guanidinium has the greatest binding affinity in most of 
the conditions tested and the aniline proved the most selective, followed by the 
guanidinium and urea.   Due to sensitivity of intermediates in the synthesis of the 
guanidinium monomer, either the urea or aniline are probably more suitable.
6.4. Melting Study Comparison
The fluorescence melting study data (Section 6.3) correlates with previous fluorescence 
melting data (Sections 4.2.2, 6.1), but not with the UV melting study data (Section 6.2). 
Importantly, the order of binding affinity has stark differences between the two studies.
It is possible that the sequence composition may be partly responsible for the observed 
differences.  Examining the neighbouring triplets to the central three-triplet triplex core 
of the UV and fluorescence melting motifs, only the triplet on the 5’-side is the same 
(M
+.GC) (Figure 6.4).
113 ..TTM VXW MTM..        ..TPM VXW TPT..
...AAG AYA GAG...      ...AAG AYA AAA...
...TTC TZT CTC...      ...TTC TZT TTT...
UV melting Fluorescence Melting
Figure 6.4.   Central sections of UV and fluorescence melting triplex motifs highlighting 
matched triplets (boxed) and differences (red).
It is difficult to explain all the differences between the two studies, however, by 
analysing the differences in the sequence around the central core, without extensive and 
time-consuming melting and NMR experiments.  It is likely that the general triplex 
shape, general TFO composition and whether the duplex part is a hairpin or comprises 
separate strands, contributes to the differences in trends between systems.
In order to rule out the possibility that the method of analysis is responsible, although 
unlikely, UV melting experiments should be performed using the fluorescence melting 
triplex motif.  The fluorophore and quencher should not affect the trends, only causing a 
slight general increase in Tm.  The oligonucleotides could also be resynthesised without 
DABCYL and FAM, although this would create significant work.
If the method of analysis is proven not to be a factor, the differences must be sequence-
dependent.  This would have considerable implications when designing TFOs for gene-
targeting and oligotherapeutics.  Depending on the sequence and also interaction with 
other modified/un-natural nucleotides and recognition monomers, the same monomer 
may have significant differences in selectivity and binding affinity.  Optimising both of 
these properties is vitally important for achieving mixed-sequence recognition under 
physiological conditions.
6.5. Fluorescence Properties of CG Recognition Monomers
The synthesis and fluorescent properties of pyrrolo-C nucleobases, nucleosides and 
PNA monomers have been studied in detail by Robert Hudson et al.
120,230-235 and others
119 
as they can be used as fluorescent reporter  groups in SNP analysis
236  and  for 
fluorimetric detection of guanosine.
120,233  Fluorescence decreases significantly only on 
duplex hybridisation with G, such that the change is visible to the naked eye on 
irradiation of the solution with long-wave UV light (365 nm).
114These   pyrrolo-dC   compounds   have   not,   however,   been   evaluated   as   probes   or 
fluorophores in triplexes, and only the triplex-forming properties of N-methylpyrrolo-
dC derivatives have been studied thus far.
67,122,207   For this purpose, the fluorescence 
properties of the four deprotected nucleosides, 
APP 143, 
AcPP 225, 
UPP 182 and 
GPP 226 
were evaluated to afford an indication of their usefulness in this application.  Their 
deprotection procedures are described in Section 9.2.6 (Scheme 6.1)
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Scheme 6.1.  Deprotection of N-methylpyrrolo-dC nucleosides 184,193,195,207.
The excitation and emission wavelengths were measured in HPLC grade methanol (
APP 
143, 
AcPP 225) or anhydrous DMF (
UPP 182, 
GPP 226) using a Varian Cary 400 Scan 
UV-Visible   Spectrophotometer   and   a   Varian   Cary   Eclipse   Fluorescence 
Spectrophotometer respectively (Section 9.2).  The extinction coefficient was calculated 
for each excitation maximum using the Beer-Lambert Law (A = ecL; A = absorbance,
e  = molar extinction coefficient, c = molar concentration, L = pathlength/cm – see 
Section 9.2) and all data is detailed in Table 6.4 below.
X labs1 e1 labs2 e2 labs3 e3 lem lem–labs1
APPp 356.3 3730 237.8 16680 203.2 12100 448.5 92.2
AcPPp 355.5 5530 243.4 33060 202.8 19130 458.0 102.5
UPPp 358.5 15140 287.4 13740 276.4 13410 429.5 71.0
GPPp 366.6 6690 270.2 22380 – – 458.0 91.4
Table 6.4.   UV/Fluorescence data for  N-methylpyrrolo-dC nucleosides  143,225,182,226:
labs1,2,3 = excitation/absorption maxima (nm), lem = emission wavelength (nm) from excitation at 
labs1, e = molar extinction coefficient (L mol
-1 cm
-1), lem–labs1 = Stokes Shift (nm).
Absorption and emission spectra are displayed in Figure 6.5.  Absorption data has been 
truncated for samples run in DMF due to noise caused by loss of solvent transparency 
115below ~270 nm.  Emission data has been scaled for easy visual comparisons between 
curves.
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Figure 6.5.   UV absorption (solid line) and fluorescence emission (dashed line) spectra for
N-methylpyrrolo-dC nucleosides.  Properties measured at different concentrations.   
UPPp and 
GPPp absorption data were truncated below ~260 nm.  Emission data scaled by scale factor = 1 
(
APPp), 0.1 (
AcPPp), 10 (
UPPp), 0.6 (
GPPp).  Fluorescence spectra obtained by excitation at labs1 
maxima (350-370 nm).
The urea, which demonstrated good binding affinity and selectivity, has the highest 
extinction coefficient (15140 L mol
-1 cm
-1) by greater than a factor of 2.  The Stokes 
shift, although lowest at 71.0 nm, is still very good.  The acetamide, despite performing 
poorest in melting studies, has the highest Stokes Shift (102.5 nm), comparable with 
that of the 6-arylpyrrolo-C nucleobases  227-229  and PNA monomers  230,231  of 
Hudson et al..
230,231  The guanidine demonstrated a good Stokes Shift (91.4 nm) and has 
the second highest extinction coefficient of 6690 L mol
-1 cm
-1, thus may show most 
potential as a triplex probe.  Additionally, all emission spectra maxima have minimal 
spectral overlap with their corresponding excitation maxima. 
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Figure 6.6.  6-Arylpyrrolo-C derivatives 227-231 of Hudson et al..
230,231
All nucleosides emit close to the excitation wavelength of DABCYL (471 nm), and 
therefore could be used instead of fluorescein (FAM) in fluorescence melting studies, or 
in combination with other acceptors for FRET analysis.  There may also be a significant 
change in fluorescence emission on triplex hybridisation, analogous to that observed by 
Hudson in the duplex, on pairing with G.
120,233  3’-Pyrene-modified dT has also found 
use as a probe,  showing marked  increase in fluorescence  on triplex  formation, 
depending on position within the triplex.
237   Fluorescence was strongly dependent on 
correct hybridisation, which offered the potential for detection of duplex mutations.
The quantum yields should be determined next, for absolute confirmation of the best N-
methylpyrrolo-dC probe candidate.
6.6 Conclusions & Future Work
The final melting studies confirm the efficacy of these monomers to specifically 
recognise a CG inversion in a homopurine tract.   Comparing the results from both 
studies, the monomers of choice should be the urea and the aniline.   The aniline 
outperformed the other monomers in the UV melting study for both binding affinity and 
selectivity, and the urea also demonstrated its efficacy.  The guanidinium monomer 
demonstrated the highest binding affinity in the fluorescence melting study, followed by 
the urea.  However, the aniline proved slightly more selective and the urea less so on 
average, and these are easier to synthesise than the guanidinium.   The acetamide 
performed relatively poorly throughout both studies, comparibly with T, except where 
placing pdU on the 5’-side caused destabilisation of the other monomers.
It is difficult to rationalise the differences between the two studies, which should be 
well correlated.   Differences such as the change in order of stability of the pdU-
117containing triplexes, and relative binding affinities and selectivity have not yet been 
explained, but several factors may contribute and there are some studies, which can be 
carried out to examine this.  The three best monomers have been tested against real gene 
targets, and are currently being re-synthesised for further tests, in conjunction with other 
recognition monomers.   Such mixed-sequence triplex-based recognition has already 
been evaluated,
67 and gene targeting studies are in progress.
The 6-phenyl-N-methylpyrrolo-dC phosphoramidite monomer 221 was synthesised by 
Dr. Edrees-Abdou, as detailed in Section 5.2, in excellent yield and melting studies are 
underway.  Further modifications for assessment are described also in Section 5.2.
Finally, the fluorescence properties of the four CG recognition monomer nucleosides 
show potential for their use as probes within triple helices and in fluorescence studies, 
including melting.  The Stokes Shifts and extinction coefficients are comparable with 
the NH-pyrrolo-C analogues of Hudson et al.,
230,231 which have already found use in 
fluorimetric detection of G.
120,233  Quantum yields must be determined, however, so the 
most efficient substrate can be chosen.
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7.1 Introduction
238
The industry standard method for custom chemical oligonucleotide synthesis is the 
automated   phosphoramidite   or   ‘phosphite   triester’   cycle   on   solid-support,   first 
developed   by   Prof.   Marvin   Caruthers  et   al.  in   1981.
239,240    Modern   automated 
DNA/RNA synthesisers can synthesise oligonucleotides on solid-support, from 2-250 
nucleotides long, with stepwise coupling efficiencies of 98.0-99.5% for the standard 
DNA phosphoramidites, dA, dC, dG and dT.  Oligonucleotides may be synthesised on a 
40 nmole up to multi-millimole scale for therapeutic applications.  Syntheses of up to 
0.2 and 1.0 mmole are typical for research applications.  The method, to be successful, 
requires a robust protecting group strategy due to the conditions, which the developing 
oligonucleotide is exposed to during synthesis.   Equally, protecting groups must be 
labile under easily accessible deprotection conditions after synthesis, and ideally 
cleavage from the support should be facile and as near to quantitative as possible.
Standard solid-supports include controlled pore glass (CPG) and polystyrene-based 
resin/beads, to which the oligonucleotide is attached by a base-labile linker.   The 
exocyclic amines in the standard nucleotides are protected with base-labile protecting 
groups, such as benzoyl and isobutyryl, which are stable during synthesis but easily 
removed afterwards (Figure 7.1).
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Figure 7.1.   Protected oligodeoxynucleotide (ODN) on solid-support and standard DNA 
nucleobases,   illustrating   base-labile   functionalities   (succinyl   linker   –   red;   2-cyanoethyl 
phosphate protecting group – blue; acyl protecting groups – violet).  dT nucleobase requires no 
protection.
120Non-standard nucleosides, either natural or synthetically modified, are incorporated by 
the same method, appropriately protected with base-labile or other labile groups. 
Alternative   compatible   protecting   groups   for   primary/exocyclic   amines   include 
phthalimide, trifluoroacetyl and phenoxyacetyl.  Hydroxyl groups may be protected as 
the TBDMS- or allyl-ether for example.  The protecting group lability can be altered 
depending on the oligonucleotide sensitivity and desired deprotection conditions.
7.2 Deprotection Conditions for Oligonucleotides
238
The standard reagents for deprotection of non-modified oligodeoxynucleotides (ODNs), 
are concentrated (~33 wt%) aqueous ammonia and concentrated (40 wt%) aqueous 
methylamine.  The oligonucleotide may be cleaved from the solid-support under mild 
conditions (conc. aq ammonia, rt, 1 hour) before heating or further treatment, or the 
support may be removed from the synthesis column and all deprotections carried out in 
one step.  Treatment at rt overnight or at 55 °C for 4-6 hours is usually sufficient to 
ensure full deprotection of shorter ODNs.  Using a 1:1 mixture of conc. aq ammonia 
and conc. aq methylamine (AMA) may also be used to significantly reduce deprotection 
time for nucleosides such as 
AcdC, 
BzdA and 
iBudG.  AMA can also be used for quick 
cleavage of DNA from the solid-support (5-15 minutes).   Methylamine and AMA 
should not be used for deprotection of 
BzdC, however, as there is precedent for attack of 
the C
4-position by alkylamines, to form the 4N-alkyl-dC derivative.  Oligonucleotides 
may also be deprotected using pressurised ammonia or methylamine gas, following 
cleavage from the support.
Standard deprotection conditions are also usually sufficient for deprotection of other 
base-labile groups.  Phthalimide may be cleaved using methylamine or hydrazine, and 
allyl groups can be removed by automated treatment with palladium (0), such as a 
solution   of   Pd(PPh3)4  in   chloroform,   containing   5%   acetic   acid   and   2.5%  N-
methylmorpholine,
241,242 before removal from the synthesiser for cleavage/deprotection. 
Oligonucleotides may also be treated with diethylamine before cleavage from the 
resin,
243,244 or by addition of nitromethane during deprotection.
245  These reagents cleave 
2-cyanoethyl groups from the phosphate esters and scavenge acrylonitrile, a by-product 
of oligonucleotide synthesis.   Nitromethane acts predominantly as a scavenger of 
acrylonitrile.   Without such treatments, a small proportion of dT nucleotides are 
121cyanoethylated at the N
3-position.  Such adducts however, do not form readily when 
deprotecting using methylamine, which also acts as a scavenger.   Ammonia is not 
nucleophilic enough to act as an effective scavenger.
Washing of the solid-support with 20% diethylamine/acetonitrile is incorporated into 
the automated synthesis procedure on some new DNA/RNA synthesisers.  2-Cyanoethyl 
groups  are cleaved   and  acrylonitrile  scavenged  before  cleavage  from  the solid-
support.
246  Diethylamine will only cause cleavage from solid-support upon prolonged 
exposure (>5 hours).
7.3 Oligonucleotide Deprotection Study
7.3.1 Background
Oligonucleotides synthesised for the initial UV and fluorescence melting studies 
(Chapters 4, 6) were analysed by analytical HPLC and either electrospray or MALDI-
TOF MS.   Analysis of the non-labelled furano-dT modified TFOs for UV melting, 
showed that after deprotection with 30 wt% aqueous methylamine (rt, 6-24 hours), and 
treatment   with   DOWEX-H
+  resin,   cyclisation   of   the   methylamine   ring-opened 
intermediate was not quantitative (Figure 7.2).  However, HPLC purification of these 
oligonucleotides was successful as resolution was obtained.
Figure 7.2.  HPLC traces of UV melting TFOs (OL4,5) following first HPLC purification and 
treatment with DOWEX-H
+ resin.
OL4
OL5
122HPLC analysis of the DABCYL-labelled TFOs for fluorescence melting, however, 
could not resolve the components.  The large lipophilic DABCYL moiety causes the 
labelled DNA to adhere strongly to the stationary phase, thus causing reduction in 
resolution (”streaking”).   MS analysis of several of the first DABCYL-labelled  N-
methylpyrrolo-dC modified TFOs (OL18-21, 
AcPPp; OL23, 
UPPp), indicated they were 
clean following HPLC purification, and they were subsequently used in melting studies.
HPLC analysis of some of the crude mixtures before purification (OL18-21), identified 
a normal distribution of minor impurities around the major peak.   Analytical ion-
exchange (IONEX) chromatography of HPLC-purified TFO OL19, resolved a small 
possible failure sequence peak, and due to the long retention time was deemed 
unsuitable as a method of purification (Figure 7.3).
                 
Figure 7.3.  HPLC traces of 
AcPPp-modified TFOs (OL18-21) before purification and IONEX 
trace of OL19 after HPLC purification.
Following this work, a Capillary Electrophoresis system was acquired, from which very 
high resolution chromatograms could be obtained.   CE analysis of several of the 
DABCYL-modified TFOs, resolved each into three peaks for both furano-dT (OL14, 
APPf) and N-methylpyrrolo-dC modified TFOs (OL20, 
AcPPp; OL23, 
UPPp) (Figure 7.4). 
This result could be rationalised for the furano-dT modified TFO, as a mixture of 
cyclised (highest retention time), uncyclised/ring-opened TFOs and a sequence where 
one phosphoramidite coupling did not occur (failure sequence, lowest retention time). 
The observation is harder to explain for the  N-methylpyrrolo-dC modified TFOs 
OL19
123(deprotected using conc. aq NH3), where only ring-opening by ammonia or failure 
sequences could be held accountable.   Failure sequences are usually capped by 
treatment   with   acetic   anhydride,   before   the   oxidation   step   in   each   cycle   of 
oligonucleotide synthesis.  If synthesised without capping, failure sequences, which are 
usually minor, may become more prominent, especially when using synthetically-
modified nucleosides.  However, this may account only for the smaller peak of lowest 
retention time, and ring-opening by ammonia appears unlikely.  Secondary structures 
may also provide an explanation but are even more unlikely.
Figure 7.4.  CE traces of DABCYL-modified TFOs (OL14, OL20, OL23).
Concurrently there were problems with TFOs containing the GC-recognition monomer, 
bis-amino-U (
BAU).   Following incorporation into the TFO, the oligonucleotide was 
deprotected using 40 wt% aqueous methylamine.  Methylamine was also required for 
cleavage of the phthalimide protecting group on the 2’-moiety (Scheme 7.1).  Despite 
previous   successful   deprotections   and   melting   studies,
35-37  problems   were   later 
encountered.  Although HPLC analysis of the TFOs indicated they were pure, melting 
studies afforded poor results, i.e. little or no triplex formation.  On receipt of the CE 
machine, analysis of some of these TFOs revealed a mixture of peaks, which could only 
be accounted for by excessive degradation of the TFO, not by failure sequences alone. 
This suggested that the deprotection conditions must have changed since the previous 
TFOs containing this monomer were synthesised, deprotected and purified.
OL14 OL20 OL23
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Scheme 7.1.  
BAU nucleotide deprotection in TFO.
After these results, it was decided to investigate oligonucleotide deprotection conditions 
to determine the optimum conditions for monomers used within the research group.
7.3.2 Deprotection Study
A series of oligonucleotides were synthesised on a 1.0 mmole scale (with capping) based 
on oligoT (T12), containing the monomers under examination (Figure 7.5).
TTT TTT TTX TTT TTT TYT YTY TTT TZZ ZTZ ZTZ TZT
Figure 7.5.  Sequences for oligonucleotide deprotection study; X = T (OL64), pdU (OL65), 
BAU 
(OL68), 
AcPPp (OL69), S (OL70), 
GpdU (OL74), 
MOEpU (OL71), 
AET (OL72); Y = pdU (OL66); 
Z = pdU (OL67).
After each oligonucleotide synthesis, the solid-support was removed from the column. 
Small portions of the resin (5-8 mg) were deprotected for varying lengths of time, at 
different temperatures using conc. aq ammonia, 20 wt% aq MeNH2 and 40 wt% aq 
MeNH2.  A list of all deprotections for each oligonucleotide is given in Table 7.1.
Following   deprotection,   the   resin   was   removed   and   solvent   evaporated,   the 
oligonucleotide residue was dissolved in distilled water (1.0 mL) and desalted using a 
disposable Sephadex NAP™  10 column.   All samples were then analysed, without 
HPLC purification,  by CE.   ES and MALDI-TOF MS analyses  were taken as 
appropriate.  Analytical HPLC and IONEX were also used for several samples.
125ODN X Sequence
Deprotection Conditions MS
Conc
n Base Temp Time/h ES MALDI
OL64 – TTT TTT TTT TTT
conc NH3 55 °C 5
20% MeNH2 rt 15
40% MeNH2 rt 15
OL65 pdU TTT TTT TTX TTT
conc NH3 rt 5  
conc NH3 rt 15 
conc NH3 55 °C 5
conc NH3 55 °C 15 
20% MeNH2 rt 15
40% MeNH2 rt 15  
OL66 pdU TTT TXT XTX TTT
conc NH3 rt 1  
**conc NH3 rt 1
conc NH3 rt 5
conc NH3 rt 15
conc NH3 55 °C 4  
conc NH3 55 °C 15 
20% MeNH2 rt 5
20% MeNH2 rt 15 
40% MeNH2 rt 15
OL67 pdU TXX XTX XTX TXT
conc NH3 55 °C 1 
**conc NH3 55 °C 1 
OL68
BAU TTT TTT TTX TTT
conc NH3 55 °C 15  
conc AMA rt 15
20% MeNH2 rt 5  
20% MeNH2 rt 8
20% MeNH2 rt 15 
20% MeNH2 rt 30  
OL69
AcPPp TTT TTT TTX TTT
conc NH3 rt 5  
conc NH3 55 °C 4 
20% MeNH2 rt 5
40% MeNH2 rt 6 
40% MeNH2 rt 15  
OL70 S base TTT TTT TTX TTT
conc NH3 rt 5  
conc NH3 rt 15 
conc NH3 55 °C 5 
conc NH3 55 °C 15  
20% MeNH2 rt 5
40% MeNH2 rt 15 
OL71
MOEpU TTT TTT TTX TTT
conc NH3 rt 5
conc NH3 55 °C 5
20% MeNH2 rt 5
OL72
AET TTT TXT XTX TTT conc NH3 55 °C 4
OL73
AET TTT TTT TTX TTT conc NH3 55 °C 4
OL74
GpdU TTT TTT TTX TTT
conc NH3 rt 5
tBuNH2:MeOH:H2O (1:1:2) rt 21
Table 7.1.  Oligonucleotides, deprotection conditions and MS analysis.  Optimum conditions 
evaluated are in bold.   **Column washed with 20% Et2NH/MeCN for 10 minutes before 
removal of resin for deprotection.
1267.3.2.1 Control T12 Oligonucleotide
Control oligonucleotide T12 (OL64) was deprotected successfully by three methods.  No 
degradation was observed by CE, hence even the strongest deprotection conditions
(40 wt% aq MeNH2) caused no degradation of the DNA backbone (Figure 7.6).
Figure 7.6.  CE traces for deprotections of T12 (OL64).
It was deduced therefore, that any impurities observed for other oligonucleotides must 
be due to failure sequences (n-1, n-2 etc.), degradation of the modified nucleotide, or 
fragmentation of the oligonucleotide due to the modification.
7.3.2.2 Test Oligonucleotides – 5-(3-Aminopropynyl)-dU (pdU)
The first modified monomer to be tested, pdU, was incorporated into three sequences 
with one, three and seven insertions.
conc. aq NH3, 55 °C, 5 hrs 20% aq MeNH2, rt, 15 hrs 40% aq MeNH2, rt, 15 hrs
127Figure 7.7.  CE traces for deprotections of T8XT3 (X = pdU, OL65).
The best conditions for T8XT3 (X = pdU, OL65), giving the least degradation, are conc. 
aq ammonia at rt for 5 hours (Figure 7.7).  A longer time does not significantly affect 
the impurity profile.  Heating at 55 °C for 5 hours is also suitable, but heating overnight 
(15 hrs) caused further appearance of impurities.   A 20 wt% aqueous solution of 
methylamine also deprotected causing little degradation overnight.
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Scheme 7.2.  Proposed cleavage/degradation of T8XT3 by methylamine at high concentration.
However, it is very clear that using conc. aq methylamine (40 wt%) causes formation of 
a significant impurity (2581 Da) plus other minor peaks.  This major impurity can be 
explained by cleavage of the oligonucleotide at the 3’-side of pdU, and displacement of 
the alkynyl-U nucleobase by methylamine (Scheme 7.2, Figure 7.8).
conc. NH3, 55 °C, 5 hrs 20% MeNH2, rt, 15 hrs 40% MeNH2, rt, 15 hrs conc. NH3, rt, 15 hrs conc. NH3, 55 °C, 15 hrs
128Figure 7.8.  MALDI-TOF MS spectra for two deprotections of T8XT3 (X = pdU, 3627.4 Da, 
OL65).  * Internal T10 and T15 references.
Similar observations were made for three additions of pdU (T4XTXTXT3, OL66).  The 
mildest successful deprotection conditions were treatment with conc. aq ammonia at rt 
for 1 hour only, after washing the resin with 20% Et2NH/CH3CN for 10 minutes. 
Without the diethylamine wash, impurities were present.  For this sample, this was due 
either   to   poor   coupling   of   pdU,   perhaps   caused   by   presence   of   pyridine   in 
phosphoramidite, or too little time for complete deprotection, not the lack of a 
diethylamine wash.  Under these conditions, 1 hour is the shortest possible time for 
cleavage from the resin, but may not be long enough for consistent deprotection of all 
protecting groups (Figures 7.9, 7.10).
Figure 7.9.  CE traces for deprotections of T4XTXTXT3 (X = pdU, OL66).
conc. NH3, rt, 5 hrs
40% MeNH2, rt, 15 hrs
20% MeNH2, rt, 15 hrs
40% MeNH2,
rt, 15 hrs 20% MeNH2, rt, 5 hrs conc. NH3, 55 °C, 4 hrs conc. NH3, rt, 1 hr
129Heating at 55  °C for only 4 hours with conc. aq ammonia formed several small 
impurities, and treatment overnight at rt with 40 wt% methylamine caused extensive 
oligonucleotide degradation.  Treatment with 20 wt% methylamine at rt could be used 
for 5 hours, but impurities formed over 15 hours.
Figure 7.10.   ES MS spectra for two deprotections of T4XTXTXT3 (X = pdU, 3705.5 Da, 
OL66).  Data deconvoluted to resolution of 1 Da.
Oligonucleotide TX3TX2TXTXT (X = pdU, OL67) was successfully deprotected under 
mild conditions (conc. aq ammonia, 55 °C, 1 hr) with and without a prior diethylamine 
wash.  The small impurities were slightly greater without washing and failure sequences 
became slightly more prominent.  A slightly longer deprotection time (~2 hours) may 
have removed some of these trace impurities.  HPLC and IONEX traces were similar 
for both (Figure 7.11).
A small impurity was present in these oligonucleotides (3651 Da in OL66), due to 
incorporation of a single dU nucleoside instead of pdU.  The dU impurity was formed 
during the Sonogashira cross-coupling reaction in synthesis of the pdU phosphoramidite 
monomer 164 and was present at approximately 2-3%.  When used in synthesis of the 
deprotection study oligonucleotides, it only became noticeable on multiple additions. 
When oligonucleotide OL66 was re-synthesised using a different batch of monomer, 
with   and   without   capping   for   comparison,   only   trace   baseline   impurities   were 
noticeable.   Synthesis was as effective with capping as without capping indicating 
absence of failure sequences.
conc. NH3, rt, 1 hr
conc. NH3, 55 °C, 15 hrs
130     
Figure 7.11.  HPLC/CE traces for deprotections of TX3TX2TXTXT (X = pdU, OL67).
7.3.2.3 Test Oligonucleotides – Bis-amino-U (
BAU)
The next monomer under test was  bis-amino-U (
BAU).   The best conditions for 
deprotection were discovered to be 20 wt% aq methylamine, at rt for 5 hours.
Figure 7.12.  CE traces for deprotections of T8XT3 (X = 
BAU, OL68).
Little change was noted after 8 hours, but after 15 and 30 hours notable impurities had 
formed.  Heating at 55 °C in conc. aq ammonia for 15 hours, and treating with AMA 
(conc. aq NH3/40 wt% aq MeNH2, 1:1 v/v) at rt for 15 hours produced a similar 
significant pattern of impurities (Figure 7.12).
20% Et2NH/MeCN
conc. NH3, 55 °C, 1 hr conc. aq NH3, 55 °C, 1 hr
AMA, rt, 15 hrs conc. NH3, 55 °C, 15 hrs 20% MeNH2, rt, 30 hrs 20% MeNH2, rt, 15 hrs 20% MeNH2, rt, 5 hrs
131Figure 7.13.  MALDI-TOF/ES MS spectra for two deprotections of T8XT3 (X = 
BAU, 3686.5 
Da, OL68).  ES data deconvoluted to resolution of 1 Da.  * Internal T10 and T15 references.
Only a ‘minus T’ failure sequence (3382.3 Da) was identified by MS.  The other MS 
peaks could not be assigned (Figure 7.13).  Methylamine is required for phthalimide 
cleavage, but a high concentration causes significant degradation.
7.3.2.4 Test Oligonucleotides – 6-(3-Acetamidophenyl)-N-methylpyrrolo-dC (
AcPPp)
The   acetamide   monomer   for   CG   recognition   was   incorporated   into   a   ‘T12 
oligonucleotide’ (T8XT3, X = 
AcPPp, OL69) and proved stable to conc. aq ammonia at rt 
for 5 hours, and 55 °C for 4 hours, and also to 20 wt% aq methylamine at rt for 5 hours 
(Figure 7.14).     Heating at 55  °C in conc. aq ammonia for 15 hours caused more 
significant degradation than AMA at rt for the same time.
20% MeNH2, rt, 5 hrs
conc. NH3, 55 °C, 15 hrs
132Figure 7.14.  CE traces for deprotections of T8XT3 (X = 
AcPPp, OL69).
Concentrated aq methylamine, however, primarily caused major conversion to the 
cleavage product (2581 Da) shown in Scheme 7.2 (Figure 7.15).
Figure 7.15.  ES MS spectra for two deprotections of T8XT3 (X = 
AcPPp, 3744.6 Da, OL69). 
Data deconvoluted to resolution of 1 Da.
This was originally presumed to be the deacetylated oligonucleotide, but was confirmed 
otherwise   by   ES   and   MALDI-TOF   MS.     No   ring-opening   of   the  N-
methylpyrrolopyrimidine nucleobase by methylamine was observed.
AMA, rt, 15 hrs conc. NH3,
55 °C, 15 hrs
20% MeNH2, rt, 30 hrs 20% MeNH2,
rt, 15 hrs
20% MeNH2,
rt, 5 hrs
conc. NH3, rt, 5 hrs
40% MeNH2, rt, 15 hrs
1337.3.2.5 Test Oligonucleotides – S base (TA recognition monomer, S)
The ‘S base’ monomer for TA recognition (Section 1.2.2.1), was incorporated into oligo 
OL70 (T8XT3, X = S) for deprotection studies.  The main aim for this modification was 
to find conditions, to which the acetamide moiety would be stable.   CE analysis 
produced only a single peak for each sample, but was unable to resolve acetylated and 
deacetylated products.
Figure 7.16.  CE trace for strongest deprotection conditions (40% aq methylamine, rt, 15 hrs), 
and ES/MALDI-TOF MS spectra for two deprotections of T8XT3 (X = S, 3737.6 Da, OL70). 
Deacetylated oligonucleotide mass (3695.6 Da).  ES data deconvoluted to resolution of 1 Da.  * 
Internal T10 and T15 references.  Structure of ‘S’ is shown.
MS analysis highlighted stability in conc. aq ammonia at rt for up to 15 hrs.  Heating at 
55 °C in conc. ammonia for only 5 hours caused some deacetylation, and in 40 wt% aq 
methylamine at rt, a significant amount (Figure 7.16).   CE analysis of the sample 
deprotected with 20% aq methylamine (rt, 5 hrs) showed a very sharp peak, but conc. 
ammonia was concluded as the best deprotection medium.
7.3.2.6 Test Oligonucleotides – 5-(3-aminopropynyl)-2’-O-methoxyethyl-U (
MOEpU)
AT recognition monomer, 
MOEpU, was incorporated into sequence T8XT3 (OL71) for 
comparison with its 2’-unmodified analogue, pdU.  Poor coupling of the monomer, 
however, resulted in a major failure sequence (T11) of similar proportion to product by 
conc. NH3, rt, 5 hrs
conc. NH3, 55 °C, 15 hrs
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134CE.  Of the three conditions tested (Table 7.1), heating at 55 °C in conc. aq ammonia 
for 5 hrs caused an increase in the apparent failure sequence peak and a small increase 
in the general impurity profile over the other two.
7.3.2.7 Test Oligonucleotides – Other AT recognition monomers
AT recognition monomer, 2’-aminoethoxy-T (
AET) was incorporated into T8XT3 (OL72) 
and T4XTXTXT3 (OL73) and both were deprotected at 55 °C in conc. aq ammonia for 4 
hours.  Both samples produced very clean HPLC traces hence this method was deemed 
suitable, and this should be applicable also at rt.
5-(3-Guanidinylprop-1-ynyl)-dU (
GpdU) was incorporated once (T8XT3, OL74) and 
treated under two deprotection conditions.  Deprotection with conc. aq ammonia (rt, 5 
hrs) caused formation of two major peaks plus impurities by CE (Figure 7.17).  
Figure 7.17.  CE traces for deprotections of T8XT3 (X = 
GpdU, OL74).
One major peak (~22.8 minutes) appears to correspond to the oligonucleotide with a 
fully-protected guanidinyl moiety.   The other (~21.9 minutes) may correspond to a 
stable triazinedione derivative, caused by cyclisation due to attack by ammonia.  This 
was observed by Prakash et al.
225 when deprotecting oligonucleotides, containing 2-
cyanoethyloxycarbonyl- (CEOC) protected guanidinyl moieties, with ammonia (Figure 
7.18).  Prakash et al. cleaved the CEOC groups in 50% aq piperidine at rt for 24 hours, 
prior to heating at 55 °C in conc. ammonia.  Treating with 50% aq piperidine also 
tBuNH2:MeOH:H2O, rt, 21 hrs conc. NH3, rt, 5 hrs
135cleaved the 2-cyanoethyl phosphate protecting groups and cleaved the oligonucleotide 
from the resin.
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Figure 7.18.  Possible mechanism of formation of triazinedione derivative.
225
It was later discovered that another secondary amine, diethylamine, could be used 
instead of piperidine.  Washing the column with 20% Et2NH/CH3CN for at least 30 
minutes prior to deprotection, was sufficient to remove the most labile CEOC group 
thus preventing triazine formation.   It is likely that methylamine would attack the 
CEOC groups in the same manner but the steric bulk of the methyl group might prevent 
cyclisation after attack.
The second deprotection of OL74 was carried out in 
tBuNH2:CH3OH:H2O (1:1:2 v/v/v) 
at rt for 21 hours.  Tert-butylamine was used to cleave all protecting groups at the same 
time.   It was presumed that the sterically-hindering  tert-butyl group would prevent 
attack of the CEOC groups and cyclisation.  These conditions, however, proved too 
mild,   producing   a   mixture   of  bis-CEOC,  mono-CEOC   and   fully   deprotected 
oligonucleotides in an approximate ratio of 9:5:1 (Figure 7.17).  
7.4 Conclusion
The results of this study highlight the need for suitable/compatible deprotection 
conditions for each modified nucleotide within the oligonucleotide.   It cannot be 
assumed that the conditions used for one modification, will be safe to use for another, as 
proven by the compatibility of most modifications to deprotection with conc. ammonia 
at rt, except the CEOC-protected guanidinyl-modified nucleotide.
136Concentrated (40 wt%) aq methylamine was proven too strong for deprotection of all 
oligonucleotides containing modified non-natural nucleotides.  It is likely that previous 
deprotections of  
BAU-containing oligonucleotides using conc. aq methylamine were 
successful, due to evaporation of methylamine over time from the bottle in use, thus 
reducing the effective concentration.
In general, conc. aq ammonia can be used to deprotect most modified oligonucleotides, 
either at rt or sometimes with heating.  Methylamine is needed for cleaving phthalimide 
groups, and may be required for cleavage of more stable protecting groups.
Washing the column with 20% Et2NH/CH3CN solution for 10-20 minutes before 
removal from the synthesiser, was incorporated into the standard oligonucleotide 
synthesis protocol, on all synthesisers where it was not already included and could be 
easily achieved.  It cleanly cleaves 2-cyanoethyl groups and scavenges acrylonitrile, and 
proves highly effective at removing CEOC-protecting groups on guanidinyl-modified 
nucleotides.
These results were used for choosing deprotection conditions for oligonucleotides used 
within the research group, including for the TFOs used in the primary melting studies 
(Sections 6.2, 6.3).  For all TFOs used in these melting studies, following synthesis, the 
solid-support column was washed with 20% Et2NH/CH3CN for 20 minutes, or 3 hours 
for  
GPPp-containing  TFOs (OL48-51, OL56-59).   Each oligonucleotide was then 
deprotected in conc. aq ammonia at rt for 12 hours, with or without 2 hours at 50 °C, or 
at rt for 24 hours followed by heating at 50  °C for 1 hour to ensure complete 
deprotection.  CE analysis indicated good to high purity for most TFOs after one HPLC 
purification.   Where impurities constituted a significant proportion, the TFO was 
carefully repurified, collecting only the centre of the peak.  Impurities did not, however, 
hinder performance in melting studies.
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8.1. Modified 6-Oxocytidine Nucleosides for GC Recognition
Synthesis of a bis-amino-modified 6-oxocytidine monomer 64, was re-investigated as a 
potential GC recognition monomer, which exhibits pH-independent binding within a 
triplex.  Previous published studies
70,71 reported pH-independent triplex formation using 
6-oxoC nucleotides up to pH 8, and enhanced binding to GC at higher pH compared to C. 
Modifications to this nucleoside,
11,70,76  however, produced varied or negative results, 
hence   further   modifications   were   proposed   to   introduce   protonated   amine 
functionalities, which should enhance triplex stability.
Several synthetic investigations were carried out, in order to assess reaction feasibility. 
Palladium-catalysed alkynylation was ruled out as a method of introduction of amine 
functionality  at the 5-position  due to  inactivity  of the halogenated  substrate or 
degradation.  Modification by amine- or thiol-halide exchange was investigated with 
limited success, but this requires extensive optimisation if a robust synthetic route is to 
be found.  Feasibility of 2’-modification was also investigated, although this requires 
further work.   Optimised synthetic routes to some key intermediates have been 
developed.
8.2 Amino-Modified Bicyclic Nucleosides for CG Recognition
Recognition   of   pyrimidine.purine   base   pairs   is   a   greater   challenge   than 
purine.pyrimidine base pairs as fewer hydrogen-bonds are presented for binding in the 
major groove.  Previous published research describes the development of recognition 
monomers from T, based around the bicyclic C analogue, N-methylpyrrolo-dC.
122  This 
nucleobase retains the C
2 carbonyl group, vital for CG recognition, whilst blocking GC 
recognition by replacing an H for a methyl group at the 4N position.
The latest design had employed an aminoalkyl group for targeting of hydrogen-bonding 
residues on G across the base pair.  This research examined various meta-aminophenyl 
groups; rigidified linkers better placed for binding.
139Furano-dT 145-147 and N-methylpyrrolo-dC phosphoramidite monomers 178,179,191 
(199 – synthesis repeated later in house) were synthesised for assessment.  All were 
synthesised by a common synthetic route (Sonogashira cross-coupling, Cu(I)-catalysed 
cyclisation and phosphitylation) with some modifications, starting from DMT-protected 
5-iodo-2’-deoxyuridine  97,   and   analogue   5-iodo-N-methyl-2’-deoxycytidine  185 
respectively.  Yields ranged from moderate to excellent and most steps were optimised 
despite high substrate polarity.
Furano-dT monomers underwent post-synthetic modification to the N-methylpyrrolo-dC 
nucleotide after incorporation into DNA.   N-Methylpyrrolo-dC monomers could be 
incorporated   with   no   further   modification   necessary.     Although   post-synthetic 
modification was not complete, and HPLC purification was unable to resolve the 
mixture for DABCYL-labelled oligonucleotides, both performed equally in melting 
studies.
Thiourea-modified monomer  158  (synthesis finished later in house) could not be 
incorporated into TFOs due to issues with stability to oligonucleotide synthesis or 
deprotection, hence could not be assessed in biophysical studies.
Extensive   melting   studies   demonstrated   the   effectiveness   of   these   monomers   at 
recognising CG with high selectivity and good binding affinity compared to previous 
monomers (T, 
4HT, 
MP). The order of stability was altered, however, between UV and 
fluorescence melting studies.   This was proposed to be due to changes in target 
sequence and local environment around the CG inversion target, but requires further 
investigation.
The effect of neighbouring groups on the modification was also highlighted. The CG 
recognition monomers appear to interact differently with 5-(3-aminoprop-1-ynyl)-dU 
(pdU, P), depending on which side it is located.  This neighbouring group interaction 
introduces   important   implications   when   using   TFOs   as   oligotherapeutics,   as   all 
interactions must be taken in to account for successful development.
1408.3 Oligonucleotide Deprotection
A   study   was   conducted   to   determine   the   optimum   deprotection   conditions   for 
monomers used within the research group, after experiencing several problems.
Concentrated aq ammonia was determined the best medium for deprotection at rt or 
sometimes with heating.   Most monomers also tolerated 20% aq methylamine for 
approximately 5 hours.   Deprotection times of 15 hours or greater caused some 
degradation for several monomers, and the standard deprotection media, conc. aq 
methylamine and AMA, as used for non-modified DNA, caused significant to extensive 
degradation and strand cleavage for everything except the oligonucleotide T12.  
A  column   wash  with   20%  Et2NH/CH3CN  solution   was  introduced  on  to   DNA 
synthesisers where not already incorporated, after demonstrating efficient cleavage of 2-
cyanoethyl   phosphate   protecting   groups   and   prevention   of   cyanoethylation   by 
scavenging of acrylonitrile.  This wash also proved very effective at partial deprotection 
of the guanidine moiety of two monomers, thus avoiding subsequent side-reactions 
during deprotection.
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1429. Experimental
9 Synthesis
10 General
HPLC grade acetonitrile, methanol and water were purchased from Fisher Scientific. 
Pyridine, dichloromethane, triethylamine and diisopropylethylamine were distilled over 
calcium hydride; methanol, ethanol and isopropanol over magnesium and iodine; 
phosphorous oxychloride over sodium wire, and tetrahydrofuran over sodium wire and 
benzophenone before use.  Anhydrous N,N-dimethylformamide and 1,2-dichloroethane 
were purchased from Aldrich.  Diethyl ether was purchased from Fisher Scientific and 
dried by passing through a column of dry alumina then degassed at low temperature, or 
argon-degassed over 4Å molecular sieves.  Molecular sieves were oven-dried at greater 
than 120 °C over 2 days or microwave-activated.  Acetone was purchased from Fisher 
Scientific and dried over Drierite (anhydrous CaSO4).  6-Aminouracil was purchased 
from Aldrich, recrystallised from boiling water and dried over P2O5 before use.  Iodine/
pyridine/THF/water   solution   (0.02   M),   phosphitylating   reagents   and   DIHT   were 
purchased from Link Technologies.   N-Iodosuccinimide was purchased from Aldrich 
and recrystallised from 1,4-dioxane/carbon tetrachloride before use.  Deuterated NMR 
solvents were purchased from Apollo Scientific Ltd.  DOWEX 50WX8 ion-exchange 
resin was purchased from Aldrich and washed with 0.2 M HCl before treatment.  All 
other reagents were purchased from Aldrich, Lancaster, Avocado, Alfa Aesar, BDH, 
Fisher Scientific, Acros and Fluka, and used without purification.   All reactions 
requiring absence of oxygen were carried out under an atmosphere of argon.  Glassware 
was oven-dried overnight before use, for reactions requiring exclusion of moisture. 
Reactions were monitored by TLC, using Merck Kieselgel 60 F254 or Machenary-Nagel 
Alugram  Sil G/UV254  silica  gel  plates   (0.22  mm   thickness,  aluminium  backed). 
Compounds   were   visualised   by   irradiation   at   254/365   nm,   or   staining   with
p-anisaldehyde   (A’),   potassium   permanganate   (B’),   ninhydrin   (C’,   D’),
10% H2SO4/ethanol (E’) or ceric sulfate (F’), followed by heating.
143A’ – p-anisaldehyde / glacial AcOH / conc. H2SO4 / ethanol (9.2:3.8:12.5:338 v/v)
B’ – KMnO4 / K2CO3 / 5% aq NaOH / water (3:20 g/5:300 mL)
C’ – ninhydrin (5 g) / acetone (100 mL)
D’ – 0.3% w/v ninhydrin / butan-1-ol / 3% v/v glacial AcOH 
E’ – 10% v/v conc. sulfuric acid / ethanol
F’ – 8% w/v Ce(SO4)2.2H2SO4 hydrate / 15% v/v sulphuric acid
Column chromatography was carried out under air or argon pressure using Fisher 
Scientific DAVISIL 60Å (35-70 micron) silica gel.  Silica gel was pre-equilibrated with 
triethylamine or pyridine for purification of acid-senstive compounds.
Proton and carbon NMR spectra were recorded at 300/400 MHz and 75/100 MHz, 
respectively, using either a Bruker AC300 or Bruker DPX400 spectrometer.  Fluorine 
and phosphorous NMR spectra were recorded at 282 MHz and 121 MHz respectively, 
using a Bruker AC300 spectrometer.   NMR spectra were recorded in deuterated 
chloroform or dimethylsulfoxide.  Chemical shifts are given in ppm and spectra are 
calibrated to the residual solvent peak.
247   J  values are correct to within 0.5 Hz. 
Assignment was aided by DEPT-135,
1H–
1H COSY, HMQC and HMBC experiments 
and Lorentz-Gauss resolution enhancement data reprocessing (Win-NMR Lite).
Low-resolution mass spectra were recorded using electrospray ionisation (ES) on a 
Fisons VG platform instrument, or on a Waters ZMD quadrupole mass spectrometer in 
HPLC grade acetonitrile, methanol or water, or using electron ionisation (EI) on a 
ThermoQuest TraceMS single quadrupole GC-MS instrument in dichloromethane. 
High-resolution mass spectra were recorded in HPLC grade acetonitrile, methanol or 
water using electrospray ionisation on a Bruker APEX III FT-ICR mass spectrometer.
IR spectra were recorded on a Satellite FT-IR instrument using a ‘Golden Gate’ or 
‘Smart   Orbit’   adapter,   and   visualised   using   Win   First-lite   or   OMNIC   software 
respectively.  All absorptions are measured in cm
-1 and are described as broad (br), 
weak (w), medium (m), strong (s) or very strong (vs).
Melting points were recorded on a Gallenkamp Electrothermal melting point apparatus 
and uncalibrated.
144Elemental (CHN) Thermal Combustion Analysis was carried out by MEDAC Ltd., 
Egham, Surrey, UK.
1459.1.2 Experimental Procedure
1,3,5-Tri-O-acetyl-2-O-(2-phthalimidoethyl)-D-ribofuranose, 65
37
O
O O
O
Si
Si
O
89
1a
2
5
N
1'
2'
O
O C28H45NO8Si2
Mol. Wt.: 579.83
OMe
3' 4' 5'
6'
conc. H2SO4 (cat.)
AcOH / Ac2O (1:1, v/v), argon, rt
O
O AcO
AcO
65
1
2
5
N
1'
2'
O
O
5'
6'
OAc
C21H23NO10
Mol. Wt.: 449.41
To a stirred solution of 89 (3.31 g, 5.71 mmol) in glacial acetic acid/acetic anhydride 
(1:1 v/v, 30 mL), under an argon atmosphere, conc. sulfuric acid (0.35 mL, 6.57 mmol, 
1.1 eq) was added slowly.  The reaction mixture was stirred at rt for 1 hour.  Saturated 
aq sodium bicarbonate (250 mL) was added carefully to the dark green reaction 
mixture, which was extracted with CH2Cl2  (3  ´  100 mL).   The combined organic 
fraction was washed with sat. aq sodium bicarbonate and sat. aq KCl, dried (Na2SO4) 
and concentrated in vacuo to yield an orange-brown oil/solid.  Following purification by 
column chromatography (1:1, hexane/ethyl acetate), and drying under high vacuum, the 
product 65 was isolated, as an anomeric mixture (a:b ca 2:1), as a very pale yellow oil 
(2.11 g, 4.70 mmol, 82% yield).
Rf 0.17 (1:1, hexane/ethyl acetate, A’); 
1H NMR (400 MHz, CDCl3) d signals due to a 
anomer 7.86-7.80 (2H, m, H
5’), 7.74-7.68 (2H, m, H
6’), 6.07 (1H, s, H
1), 5.00 (1H, dd, J 
= 4.8, 6.8 Hz, H
3), 4.35-4.30 (1H, m, H
4), 4.29 (1H, t, J = 4.8 Hz, H
5), 4.14-4.08 (1H, 
m, H
5), 4.12-4.07 (1H, m, H
2), 3.94-3.83 (2H, m, H
2’), 3.83-3.72 (2H, m, H
1’), 2.05, 
2.04 (3H, s, COCH3), 2.00 (3H, s, COCH3), signals due to b anomer 7.86-7.80 (2H, m, 
H
5’), 7.74-7.68 (2H, m, H
6’), 6.29 (1H, d, J = 4.5 Hz, H
1), 5.13 (1H, dd, J = 2.5, 6.5 Hz, 
H
3), 4.38 (1H, br dd, J = 3.3, 7.3 Hz, H
4), 4.24 (1H, dd, J = 3.5, 12.6 Hz, H
5), 4.06 (1H, 
dd, J = 5.5, 12.1 Hz, H
5), 3.96 (1H, dd, J = 4.5, 6.5 Hz, H
2), 3.94-3.83 (2H, m, H
2’), 
3.83-3.72 (2H, m, H
1’), 2.07, 2.03, 1.96 (3H, s, COCH3); 
13C NMR (100 MHz, CDCl3) 
d signals due to a anomer 170.6, 170.4, 169.5 (COCH3), 168.2 (C
3’), 134.2 (C
6’), 132.2 
(C
4’), 123.4 (C
5’), 98.9 (C
1), 80.8 (C
2), 79.5 (C
4), 71.9 (C
3), 67.8 (C
1’), 63.8 (C
5), 37.6 
(C
2’), 21.2, 20.8, 20.5 (COCH3), signals due to b anomer 171.2, 170.5, 170.0 (COCH3), 
168.2 (C
3’), 134.1 (C
6’), 132.3 (C
4’), 123.3 (C
5’), 94.8 (C
1), 81.4 (C
4), 77.9 (C
2), 69.7 
(C
3), 68.6 (C
1’), 63.4 (C
5), 37.6 (C
2’), 21.1, 20.9, 20.7 (COCH3); LRMS (ES
+): m/z (%): 
546 (38), 472 ([M + Na]
+, 100).
146Analytical results consistent with reported data.
37
N-Trifluoroacetyl propargylamine, 68
117,170
O
N
H
F3C
H2N
O
O F3C (1.3 eq)
dry MeOH, argon, 0 oC - rt
C3H5N
Mol. Wt.: 55.08 C5H4NOF3
Mol. Wt.: 151.09
98
68
Propargylamine (3.71 g, 67.3 mmol) 98 was added dropwise to an ice-cooled, stirred 
solution of ethyl trifluoroacetate (10.4 mL, 87.6 mmol, 1.3 eq) in distilled methanol (50 
mL) under an argon atmosphere.  After addition, the solution was allowed to warm to rt 
and stirred for 15 hrs.  The reaction mixture was concentrated in vacuo and redissolved 
in CH2Cl2 (200 mL).  The solution was washed with 10% w/v aq citric acid (2 ´ 100 
mL) and sat aq KCl (100 mL), dried (Na2SO4) and concentrated in vacuo to give an 
orange/brown oil.  Following column chromatography (CH2Cl2), and drying in vacuo, 
the product 68 was isolated as a very pale yellow oil (5.81 g, 38.4 mmol, 57%).
Rf 0.27, 0.33 (CH2Cl2, B’, D’), 0.53, 0.66 (1:9, methanol/CH2Cl2, B’, D’); IR (film): n 
3300 (br m, CC–H), 3092 (br w, N–H), 1703 (vs, C=O), 1551 (m, N–H), 1428, 1363, 
1335 (w), 1207 (s), 1152 (br vs, C–F), 1046 (w), 997 (m), 926, 826 (w), 724 (m, C–F), 
667 (m), 638 (br s), 602, 556 (m) cm
-1; 
19F NMR (282 MHz, CDCl3) d -76.2 (CF3); 
1H 
NMR (300 MHz, CDCl3) d 6.73 (1H, br s, NH), 4.15 (2H, dd, J = 2.6, 5.3 Hz, CH2), 
2.33 (1H, t, J = 2.6 Hz, CºCH); 
13C NMR (75 MHz, CDCl3) d 157.2 (q, J = 37.6 Hz, 
COCF3), 115.7 (q, J = 287.5 Hz, COCF3), 77.2 (CºCH), 73.3 (CºCH), 29.8 (CH2); 
LRMS (ES
+): m/z : 206 ([M + CH3OH + Na]
+, 100), 174 ([M + Na]
+, 45); (ES
–): m/z : 
150 ([M – H]
–, 100), 80 (57).
Analytical results consistent with reported data.
117,170 
147Benzyltriethylammonium dichloroiodate 71
154
i) NaI, conc. HCl, aqu. NaClO
ii) 10% aqu. NaI
iii) BnEt3N+Cl- 72, H2O
N
ICl2
N
Cl
72 71
C13H22NCl
Mol. Wt.: 227.77
C13H22NCl2I
Mol. Wt.: 390.13
1
2
3
4
5
6
7
Sodium iodide (6.63 g, 44.2 mmol, 1.0 eq) was dissolved in conc. aq HCl (15.5 mL) and 
cooled in an ice bath.  To this, an 8.8% w/v aqueous solution of NaClO (37.4 mL, 44.1 
mmol) was added slowly, with swirling, so that the temperature was kept below 20 °C. 
Effervescence and a brown residue were observed.  Towards the end of addition, the 
bleach solution was added dropwise until all brown colouration had disappeared.  A 
10% aq solution of NaI was added dropwise (20 mL) until a trace amount of iodine 
reappeared.  The resulting yellow/orange solution was added portionwise to a solution 
of benzyltriethylammonium chloride 72 (10.0 g, 44.1 mmol) in water (14 mL) to give a 
brilliant yellow precipitate.  The mixture was filtered, and the precipitate was washed 
with water and dried under high vacuum over P2O5, to give the product salt 71 as a fine, 
bright yellow powder (16.5 g, 42.2 mmol, 96% yield).
Mp 89-98 °C, lit. 84-86 °C;
154 IR (solid): 3053 (w, C–H), 2984 (m, C–H), 1479 (s, C–
H, Aryl C=C), 1390 (m, C–H), 1360 (m), 1155 (m), 1004 (m), 903 (w), 796 (m), 757 (s, 
Aryl C–H), 708 (vs Aryl C–H), 605 (w) cm
-1; 
1H NMR (300 MHz, d6-DMSO): δ 7.52 
(5H, app. t, J = 1.8 Hz, CH
Ar), 4.48 (2H, s, H
3), 3.17 (6H, q, J = 7.3 Hz, H
2), 1.31 (9H, 
t, J = 7.3 Hz, H
1); 
13C NMR (75 MHz, d6-DMSO): δ 132.5 (C
5), 130.2 (C
6), 129.0 (C
7), 
127.8 (C
4), 59.5 (C
3), 52.0 (C
2), 7.5 (C
1); LRMS (ES
+): m/z (%): 192 (M
+, 100); (ES
–): 
m/z (%): 380 (I3
–, 16), 197/199/201 (ICl2
–, 4, 11:3:1), 126 (I
–, 100).
Analytical results are consistent with the reported data.
154
148N
1-[1-(3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-b-D-ribofuranosyl)]-(5-
chloro-6-oxocytosin-4-yl)-N,N-dimethylformamidine, 74
BTEA-ICl2 (1.5 eq), NaHCO3 (3.0 eq)
distilled CH2Cl2, distilled MeOH, rt 1'
2' 3'
4'
5'
2
4 5
6
O
OH O
O
Si
Si
O
N
NH
N
O O
NMe2
O
OH O
O
Si
Si
O
N
NH
N
O O
Cl
NMe2
C24H44N4O7Si2
Mol. Wt.: 556.80
C24H43N4O7ClSi2
Mol. Wt.: 591.24
73 74
To a stirred solution of nucleoside 73 (0.66 g, 1.18 mmol) in distilled CH2Cl2 (20 mL) 
and distilled methanol (10 mL), was added anhydrous sodium bicarbonate (0.30 g, 3.56 
mmol, 3.0 eq), followed by a solution of benzyltriethylammonium dichloroiodate 71 
(0.69 g, 1.77 mmol, 1.5 eq) in distilled CH2Cl2 (15 mL), and the reaction mixture was 
stirred vigorously at rt for 50 minutes.  The crude reaction mixture was filtered and 
concentrated in vacuo to give an orange/brown gum.  The residue was redissolved in 
CH2Cl2 (50 mL) and washed with water (3 ´ 50 mL).  This was further washed with sat. 
aq sodium thiosulfate (50 mL), water (2  ´  50 mL) and brine (2  ´  50 mL), dried 
(Na2SO4) and concentrated in vacuo to yield a pink foam.  The compound was twice 
purified by column chromatography (0-2% methanol/CH2Cl2) to yield after drying in 
vacuo, the chlorinated product 74 as a white crystalline solid (0.37 g, 0.54 mmol, 46%).
Rf 0.50 (14:1, CH2Cl2/methanol, A’); Mp 94-99 °C (methanol/CH2Cl2); IR (solid): n 
3485 (w), 2942, 2891, 2864 (m, C–H), 1714 (m, C=O), 1637 (s, C=O, C=C), 1578 (vs, 
C=N, C=C), 1462 (m), 1418 (s), 1371 (s, O–H), 1296, 1246 (m), 1122 (s), 1074 (s, C–
O), 1029 (vs, Si–O), 917 (m), 882, 861, 761 (s), 690 (vs, C–Cl), 587 (s) cm
-1; 
1H NMR 
(300 MHz, CDCl3) d 8.16 (1H, s, H
7), 6.24 (1H, d, J = 1.5 Hz, H
1’), 4.98 (1H, t, J = 7.0 
Hz, H
3’), 4.60 (1H, dd, J = 1.5, 6.2 Hz, H
2’), 4.01 (2H, d, J = 5.5 Hz, H
5’), 3.84 (1H, td, 
J = 5.3, 7.3 Hz, H
4’), 3.33 (1H, v br s, 2’-OH), 3.19, 3.12 (3H, s, NCH3), 1.15-1.02 
(28H, m, CH(CH3)2); 
13C NMR (75 MHz, CDCl3) d 160.0 (C
6), 156.8 (N=C
7–N), 151.4 
(C
2, C
4), 94.2 (C
5–Cl), 89.4 (C
1’), 82.8 (C
4’), 73.7 (C
2’), 73.1 (C
3’), 64.1 (C
5’), 41.6, 35.2 
(N–CH3), 17.6, 17.5, 17.5, 17.4, 17.3, 17.3, 17.3, 17.2 (Si–CH(CH3)2), 13.4, 13.3, 12.9, 
12.8 (Si–CH(CH3)2); LRMS (ES
+): m/z (%): 1203 ([2M + Na]
+, 44), 613 ([M + Na]
+, 
100);  HRMS  (ES
+): calcd for C24H43O7N4ClSi2  (M), [M + Na]
+  = 613.2251, found 
613.2267.
1492’,3’,5’-Tri-O-acetyl-6-oxocytidine, 75
71,248
i) HMDS (10.0 eq), (NH4)2SO4 (0.2 eq)
ii) sugar 65, TMSOTf (1.0 eq), anh. DCE
reflux / rt, argon
N
H
NH
NH2
O O
NH
NH2
O N
O
OAc AcO
AcO O
5
5
1'
5'
4'
3' 2'
4
2 6
62
75
C15H19N3O9
Mol. Wt.: 385.33
C4H5N4O2
Mol. Wt.: 141.1081
A suspension of dry 6-aminouracil  62  (8.00 g, 62.9 mmol, 1.1 eq) and ammonium 
sulfate (1.67 mg, 12.6 mmol, 0.2 eq) in HMDS (131.5 mL, 631 mmol, 10.5 eq) was 
heated to reflux, under an argon atmosphere, whilst stirring vigorously, for 24 hours, 
during which the starting material dissolved.  The reaction was allowed to cool to rt and 
the   solvent   was   removed   under   high   vacuum.     The   cream-coloured   solid   was 
redissolved in anhydrous DCE (150 mL) under an argon atmosphere, to which was 
added acetylated sugar 65 (19.0 g, 59.8 mmol).  Trimethylsilyl triflate (11.4 mL, 63.0 
mmol, 1.1 eq) was carefully added dropwise and the reaction was stirred at rt, under an 
argon atmosphere, for 43 hours.   After concentrating  in vacuo  the residue was 
redissolved in CH2Cl2 (250 mL), and washed with water (150 mL) and dilute aq sodium 
bicarbonate (150 mL), during which a white solid precipitated out of solution.  The 
mixture was filtered, and following drying under high vacuum at 50 °C for 2 days, the 
product b-anomer 75 was afforded as a fine white solid (16.9 g, 43.8 mmol, 73% yield). 
The aqueous layer was re-extracted (CH2Cl2, 100 mL) and the combined, filtered 
organic fractions were washed with sat. aq KCl (200 mL), dried (Na2SO4) and 
concentrated  in vacuo  to yield a peach-coloured foam/solid (3.52 g) containing the 
sugar 65 and a- 76 and b-anomers 75 of the product nucleoside.
Rf  0.28 (1:9 methanol/CH2Cl2, A’);  Mp  197-201  °C (CH2Cl2),  lit.
71  228-229  °C 
(ethanol/diethyl ether); IR (solid): n 3447, 3324 (w, N–H), 3211, 2992 (w), 2911, 2789 
(w, C–H), 1736 (m, C=O), 1718 (s, C=O), 1652 (s, N–H), 1586 (br m), 1537, 1427 (m), 
1372 (m, C–H), 1252, 1215 (s, C–O), 1071, 1044 (s), 973, 796, 750 (m), 641 (s), 623, 
582 (m), 547 (vs) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 10.64 (1H, br s, NH
3), 6.47 
(2H, br s, NH2), 6.15 (1H, br s, H
1’), 5.64 (1H, dd, J = 2.8, 6.8 Hz, H
2’), 5.47 (1H, app. t, 
J = 7.0 Hz, H
3’), 4.55 (1H, s, H
5), 4.31 (1H, dd, J = 3.0, 11.5 Hz, H
5’), 4.08 (1H, ddd, J 
= 3.1, 6.4, 8.0 Hz, H
4’), 4.02 (1H, dd, J = 6.5, 11.0 Hz, H
5’), 2.06, 2.03, 2.00 (3H, s, 
COCH3); 
13C NMR (100 MHz, d6-DMSO) d 170.1, 169.5, 169.3 (COCH3), 161.9 (C
6), 
150154.5 (C
4–NH2), 150.4 (C
2), 84.4 (C
1’), 77.7 (C
4’), 73.6 (C
5), 72.6 (C
2’), 69.9 (C
3’), 63.1 
(C
5’), 20.5, 20.4, 20.2 (COCH3); LRMS (ES
+): m/z (%): 793 ([2M + Na]
+, 12), 430 (32), 
408 ([M + Na]
+, 100); (ES
–): m/z (%): 769 ([2M – H]
–, 32), 384 ([M – H]
–, 100).
Analytical results consistent with reported data.
71,248
5-Bromo-2’,3’,5’-tri-O-acetyl-6-oxocytidine, 79
NBS (1.0 eq), AIBN (2 mol %)
dist. THF, dark, argon, rt
C15H19N3O9
Mol. Wt.: 385.33
C15H18N3O9Br
Mol. Wt.: 464.22
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
75
NH
NH2
O N
O
OAc AcO
AcO O
5
79
Br
To a stirred suspension of 2’,3’,5’-tri-O-acetyl-6-oxocytidine 75 (3.05 g, 7.91 mmol) 
and NBS (1.41 g, 7.92 mmol, 1.0 eq) in distilled THF (30.0 mL) was added AIBN (27.0 
mg, 0.16 mmol, 2.1 mol %), and the reaction was stirred in absence of light, under an 
argon atmosphere at rt for 30 minutes.  The white slurry was concentrated in vacuo to 
yield a white solid.   Following purification by column chromatography (25-80% 
acetone/toluene), and drying in vacuo, the product 79 was afforded as a powdery white 
solid (3.47 g, 7.48 mmol, 95% yield) containing 2.0 mol % succinimide.
Rf 0.35 (1:1, acetone/toluene, A’), 0.41 (1:9 methanol/CH2Cl2, A’); IR (solid): n 3412 
(w, N–H), 3301 (br w, N–H), 3240, 3194, 3137 (w), 3089 (w, N–H), 3020, 2909 (w, 
CH2), 1739 (s, C=O), 1718 (vs, C=O), 1628, 1557 (s, N–H), 1426 (m), 1371 (s, CH3), 
1225 (vs, C–O), 1156, 1128, 1091 (s), 1040 (vs), 1013 (s), 941, 930 (m), 897, 765, 727 
(s), 678 (m), 617 (s), 538 (s, C–Br) cm
-1; 
1H NMR (300 MHz, d6-DMSO) d 11.00 (1H, 
br s, NH
3), 6.70 (2H, s, NH2), 6.16 (1H, br s, H
1’), 5.62 (1H, dd, J = 2.5, 6.5 Hz, H
2’), 
5.49 (1H, app. t, J = 7.3 Hz, H
3’), 4.33 (1H, dd, J = 3.3, 11.8 Hz, H
5’), 4.11 (1H, ddd, J 
= 3.0, 6.5, 8.0 Hz, H
4’), 4.02 (1H, dd, J = 6.3, 11.8 Hz, H
5’), 2.07, 2.03, 2.00 (3H, s, 
COCH3); 
13C NMR (75 MHz, d6-DMSO) d 170.0, 170.0, 169.3 (COCH3), 158.1 (C
6), 
151.4 (C
4-NH2), 149.2 (C
2), 85.9 (C
1’), 77.9 (C
4’), 72.6 (C
2’), 69.7 (C
3’), 69.1 (C
5), 62.9 
(C
5’), 20.5, 20.3, 20.2 (COCH3); LRMS (ES
+): m/z : 949/951/953 ([2M + Na]
+, 1:2:1, 
52), 527/529 ([M + CH3CN + Na]
+, 1:1, 40), 495/497 (1:1, 100), 486/488 ([M + Na]
+, 
1:1, 99); HRMS (ES
+): calcd for C15H18N3O9Br (M), [M + Na]
+ = 486.0124/488.0104, 
151found 486.0114/488.0097 (1:1), [2M + Na]
+  = 949.0351/951.0330/953.0310, found 
951.0254 (1:2:1).
5-Iodo-2’,3’,5’-tri-O-acetyl-6-oxocytidine, 83
NIS (1.0 eq), AIBN (2 mol%)
dist. THF, dark, argon, rt
C15H19N3O9
Mol. Wt.: 385.33
C15H18N3O9I
Mol. Wt.: 511.22
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
75
NH
NH2
O N
O
OAc AcO
AcO O
5
83
I
To a stirred suspension of 2’,3’,5’-tri-O-acetyl-6-oxocytidine 75 (5.00 g, 13.0 mmol) 
and AIBN (46.3 mg, 0.28 mmol, 2.2 mol %) in distilled THF (50.0 mL) was added NIS 
(2.95 g, 13.1 mmol, 1.0 eq), and the reaction was stirred in absence of light, under an 
argon atmosphere, at rt for 15 minutes.  The orange/brown slurry was concentrated in 
vacuo to yield an orange/brown solid.  A portion of the solid (~0.5 g) was dissolved in 
ethyl acetate (250 mL) and washed with dilute aq Na2S2O3 (100 mL, adjusted to pH 7 
using NaHCO3) until decolourised then separated immediately.   The solution was 
further washed with sat. aq KCl (2 ´ 100 mL), dried (Na2SO4) and concentrated in 
vacuo to give an off-white solid (0.34 g).  The remainder was suspended in ethyl acetate 
(550 mL) and allowed to stand in the fridge for 2 hours.  The mixture was vacuum 
filtered, and the residue was washed with ice-cold ethyl acetate (3 ´ 150 mL) and dried 
under high vacuum over P2O5, to yield the product 83 as a white, powdery solid (5.47 g) 
containing 0.4 mol % succinimide (recalculated yield - 10.7 mmol, 82%).
Rf 0.35 (1:1, acetone/toluene, A’), 0.54 (tetrahydrofuran, A’); IR (solid): n 3400, 3295 
(w, N–H), 3207 (br w, N–H), 1740, 1719 (s, C=O), 1624 (s, C=C), 1551 (s, N–H), 1422 
(m), 1371 (s, CH3), 1228 (vs), 1096, 1040 (s, C–O), 942, 931, 898 (m), 763 (s), 736 (m), 
722 (m, CH2), 677, 647, 630 (m), 602, 571, 537 (s), 512 (m, C–I) cm
-1; 
1H NMR (300 
MHz, d6-DMSO) d 10.91 (1H, br s, NH
3), 6.54 (2H, s, NH2), 6.17 (1H, s, H
1’), 5.61 
(1H, dd, J = 1.8, 6.4 Hz, H
2’), 5.49 (1H, app. t, J = 7.2 Hz, H
3’), 4.33 (1H, dd, J = 2.7, 
11.5 Hz, H
5’), 4.10 (1H, ddd, J = 2.9, 6.4, 8.0 Hz, H
4’), 4.02 (1H, dd, J = 6.2, 11.5 Hz, 
H
5’), 2.07, 2.03, 2.00 (3H, s, COCH3); 
13C NMR (100 MHz, d6-DMSO) d 170.0, 169.5, 
169.3 (COCH3), 159.3 (C
6), 153.3 (C
4–NH2), 149.5 (C
2), 86.1 (C
1’), 77.8 (C
4’), 72.7 
152(C
2’), 69.6 (C
3’), 62.8 (C
5’), 41.7 (C
5-I), 20.5 (2’-OCOCH3), 20.3 (3’-OCOCH3), 20.2 
(5’-OCOCH3); LRMS (ES
+): m/z : 1061 ([2M + K]
+, 3), 1045 ([2M + Na]
+, 8), 1023 
([2M + H]
+, 2), 550 ([M + K]
+, 24), 534 ([M + Na]
+, 100), 512 ([M + H]
+, 77); (ES
–): m/
z (%): 1021 ([2M – H]
–, 2), 608 ([M + H3PO4 – H]
–, 4), 510 ([M – H]
–, 100); HRMS 
(ES
+): calcd for C15H18N3O9I (M), [M + Na]
+ = 533.9980, found 533.9993, [M + NH4]
+ = 
529.0426, found 529.0445, [M + H]
+ = 512.0160, found 512.0184.
1-O-Methyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-D-ribofuranose, 86
37
ii) (TIPSCl)2O (1.2 eq), dist. pyridine
0
oC to rt, argon
i) AcCl (0.06eq), dist. MeOH
O
OH O
O
Si
Si
O
OMe OH O
OH OH
OH
84 86
C5H10O5
Mol. Wt.: 150.13
C18H38O6Si2
Mol. Wt.: 406.66
1
2 3
4
5
Acetyl chloride (0.91 mL, 12.8 mmol, 0.1 eq) in distilled methanol (50 mL) was added 
portionwise to a stirred solution of D-ribose 84 (30.0 g, 200 mmol) in distilled methanol 
(200 mL).  The reaction mixture was stirred at rt, under an argon atmosphere, for 22 
hours.  Sodium bicarbonate (10.1 g, 120 mmol, 0.6 eq) was added and the mixture was 
stirred for 10 minutes.  The mixture was filtered and concentrated in vacuo to yield the 
crude product, 1’-O-methylribofuranoside 85 as an anomeric mixture (a:b ca 1:1) as a 
viscous, orange/red oil (38.3 g), which was used without further purification.
Rf 0.47, 0.32 (4:1, ethyl acetate/methanol, A’); LRMS (ES
+): m/z (%): 187 ([M + Na]
+, 
100).
The crude product 85 (5.63 g) was co-evaporated with distilled pyridine and dried under 
high vacuum before re-dissolving in distilled pyridine (40 mL).   The solution was 
cooled to 0 °C, under an argon atmosphere, and 1,3-dichloro-1,1,3,3-tetraisopropyl-
disiloxane (13.2 mL, 41.3 mmol, 1.4 eq) was added dropwise.  The reaction mixture 
was allowed to warm to rt and stirred for 15 hours, then concentrated under high 
vacuum, co-evaporating with toluene.   The resulting cream slurry was partitioned 
between ethyl acetate (400 mL) and water (200 mL).  The organic layer was washed 
with water (2 ´ 200 mL), 2 M aq HCl (200 mL) then water (200 mL), dried (Na2SO4) 
and concentrated  in vacuo  to yield a yellow oil.   Following partial purification by 
153column chromatography (4:1, hexane/ethyl acetate), and drying under high vacuum the 
product 86 was afforded, as an anomeric mixture (a:b ca 6:1), as a very pale yellow 
viscous oil (15.1 g, 37.1 mmol, quant.).
Rf 0.47, 0.30 (4:1, hexane/ethyl acetate, A’), 0.74 (4:1, ethyl acetate/methanol, A’); 
1H 
NMR (300 MHz, CDCl3) d signals due to a anomer 4.85 (1H, s, H
1), 4.70 (1H, br t, J = 
5.3 Hz, H
3), 4.13-4.02 (1H, m, H
2), 3.99 (1H, dd, J = 4.9, 8.9 Hz, H
4), 3.85 (1H, dd, J = 
2.5, 12.3 Hz, H
5), 3.69 (1H, dd, J = 2.2, 12.3 Hz, H
5), 3.40 (3H, s, Me), 2.75 (1H, br s, 
2-OH), 1.11-0.80 (28H, m, CH(CH3)2), signals due to b anomer 4.87 (1H, d, J = 4.5 Hz, 
H
1), 4.50 (1H, br s, H
3), 4.29-4.16 (1H, m, H
4), 4.13-4.01 (2H, m, H
2, H
5), 3.78 (1H, br 
d,  J  = 10.6 Hz,  H
5), 3.32 (3H, s, Me), 2.75 (1H, br s, 2-OH), 1.10-0.80 (28H, m, 
CH(CH3)2); LRMS (ES
+): m/z (%): 447 (100), 429 ([M + Na]
+, 50).
Analytical results consistent with reported data.
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1-O-Methyl-2-O-methylethanoyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-
D-ribofuranose, 87
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(5.1 eq)
NaH (4.4 eq), anh. DMF
-5 oC to rt, argon
O
OH O
O
Si
Si
O
OMe
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C18H38O6Si2
Mol. Wt.: 406.66
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OMe
1'
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C21H42O8Si2
Mol. Wt.: 478.72
OMe
O
Br
Compound 86 (15.1 g, 37.1 mmol) was dissolved in anhydrous DMF, and cooled to 
–5 °C (ice/methanol) under an argon atmosphere.  Methyl bromoacetate (18.0 mL, 190.2 
mmol, 5.13 eq) was added followed by sodium hydride (60% w/w dispersion in mineral 
oil) (6.48 g, 162 mmol, 4.4 eq) portionwise.  The reaction was stirred under an argon 
atmosphere at 
–5 °C for 15 minutes, then allowed to warm and stirred vigorously at rt 
for 17 hours.  Saturated aq KCl (100 mL) was added carefully to the stirred reaction, 
and the mixture was extracted with diethyl ether (3 ´ 150 mL).  The combined organic 
fraction was dried (Na2SO4) and concentrated under high vacuum, co-evaporating with 
toluene to yield a two-layered liquid (yellow/colourless).  The crude compound was 
twice-purified by column chromatography (5-20% ethyl acetate/hexane) to yield, after 
drying under high vacuum, the product 87, as an anomeric mixture (a:b ca. 5:1), as a 
white solid (10.6 g, 22.1 mmol, 60% yield).
154Rf 0.33, 0.21 (4:1, hexane/ethyl acetate, A’); 
1H NMR (300 MHz, CDCl3) d signals due 
to a anomer 4.86 (1H, s, H
1), 4.48 (1H, dd, J = 4.2, 7.9 Hz, H
3), 4.45 (1H, d, J = 16.7 
Hz, H
1’), 4.32 (1H, d, J = 16.7 Hz, H
1’), 4.04 (1H, td, J = 2.9, 7.9 Hz, H
4), 3.98 (1H, dd, 
J = 2.9, 12.1 Hz, H
5), 3.86 (1H, dd, J = 5.9, 12.1 Hz, H
5), 3.83 (1H, d, J = 4.0 Hz, H
2), 
3.74 (3H, s, CO2CH3), 3.32 (3H, s, 1-OCH3), 1.10-0.93 (28H, m, CH(CH3)2), d signals 
due to b anomer 4.71 (1H, s, H
1), 4.45 (1H, d, J = 16.7 Hz, H
1’), 4.32 (1H, d, J = 16.7 
Hz, H
1’), 4.05-4.02 (1H, m, H
4), 4.02-3.77 (4H, m, H
2, H
3, H
5), 3.78 (3H, s, CO2CH3), 
3.32 (3H, d, J = 1.0 Hz, 1-OCH3), 1.10-0.93 (28H, m, CH(CH3)2); 
13C NMR (75 MHz, 
CDCl3) d signals due to a anomer 170.5 (C
2’), 106.0 (C
1), 83.3 (C
2), 81.0 (C
4), 74.2 
(C
3), 68.4 (C
1’), 63.9 (C
5), 54.9 (1-OCH3), 51.9 (CO2CH3), signals due to b anomer 
171.0 (C
2’) other signals not visible, indistinguishable signals due to both anomers 17.6, 
17.5, 17.5, 17.5, 17.4, 17.4, 17.2, 17.1 (Si–CH(CH3)2), 13.5, 13.4, 12.9, 12.8 (Si– 
CH(CH3)2); LRMS (ES
+): m/z (%): 501 ([M + Na]
+, 100).
Analytical results consistent with reported data.
37
1-O-Methyl-2-O-(2-hydroxyethyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-
D-ribofuranose, 88
37
O
O O
O
Si
Si
O
OMe
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2
5
O
OMe
1'
2'
C21H42O8Si2
Mol. Wt.: 478.72
LiBH4 (2.0 eq)
dist. THF, argon, rt
O
O O
O
Si
Si
O
OMe
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1
2
5
OH
1'
2'
C20H42O7Si2
Mol. Wt.: 450.71
To a solution of compound 87 (9.13 g, 19.1 mmol) in distilled THF (80 mL), under an 
argon atmosphere, LiBH4 (0.84 g, 38.5 mmol, 2.0 eq) was added portionwise and the 
reaction was stirred at rt.  Further LiBH4 (0.21 g, 9.6 mmol, 0.5 eq) was added after 55 
minutes and the reaction was stirred for a further 20 minutes.  The reaction mixture was 
poured into a conical flask, cooled in an ice bath and stirred vigorously.  A solution of 
methanol (7 mL) in THF (50 mL) was added with extreme caution and the reaction 
mixture was left to stir for 20 minutes.  Methanol (30 mL) was added with care, and the 
mixture was diluted with diethyl ether (150 mL).  The solution was washed with water, 
dried (Na2SO4) and concentrated in vacuo to yield an orange oil.  Following purification 
by column chromatography (14-20% ethyl acetate/hexane), and drying under high 
155vacuum, the product 88 was isolated as an anomeric mixture (a:b ca 1:3), as a very pale 
yellow to colourless oil (3.10 g, 6.87 mmol, 36% yield).
Rf 0.09 (4:1, hexane/ethyl acetate, A’); 
1H NMR (300 MHz, CDCl3) d signals due to a 
anomer 4.77 (1H, s, H
1), 4.50 (1H, dd, J = 4.5, 7.8 Hz, H
3), 4.05-3.96 (1H, m, H
4), 4.00 
(1H, dd, J = 5.4, 11.3 Hz, H
5), 3.91-3.79 (3H, m, H
5, H
1’), 3.73-3.67 (2H, m, H
2’), 3.54 
(1H, d, J = 7.7 Hz, H
2), 3.32 (3H, s, OCH3), 2.06 (1H, br s, OH), 1.10-1.00 (28H, m, 
CH(CH3)2), signals due to b anomer 4.63 (1H, d, J = 7.5 Hz, H
1), 4.12 (1H, app. t, J = 
3.6 Hz, H
4), 3.91-3.79 (1H, m, H
3), 3.91-3.73 (2H, m, H
2’), 3.78-3.73 (2H, m, H
1’), 3.75 
(1H, t, J = 4.8 Hz, H
2), 3.73 (1H, dd, J = 4.8, 11.2 Hz, H
5), 3.66 (1H, dd, J = 2.6, 11.2 
Hz, H
5), 3.47 (3H, s, OCH3), 2.06 (1H, br s, OH), 1.10-1.00 (28H, m, CH(CH3)2);
13C NMR (75 MHz, CDCl3) d signals due to a anomer 106.1 (C
1), 83.8 (C
2), 79.4 (C
4), 
73.2 (C
5), 71.8 (C
3), 66.2 (C
1’), 62.7 (C
2’), 56.5 (OCH3), signals due to b anomer 100.5 
(C
1), 81.2 (C
2), 73.7 (C
4), 71.3 (C
3), 65.0 (C
1’), 63.8 (C
5), 61.8 (C
2’), 54.8 (OCH3), 
indistinguishable signals due to both anomers 17.6, 17.6, 17.5, 17.4, 17.4, 17.4, 17.1, 
17.0 (Si–CH(CH3)2), 13.6, 13.4, 12.8, 12.7 (Si–CH(CH3)2); LRMS (ES
+): m/z (%): 473 
([M + Na]
+, 100).
Analytical results consistent with reported data.
37
1-O-Methyl-2-O-(2-phthalimidoethyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-a-D-ribofuranose, 89
37
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2'
C20H42O7Si2
Mol. Wt.: 450.71
PPh3 (1.1 eq), DEAD (1.1 eq)
phthalimide (1.1 eq)
dist. THF, argon, rt
O
O O
O
Si
Si
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2
5
N
1'
2'
O
O C28H45NO8Si2
Mol. Wt.: 579.83
OMe
3' 4' 5'
6'
To a solution of compound 88 (2.90 g, 6.43 mmol) in distilled THF (30 mL), under an 
argon atmosphere, triphenylphosphine (1.86 g, 7.07 mmol, 1.1 eq) and phthalimide 
(1.04 g, 7.07 mmol, 1.1 eq) were added, followed by DEAD (1.1 mL, 6.99 mmol, 1.1 
eq) dropwise, whilst cooling in a water bath.  The reaction mixture was then stirred 
under an argon atmosphere, at rt for 2 hours.  The solvent was removed in vacuo and the 
crude material was eluted through a short silica plug (4:1, hexane/ethyl acetate). 
Following further purification by column chromatography (4:1, hexane/ethyl acetate), 
156and drying under high vacuum, the product  a-anomer  89  was isolated as a cream-
coloured solid (3.49 g, 6.0 mmol, 94% yield).
Rf 0.26 (89, a), 0.10 (b) (4:1, hexane/ethyl acetate, A’); 
1H NMR (400 MHz, CDCl3) d 
signals for a anomer 89 only 7.84 (2H, dd, J = 3.0, 5.5 Hz, H
5’), 7.70 (2H, dd, J = 3.0, 
5.5 Hz, H
6’), 4.67 (1H, s, H
1), 4.42 (1H, dd, J = 4.3, 7.8 Hz, H
3), 4.09 (1H, d, J = 4.7, 
9.3 Hz, H
1’), 3.98-3.90 (1H, m, H
1’), 3.95-3.90 (1H, m, H
4), 3.94 (1H, dd, J = 3.0, 12.0 
Hz, H
5), 3.87-3.80 (2H, m, H
2’), 3.86 (1H, dd, J = 5.8, 12.3 Hz, H
5), 3.73 (1H, d, J = 4.3 
Hz, H
2), 3.28 (3H, s, OCH3), 1.09-0.93 (28H, m, CH(CH3)2); 
13C NMR (100 MHz, 
CDCl3) d signals for a anomer 89 only 168.3 (C
3’), 134.0 (C
6’), 132.3 (C
4’), 123.4 (C
5’), 
106.2 (C
1), 83.0 (C
2), 81.0 (C
4), 73.8 (C
3), 68.2 (C
1’), 63.7 (C
5), 54.8 (OCH3), 38.0 
(C
2’), 17.6, 17.5, 17.5, 17.5, 17.5, 17.4, 17.2, 17.1 (Si–CH(CH3)2), 13.5, 13.4, 12.8, 12.8 
(Si-CH(CH3)2); LRMS (ES
+): m/z (%): 602 ([M + Na]
+, 100).
Analytical results consistent with reported data.
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1,2,3,5-Tetra-O-acetyl-b-D-ribofuranose, 91
249,250
i) Ac2O / AcOH (4:3 v/v), conc. H2SO4 (cat.)
ii) NaOAc (1.5 eq), rt
OAc
O
OAc AcO
AcO
O
OH OH
HO
OMe
C6H12O5
Mol. Wt.: 164.16
C13H18O9
Mol. Wt.: 318.28
85 91
1-O-Methylribofuranoside 85 (30.0 g, 183 mmol) was dissolved in acetic anhydride 
(105 mL) and glacial acetic acid (80 mL), to which was added conc. sulfuric acid (3.00 
mL, 56.3 mmol, 0.3 eq) dropwise with ice-cooling.  The deep red-brown solution was 
stirred at rt for 1 hour after which further conc. sulfuric acid (5.00 mL, 93.8 mmol, 0.5 
eq) was added dropwise with ice-cooling.  After stirring the solution for a further 2 
hours at rt, sodium acetate (22.6 g, 275 mmol, 1.5 eq) was added, and the solution was 
stirred vigorously for 10 minutes.  The solvent was removed under high vacuum, co-
evaporating with ethanol/isopropanol, to yield a brown, opaque syrup.  The syrup was 
dissolved in chloroform (1.5 L) and washed with water (2 ´ 400 mL) and sat. aq KCl
(2 ´ 400 mL), dried (Na2SO4) and concentrated under high vacuum to afford a clear, 
brown syrup.  To the syrup was added ice-cold ethanol (100 mL) and the mixture was 
cooled, from which crystallised the product.  Following washing with ice-cold ethanol 
157(2 ´ 50 mL) and ice-cold diethyl ether (3 ´ 100 mL), and drying under high vacuum 
over KOH, the product b-anomer 91 was afforded, as a white, crystalline solid (22.6 g, 
71.2 mmol, 39% yield).  The remaining fractions and washings were dried under high 
vacuum to give a brown syrup, as an anomeric mixture (a:b ca 65:35) (37.4 g) from 
which further product could not be crystallised.
Rf 0.47 (91, b), 0.40 (a) (2:1, ethyl acetate/hexane, A’), 0.30 (91, b), 0.26 (a) (1:1, 
ethyl acetate/hexane, A’);  Mp  79-81 °C (ethanol),  lit.
249,250  81-83 °C (ethanol);  IR 
(solid): n 3025, 2992, 2961, 2932 (w, C–H), 1751 (s, C=O), 1740 (vs, C=O), 1445 (m), 
1374 (m, C–H), 1215 (br vs, C–O), 1095, 1072, 1030 (m, C–O), 956, 913, 893, 883 (s), 
815, 729, 679, 643, 621, 603, 589, 552, 536 (m) cm
-1; 
1H NMR (300 MHz, CDCl3) d 
signals for b anomer 91 only 6.15 (1H, s, H
1), 5.34 (1H, dd, J = 4.8, 8.1 Hz, H
3), 5.33 
(1H, app. s, H
2), 4.40-4.33 (1H, m, H
4), 4.32 (1H, dd, J = 3.3, 12.1 Hz, H
5), 4.14 (1H, 
dd, J = 5.3, 11.9 Hz, H
5), 2.11 (3H, s, COCH3), 2.08 (3H, s, COCH3), 2.08 (3H, s, 
COCH3), 2.06 (3H, s, COCH3); 
13C NMR (75 MHz, CDCl3) d 170.5, 169.8, 169.5, 
169.1 (COCH3), 98.3 (C
1), 79.4 (C
4), 74.3 (C
2), 70.7 (C
3), 63.8 (C
5), 21.1, 20.8, 20.6, 
20.6 (COCH3); LRMS (ES
+): m/z (%): 659 ([2M + Na]
+, 22), 382 ([M + CH3CN + Na]
+, 
87), 341 ([M + Na]
+, 100).
Analytical results consistent with reported data.
250
5’-O-(4,4’-Dimethoxytrityl)-5-iodo-2’-deoxyuridine, 97
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2 DMTCl 112 (1.1 eq)
dist. pyridine, argon, rt
C9H11N2O5I
Mol. Wt.: 354.10
C30H29N2O7I
Mol. Wt.: 656.47
97 148
5-Iodo-2’-deoxyuridine  148  (25.0 g, 70.6 mmol) was dried by co-evaporation with 
distilled pyridine (2 ´ 50 mL) under high vacuum, then dissolved in distilled pyridine 
(120 mL).  4,4’-Dimethoxytrityl chloride 112 (25.1 g, 74.1 mol, 1.1 eq) was added in 
five portions over 4 hours, under an argon atmosphere, whilst stirring vigorously, at rt. 
The reaction mixture was stirred for a further 3.5 hours cooling in ice, then quenched 
with methanol/water (1:1 v/v, 20 mL) stirring for 10 minutes at rt.  The reaction mixture 
158was   concentrated  in   vacuo  and   by   co-evaporation   with   methanol/toluene.     The 
foam/syrup was dissolved in CH2Cl2 (400 mL), washed with water (2 ´ 200 mL) during 
which unreacted material 148 precipitated.  The aqueous was filtered and the precipitate 
was washed with water (50 mL), CH2Cl2 (150 mL), ethanol (30 mL) and diethyl ether (2 
´ 60 mL) and dried over P2O5 to give 148 as a white powder (2.41 g. 6.82 mmol, 10%). 
The combined aqueous fraction was re-extracted (CH2Cl2, 150 mL) and combined 
CH2Cl2  layers were washed with sat aq KCl (3  ´  150 mL), dried (Na2SO4), and 
concentrated in vacuo and dried under high vacuum to give a yellow foam.  Following 
purification by column chromatography (50-95% ethyl acetate/hexane + 0.5% Et3N ® 
0.5-1.0% methanol/ethyl acetate + 0.5% Et3N ® 10-15% methanol/ethyl acetate + 0.5-
1.0% Et3N), and drying under high vacuum, the desired mono-tritylated product 97, the 
bis-tritylated by-product, and a mixture thereof, were afforded as a white foam (37.1 g, 
56.5 mmol, 80%), a yellow foam/solid (3.41 g, 3.56 mmol, 5%) and a pale yellow foam 
(2.19 g) respectively.
Rf 0.19 (97), 0.58 (bis) (5:95 methanol/CH2Cl2 + 0.3% Et3N, A’); 0.39 (97), 0.66 (bis) 
(1:9 methanol/CH2Cl2 + 0.3% Et3N, A’); 0.29 (1:9 acetone/CH2Cl2 + 0.7% pyridine, 
A’); 
1H NMR (400 MHz, d6-DMSO) d 11.67 (1H, NH
3), 8.01 (1H, s, H
6), 7.40 (2H, d, 
J = 7.6 Hz, H
13), 7.32 (2H, t, J = 7.3 Hz, H
14), 7.29 (4H, d, J = 9.0 Hz, H
9), 7.23 (1H, t, 
J = 7.2 Hz, H
15), 6.90 (4H, d, J = 8.8 Hz, H
10), 6.10 (1H, t, J = 6.8 Hz, H
1’), 5.29 (1H, br 
s, 3’-OH), 4.23 (1H, br s, H
3’), 3.90 (1H, dd, J = 3.6, 7.5 Hz, H
4’), 3.74 (6H, s, OCH3), 
3.20 (1H, dd, J = 4.8, 10.8 Hz, H
5’), 3.16 (1H, dd, J = 3.3, 10.6 Hz, H
5’), 2.25 (1H, td, J 
= 6.8, 13.6 Hz, H
2’), 2.17 (1H, ddd, J = 3.4, 6.2, 13.3 Hz H
2’); 
13C NMR (100 MHz, d6-
DMSO) d 160.5 (C
4), 158.1 (C
11-OCH3), 150.1 (C
2), 144.7 (C
12), 144.2 (C
6), 135.5, 
135.4 (C
8), 129.7 (C
9), 127.9 (C
14), 127.6 (C
13), 126.7 (C
15), 113.3 (C
10), 85.8 (C
7Ar3), 
85.8 (C
4’), 84.9 (C
1’), 70.5 (C
3’), 69.8 (C
5-I), 63.7 (C
5’), 55.0 (OCH3), 39.8 (C
2’); LRMS 
(ES
+) m/z: 679 ([M + Na]
+, 100).
Analytical results consistent with reported data.
61,170,251 
1595-Bromo-6-oxocytidine, 99
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
79
Br
0.4 M K2CO3/ MeOH / H2O (4:1, v/v)
heat until dissolved, then rt
NH
NH2
O N
O
OH OH
HO O
5
99
Br
C15H18N3O9Br
Mol. Wt.: 464.22
C9H12N3O6Br
Mol. Wt.: 338.11
Nucleoside 79 (1.57g, 3.37 mmol) was dissolved with heating in a 0.4 M solution of 
K2CO3 in methanol/water (4:1, v/v) (34.0 mL, 13.6 mmol K2CO3, 4.0 eq) over 2 minutes 
then stirred at rt.  After 10 minutes, DOWEX 50Wx8-400 (pyridinium form) was added 
with stirring until the solution was neutralised (pH 12.0®7.0).   The mixture was 
filtered, the DOWEX washed with methanol (2 ´ 20 mL), water (2 ´ 20 mL), and 
water/methanol (1:1 v/v, 40 mL) and the filtrate was concentrated in vacuo to yield a 
gum.  The gum was suspended in ethanol (60 mL) and allowed to stand for 2 days in the 
fridge.  The powder obtained after filtration, washing and drying was hygroscopic and 
was therefore treated again with DOWEX in methanol/water (1:1 v/v, 25 mL) solution 
to acidify (pH 8.0®6.0).  The DOWEX was washed and filtrate was concentrated in 
vacuo as previously described.  The solid was suspended in isopropanol (70 mL) and 
allowed to stand overnight in the fridge.  Following vacuum filtration, the solid was 
washed with ice-cold isopropanol (10 mL) and ice-cold diethyl ether (2 ´ 25 mL) and 
dried under high vacuum over P2O5, to afford the desired product 99, as an off-white 
chalky solid (1.04 g, 3.06 mmol, 91%).
Rf 0.49 (3:1:1, n-BuOH:AcOH:water, A’); IR (solid): n 3306 (m, N–H), 3207 (m, O–
H), 2979 (w, O–H), 2915, 2790 (w, C–H), 1716 (m, C=O), 1604 (vs, C=O), 1538 (s, 
C=C), 1468, 1444 (m, CH2), 1372 (m, O–H), 1256, 1172 (w), 1107 (m, C–O), 1037 (s, 
C–O), 957, 902, 760, 741, 680 (m), 624 (s), 554 (s, C–Br) cm
-1; 
1H NMR (400 MHz, d6-
DMSO) d 10.80 (1H, br s, NH
3), 6.58 (2H, s, NH2), 6.02 (1H, d, J = 3.8 Hz, H
1’), 4.96 
(1H, br d, J = 4.8 Hz, 2’-OH), 4.77 (1H, br d, J = 5.5 Hz, 3’-OH), 4.53 (1H, br t, J = 5.5 
Hz, 5’-OH), 4.46 (1H, br dd, J = 4.8, 9.6 Hz, H
2’), 4.07 (1H, br dd, J = 5.5, 11.1 Hz, 
H
3’), 3.66 (1H, td, J = 3.3, 6.0 Hz, H
4’), 3.58 (1H, br td, J = 3.6, 11.5 Hz, H
5’), 3.40 (1H, 
td, J = 6.0, 12.0 Hz, H
5’); 
13C NMR (100 MHz, d6-DMSO) d 158.8 (C
6), 151.1 (C
4–
NH2), 149.5 (C
2), 88.1 (C
1’), 84.2 (C
4’), 71.0 (C
2’), 70.1 (C
3’), 69.6 (C
5), 62.4 (C
5’); 
LRMS (ES
+): m/z: 360/362 ([M + Na]
+, 1:1, 100); (ES
–): m/z: 336/338 ([M – H]
–, 1:1, 
160100);  HRMS  (ES
+): calcd for C9H12N3O6Br (M), [M + Na]
+  = 359.9802/361.9787, 
found 359.9802/361.9773 (1:1).  Found also 301.1405.
5-Iodo-6-oxocytidine, 100
C15H18N3O9I
Mol. Wt.: 511.22
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
83
I
0.4 M K2CO3/ MeOH / H2O (4:1, v/v)
heat until dissolved, then rt
NH
NH2
O N
O
OH OH
HO O
5
100
I
C9H12N3O6I
Mol. Wt.: 385.11
Nucleoside 83 (1.01 g, 1.98 mmol) was dissolved with heating in a 0.4 M solution of 
K2CO3 in methanol/water (4:1, v/v) (17.0 mL, 6.8 mmol K2CO3, 3.4 eq) over 1 minute 
then stirred at rt.  After 20 minutes, DOWEX 50WX8-400 (pyridinium form) was added 
with stirring until the solution was slightly acidified (pH 11.0®5.5).  The mixture was 
filtered, the DOWEX was washed with methanol (8 mL), water (8 mL), then methanol 
again (20 mL), and the filtrate was concentrated in vacuo to yield a white solid.  The 
solid was suspended in ethanol (100 mL) and allowed to stand in the fridge for 2.5 
hours.  Following vacuum filtration the residue was washed with the filtrate, ethanol (30 
mL) and diethyl ether (2 ´ 20 mL), and dried under high vacuum over P2O5, to afford 
the product 100 as a white, chalky solid (0.59 g, 1.53 mmol, 77%).
Rf 0.56 (3:1:1, n-BuOH:AcOH:water, A’); IR (solid): n 3368 (br m, N–H, O–H), 3297, 
3191 (br m, O–H), 2923 (w, C–H), 1703, 1614 (s, C=O), 1542 (s, C=C), 1422 (s), 1368 
(m, O–H), 1102, 1037 (s, C=O), 982, 904, 850 (m), 758, 706, 676, 601 (s), 564 (vs), 
524 (s, C–I) cm
-1; 
1H NMR (300 MHz, d6-DMSO) d 10.73 (1H, br s, NH
3), 6.42 (2H, s, 
NH2), 6.03 (1H, d, J = 3.8 Hz, H
1’), 4.96 (1H, br d, J = 4.9 Hz, 2’-OH), 4.77 (1H, br d, 
J = 5.7 Hz, 3’-OH), 4.53 (1H, br t, J = 5.4 Hz, 5’-OH), 4.44 (1H, br dd, J = 4.9, 9.8 Hz, 
H
2’), 4.06 (1H, br dd, J = 5.6, 11.3 Hz, H
3’), 3.65 (1H, td, J = 3.5, 6.2 Hz, H
4’), 3.58 (1H, 
br td, J = 3.7, 11.6 Hz, H
5’), 3.40 (1H, td, J = 5.9, 11.8 Hz, H
5’); 
13C NMR (100 MHz, 
d6-DMSO) d 160.0 (C
6), 153.1 (C
4–NH2), 150.0 (C
2), 88.3 (C
1’), 84.2 (C
4’), 71.0 (C
2’), 
70.1 (C
3’), 62.4 (C
5’), 42.3 (C
5); LRMS (ES
+): m/z : 430 ([M – H + 2Na]
+, 26), 408 ([M 
+ Na]
+, 100); (ES
–): m/z : 384 ([M – H]
–, 100); HRMS (ES
+): calcd for C9H12N3O6I (M), 
161[2M + H]
+ = 770.9620, found 770.9570, [M + Na]
+ = 407.9663, found 407.9654, [M + 
H]
+ = 385.9844, found 385.9834.
6-Oxocytidine, 101
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
75
0.4 M K2CO3/ MeOH / H2O (4:1, v/v)
heat until dissolved, then rt
NH
NH2
O N
O
OH OH
HO O
5
101
C15H19N3O9
Mol. Wt.: 385.33
C9H13N3O6
Mol. Wt.: 259.22
Nucleoside 75 (1.55 g, 4.03 mmol) was dissolved with heating in a 0.4M solution of 
K2CO3 in methanol/water (4:1 v/v) (40.0 mL, 16.0 mmol K2CO3, 4.0 eq) over 3 minutes, 
then stirred at rt for 5 minutes.  DOWEX 50WX8-400 (pyridinium form) was added 
with stirring until the solution was slightly acidified (pH 12.0®5.5).  The mixture was 
filtered, the DOWEX washed with the filtrate, methanol/water (1:1 v/v, 60 mL) then 
water (20 mL), and the combined filtrate was concentrated in vacuo, co-evaporating 
with methanol/toluene (´5) to yield a sticky white foam.  The residue was suspended in 
isopropanol (50 mL) and allowed to stand in the fridge overnight.  The mixture was 
vacuum filtered, washed with ice-cold isopropanol (25 mL) and diethyl ether (2 ´ 50 
mL), and dried under high vacuum over P2O5, to afford the product 101 as a powdery 
white solid (0.91 g) containing 37.7 mol % potassium acetate (recalculated yield - 2.52 
mmol, 71%).
Rf 0.13 (8:2:1, CH2Cl2/methanol/acetic acid, A’), 0.11 (1:4, methanol/CH2Cl2, A’); IR 
(solid): n 3334 (br w, O–H, N–H), 3191 (br w, O–H), 1704 (m, C=O), 1603 (s, C=O), 
1404 (br m, O–H), 1290 (m), 1200 (w), 1098 (m), 1020 (br s, C–O), 896, 781, 768 (m), 
640 (br s), 533 (vs) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 7.18 (2H, br s, NH2), 6.06 
(1H, d, J = 4.0 Hz, H
1’), 4.47 (1H, dd, J = 4.3, 5.8 Hz, H
2’), 4.44 (1H, s, H
5), 4.08 (1H, t, 
J = 6.0 Hz, H
3’), 3.65 (1H, td, J = 2.8, 8.5 Hz, H
4’), 3.56 (1H, dd, J = 2.9, 11.7 Hz, H
5’), 
3.40 (1H, dd, J = 5.4, 11.7 Hz, H
5’); 
13C NMR (100 MHz, d6-DMSO) d 163.3 (C
6), 
156.8 (C
4–NH2), 152.7 (C
2), 86.8 (C
1’), 84.1 (C
4’), 73.7 (C
5), 71.1 (C
2’), 70.3 (C
3’), 62.5 
(C
5’); LRMS (ES
+) m/z: 282 ([M + Na]
+, 100); (ES
–) m/z: 356 ([M + H3PO4 – H]
–, 53), 
258 ([M – H]
–, 100); HRMS (ES
+): calcd for C9H13N3O6 (M), [3M + Na]
+ = 800.2311, 
162found 800.2285, [2M + Na]
+ = 541.1506, found 541.1497, [M + Na]
+ = 282.0697, found 
282.0700.
Analytical results consistent with reported data.
71,248
5-Chloro-6-oxocytidine, 108
C15H18N3O9Cl
Mol. Wt.: 419.77
C9H12N3O6Cl
Mol. Wt.: 293.66
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
109
Cl
0.4 M K2CO3/ MeOH / H2O (4:1, v/v)
heat until dissolved, then rt
NH
NH2
O N
O
OH OH
HO O
5
108
Cl
Nucleoside 109 (1.42 g, 3.38 mmol) was dissolved with heating in a 0.4 M solution of 
K2CO3 in methanol/water (4:1 v/v) (33.9 mL, 13.5 mmol K2CO3, 4.0 eq) over 3 minutes 
then stirred at rt.  After 5 minutes, DOWEX 50WX8-400 (pyridinium form) was added 
with stirring, until the solution was slightly acidified (pH 12.0®5.5).  The mixture was 
filtered, the DOWEX washed with methanol/water (1:1 v/v, 2 ´ 50 mL) then water (50 
mL), and the combined filtrate was concentrated in vacuo to dryness.  The residue was 
suspended in ethyl acetate (60 mL) and allowed to stand in the fridge overnight.  The 
mixture   was   vacuum   filtered,   washed   with   ethyl   acetate   (30   mL),   ethyl 
acetate/isopropanol (2:1 v/v, 30 mL) and diethyl ether (2 ´ 30 mL), and dried under 
high vacuum over P2O5, to afford a powdery white solid (1.24 g).
The solid was retreated with 0.4 M solution of K2CO3 in methanol/water (4:1 v/v) (12.7 
mL, 5.08 mmol K2CO3, 1.5 eq) for 15 minutes, then DOWEX 50WX8-400 (pyridinium 
form), and concentrated in vacuo to dryness.  Following suspension in isopropanol (35 
mL) overnight, filtration, washing and drying under high vacuum, over P2O5, the 
product 108 was afforded as a white powdery solid (1.07 g) containing. 35.6 mol % 
potassium acetate and 1.8 mol % succinimide (recalculated yield - 3.05 mmol, 90%).
Rf 0.52 (3:1:1, n-propanol/conc. aq NH3/water, A’); IR (solid) n 3306 (br w, O–H, N–
H), 3213 (br w, O–H), 2980 (br w, C–H), 1714 (m, C=O), 1613 (br vs, C=O), 1434 (m), 
1322, 1267 (w), 1113 (s), 1051, 1023 (s, C–O), 962, 897, 861 (m), 756 (s), 658 (s, C–
Cl), 557 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 6.69 (2H, v br s, NH2), 6.12 (1H, d, 
163J = 4.3 Hz, H
1’), 4.73 (3H, extremely br s, OH), 4.53 (1H, dd, J = 4.5, 6.0 Hz, H
2’), 4.13 
(1H, t, J = 5.8 Hz, H
3’), 3.67 (1H, dt, J = 2.8, 4.9 Hz, H
4’), 3.56 (1H, dd, J = 2.6, 11.7 
Hz, H
5’), 3.41 (1H, dd, J = 4.2, 11.6 Hz, H
5’); 
13C NMR (100 MHz, d6-DMSO) d 159.8 
(C
6), 159.2 (C
4–NH2), 154.0 (C
2), 87.9 (C
1’), 84.3 (C
4’), 80.5 (C
5), 71.1 (C
3’), 70.4 (C
2’), 
62.5 (C
5’); LRMS (ES
+) m/z: 316/318 ([M + Na]
+, 3:1, 100); (ES
–) m/z: 585/587/589 
([2M – H]
–, 3:2:1, 9). 292/294 ([M – H]
–, 3:1, 100);  HRMS  (ES
+): calcd for 
C15H18N3O9Cl (M), [2M + Na]
+ =609.0721/611.0692, found 609.0702 (2:1), [M + Na]
+ 
= 316.0307/318.0277, found 316.0298 (3:1).
5-Chloro-2’,3’,5’-tri-O-acetyl-6-oxocytidine, 109
2) NCS (1.1 eq), AIBN (2 mol %), dist. THF, dark, argon, rt
C15H19N3O9
Mol. Wt.: 385.33
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
75
C15H18N3O9Cl
Mol. Wt.: 419.77
NH
NH2
O N
O
OAc AcO
AcO O
5
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Cl
1) BTEA-ICl2 71 (1.5 eq), NaHCO3 (3.0 eq), CH2Cl2, MeOH, rt
Method 1: To a stirred solution of 2’,3’,5’-tri-O-acetyl-6-oxocytidine 75 (0.39 g, 1.00 
mmol) in CH2Cl2 (7 mL) and methanol (5 mL), was added sodium bicarbonate (0.25 g, 
3.02 mmol, 3.0 eq), followed by a solution of iodinating agent benzyltriethylammonium 
dichloroiodate 71 (0.59 g, 1.51 mmol, 1.5 eq) in CH2Cl2 (8 mL), and the reaction was 
stirred vigorously at rt for 30 minutes.   The reaction mixture was filtered and 
concentrated in vacuo to yield a brown gum.  The residue was redissolved in CH2Cl2 (40 
mL), washed with sat. aq sodium thiosulfate (30 mL) and brine (2 ´ 40 mL), dried 
(Na2SO4) and concentrated in vacuo to yield a yellow foam (466 mg).  The compound 
was twice purified by column chromatography (0-5% methanol/CH2Cl2) to afford, after 
drying under high vacuum, the undesired chlorinated product 109 as a white foam (0.11 
g, 0.26 mmol, 26% yield).
Method 2: To a stirred suspension of 2’,3’,5’-tri-O-acetyl-6-oxocytidine 75 (1.52 g, 
3.95 mmol) and AIBN (13.3 mg, 0.08 mmol, 2.1 mol %) in distilled THF (15.0 mL), 
was added NCS (0.56 g, 4.15 mmol, 1.1 eq), and the reaction was stirred in absence of 
light, under an argon atmosphere, at rt for 18 hours.   The thick white slurry was 
dissolved in acetone/methanol (1:1 v/v, 100 mL), and concentrated in vacuo to dryness. 
164Following   purification   by  column   chromatography   (40-60%   acetone/toluene),   the 
desired product 109 was afforded as a white powdery solid (1.64 g) containing 29.6 mol
% succinimide (recalculated yield - 3.57 mmol, 90%).
Rf 0.37 (5:95, methanol/CH2Cl2, A’), 0.36 (1:1, acetone/toluene, A’); IR (solid): n 3419, 
3307 (w, N–H), 3198, 3140, 3087, 3024 (w), 2909 (w, C–H), 1741, 1718 (s, C=O), 
1629 (s, N–H), 1559 (br s, N–H), 1430 (m), 1372 (s, C–H), 1228 (br vs, C–O), 1155 
(m), 1044 (s, C–O), 939, 897, 766, 747 (m), 629 (C–Cl), 601 (m) cm
-1; 
1H NMR (400 
MHz, d6-DMSO) d 10.96 (2H, br s, NH2), 6.15 (1H, br s, H
1’), 5.64 (1H, dd, J = 2.5, 6.5 
Hz, H
2’), 5.49 (1H, t, J = 7.3 Hz, H
3’), 4.33 (1H, dd, J = 3.3, 11.8 Hz, H
5’), 4.11 (1H, 
ddd, J = 3.3, 6.4, 8.0 Hz, H
4’), 4.03 (1H, dd, J = 6.3, 11.8 Hz, H
5’), 2.07 (3H, s, CH3), 
2.03 (3H, s, CH3), 2.00 (3H, s, CH3); 
13C NMR (100 MHz, d6-DMSO) d 170.0, 169.5, 
169.3   (COCH3),   158.0   (C
6),   150.5   (C
4–NH2),   148.7   (C
2),   85.6   (C
1’),   80.3
(C
5–Cl), 77.9 (C
4’), 72.5 (C
2’), 69.7 (C
3’), 62.9 (C
5’), 20.4, 20.3, 20.2 (COCH3); LRMS 
(ES
+) m/z: 861/863/865 ([2M + Na]
+, 6:5:2, 11), 442/444 ([M + Na]
+, 3:1, 100), 420/422 
([M + H]
+, 3:1, 26); (ES
–) m/z: 418/420 ([M – H]
–, 3:1, 100); HRMS (ES
+): calcd for 
C15H18N3O9Cl (M), [2M + Na]
+ = 861.1355/863.1326/865.1296, found 861.1374 (6:4:1), 
[M + Na]
+ = 442.0624/444.0594, found 442.0627 (3:1).
N-(2-aminoethyl)-bis-N,N-[2-(trifluoroacetamido)ethyl]amine, 110
(2.0 eq), dist. Et3N (1.1 eq)
dist. MeOH, -5 oC, argon
F3C N
H
N
N
H
CF3
NH2
O O
H2N
N
NH2
NH2
C6H18N4
Mol. Wt.: 146.23
C10H16F6N4O2
Mol. Wt.: 338.25
103 110
F3C O
O
1 2
3
4 4
3
5 5
6 6
To a stirred solution of tris(2-aminoethyl)amine 103 (0.50 mL, 3.34 mmol) in distilled 
methanol (4.0 mL) and distilled Et3N (0.51 mL, 3.66 mmol, 1.1 eq), under an argon 
atmosphere, at 
–5 °C, was added ethyl trifluoroacetate (0.80 mL, 6.72 mmol, 2.0 eq) 
dropwise over 30 minutes.   The mixture was stirred for a further 2.5 hours, then 
concentrated  in   vacuo  and   dried   under   high   vacuum   co-evaporating   with 
methanol/toluene.  Following purification by column chromatography (20-40% acetone/
ethyl acetate + 0.5% Et3N), bis-trifluoroacetamide 110 was afforded, following drying 
under high vacuum, as a viscous, pale yellow oil (422 mg, 1.25 mmol, 37%).
165Rf 0.21 (2:3, acetone/ethyl acetate + 0.3% Et3N, D’), 0.15 (1:9, methanol/CH2Cl2 + 
0.3% Et3N, D’),  
1H NMR  (300 MHz,  d6-DMSO)  d  9.12 (2H, extremely br s, 
NHCOCF3), 3.25 (4H, t, J = 6.4 Hz, H
3), 3.18 (2H, app. t, J = 7.0 Hz, H
2), 2.65 (4H, q, 
J = 6.6 Hz, H
4), 2.59 (2H, t, J = 6.6 Hz, H
1), 1.88 (2H, t, J = 1.3 Hz, NH2); LRMS 
(ES
+) m/z: 379 (100), 339 ([M + H]
+, 13); HRMS (ES
+): calcd for C10H16N4O2F6 (M), 
[M + H]
+ = 339.1250, found 339.1258. Found also 379.1568.
Bis-N,N-[2-(trifluoroacetamido)ethyl]ammonium trifluoroacetate, 111
182,192
(3.5 eq), dist. H2O (1.2 eq)
MeCN, reflux, argon
F3C N
H
H2
+
N
N
H
CF3
O O
H2N
H
N
NH2
C6H18N4
Mol. Wt.: 146.23
127 111
F3C O
O
1
2 2
3 3
4
CF3CO2
-
C10H12N3O4F9
Mol. Wt.: 409.21
To a stirred solution of diethylene triamine 127 (3.20 mL, 29.6 mmol) in HPLC grade 
acetonitrile (50.0 mL), was added distilled water (0.64 mL, 35.5 mmol, 1.2 eq), 
followed by slow addition of ethyl trifluoroacetate (12.3 mL, 104 mmol, 3.5 eq).  The 
solution was heated at reflux, under argon pressure at 105 °C for 16 hours.  The reaction 
mixture was concentrated in vacuo and dried under high vacuum co-evaporating with 
methanol (2 ´ 50 mL).  The syrup was soaked in CH2Cl2 (100 mL) overnight, then 
suspended and the resulting ‘gel’ was filtered.  The solid was washed with CH2Cl2 (2 ´ 
100 mL) and dried under high vacuum over P2O5, to afford the product salt 111 as an 
off-white, papery solid (11.3 g, 27.6 mmol, 93%).
Rf 0.44 (1:1, acetone/ethyl acetate + 0.3% Et3N, C’), 0.21 (3:7, acetone/CH2Cl2 + 0.3% 
Et3N, C’), 0.31 (1:1, acetone/CH2Cl2 + 0.3% Et3N, C’); IR (solid): n 3282 (br w, N–H, 
O-H), 3118 (w, N–H), 2838 (w, N
+–H), 1717, 1673 (s, C=O), 1558 (m, N–H, C=O), 
1445 (w, C–H), 1175 (s, C–F), 1142 (vs, C–F), 1015, 837, 797 (m), 724 (s, CH2), 694 
(br   m,   C–F)   cm
-1;  
19F   NMR  (282   MHz,  d6-DMSO)  d  -73.5   (CF3CO2
–),   -74.2 
(NHCOCF3); 
1H NMR (400 MHz, d6-DMSO) d 9.60 (2H, br s, NHCOCF3), 8.80 (2H, v 
br s, R2NH2
+), 3.50 (4H, br dd, J = 5.0, 9.5Hz, H
2), 3.13 (4H, t, J = 6.4 Hz, H
1); 
13C 
NMR (100 MHz, d6-DMSO) d 159.2 (q, J = 31.6 Hz, CF3CO2
–), 157.3 (q, J = 36.5 Hz, 
NHCOCF3), 117.5 (q, J = 298.9 Hz, CF3CO2
–), 116.2 (q, J = 287.7 Hz, NHCOCF3), 
45.8 (C
1), 36.3 (C
2);  LRMS  (ES
+)  m/z: 296 ([M + H]
+, 100); (ES
–)  m/z: 522 
([M.CF3CO2H + CF3CO2H – H]
–, 7), 408 ([M.CF3CO2H – H]
–, 100), 392 ([M + H3PO4 – 
166H]
+, 56), 294 ([M – H]
–, 59);  HRMS  (ES
+): calcd C8H11N3O2F6  (M), [M + H]
+  = 
296.0828, found 296.0823.
Analytical results consistent with reported data.
192
N-[2-N’-(4-Methoxytritylamino)ethyl]-bis-N,N-(2-ethyl trifluoroacetamide), 116
F3C N
H
N
NH
HN
O
O
CF3 O
i) TAEA 103 (7.0 eq), dist. pyridine, dist. CH2Cl2, argon, 0 oC
C30H32N4O3F6
Mol. Wt.: 610.59
ii) ethyl trifluoroacetate (10.0 eq)
dist. CH2Cl2/dist. Et3N (1:1 v/v), argon, rt
1
2
3
5
4
6
7
8
9
10
11
8
11
12
13
14
15
115
116
Cl
H3CO
C20H17ClO
Mol. Wt.: 308.80
To a stirred solution of tris(2-aminoethyl)amine (TAEA) 103 (1.79 mL, 11.9 mmol, 7.0 
eq) in distilled CH2Cl2 (4.0 mL), under an argon atmosphere at 0 °C, was added very 
slowly dropwise in portions, a solution of MMTCl 115 (0.53 g, 1.70 mmol) in distilled 
pyridine (3.5 mL), over 5.5 hours.  The reaction was quenched with methanol (2 mL), 
stirring for 5 minutes, then concentrated in vacuo, co-evaporating with CH2Cl2 (´5) then 
under high vacuum, co-evaporating with methanol/toluene (´3). The wet bottle-green 
powder was washed with hexane (2 ´ 50 mL) and CH2Cl2 (4 ´ 25 mL).  The resulting 
blue solid was washed a third time with CH2Cl2 (4 ´ 25 mL) and all combined organic 
fractions were concentrated in vacuo and under high vacuum to give a brown/green oil. 
The oil was dissolved in CH2Cl2 (100 mL), washed with water (100 mL), the aqueous 
was re-extracted (CH2Cl2, 3 ´ 50 mL), and the organic fraction was dried (Na2SO4), and 
concentrated  in vacuo  and under high vacuum, to afford the crude mono-MMT 
protected polyamine, as a pale bottle green gum. (0.61 g).
Rf 0.35 (5:1:1, ethyl acetate/methanol/aq NH3, C’); 
To a stirred solution of the green resin (0.40 g) in distilled CH2Cl2 (5.0 mL) and distilled 
Et3N (5.00 mL), under an argon atmosphere, at rt, was added, ethyl trifluoroacetate 
(1.15 mL, 9.66 mmol, 10.0 eq) dropwise, and the reaction was stirred for 3 hours.  The 
reaction was diluted with CH2Cl2  (100 mL), washed with water (2  ´  50 mL), the 
aqueous was re-extracted (CH2Cl2, 50 mL).  The combined organic fraction was washed 
with sat. aq KCl (50 mL), dried (Na2SO4) and concentrated  in vacuo  to give a 
167yellow/brown syrup.  The compound was twice-purified by column chromatography 
(1% methanol/CH2Cl2 + 0.5% Et3N; toluene + 0.5% Et3N ® 1.5% methanol/CH2Cl2 + 
0.5% Et3N) to afford the product 116 as a pale yellow foam (0.14 g, 0.23 mmol, 20% 
over two steps).
Rf 0.53 (3% methanol/CH2Cl2 + 0.3% Et3N, C’, E’); IR (solid) n 3303 (br w, water), 
3057 (br w, N–H), 2952, 2837 (br w, C–H), 1703 (s, C=O), 1607, 1556 (w, Aryl C–H), 
1508 (m, Aryl C–H), 1448 (m), 1297 (w), 1248 (m), 1206 (s, C–F), 1148 (br vs, C–F), 
1032 (m), 903 (w), 830, 768, 750 (m, Aryl C–H), 703 (s, Aryl C–H), 583 (m) cm
-1; 
19F 
NMR (282 MHz, d6-DMSO) d 
–74.1 (COCF3); 
1H NMR (400 MHz, d6-DMSO) d 9.20 
(1H, br s, NHCOCF3), 7.38 (4H, d, J = 8.0 Hz, H
9), 7.29-7.23 (2H, m, H
13), 7.27 (4H, d, 
J = 8.5 Hz, H
10), 7.16 (2H, t, J = 7.3 Hz, H
11), 6.83 (2H, d, J = 9.0 Hz, H
14), 3.71 (3H, s, 
OCH3), 3.31 (1H, s, NHMMT), 3.19 (4H, br dd, J = 6.3, 10.8 Hz, H
2), 2.58 (2H, t, J = 
6.5 Hz, H
6), 2.48 (4H, t, J = 6.5 Hz, H
1), 2.07 (2H, dd, J = 6.0, 12.6 Hz, H
5); 
13C NMR 
(100 MHz, d6-DMSO) d 157.3 (C
15), 156.2 (q, J = 36.0 Hz, COCF3), 146.5 (C
8), 138.1 
(C
12), 129.5 (C
13), 128.2 (C
9), 127.6 (C
10), 125.9 (C
11), 115.9 (q, J = 288.2 Hz, COCF3), 
113.0 (C
14), 69.7 (C
7Ar3), 54.9 (OCH3), 54.0 (C
6), 52.1 (C
1), 41.1 (C
5), 37.3 (C
2); 
LRMS (ES
–) m/z: 723 ([M + F3CCO2H – H]
–, 38), 672 (21), 609 ([M – H]
–, 13), 145 
(100);  HRMS  (ES
+): calcd for C30H32N4O3F6  (M), [M + Na]
+  = 633.2271, found 
633.2274.
Bis-N,N-[2-(trifluoroacetamido)ethyl]amine, 128
194,252
H2N
H
N
NH2
C6H18N4
Mol. Wt.: 146.23
127
(2.3 eq), dist. Et3N (2.5 eq)
CH2Cl2 (distilled), -5 oC, argon
F3C N
H
H
N
N
H
CF3
O O
F3C O
O
1
2 2
3 3
4
C8H11N3O2F6
Mol. Wt.: 295.18
128
To a stirred solution of diethylene triamine  127  (2.00 mL, 18.5 mmol) in distilled 
CH2Cl2 (40.0 mL), and distilled Et3N (6.45 mL, 46.3 mmol, 2.5 eq), under an argon 
atmosphere, at 
-5 °C, ethyl trifluoroacetate (5.07 mL, 42.6 mmol, 2.3 eq), was added 
dropwise over 1 hour.  After stirring for a further 1¼ hours, the reaction mixture was 
concentrated  in vacuo  and redissolved in argon-degassed CH2Cl2  (100 mL).   The 
solution was washed with degassed sat. aq KCl (2 ´ 50 mL), and the combined aqueous 
fraction was re-extracted (degassed CH2Cl2, 2  ´  30 mL).   The combined CH2Cl2 
168fractions were dried (Na2SO4), concentrated in vacuo and dried under high vacuum, to 
afford the product  bis-trifluoroacetamide  128, as an off-white, slightly air-sensitive 
solid (5.13 g, 17.4 mmol, 94%).
Rf 0.27 (3:7, acetone/CH2Cl2 + 0.3% Et3N, C’), 0.35 (1:1, acetone/CH2Cl2 + 0.3% Et3N, 
C’); IR (solid): n 3287 (w, N–H), 2945, 2850 (w, C–H), 1704 (s, C=O), 1563 (m, N–H, 
C=O), 1435 (m, C–H), 1349 (w), 1183, 1140 (br vs, C–F), 950 (w), 866, 843 (m), 724 
(s, CH2), 681 (br m, C–F) cm
-1; 
19F NMR (282 MHz, d6-DMSO) d -74.1 (COCF3); 
1H 
NMR (400 MHz, d6-DMSO) d 9.25 (2H, v br s, NHCOCF3), 3.24 (4H, t, J = 6.4 Hz, 
H
2), 2.64 (4H, t, J = 6.5 Hz, H
1); 
13C NMR (100 MHz, d6-DMSO) d 156.3 (q, J = 36.0 
Hz, NHCOCF3), 115.9 (q, J = 287.7 Hz, NHCOCF3), 47.1 (C
1), 39.3 (C
2); LRMS (ES
+) 
m/z: 296 ([M + H]
+, 100); (ES
–) m/z: 408 ([M + CF3CO2H – H]
–, 20), 392 ([M + H3PO4 
– H]
–, 100), 294 ([M – H]
–, 77); HRMS (ES
+): calcd for C8H11N3O2F6 (M), [M + Na]
+ = 
318.0648, found 318.0672; [M + H]
+ = 296.0828, found 296.0830.
Analytical results consistent with reported data.
252
2,2’-Anhydro-6-oxocytidine and 6,2’-anhydro-6-oxocytidine, 141,142
NH
NH2
O N
O
OH OH
HO O
5
1'
5'
4'
101
C9H13N3O6
Mol. Wt.: 259.22
NH
NH
O N O
OH
HO O
2'
5'
1'
Ph2CO3 (1.1 eq), NaHCO3 (5 mol%)
5 N
NH2
O N O
OH
HO O
2'
5'
3'
1'
5
+
anh. DMF, argon, 100 oC
2 6
C9H11N3O5
Mol. Wt.: 241.20
141 142
To a stirred solution of 6-oxocytidine 101 (0.20 g, 0.60 mmol) in anhydrous DMF (2.50 
mL), under an argon atmosphere, was added diphenyl carbonate (0.14 g, 0.66 mmol, 1.1 
eq) and sodium bicarbonate (3.0 mg, 0.04 mmol, 6.0 mol %) and the mixture was stirred 
at 100 °C for 3 hours.  The reaction mixture was allowed to cool to rt, then diethyl ether 
(35 mL) was slowly added with rapid stirring, and the suspension was stirred for 30 
minutes.  The ether was decanted, and the precipitate was washed with ether (2 ´ 15 
mL) and dried under high vacuum to afford the crude product as a hygroscopic, 
powdery solid. The solid was redissolved in water/methanol (2:1, v/v, 30 mL) and 
concentrated in vacuo and under high vacuum.  The gum was redissolved in DMF (2 
mL) and diethyl ether (25 mL) was added slowly with vigorous stirring. After stirring 
169for 30 minutes, the ether was decanted, the solid was washed with diethyl ether (2 ´ 75 
mL) and dried in vacuo and under high vacuum to give the product as an isomeric 
mixture 141,142 (ca. 1:1), as an off-white chalky solid (0.14 g, 0.59 mmol, 98%).
Rf 0.13, 0.23 (5:1:1, ethyl acetate/methanol/conc. aq NH3, A’); LRMS (ES
+) m/z: 280 
([M + Na]
+, 24), 264 ([M + Na]
+, 100).
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-[3-
(trifluoroacetamido)phenyl]-(2,3H)-furano[2,3-d]pyrimidine-2-one-3’-O-(2-O-
cyanoethyl-N,N-diisopropyl) phosphoramidite, 145
206
(1.2 eq), dist. DIPEA (2.5 eq)
dist. THF, ARGON, rt
N
N
O N
O
O
O
MeO
MeO
O
HN
P
N
O
CN
PO
Cl
CN
C49H51N5O9F3P
Mol. Wt.: 941.93
C40H34N3O8F3
Mol. Wt.: 741.71
N
O N
O
OH
O
MeO
MeO
O
HN
4
5
6
2'
5' 8
9
12
13
16
12
1''
3''
155
O
F3C
70
145
4
5
6
2'
5'
8
9
12
13
16
12
1''
3''
17
18
19 20
F3C
O
To a solution of nucleoside 155 (0.49 g, 0.66 mmol) in distilled THF (4.0 mL) and 
distilled DIPEA (0.29 mL, 1.67 mmol, 2.5 eq), strictly under an argon atmosphere and 
excluding moisture, was added chloro-phosphitylating reagent 70 (0.18 mL, 0.81 mmol, 
1.2 eq) dropwise, and the reaction was stirred at rt for 80 minutes.  The reaction was 
diluted with argon-degassed ethyl acetate (40 mL), then washed, under an argon 
atmosphere, with degassed sat aq KCl (3 ´ 10 mL).  The organic fraction was dried 
(Na2SO4), the inorganics were washed with degassed ethyl acetate (3 ´ 10 mL) and the 
combined fraction was transferred under argon and concentrated in vacuo to give a pale 
yellow residue.   Following purification by column chromatography (degassed 30% 
ethyl acetate/CH2Cl2 + 0.5% Et3N), on silica gel pre-equilibrated with Et3N, under argon 
pressure, and after drying under high vacuum, the product phosphoramidite 145 was 
afforded, as a diastereomeric mixture (ca. 3:2), as an air-sensitive, off-white foam (0.40 
g, 0.42 mmol, 64%).
170Rf 0.49, 0.61 (1:1, ethyl acetate/CH2Cl2  + 0.3% Et3N, A’), 0.58 (4:1, ethyl acetate/ 
CH2Cl2 + 0.3% Et3N, A’); 
31P NMR (121 MHz, d6-DMSO) d 149.2, 149.0 (P
III); 
1H 
NMR (300 MHz, d6-DMSO) d 11.39 (1H, br s, NHCOCF3), 8.78 and 8.77 (1H, s, H
4), 
8.05 (1H, t, J = 1.5 Hz, H
2”), 7.71 (1H, td, J = 1.8, 7.0 Hz, H
4”), 7.55 (1H, br s, H
6”), 
7.53 (1H, t, J = 7.7 Hz, H
5”), 7.42 and 7.40 (2H, td, J = 1.6, 7.1 Hz and J = 1.5, 6.6 Hz, 
H
14), 7.36-7.19 (3H, m, H
15, H
16), 7.28 (4H, d, J = 8.8 Hz, H
10), 6.91 and 6.90 (2H, d, J 
= 9.2 Hz and J = 8.8 Hz, H
11), 6.90 and 6.89 (2H, d, J = 9.2 Hz, H
11), 6.34 and 6.32 (1H, 
s, H
5), 6.20 and 6.16 (1H, dd, J = 4.2, 6.8 Hz, and J = 4.0, 6.6 Hz, H
1’), 4.73-4.57 (1H, 
m, H
3’), 4.20 and 4.15 (1H, dd, J = 3.7, 8.6 Hz and J = 3.8, 8.5 Hz, H
4’), 3.81-3.68 and 
3.74-3.60 (2H, m, H
17), 3.71, 3.71 and 3.70 (3H, 3H and 6H, s, OCH3), 3.62-3.45 (2H, 
m, H
19), 3.46-3.35 (2H, m, H
5’), 3.36-3.26 (2H, m, H
5’), 2.77 and 2.67 (2H, t, J = 5.9 
Hz, H
18), 2.69-2.55 (1H, m, H
2’), 2.55-2.38 (1H, m, H
2’), 1.16 (3H, d, J = 7.0 Hz, H
20), 
1.13 (3H, d, J = 7.0 Hz, H
20), 1.12 (3H, d, J = 7.0 Hz, H
20), 1.02 (3H, d, J = 6.6 Hz, 
H
20); LRMS (ES
+) m/z: 980 ([M + K]
+, 41), 964 ([M + Na]
+, 100), 942 ([M + H]
+, 52).
Analytical results consistent with reported data.
206
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-ureidophenyl)-
(2,3H)-furano[2,3-d]pyrimidine-2-one-3’-O-(2-O-cyanoethyl-N,N-diisopropyl) 
phosphoramidite, 146
N
O N
O
OH
O
MeO
MeO
O
HN
C39H36N4O8
Mol. Wt.: 688.73
H2N
O
2 4
4a
5
6
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2'
5'
8 9
12
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16
12
1''
3''
160
(1.2 eq), dist. DIPEA (2.5 eq)
dist. THF, ARGON, rt
N
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P
N
O
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17
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20
C48H53N6O9P
Mol. Wt.: 888.94
H2N
O
70
To a solution of nucleoside 160 (1.22 g, 1.77 mmol) in distilled THF (10.0 mL) and 
distilled DIPEA (0.77 mL, 4.42 mmol, 2.5 eq), strictly under an argon atmosphere and 
excluding moisture, was added chloro-phosphitylating reagent 70 (0.48 mL, 2.15 mmol, 
1.2 eq) dropwise, and the reaction was stirred at rt for 2 hours.  Further reagent 70 (0.08 
mL, 0.36 mmol, 0.2 eq) was added and the reaction was stirred for 45 minutes.  The 
reaction was quenched with argon-degassed sat aq KCl (1 ml), diluted with degassed 
171ethyl acetate (60 mL), then washed, under an argon atmosphere, with degassed sat aq 
KCl (2 ´ 20 mL).  The organic fraction was dried (Na2SO4), the inorganics were washed 
with degassed ethyl acetate (2  ´  10 mL) and the combined organic fraction was 
transferred under argon and concentrated in vacuo to give a yellow gum.  Following 
purification by column chromatography (degassed 65% acetone/CH2Cl2 + 1.0% Et3N), 
on silica gel pre-equilibrated with Et3N, under argon pressure, then precipitation at rt 
from distilled  CH2Cl2  (3 mL) into degassed hexane (150 mL), under an argon 
atmosphere, the desired product 146 was afforded as a diastereomeric mixture (ca. 2:3), 
as an air-sensitive, powdery white solid (1.08 g, 1.22 mmol, 69%).
Rf 0.33 (65:35, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.44 (9:1, acetone/CH2Cl2 + 0.3% 
Et3N,   A’);  
31P   NMR  (121   MHz,  d6-DMSO)  d  149.3,   149.1   (P
III),   15.1 
(HO(H)P
V(O)OCH2CH2CN); 
1H NMR (400 MHz, d6-DMSO) d 8.75 and 8.74 (1H, s, 
H
4), 8.74 (1H, br s, NHCONH2), 7.90 (1H, br s, H
2”), 7.42 and 7.40 (2H, d, J = 8.5 Hz 
and J = 9.0 Hz, H
14), 7.38-7.33 (1H, m, H
4”), 7.34 (2H, d, J = 7.0 Hz, H
15), 7.34-7.27 
(2H, m, H
16, H
5”), 7.30 and 7.27 (4H, d, J = 9.0 Hz, H
10), 7.24 (1H, ddd, J = 1.8, 3.3, 6.5 
Hz, H
6”), 6.91, 6.91 and 6.90 (2H, 2H and 4H, d, J = 9.0 Hz, H
11), 6.21 and 6.17 (1H, 
dd, J = 4.5, 6.5 Hz, H
1’), 6.20 and 6.18 (1H, s, H
5), 5.93 (2H, br s, CONH2), 4.69 and 
4.65 (1H, td, J = 6.4, 13.1 Hz and J = 6.1, 12.5 Hz, H
3’), 4.19 and 4.15 (1H, td, J = 3.5, 
5.0 Hz, H
4’), 3.81-3.70 and 3.71-3.62 (2H, m, H
17), 3.72, 3.72 and 3.71 (3H, 3H and 6H, 
s, OCH3), 3.63-3.47 (2H, m, H
19), 3.46 and 3.43 (1H, dd, J = 3.4, 10.9 Hz and 3.4, 11.4 
Hz, H
5’), 3.43-3.38 and 3.39 (1H, m and dd, J = 2.8, 12.1 Hz, H
5’), 2.77 and 2.67 (2H, t, 
J = 6.0 Hz, H
18), 2.64 and 2.60 (1H, td, J = 6.4, 12.8 Hz and J = 6.3, 12.4 Hz, H
2’), 2.47-
2.39 (1H, m, H
2’), 1.15 (3H, d, J = 6.8 Hz, H
20), 1.13 (3H, d, J = 6.8 Hz, H
20), 1.12 (3H, 
d, J = 6.8 Hz, H
20), 1.02 (3H, d, J = 6.8 Hz, H
20); LRMS (ES
+) m/z: 927 ([M + K]
+, 9), 
911 ([M + Na]
+, 28), 889 ([M + H]
+, 17), 618 (100).
1723-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-
acetamidophenyl)-(2,3H)-furano[2,3-d]pyrimidine-2-one-3’-O-(2-O-cyanoethyl-
N,N-diisopropyl) phosphoramidite, 147
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(1.2 eq), dist. DIPEA (2.5 eq)
dist. THF, ARGON, rt
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C40H37N3O8
Mol. Wt.: 687.74 C49H54N5O9P
Mol. Wt.: 887.95
To a solution of nucleoside 163 (1.00 g, 1.46 mmol) in distilled THF (8.0 mL) and 
distilled DIPEA (0.64 mL, 3.67 mmol, 2.5 eq), strictly under an argon atmosphere and 
excluding moisture, was added chloro-phosphitylating reagent 70 (0.39 mL, 1.75 mmol, 
1.2 eq) dropwise, and the reaction was stirred at rt for 2½ hours.  The reaction was 
quenched with argon-degassed sat aq KCl (2 ml) stirring for 5 minutes, diluted with 
degassed ethyl acetate (100 mL), then washed, under an argon atmosphere, with 
degassed sat aq KCl (2  ´  20 mL).   The organic fraction was dried (Na2SO4), the 
inorganics were washed with degassed ethyl acetate (2 ´ 15 mL) and the combined 
fraction was transferred under argon and concentrated in vacuo to give a pale yellow 
foam.  Following purification by column chromatography (degassed 10-60% acetone/ 
CH2Cl2 + 0.5% Et3N), on silica gel pre-equilibrated with Et3N, under argon pressure, 
then precipitation twice from distilled CH2Cl2 (2 mL) into degassed hexane (200/250 
mL) at 
–78 °C/rt, under an argon atmosphere, the desired phosphoramidite 147 was 
afforded as a diastereomeric mixture (ca. 2:3), as an air-sensitive, pale cream foam 
(0.89 g) containing 18.9 mol % hydrolysed phosphitylating reagent (recalculated yield - 
0.97 mmol, 66%).
Rf 0.42, 0.50 (2:3, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.21, 0.30 (1:9, acetone/CH2Cl2 + 
0.3%   Et3N,   A’);  
31P   NMR  (121   MHz,  d6-DMSO)  d  149.3,   149.0   (P
III),   15.1 
(HO(H)P
V(O)OCH2CH2CN);  
1H   NMR  (400   MHz,  d6-DMSO)  d  10.10   (1H,   s, 
NHCOCH3), 8.76 and 8.75 (1H, s, H
4), 8.02 (1H, s, H
2”), 7.59 (1H, br d, J = 7.5 Hz, 
H
4”), 7.44-7.40 (1H, m, H
5”), 7.42-7.37 (2H, m, H
14), 7.37-7.30 (2H, m, H
15, H
6”), 7.30 
and 7.27 (4H, d, J = 8.5 Hz and J = 9.0 Hz, H
10), 7.30-7.25 (1H, m, H
16), 6.91, 6.91 and 
1736.90 (2H, 2H and 4H, d, J = 8.5 Hz, J = 9.0 Hz and J = 9.0 Hz, H
11), 6.25 and 6.23 (1H, 
s, H
5), 6.20 and 6.10 (1H, dd, J = 4.3, 6.8 Hz and J = 4.8, 6.3 Hz, H
1’), 4.67 and 4.65 
(1H, td, J = 6.2, 12.3 Hz and J = 6.0, 12.1 Hz, H
3’), 4.19 and 4.15 (1H, td, J = 3.3, 5.0 
Hz and J = 3.5, 5.8 Hz, H
4’), 3.81-3.69 and 3.73-3.61 (2H, m, H
17), 3.72, 3.71 and 3.70 
(3H, 3H and 6H, s, OCH3), 3.62-3.48 (2H, m, H
19), 3.49-3.35 (2H, m, H
5’), 2.76 and 
2.67 (2H, t, J = 6.0 Hz, H
18), 2.62 and 2.61 (1H, td, J = 6.4, 12.7 Hz and J = 6.3, 12.6 
Hz, H
2’), 2.43 and 2.42 (1H, ddd, J = 4.0, 6.8, 13.8 Hz and J = 3.0, 7.0, 13.6 Hz, H
2’), 
2.08 (3H, s, COCH3), 1.15 (3H, d, J = 7.0 Hz, H
20), 1.13 (3H, d, J = 7.0 Hz, H
20), 1.12 
(3H, d, J = 6.5 Hz, H
20), 1.02 (3H, d, J = 7.0 Hz, H
20); LRMS (ES
+) m/z: 910 ([M + Na]
+, 100), 888 ([M + H]
+, 4); (ES
–) m/z: 949 (32), 922/924 ([M + HCl – H]
–, 3:1, 33), 886 
([M – H]
–, 100).
4-(3-Aminophenyl)-2-methyl-but-3-yn-2-ol, 151
206,253
NH2
OH
7
8
9
10 1
2
3
4
5
6
NH2
I
OH (2.5 eq), CuI (1 mol%)
distilled Et3N, 50 oC - reflux
PPh3 (3 mol%), (Ph3P)2PdCl2 (3 mol%)
C6H6NI
Mol. Wt.: 219.02 C11H13NO
Mol. Wt.: 175.23
151 149
150 1
3
To a solution of 3-iodoaniline 149 (1.00 g, 4.56 mmol) in distilled Et3N (1.5 mL) under 
an argon atmosphere, in absence of light, was added CuI (8.7 mg, 0.05 mmol, 1.0 mol 
%) then 2-methyl-but-3-yn-2-ol 150 (1.10 mL, 11.4 mmol, 2.5 eq), and the mixture was 
stirred at rt for 5 minutes.  Triphenylphosphine (36.0 mg, 0.14 mmol, 3.0 mol %) was 
added and the reaction was stirred for a further 5 minutes.   Bis(triphenylphosphine) 
palladium dichloride (96.2 mg, 0.14 mmol, 3.0 mol %) was added and the reaction was 
stirred at 50 °C for 20 minutes then refluxed for 50 minutes.  The reaction mixture was 
cooled and concentrated under high vacuum, co-evaporating with methanol/toluene, 
then the brown syrupy solid was suspended in diethyl ether (70 mL) and allowed to 
stand in the fridge overnight.  The solution was decanted and the solid washed again 
with diethyl ether (9 ´ 30 mL), followed by ice-cold ethyl acetate/diethyl ether (1:1 v/v, 
100 mL).   All fractions were combined, vacuum filtered and the solid was further 
washed with diethyl ether (30 mL).  The combined fractions were concentrated in vacuo 
and redissolved in hot ethyl acetate (10 mL).  The hot solution was added dropwise to 
diethyl ether at 
–70 °C with vigorous stirring.  The suspension was vacuum filtered, the 
174solid washed with very cold diethyl ether (150 mL) and the filtrate was concentrated in 
vacuo.  The resultant syrup was dissolved in CH2Cl2 (70 mL) and washed with water (3 
´ 100 mL).  The aqueous fraction was re-extracted (CH2Cl2, 200 mL), and combined 
CH2Cl2  fractions were washed with sat aq KCl (100 mL),  dried (Na2SO4) and 
concentrated in vacuo to give an orange/brown gum.  Following purification by column 
chromatography (0–30% CH2Cl2/diethyl ether), and drying under high vacuum, the 
product alkyne 151 was isolated as a pale yellow solid (0.43 g, 2.43 mmol, 53%).
Rf  0.29 (1:1, ethyl acetate/hexane, A’), 0.31 (1:1, CH2Cl2/diethyl ether, A’), 0.04 
(CH2Cl2, A’), 0.36 (diethyl ether, A’); 
1H NMR (300 MHz, d6-DMSO) d 6.97 (1H, t, J 
= 7.9 Hz, H
5), 6.58 (1H, dd, J = 1.3, 2.0 Hz, H
2), 6.53 (1H, ddd, J = 1.1, 2.6, 8.1 Hz, 
H
4), 6.50 (1H, td, J = 1.3, 7.4 Hz, H
6), 5.37 (1H, s, OH), 5.14 (2H, br s, NH2), 1.44 (6H, 
s, CH3); 
13C NMR (75 MHz, d6-DMSO) d 148.7 (C
3–NH2), 129.0 (C
5), 122.8 (C
1), 
118.6   (C
6),   116.3   (C
2),   114.0   (C
4),   94.6   (ArCºC
8R),   81.1   (ArC
7ºCR),   63.5 
(C(CH3)2OH), 31.7 (CH3); LRMS (ES
+): m/z: 277 ([M + Et3N + H]
+, 10), 217 ([M + 
CH3CN + H]
+, 35), 176 ([M + H]
+, 37), 102 ([Et3N + H]
+, 100).
Analytical results consistent with reported data.
253 
3-Aminophenyl acetylene (or 3-ethynylaniline), 152
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Potassium hydroxide (0.21 g, 3.80 mmol, 2.3 eq) was dissolved in dry, refluxing 
isopropanol (5 mL) with 4Å molecular sieves.  Immediately on dissolution, protected 
alkyne 151 (0.29 g, 1.63 mmol) was added and the mixture was refluxed for 2½ hours. 
Further KOH (0.10 g, 1.82 mmol, 1.1 eq) was added and the reaction was refluxed for 1 
hour.  The mixture was cooled and concentrated to dryness under high vacuum at rt. 
Dichloromethane (40 mL) was added and the mixture was vacuum filtered.  The residue 
was washed with CH2Cl2 (2 ´ 20 mL), and the filtrate was concentrated to dryness in 
vacuo and under high vacuum to give a tan-coloured solid.  Following purification by 
column chromatography (0–10% diethyl ether/CH2Cl2), and drying under high vacuum, 
175the product alkyne 152 was afforded as a pale orange/brown oil (0.08 g, 0.64 mmol, 
39%).
Rf 0.23 (CH2Cl2, A’), 0.47 (1:1, diethyl ether/CH2Cl2, A’), 0.68 (1:9, methanol/CH2Cl2, 
A’); 
1H NMR (300 MHz, CDCl3) d 7.10 (1H, t, J = 8.1 Hz, H
5), 6.90 (1H, td, J = 1.2, 
7.7 Hz, H
6), 6.81 (1H, dd, J = 1.5, 2.2 Hz, H
2), 6.67 (1H, ddd, J = 1.1, 2.6, 8.1 Hz, H
4), 
3.60 (2H, v br s, 3-NH2), 3.02 (1H, s, CºCH
8); 
13C NMR (75 MHz, CDCl3) d 146.4 
(C
3–NH2), 129.4 (C
5), 122.9 (C
1), 122.6 (C
6), 118.4 (C
2), 115.9 (C
4), 84.0 (C
7ºCH), 
76.6 (CºC
8H); LRMS (EI
+): calcd 177.1 (M
+), found 117.0 (M
+).
Analytical results consistent with reported data.
254 
5-[(3-Aminophenyl)ethynyl]-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyuridine, 153
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C30H29N2O7I
Mol. Wt.: 656.47
C38H35N3O7
Mol. Wt.: 645.70
153
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To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine 97 (2.32 g, 3.53 
mmol) in anhydrous DMF (20.0 mL), under an argon atmosphere, in absence of light, 
was added CuI (0.27 g, 1.41 mmol, 0.4 eq), distilled Et3N (1.50 mL, 10.8 mmol, 3.1 eq) 
then 3-ethynylaniline 152 (1.19 mL, 10.6 mmol, 3.0 eq).  The mixture was stirred for 10 
minutes then tetrakis(triphenylphosphine) palladium (0) (0.41 g, 0.35 mmol, 0.1 eq) 
was added and the reaction was stirred at rt for 75 minutes.  The reaction mixture was 
concentrated under high vacuum, co-evaporating with toluene to give a sticky dark 
brown gum.   The residue was soaked in diethyl ether (2  ´  50 mL), the ether was 
decanted, and residue was co-evaporated with toluene to yield a dark brown foamy 
resin.   The crude material was twice-purified by column chromatography (0–15% 
methanol/CH2Cl2 + 1-5% Et3N) to afford, and drying under high vacuum, the desired 
product  153  as an orange/brown glassy solid (2.09 g), containing 57 mol % Et3N 
(recalculated yield - 2.67 mmol, 76%).
176Rf 0.35 (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’); 0.35 (4:1, ethyl acetate/toluene + 0.3% 
Et3N, A’); Mp 116-120 °C (CH2Cl2); IR (solid): n 3342 (w, O–H, N–H), 3232 (w, O–
H), 3056, 2973, 2931, 2834 (w, C–H), 2171 (w, CºC), 1689 (br m, C=O), 1632 (s, N–
H), 1596 (s, C=C), 1507 (s, Aryl C=C), 1442 (C–H), 1385 (m, O–H), 1276 (s), 1246 
(vs), 1174, 1087, 1030 (s, C–O), 943, 866 (m), 826 (s, C–H), 788 (s), 754, 688 (s, Aryl 
C–H), 583, 515 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 11.3 (1H, br s, NH
3), 7.97 
(1H, s, H
6), 7.41 (2H, d, J = 7.5 Hz, H
15), 7.32–7.26 (2H, m, H
16), 7.30 (2H, d, J = 9.0 
Hz, H
11), 7.29 (2H, d, J = 9.0 Hz, H
11), 7.18 (1H, br t, J = 7.3 Hz, H
17), 6.95 (1H, t, J = 
7.7 Hz, H
5”), 6.86 (2H, d, J = 9.0 Hz, H
12), 6.84 (2H, d, J = 9.0 Hz, H
12), 6.55 (1H, ddd, 
J = 0.6, 2.0, 8.0 Hz, H
4”), 6.52 (1H, app. t, J = 1.6 Hz, H
2”), 6.33 (1H, br d, J = 7.8 Hz, 
H
6”), 6.14 (1H, t, J = 6.8 Hz, H
1’), 5.31 (1H, br s, 3’-OH), 5.13 (2H, s, NH2), 4.28 (1H, 
td, J = 3.3, 6.0 Hz, H
3’), 3.95 (1H, td, J = 3.3, 4.8 Hz, H
4’), 3.68 (3H, s, OCH3), 3.67 
(3H, s, OCH3), 3.24 (1H, dd, J = 5.3, 10.5 Hz, H
5’), 3.15 (1H, dd, J = 2.8, 10.5 Hz, H
5’), 
2.30 (1H, td, J = 6.7, 13.6 Hz, H
2’), 2.22 (1H, ddd, J = 3.3, 6.3, 13.6 Hz, H
2’); 
13C NMR 
(100 MHz, d6-DMSO) d 161.4 (C
4), 158.1, 158.0 (C
13), 149.3 (C
2), 148.5 (C
3”), 144.6 
(C
14), 142.4 (C
6), 135.6, 135.3 (C
10), 129.7, 129.6 (C
11), 128.8 (C
5”), 127.8 (C
16), 127.6 
(C
15), 126.6 (C
17), 122.4 (C
1”), 118.7 (C
6”), 116.0 (C
2”), 114.4 (C
4”), 113.2 (C
12-OMe), 
98.8 (C
5), 93.0 (C
8), 85.9 (C
4’), 85.8 (C
9Ar3), 85.1 (C
1’), 80.3 (C
7), 70.5 (C
3’), 63.7 (C
5’), 
54.9 (OCH3), 39.9 (C
2’); LRMS (ES
+): m/z: 1314 ([2M + Na]
+, 22), 747 ([M + Et3N + 
H]
+, 100), 719 (41), 668 ([M + Na]
+, 44), 646 ([M + H]
+, 41); HRMS (ES
+): calcd for 
C38H35N3O7 (M), [M + Na]
+ = 668.2367, found 668.2375.  Found also DMT
+: calcd 
303.1380, found 303.1387.
Analytical results consistent with reported data.
206
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-aminophenyl)-
(2,3H)-furano[2,3-d]pyrimidine-2-one, 154
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177To a solution of nucleoside 153 (1.94 g, 2.48 mmol) in distilled methanol/distilled Et3N 
(7:3 v/v, 15.0 mL), under an argon atmosphere, in absence of light, was added CuI (0.57 
g, 2.99 mmol, 1.0 eq).  The reaction mixture was stirred at 50 °C for 17 hours then 
cooled to rt and concentrated in vacuo, co-evaporating with CH2Cl2 (2 ´ 50 mL).  The 
residue was dissolved/suspended in CH2Cl2 (150 mL) and filtered.  The filtrate was 
washed with 5% w/v aq Na2EDTA (pH 9, 4 ´ 50 mL), sat aq KCl (2 ´ 50 mL), dried 
(Na2SO4), concentrated in vacuo and dried under high vacuum to afford the product 154 
as an orange/brown glassy foam (1.53 g, 2.37 mmol, 96%) containing 3.5 mol % 
uncyclised material 153.
Rf 0.35 (153), 0.34 (154) (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’); 
1H NMR (300 MHz, 
d6-DMSO) d 8.70 (1H, s, H
4), 7.40 (2H, d, J = 7.5 Hz, H
14), 7.34 (2H, t, J = 7.5 Hz, 
H
15), 7.29 (4H, d, J = 9.0 Hz, H
10), 7.31-7.24 (1H, m, H
16), 7.13 (1H, t, J = 7.8 Hz, H
5”), 
6.94-6.88 (1H, m, H
2”), 6.92 (2H, d, J = 8.8 Hz, H
11), 6.91 (2H, d, J = 9.0 Hz, H
11), 6.84 
(1H, br d, J = 7.5 Hz, H
4”), 6.62 (1H, br dd, J = 1.5, 8.0 Hz, H
6”), 6.13 (1H, dd, J = 4.6, 
6.4 Hz, H
1’), 5.42 (1H, d, J = 4.8 Hz, 3’-OH), 5.32 (2H, br s, NH2), 4.43 (1H, td, J = 
5.9, 11.1 Hz, H
3’), 4.04-3.99 (1H, m, H
4’), 3.72 (3H, s, OCH3), 3.71 (3H, s, OCH3), 3.41 
(1H, dd, J = 4.0, 10.8 Hz, H
5’), 3.32 (1H, dd, J = 2.8, 10.8 Hz, H
5’), 2.46 (1H, td, J = 
6.6, 13.1 Hz, H
2’), 2.25 (1H, ddd, J = 4.8, 6.5, 13.4 Hz, H
2’); 
13C NMR (100 MHz, d6-
DMSO) d 170.9 (C
7a), 158.2 (C
12–OCH3), 154.5 (C
2), 149.2 (C
3”–NH2), 144.4 (C
13), 
137.3 (C
4), 135.4 (C
9), 135.3 (C
6), 135.1 (C
9), 129.8, 129.7 (C
10), 129.5 (C
5”), 128.6 
(C
1”), 128.0 (C
15), 127.8 (C
14), 126.8 (C
16), 115.1 (C
6”), 113.3 (C
11), 112.0 (C
4”), 109.2 
(C
2”), 106.7 (C
4a), 97.8 (C
5), 87.3 (C
1’), 86.1 (C
8Ar3), 85.9 (C
4’), 68.8 (C
3’), 62.4 (C
5’), 
55.0 (OCH3), 41.1 (C
2’); LRMS (ES
+): m/z: 917 (20), 663 ([M + NH4]
+, 100), 646 ([M + 
H]
+, 13);  HRMS  (ES
+): calcd for C38H35N3O7  (M), [M + Na]
+  = 668.2367, found 
668.2359.  Found also DMT
+: calcd 303.1380, found 303.1382.
Analytical results consistent with reported data.
206
1783-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-[3-
(trifluoroacetamido)phenyl]-(2,3H)-furano[2,3-d]pyrimidine-2-one, 155
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To a stirred solution of nucleoside 154 (1.37 g, 2.12 mmol) and N,N-dimethylamino 
pyridine (DMAP) (0.26 g, 2.13 mmol, 1.0 eq) in distilled THF (10.0 mL), under an 
argon atmosphere, with 4Å molecular sieves, was added distilled Et3N (0.15 mL) then 
ethyl trifluoroacetate (0.50 mL, 4.24 mmol, 2.0 eq).  The solution was stirred at rt for 2 
minutes, then heated to reflux under argon pressure (80 °C).  Further DMAP (1.0 eq) 
and ethyl trifluoroacetate (2.0 eq) were added after 6 hours and 21½ hours. The 
temperature was then raised to 85 °C.  Further DMAP (0.5 eq) and ethyl trifluoroacetate 
(1.0 eq) were added at 30 hours.  At 53 hours, the reaction mixture was cooled to rt, 
dissolved in CH2Cl2/methanol (1:1 v/v, 60 mL) and concentrated  in vacuo, co-
evaporating with CH2Cl2  (4  ´  40 mL) to give an orange/brown solid.   Following 
purification by column chromatography (70-90% ethyl acetate/CH2Cl2 + 0.5% Et3N), 
and drying under high vacuum, the desired product 155 was afforded as an off-white 
foam (0.55 g, 0.74 mmol, 35%).
Rf 0.23 (9:1, ethyl acetate/CH2Cl2 + 0.3% Et3N, A’); 0.42 (1:9, methanol/CH2Cl2 + 0.3% 
Et3N, A’); 
1H NMR (400 MHz, d6-DMSO) d 11.40 (1H, br s, NHCOCF3), 8.75 (1H, s, 
H
4), 8.06 (1H, t, J = 1.8 Hz, H
2”), 7.72 (1H, td, J = 2.0, 7.3 Hz, H
4”), 7.57 (1H, dd, J = 
1.7, 7.7 Hz, H
6”), 7.53 (1H, t, J = 7.7 Hz, H
5”), 7.41 (2H, dd, J = 1.5, 8.1 Hz, H
14), 7.34 
(2H, t, J = 8.1 Hz, H
15), 7.31-7.25 (1H, m, H
16), 7.29 (2H, d, J = 8.8 Hz, H
10), 7.29 (2H, 
d, J = 9.2 Hz, H
10), 6.92 (2H, d, J = 9.1 Hz, H
11), 6.91 (2H, d, J = 9.2 Hz, H
11), 6.33 
(1H, s, H
5), 6.16 (1H, dd, J = 4.4, 6.6 Hz, H
1’), 5.43 (1H, d, J = 4.8 Hz, 3’-OH), 4.43 
(1H, td, J = 5.2, 10.5 Hz, H
3’), 4.04 (1H, dd, J = 4.5, 8.1, H
4’), 3.71 (3H, s, OCH3), 3.70 
(3H, s, OCH3), 3.41 (1H, dd, J = 4.0, 10.8 Hz, H
5’), 3.32 (1H, dd, J = 3.3, 11.0 Hz, H
5’), 
2.54-2.44 (1H, m, H
2’), 2.27 (1H, ddd, J = 4.6, 6.4, 13.5 Hz, H
2’); 
13C NMR (100 MHz, 
d6-DMSO) d 170.9 (C
7a), 158.2 (C
12–OCH3), 154.7 (q, 
2JCF = 36.9 Hz, COCF3), 153.6 
(C
2), 144.4 (C
13), 138.2 (C
4), 137.4 (C
6), 137.3 (C
3”–NHR), 135.4, 135.1 (C
9), 129.9 
179(C
5”), 129.8, 129.7 (C
10), 128.8 (C
1”), 128.0 (C
15), 127.8 (C
14), 126.8 (C
16), 121.9 (C
4”), 
121.5 (C
6”), 116.7 (C
2”), 113.3 (C
11), 113.2 (q, 
1JCF = 227.4 Hz, COCF3), 106.4 (C
4a), 
99.6 (C
5), 87.6 (C
1’), 86.1 (C
8Ar3), 86.0 (C
4’), 68.8 (C
3’), 62.4 (C
5’), 54.9 (OCH3), 41.1 
(C
2’); LRMS (ES
+) m/z: 764 ([M + Na]
+, 100); (ES
–) m/z: 740 ([M – H]
–, 100).
Analytical results consistent with reported data.
206
3-Ureidophenyl acetylene, 156
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3-Ethynylaniline 152 (3.00 mL, 26.6 mmol) and dry phenyl carbamate 157 (7.31 g, 53.3 
mmol, 2.0 eq) were heated in a sealed tube, under an argon atmosphere, excluding 
moisture, in dim light at 90 °C for 12 hours.  The mixture was cooled to rt, transferred 
using warm methanol/acetone, and dried under high vacuum.  Following purification by 
column chromatography (5-50% acetone/CH2Cl2), and drying under high vacuum, the 
desired urea 156 was afforded, as an off-white, papery solid (2.93 g, 18.3 mmol, 69%).
Rf 0.31 (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’, F’), 0.04 (1:9, acetone/CH2Cl2 + 0.3% 
Et3N, A’, F’); IR (solid): n 3467, 3329 (m, N–H), 3302 (w N–H), 3238(m, N–H), 2100 
(w, CºC), 1649 (vs, C=O), 1586, 1575 (s, Aryl C–H), 1540 (br vs, Aryl C–H), 1473 (s), 
1413 (m), 1325 (s), 1284, 1256, 1162 (m), 1120 (br w), 1029 (w), 890 (m, Aryl C–H), 
801 (m), 773 (m, Aryl C–H), 683 (s), 643 (br s), 587 (s) cm
-1; 
1H NMR (300 MHz, d6-
DMSO) d 8.61 (1H, s, NH), 7.64 (1H, t, J = 1.7 Hz, H
2), 7.32 (1H, ddd, J = 1.1, 2.0, 8.2 
Hz, H
4), 7.22 (1H, t, J = 7.9 Hz, H
5), 7.00 (1H, td J = 1.3, 7.3 Hz, H
6), 5.89 (2H, s, 
NH2), 4.08 (1H, s, CºCH
8); 
13C NMR (100 MHz, d6-DMSO) d 155.9 (CONH2), 140.8 
(C
3), 129.0 (C
5), 124.3 (C
6), 121.8 (C
1), 120.5 (C
2), 118.4 (C
4), 83.8 (C
7ºCH), 80.0 
(CºC
8H); LRMS (ES
+) m/z: 343 ([2M + Na]
+, 21), 183 ([M + Na]
+, 70), 102 ([Et3N + 
H]
+, 100); (ES
–) m/z: 159 ([M – H]
–, 100); HRMS (ES
+): calcd for C9H8N2O (M), [M + 
Na]
+ = 183.0529, found 183.0530, [2M + Na]
+ = 343.1171, found 343.1170.
Analytical results consistent with reported data.
206
1805-[(3-Ureidophenyl)ethynyl]-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyuridine, 159
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To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine 97 (3.01 g, 4.58 
mmol) in anhydrous DMF (15.0 mL), under an argon atmosphere, in absence of light, 
were added distilled Et3N (3.30 mL, 23.7 mmol, 5.0 eq), CuI (0.35 g, 1.83 mmol, 0.4 
eq), then alkyne  156  (2.20 g, 13.7 mmol, 3.0 eq).   The mixture was stirred for 15 
minutes then tetrakis(triphenylphosphine) palladium (0) (0.53 g, 0.46 mmol, 0.1 eq) 
was added and the reaction was stirred at rt for 3 hours.  The reaction mixture was 
concentrated under high vacuum, co-evaporating with CH3CN to give a dark brown 
foam/gum.  Following purification by column chromatography (5-8% methanol/CH2Cl2 
+ 0.5% Et3N), and drying under high vacuum, the desired product 159 was afforded as a 
pale orange foam (2.71 g) containing 34 mol % Et3N (recalculated yield - 3.66 mmol, 
80%).
Rf 0.23 (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’), 0.27 (7:3 acetone/CH2Cl2 + 0.3% 
Et3N, A’); IR (solid): n 3348 (w, O–H), 3208, 3067, 2931 (w, N–H), 2832 (w, C–H), 
1669 (br vs, C=O, C=C), 1605, 1580 (s, N–H), 1546, 1506, 1456, 1435 (s), 1342, 1302 
(m), 1274 (s), 1247 (vs, C–O), 1175 (s), 1088, 1030 (br s, C–O), 826 (s, Aryl C–H), 
789, 753, 698, 585 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 11.71 (1H, br s, NH
3), 
8.57 (1H, s, NHCONH2), 8.02 (1H, s, H
6), 7.59 (1H, t, J = 1.8 Hz, H
2”), 7.41 (2H, d, J = 
7.5 Hz, H
15), 7.31-7.26 (1H, m, H
16), 7.30 (2H, d, J = 9.0 Hz, H
11), 7.29 (2H, d, J = 8.8 
Hz, H
11), 7.24 (1H, ddd, J = 1.0, 2.1, 8.2 Hz, H
4”), 7.17 (1H, br t, J = 7.4 Hz, H
17), 7.14 
(1H, t, J = 7.9 Hz, H
5”), 6.85 (2H, d, J = 8.8 Hz, H
12), 6.84 (2H, d, J = 9.0 Hz, H
12), 6.65 
(1H, td, J = 1.3, 6.5 Hz, H
6”), 6.14 (1H, t, J = 6.7 Hz, H
1’), 5.90 (2H, s, CONH2), 5.32 
(1H, d, J = 4.3 Hz, 3’-OH), 4.29 (1H, td, J = 2.5, 6.5 Hz, H
3’), 3.95 (1H, td, J = 3.3, 5.0 
Hz, H
4’), 3.67 (6H, s, OCH3), 3.25 (1H, dd, J = 5.3, 10.5 Hz, H
5’), 3.14 (1H, dd, J = 2.8, 
10.5 Hz, H
5’), 2.31 (1H, td, J = 6.8, 13.6 Hz, H
2’), 2.22 (1H, ddd, J = 3.5, 6.3, 13.6 Hz, 
181H
2’); 
13C NMR (100 MHz, d6-DMSO) d 161.4 (C
4), 158.1, 158.0 (C
13–OCH3), 155.8 
(CONH2), 149.3 (C
2), 144.7 (C
14), 142.8 (C
6), 140.6 (C
3”–NHR), 135.6, 135.3 (C
10), 
129.7, 129.6 (C
11), 128.7 (C
5”), 127.8 (C
16), 127.6 (C
15), 126.7 (C
17), 124.0 (C
6”), 122.4 
(C
1”), 120.0 (C
2”), 118.0 (C
4”), 113.2 (C
12), 98.6 (C
5), 92.4 (C
8), 86.0 (C
4’), 85.8 (C
9Ar3), 
85.1 (C
1’), 81.2 (C
7), 70.5 (C
3’), 63.7 (C
5’), 54.9 (OCH3), 39.9 (C
2’); LRMS (ES
+) m/z: 
711 ([M + Na]
+, 100), 303 ([DMT
+], 9); HRMS (ES
+): calcd for C39H36N4O8 (M), [M + 
Na]
+ = 711.2425, found 711.2409, [M + NH4]
+ = 706.2877, found 706.2856. Found also 
301.1413.
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-ureidophenyl)-
(2,3H)-furano[2,3-d]pyrimidine-2-one, 160
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To a solution of nucleoside  159  (2.13 g, 3.09 mmol) in distilled/argon-degassed 
methanol/Et3N (7:3 v/v, 15.0 mL), with 4Å molecular sieves, in absence of light and 
under an argon atmosphere, was added CuI (0.65 g, 3.40 mmol, 1.1 eq), and the mixture 
was stirred at reflux under argon pressure (80 °C) for 3.5 hours.  After cooling to rt, the 
reaction cake was dissolved/suspended in CH2Cl2 (150 mL), filtered, and the solid was 
washed with CH2Cl2 (2 ´ 50 mL).  The combined filtrate was washed with 5% w/v aq 
Na2EDTA (pH 9, 4  ´  100 mL) and sat aq KCl (100 mL), dried (Na2SO4), and 
concentrated in vacuo to give a yellow solid.  The product was crystallised by addition 
of methanol (10 mL) and the mixture was allowed to stand in the fridge for 2 days.  The 
solid was filtered, washed with the filtrate (´2) then cold diethyl ether (-8 °C, 3 ´ 10 
mL), and dried under high vacuum over KOH, to afford the desired product 160 as a 
pale cream-coloured fine crystalline solid (1.34 g).  The filtrate was concentrated in 
vacuo from which two further crops were obtained (0.11 g, 0.03 g) (combined yield 
1.47 g, 2.14 mmol, 69%).
182Rf 0.18 (9:1, acetone/CH2Cl2 + 0.3% Et3N), 0.23 (acetone + 0.3% Et3N); 0.33 (1:9, 
methanol/CH2Cl2 + 0.3% Et3N); Mp 160-169 °C (dec.); IR (solid): n 3472, 3305 (m, N–
H, O–H), 2932, 2836 (w, C–H), 1663 (s, C=O), 1606 (s, N–H), 1584 (s, C=N), 1547 
(m), 1508, 1492 (s, Aryl C=C), 1445, 1408 (m), 1382 (m, C–H), 1342 (m), 1301, 1247 
(s), 1174 (vs), 1072 (br s, C–O), 1031 (vs), 972, 912, 878 (m), 828 (s, C–H), 773 (s), 
701 (s, Aryl C–H), 583, 532 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 7.73 (1H, br s, 
NHCONH2), 8.72 (1H, s, H
4), 7.90 (1H, s, H
2”), 7.40 (2H, d, J = 7.5 Hz, H
14), 7.37-7.31 
(4H, m, H
15, H
4”, H
5”), 7.31-7.24 (1H, m, H
16), 7.28 (4H, d, J = 8.3 Hz, H
10), 7.28-7.22 
(1H, m, H
6”), 6.92 (2H, d, J = 8.8 Hz, H
11), 6.91 (2H, d, J = 8.8 Hz, H
11), 6.19 (1H, s, 
H
5), 6.16 (1H, dd, J = 4.5, 6.3 Hz, H
1’), 5.92 (2H, s, CONH2), 5.42 (1H, d, J = 4.9 Hz, 
3’-OH), 4.44 (1H, td, J = 5.6, 10.8 Hz, H
3’), 4.02 (1H, dd, J = 3.5, 7.5 Hz, H
4’), 3.72 
(3H, s, OCH3), 3.71 (3H, s, OCH3), 3.41 (1H, dd, J = 3.7, 10.8 Hz, H
5’), 3.34-3.27 (1H, 
m, H
5’), 2.47 (1H, td, J = 6.5, 13.1 Hz, H
2’), 2.26 (1H, ddd, J = 4.6, 6.5, 13.6 Hz, H
2’); 
13C NMR (100 MHz, d6-DMSO) d 170.9 (C
7a), 158.2 (C
12–OCH3), 155.9 (CONH2), 
153.7 (C
2), 144.5 (C
6), 141.3 (C
13), 137.8 (C
4), 137.7 (C
3”–NHR), 135.3, 135.0 (C
9), 
129.8, 129.8 (C
10), 129.4 (C
5”), 128.4 (C
1”), 128.0 (C
15), 127.7 (C
14), 126.9 (C
16), 118.7 
(C
6”), 117.2 (C
4”), 113.3 (C
11), 113.2 (C
2”), 106.6 (C
4a), 98.6 (C
5), 87.4 (C
1’), 86.1 
(C
8Ar3), 85.9 (C
4’), 68.8 (C
3’), 62.4 (C
5’), 55.0 (OCH3), 41.1 (C
2’); LRMS (ES
+) m/z: 
743 ([M + CH3OH + Na]
+, 100), 711 ([M + Na]
+, 74); (ES
–) m/z: 687 ([M – H]
–, 100); 
HRMS (ES
+): calcd for C39H36N4O6 (M), [M + Na]
+ = 711.2425, found 711.2389, [M + 
H]
+ = 689.2606, found 689.2572.  Found also DMT
+ (calcd 303.1380, found 303.1385).
3-Acetamidophenyl acetylene, 161
211
H2N N
H
O
AcCl (1.0-1.1 eq), dist. Et3N (0.15-1.0 eq)
dry/degassed Et2O, 0 oC - rt
1 3
152 161
C8H7N
Mol. Wt.: 117.15
C10H9NO
Mol. Wt.: 159.18
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7
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Method 1: To a stirred solution of 3-ethynylaniline 152 (0.20 mL, 1.78 mmol) in 
dry, degassed diethyl ether (5.0 mL) at 0 °C, under an argon atmosphere, was added 
distilled Et3N (0.04 mL, 0.29 mmol, 0.16 eq), followed by acetyl chloride (0.14 mL, 
1.97 mmol, 1.1 eq) in dry, degassed diethyl ether (4.0 mL) dropwise.  The reaction 
mixture was stirred for 2 hours, allowed to warm to rt, then stirred for a further 4.5 
hours.  The reaction mixture was filtered, the solid was washed with diethyl ether (3 ´ 
18310 mL), and combined ether fractions were concentrated in vacuo and dried under high 
vacuum to give a pale yellow oil.   Following trituration with water (3.0 mL), the 
product 161 was afforded, following drying under high vacuum over KOH, as a pale 
cream-coloured waxy solid (228 mg, 1.43 mmol, 81%).
Method 2: To a stirred solution of 3-ethynylaniline 152 (3.50 mL, 31.1 mmol) and 
distilled Et3N (4.37 mL, 31.4 mmol, 1.0 eq) in dry, degassed diethyl ether (15.0 mL), at 
0 °C, under an argon atmosphere, was added acetyl chloride (2.23 mL, 31.4 mmol, 1.0 
eq) in dry, degassed diethyl ether (25.0 mL), dropwise over 45 minutes.  The reaction 
was stirred for a further 15 minutes then allowed to warm to rt over 30 minutes.  The 
mixture was filtered, the white precipitate was washed with diethyl ether (3 ´ 35 mL) 
and combined ether fractions were concentrated  in vacuo  to give a cream-coloured 
solid.  The solid was triturated with water (60 mL) to which was added diethyl ether 
(100 mL) and the layers were separated.  The ether layer was washed with water (50 
mL), combined aqueous layers were re-extracted (diethyl ether, 20 mL), and combined 
ether fractions were concentrated in vacuo and under high vacuum to afford the desired 
product  161  a   pale   brown   oil,   which   crystallised   on   standing   to   an   off-white 
chalky/waxy solid (4.79 g, 30.1 mmol, 97%).
Rf 0.40 (5:95, methanol/CH2Cl2 + 0.3% Et3N, A’); Mp 92-94 °C (chloroform/hexane), 
lit.
211 94-96 °C (CCl4); IR (solid): n 3300, 3282 (m, CC–H), 1666 (m, C=O), 1605, 1583 
(m, Aryl C–H), 1556 (m, C=O), 1481 (m, Aryl C–H), 1425, 1401, 1370, 1308, 1289, 
1255 (m), 1015 (w), 880, 786 (m, Aryl C–H), 721, 678, 648 (m), 601 (s), 541 (m) cm
-1; 
1H NMR (300 MHz, d6-DMSO) d 10.00 (1H, s, NHCOCH3), 7.77 (1H, app. t, J = 1.7 
Hz, H
2), 7.54 (1H, ddd, J = 1.1, 2.0, 8.1 Hz, H
4), 7.30 (1H, t, J = 7.9 Hz, H
5), 7.13 (1H, 
td, J = 1.3, 7.7 Hz, H
6), 4.13 (1H, s, CºCH
8), 2.05 (3H, s, COCH3); 
13C NMR (100 
MHz, d6-DMSO) d 169.1 (COCH3), 140.1 (C
3), 129.7 (C
5), 126.8 (C
6), 122.5 (C
1), 
122.4 (C
2), 120.1 (C
4), 84.0 (C
7ºCH), 81.0 (CºC
8H), 24.6 (COCH3); LRMS (ES
+) m/z: 
160 ([M + H]
+, 100), 182 ([M + Na]
+, 11), 201 ([M + CH3CN + H]
+, 7), 223 ([M + 
CH3CN + Na]
+, 17), 242 ([M + AcOH + Na]
+, 12); (ES
–) m/z: 158 ([M – H]
–, 100); 
HRMS (ES
+): calcd for C10H9NO (M), [2M + Na]
+ = 341.1260, found 341.1239, [M + 
Na]
+ = 182.0576, found 182.0565, [M + H]
+ = 160.0757, found 160.0755.
1845-[(3-Acetamidophenyl)ethynyl]-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyuridine, 162
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To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine 97 (3.02 g, 4.61 
mmol) in anhydrous DMF (15.0 mL), under an argon atmosphere, in absence of light, 
were added distilled Et3N (3.20 mL, 23.0 mmol, 5.0 eq), CuI (0.35 g, 1.84 mmol, 0.4 
eq), then alkyne  156  (2.20 g, 13.8 mmol, 3.0 eq).   The mixture was stirred for 15 
minutes then tetrakis(triphenylphosphine) palladium (0) (0.53 g, 0.46 mmol, 0.1 eq) 
was added and the reaction was stirred at rt for 2 hours.  After concentration under high 
vacuum and co-evaporation with methanol/toluene, the dark brown foam was purified 
four times by column chromatography (3-10% methanol/CH2Cl2 + 0.5% Et3N; 20-50% 
acetone/CH2Cl2 + 0.5% Et3N; 40-100% acetone/CH2Cl2 + 0.5% Et3N; 92:6:2-82:16:2, 
ethyl acetate/methanol/conc. aq NH3).   The desired product  162  was afforded, after 
drying under high vacuum, as a pale orange foam (2.37 g, 3.44 mmol, 75%).
Rf 0.39 (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’), 0.33 (82:16:2, ethyl acetate/methanol/ 
conc. aq NH3, A’), 0.64 (1:4, methanol/ethyl acetate + 0.3% Et3N, A’); 
1H NMR (400 
MHz, d6-DMSO) d 11.63 (1H, extremely br s, NH
3), 9.98 (1H, s, NHCOCH3), 8.04 
(1H, s, H
6), 7.74 (1H, t, J = 1.5 Hz, H
2”), 7.45 (1H, br dd, J = 1.2, 8.0 Hz, H
4”), 7.41 
(2H, d, J = 7.5 Hz, H
15), 7.30 (2H, d, J = 9.0 Hz, H
11), 7.30-7.25 (1H, m, H
5”), 7.29 (2H, 
d, J = 9.0 Hz, H
11), 7.22 (1H, t, J = 8.0 Hz, H
16), 7.16 (1H, t, J = 7.3 Hz, H
17), 6.85 (2H, 
d, J = 8.5 Hz, H
12), 6.84 (2H, d, J = 9.0 Hz, H
12), 6.74 (1H, br d, J = 7.5 Hz, H
6”), 6.14 
(1H, t, J = 6.8 Hz, H
1’), 5.32 (1H, br s, 3’-OH), 4.29 (1H, br s, H
3’), 3.95 (1H, td, J = 
3.2, 5.0 Hz, H
4’), 3.66 (6H, s, OCH3), 3.25 (1H, dd, J = 5.3, 10.8 Hz, H
5’), 3.15 (1H, dd, 
J = 2.5, 10.5 Hz, H
5’), 2.32 (1H, td, J = 6.8, 13.6 Hz, H
2’), 2.22 (1H, ddd, J = 3.5, 6.5, 
13.6 Hz, H
2’); 
13C NMR (100 MHz, d6-DMSO) d 168.4 (COCH3), 161.4 (C
4), 158.0, 
158.0 (C
13–OCH3), 149.3 (C
2), 144.7 (C
14), 142.9 (C
6), 139.3 (C
3”–NHR), 135.6, 135.3 
(C
10), 129.7, 129.6 (C
11), 128.8 (C
5”), 127.8 (C
16), 127.6 (C
15), 126.6 (C
17), 125.8 (C
6”), 
122.5 (C
2”), 121.3 (C
4”), 119.1 (C
1”), 113.2 (C
12), 98.4 (C
8), 92.0 (C
7), 86.0 (C
4’), 85.8 
185(C
9Ar3), 85.2 (C
1’), 81.6 (C
5), 70.4 (C
3’), 63.7 (C
5’), 54.9 (OCH3), 40.0 (C
2’), 24.0 
(COCH3); LRMS (ES
+) m/z: 710 ([M + Na]
+, 100), 705 ([M + NH4]
+, 8); (ES
–) m/z: 784 
([M + H3PO4 – H]
–, 100), 732 ([M + HCO2H – H]
–, 45), 686 ([M – H]
–, 12); HRMS 
(ES
+): calcd for C40H37N3O8 (M), [M + Na]
+ = 710.2473, found 710.2480.
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-acetamido-
phenyl)-(2,3H)-furano[2,3-d]pyrimidine-2-one, 163
NH
O
O N
O
OH
O
MeO
MeO
NH
2'
5'
5
7
8 1''
3''
9
10
13
14
17
13
6
162
O
N
O N
O
OH
O
MeO
MeO
O
HN
CuI (1.1 eq)
dist. MeOH/Et3N (7:3 v/v)
80
oC, argon, dark
O
2 4
4a
5
6
7a
2'
5' 8
9
10
11
12
13
14
15 16
12
1''
3''
163
C40H37N3O8
Mol. Wt.: 687.74
To a solution of nucleoside  159  (1.94 g, 2.82 mmol) in distilled/argon-degassed 
methanol/Et3N (7:3 v/v, 20.0 mL), with 4Å molecular sieves, in absence of light and 
under an argon atmosphere, was added CuI (0.59 g, 3.10 mmol, 1.1 eq), and the mixture 
was stirred at reflux under argon pressure (80 °C) for 2 hours.  The reaction was diluted 
with methanol (20 mL), filtered, and the filtrate was concentrated in vacuo.  The green 
foam was dissolved in CH2Cl2 (100 mL) and washed with 5% w/v aq Na2EDTA (pH 10, 
5 ´ 100 mL).  The combined aqueous fraction was re-extracted (CH2Cl2, 2 ´ 70 mL) 
and the combined CH2Cl2  layer was washed with sat aq KCl (2  ´  100 mL), dried 
(Na2SO4), and concentrated in vacuo to give a green foam.  Following purification by 
column chromatography (20-60% acetone/ethyl acetate + 0.5-1.0% Et3N), and drying 
under high vacuum, the desired cyclised product 163 was afforded as a pale yellow 
foam (1.73 g, 2.52 mmol, 89%).
Rf 0.31 (1:2, acetone/ethyl acetate + 0.3% Et3N, A’), 0.62 (1:4, methanol/ethyl acetate + 
0.3% Et3N, A’); 
1H NMR (400 MHz, d6-DMSO) d 10.10 (1H, s, NHCOCH3), 8.73 (1H, 
s, H
4), 8.03 (1H, t, J = 1.5 Hz, H
2”), 7.59 (1H, td, J = 1.6, 7.8 Hz, H
4”), 7.44-7.40 (1H, 
m, H
5”), 7.41 (2H, d, J = 7.5 Hz, H
14), 7.37 (1H, td, J = 1.5, 8.0 Hz, H
6”), 7.34 (2H, t, J 
= 8.0 Hz, H
15), 7.29 (2H, d, J = 9.0 Hz, H
10), 7.28 (2H, d, J = 9.0 Hz, H
10), 7.27 (1H, td, 
J = 1.3, 7.0 Hz, H
16), 6.92 (2H, d, J = 9.0 Hz, H
11), 6.91 (2H, d, J = 9.0 Hz, H
11), 6.23 
186(1H, s, H
5), 6.17 (1H, dd, J = 4.5, 6.5 Hz, H
1’), 5.44 (1H, d, J = 5.0 Hz, 3’-OH), 4.44 
(1H, td, J = 5.5, 11.0 Hz, H
3’), 4.07 (1H, td, J = 3.5, 5.0 Hz, H
4’), 3.72 (3H, s, OCH3), 
3.70 (3H, s, OCH3), 3.41 (1H, dd, J = 4.0, 10.5 Hz, H
5’), 3.32 (1H, dd, J = 3.0, 10.5 Hz, 
H
5’), 2.48 (1H, td, J = 6.5, 13.3 Hz, H
2’), 2.26 (1H, ddd, J = 4.5, 6.5, 13.5 Hz, H
2’);
13C NMR (100 MHz, d6-DMSO) d 170.9 (C
7a), 168.6 (COCH3), 158.2 (C
12–OCH3), 
153.6 (C
2), 153.4 (C
6), 144.5 (C
13), 140.0 (C
3”–NHR), 137.9 (C
4), 135.4, 135.0 (C
9), 
129.8, 129.7 (C
10), 129.5 (C
5”), 128.5 (C
1”), 128.0 (C
15), 127.7 (C
14), 126.8 (C
16), 119.8 
(C
4”), 119.0 (C
6”), 114.5 (C
2”), 113.3 (C
11), 106.5 (C
4a), 98.9 (C
5), 87.5 (C
1’), 86.1 
(C
8Ar3), 85.9 (C
4’), 68.8 (C
3’), 62.4 (C
5’), 55.0, 55.0 (OCH3), 41.1 (C
2’), 24.0 (COCH3); 
LRMS (ES
+) m/z: 710 ([M + Na]
+, 100); (ES
–) m/z: 686 ([M – H]
–, 100); HRMS (ES
+): 
calcd for C40H37N3O8 (M), [M + Na]
+ = 710.2473, found 710.2462.
5’-O-(4,4’-Dimethoxytrityl)-5-(3-trifluoroacetamidopropynyl)-2’-deoxyuridine-3’-
O-(2-O-cyanoethyl-N,N-diisopropyl) phosphoramidite, 164
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To a stirred solution of nucleoside 165 (5.02 g, 7.39 mmol) in distilled THF (25.0 mL), 
strictly under an argon atmosphere and excluding moisture, was added distilled DIPEA 
(3.22 mL, 18.5 mmol, 2.5 eq) followed by chloro-phosphitylating reagent 70 (1.82 mL, 
8.14 mmol, 1.1 eq) dropwise, and the reaction was stirred at rt for 1¼ hours.  The THF 
was removed in vacuo and the residue was dissolved in argon-degassed ethyl acetate 
(100 mL).  The solution was washed with degassed sat. aq KCl (3 ´ 50 mL), dried 
(Na2SO4), and concentrated in vacuo to give an orange foam.  Following purification by 
column chromatography (10% acetone/CH2Cl2  + 1.0% pyridine) on silica gel pre-
equilibrated with Et3N, under argon pressure, the desired phosphoramidite  164  was 
afforded, after drying under high vacuum, as a diastereomeric mixture (ca. 1:2), as an 
air-sensitive pale peach-coloured foam (5.45 g, 6.19 mmol, 84%).
187Rf 0.41 (1:9, acetone/CH2Cl2 + 0.5% pyridine, A’); 
31P NMR (121 MHz, d6-DMSO) d 
148.9, 148.5 (P
III);  
1H NMR  (400 MHz,  d6-DMSO)  d  11.66 (NH
3), 9.98 (1H, s, 
CONH), 7.97 and 7.96 (1H, s, H
6), 7.42-7.38 (2H, m, H
16), 7.33-7.28 (2H, m, H
17), 7.29 
and 7.27 (4H, d, J = 7.8 Hz and J = 8.0 Hz, H
12), 7.25-7.19 (1H, m, H
18), 6.89 and 6.87 
(4H, d, J = 8.8 Hz and J = 9.0 Hz, H
13), 6.10 and 6.08 (1H, t, J = 6.7 Hz and J = 6.8 Hz, 
H
1’), 4.50 and 4.47 (1H, ddd, J = 3.6, 6.7, 14.2 Hz and J = 3.9, 6.6, 14.2 Hz, H
3’), 4.10 
and 4.06 (2H, s,  H
9), 4.08-4.00 (1H, m,  H
4’), 3.77-3.67 (1H, m,  H
19), 3.74 (3H, s, 
OCH3), 3.73 (3H, s, OCH3), 3.67-3.59 (1H, m, H
19), 3.60-3.44 (1H, m, H
21), 3.33-3.24 
(1H, m, H
5’), 3.19 and 3.14 (1H, dd, J = 3.3, 10.5 Hz and J = 3.0, 10.3 Hz, H
5’), 2.75 
and 2.64 (2H, t, J = 5.9 Hz, H
20), 2.44 and 2.43 (1H, dd, J = 6.8, 13.6 Hz and J = 6.9, 
13.9 Hz, H
2’), 2.35 and 2.30 (1H, ddd, J = 3.9, 6.4, 13.7 Hz and J = 3.6, 6.4, 13.9 Hz, 
H
2’), 1.13 (3H, d, J = 6.8 Hz, H
22), 1.11 (3H, d, J = 7.0 Hz, H
22), 1.10 (3H, d, J = 6.8 Hz, 
H
22), 0.99 (3H, d, J = 6.8 Hz, H
22); LRMS (ES
+) m/z: 902 ([M + Na]
+, 100), 897 ([M + 
NH4]
+, 38), 880 ([M + H]
+, 32), 303 (DMT
+, 24); (ES
–) m/z: 914/916 ([M + HCl – H]
–, 
2:1, 21), 878 ([M – H]
–, 97), 825 ([M – CH2CHCN – H]
–, 100).
Analytical results consistent with reported data.
117,170
5’-O-(4,4’-Dimethoxytrityl)-5-(3-trifluoroacetamidopropynyl)-2’-deoxyuridine, 
165
117,170,255
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To a stirred solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine 97 (10.1 g, 
15.4 mmol) in anhydrous DMF (70.0 mL), under an argon atmosphere, was first added 
distilled Et3N (15.0 mL, 108 mmol, 7.0 eq) followed by, in absence of light, CuI
(0.59 g, 3.09 mmol, 0.2 eq) and 3-(trifluoroacetamido)prop-1-yne 68 (2.41 mL, 21.5 
mmol, 1.4 eq).  After stirring for 20 minutes, tetrakis(triphenylphosphine) palladium (0) 
(1.78 g, 1.54 mmol, 0.1 eq) was added and the reaction was stirred at rt for 1¾ hours, 
when solid Na2EDTA (1.20 g) was added.  After stirring for 5 minutes, the reaction 
188mixture was concentrated under high vacuum to give a dark brown syrup.  The syrup 
was dissolved in ethyl acetate (300 mL) and washed with 5% w/v aq Na2EDTA (pH 9, 3 
´ 150 mL) and sat. aq KCl (2 ´ 150 mL), dried (Na2SO4), and concentrated in vacuo 
and under high vacuum to give a golden brown foam.  This reaction was repeated on the 
same scale as described above.
Following  joint  purification by column chromatography (10-30% acetone/CH2Cl2  + 
1.0% pyridine), the desired product 165 was afforded, after drying under high vacuum, 
as a very pale orange foam (16.6 g, 24.4 mmol, 80%).  A mixture of starting material 97 
and product 165 (1.84 g) was also isolated.
Rf 0.19 (1:9, acetone/CH2Cl2 + 0.5% pyridine, A’, B’); 
19F NMR (282 MHz, d6-DMSO) 
d  -73.9 (NHCOCF3);  
1H NMR  (400 MHz,  d6-DMSO)  d  11.66 (NH
3), 9.98 (1H, s, 
NHCOCF3), 7.93 (1H, s, H
6), 7.40 (2H, d, J = 7.5 Hz, H
16), 7.31 (2H, t, J = 7.5 Hz, 
H
17), 7.29 (2H, d, J = 9.0 Hz, H
12), 7.28 (2H, d, J = 9.0 Hz, H
12), 7.22 (1H, tt, J = 1.5, 
7.3 Hz, H
18), 6.89 (2H, d, J = 9.0 Hz, H
13), 6.89 (2H, d, J = 9.0 Hz, H
13), 6.10 (1H, t, J = 
6.7 Hz, H
1’), 5.32 (1H, d, J = 4.5 Hz, 3’-OH), 4.27 (1H, td, J = 4.0, 10.3 Hz, H
3’), 4.06 
(2H, br d, J = 3.8 Hz, H
9), 3.92 (1H, td, J = 3.3, 5.3 Hz, H
4’), 3.74 (6H, s, OCH3), 3.26 
(1H, dd, J = 5.4, 10.4 Hz, H
5’), 3.09 (1H, dd, J = 2.9, 10.4 Hz, H
5’), 2.29 (1H, td, J = 
6.8, 13.6 Hz, H
2’), 2.19 (1H, ddd, J = 3.8, 6.3, 13.3 Hz, H
2’); 
13C NMR (100 MHz, d6-
DMSO) d 161.5 (C
4), 158.1, 158.1 (C
14–OMe), 156.0 (q, 
2JCF = 36.9 Hz, COCF3), 149.3 
(C
2), 144.8 (C
15), 143.7 (C
6), 135.6, 135.2 (C
11), 129.7, 129.6 (C
12), 127.8 (C
17), 127.5 
(C
16), 126.6 (C
18), 115.7 (q, 
1JCF = 288.7 Hz, COCF3), 113.2, 113.2 (C
13), 97.8 (C
5), 87.4 
(C
10Ar3), 85.8 (C
4’,C
7), 85.1 (C
1’), 75.1 (C
8), 70.4 (C
3’), 63.8 (C
5’), 55.0 (OCH3), 39.7 
(C
2’), 29.4 (C
9); LRMS (ES
+) m/z: 803 ([M + Et3N + Na]
+, 14), 718 ([M + K]
+, 14), 702 
([M + Na]
+, 100), 697 ([M + NH4]
+, 5), 303 (DMT
+, 5); (ES
–) m/z: 678 ([M – H]
–, 100).
Analytical results consistent with reported data.
170,255 
1893-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-
trifluoroacetamidophenyl)-(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-
2(7H)-one-3’-O-(2-O-cyanoethyl-N,N-diisopropyl) phosphoramidite, 178
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To a stirred solution of nucleoside 197 (5.02 g, 7.39 mmol) in distilled CH2Cl2 (25.0 
mL), strictly under an argon atmosphere and excluding moisture, was added distilled 
DIPEA (3.22 mL, 18.5 mmol, 2.5 eq) followed by chloro-phosphitylating reagent 70 
(1.82 mL, 8.14 mmol, 1.1 eq) dropwise, and the reaction was stirred at rt for 4¾ hours. 
The reaction mixture was diluted with argon-degassed CH2Cl2 (15 mL) and washed, 
under an argon atmosphere, with degassed sat. aq KCl (15 mL).  The aqueous was re-
extracted (degassed  CH2Cl2, 3  ´  5 mL) and combined  CH2Cl2  fractions were dried 
(Na2SO4), and concentrated in vacuo and dried under high vacuum to give a yellow 
foam.   Following purification by column chromatography (degassed 1% acetone/ 
CH2Cl2 + 0.5% Et3N ® 5% acetone/CH2Cl2 + 0.5% Et3N), on silica gel pre-equilibrated 
with Et3N, under argon pressure, then precipitation at rt from degassed CH2Cl2 (3 mL) 
into degassed hexane (180 mL), the desired phosphoramidite 178 was afforded, after 
drying under high vacuum, as a diastereomeric mixture (ca. 2:1), as a pale yellow foam 
(0.18 g) containing 38.0 mol % Et3N.HCl (recalculated yield - 0.18 mmol, 70%).
Rf 0.50, 0.57 (1:1, acetone/CH2Cl2 + 0.5% Et3N, A’), 0.29, 0.34 (1:4, acetone/CH2Cl2 + 
0.5% Et3N, A’), 0.18, 0.25 (CH2Cl2 + 0.5% Et3N, A’); 
31P NMR (121 MHz, d6-DMSO) 
d 149.1, 148.9 (P
III); 
19F NMR (282 MHz, d6-DMSO) d -73.5 (NHCOCF3); 
1H NMR 
(400 MHz, d6-DMSO) d 11.47 (NHCOCF3), 8.71 and 8.68 (1H, s, H
4), 7.85 (1H, br s, 
H
2”), 7.75 (1H, br dd, J = 1.1, 8.2 Hz, H
4”), 7.54 (1H, t, J = 8.0 Hz, H
5”), 7.42 and 7.40 
(2H, d, J = 8.3 Hz and J = 8.8 Hz, H
14), 7.16 (1H, br dd, J = 0.9, 7.9 Hz, H
6”), 7.34-7.28 
(2H, m, H
15), 7.30 and 7.27 (4H, d, J = 8.5 Hz and J = 8.8 Hz, H
10), 7.28-7.23 (1H, m, 
H
16), 6.89, 6.88 and 6.87 (2H, 2H and 4H, d, J = 8.8 Hz, J = 9.0 Hz and J = 8.5 Hz, 
190H
11), 6.30 and 6.26 (1H, dd, J = 5.1, 6.4 Hz and J = 5.0, 6.5 Hz, H
1’), 5.69 and 5.65 (1H, 
s, H
5), 4.68 and 4.64 (1H, td, J = 5.3, 10.7 Hz and J = 5.6, 11.2 Hz, H
3’), 4.17 and 4.13 
(1H, dd, J = 3.5, 7.8 Hz and J = 3.8, 8.0 Hz, H
4’), 3.81-3.68 (1H, m, H
17), 3.70, 3.69 and 
3.69 (3H, 3H and 6H, s, OCH3), 3.69-3.59 (1H, m, H
17), 3.61-3.47 (2H, m, H
19), 3.49 
(3H, s, NCH3), 3.46-3.28 (2H, m, H
5’), 2.77 and 2.67 (1H, t, J = 5.9 Hz, H
18), 2.60 and 
2.58 (1H, td, J = 6.7, 13.3 Hz and J = 6.5, 13.2 Hz, H
2’), 2.35 (1H, td, J = 6.0, 12.2 Hz, 
H
2’), 1.15 (3H, d, J = 6.8 Hz, H
20), 1.13 (3H, d, J = 6.8 Hz, H
20), 1.12 (3H, d, J = 6.8 Hz, 
H
20), 1.01 (3H, d, J = 6.8 Hz, H
20); LRMS (ES
+) m/z: 977 ([M + Na]
+, 100), 955 ([M + 
H]
+, 13); (ES
–) m/z: 953 ([M – H]
–, 100); HRMS (ES
+): calcd for C50H54N6O8F3P (M), 
[M + Na]
+ = 977.3585, found 977.3591; [M + H]
+ = 955.3766, found 955.3783.  Found 
also DMT
+ (calcd 303.1380, found 303.1070).
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-ureidophenyl)-
(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one-3’-O-(2-O-cyanoethyl-N,N-
diisopropyl) phosphoramidite, 179
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Method 1: To a stirred solution of cyclised nucleoside 188 (0.22 g, 0.32 mmol) in 
distilled THF (1.5 mL) and anhydrous DMF (0.5 mL), under an argon atmosphere and 
excluding moisture, was added DIHT 190 (0.03 g, 0.16 mmol, 0.5 eq) followed by 
phosphitylating reagent 189 (0.11 mL, 0.36 mmol, 1.1 eq), and the reaction was stirred 
at rt.  After 18½ hours, further reagent 189 was added (0.05 mL, 0.16 mmol, 0.5 eq).  At 
22 hours, further DIHT 190 (27.8 mg, 0.16 mmol, 0.5 eq) was added, then at 24 hours, 
further reagent 189 was added (0.10 mL, 0.32 mmol, 1.0 eq).  After 41 hours, THF was 
removed in vacuo, and the syrup was dissolved in argon-degassed ethyl acetate (5 mL). 
The sticky yellow precipitate was washed with degassed ethyl acetate (3 ´ 5 mL), and 
the combined solution was washed with degassed sat. aq NaHCO3 (3 ´ 8 mL) and sat. 
191aq KCl (2 ´ 8 mL), dried (Na2SO4), concentrated in vacuo and dried under high vacuum 
to give a viscous yellow syrup.   Following purification by column chromatography 
(degassed 2% methanol/acetone + 0.5% Et3N) on silica gel pre-equilibrated with Et3N, 
under argon pressure, and drying under high vacuum, the desired phosphoramidite 179 
was afforded as a diastereomeric mixture (ca. 1:1), as an air-sensitive, pale yellow foam 
(0.08 g, 0.09 mmol, 29%).
Method 2: To a stirred solution of cyclised nucleoside 188 (0.92 g, 1.31 mmol) in 
distilled THF (5.0 mL) and anhydrous DMF (1.0 mL), under an argon atmosphere and 
excluding moisture, was added distilled DIPEA (0.58 mL, 3.30 mmol, 2.5 eq) followed 
by chloro-phosphitylating reagent 70 (0.33 mL, 1.46 mmol, 1.1 eq), and the reaction 
was stirred at rt for 2 hours.  The reaction mixture was concentrated in vacuo and under 
high vacuum to give a viscous orange syrup, which was dissolved in argon-degassed 
CH2Cl2 (80 mL).  The solution was washed with degassed sat. aq KCl (60 mL) and the 
aqueous was re-extracted (degassed CH2Cl2, 3  ´  10 mL).   The combined CH2Cl2 
fractions were dried (Na2SO4) and concentrated in vacuo and under high vacuum to give 
an orange foam.  Following purification by column chromatography (degassed acetone 
+ 0.5% Et3N ® 2% methanol/acetone + 0.5% Et3N) on silica gel pre-equilibrated with 
Et3N, under argon pressure, and precipitation at rt from degassed CH2Cl2 (6 mL) into 
degassed hexane (350 mL), the desired phosphoramidite 179 was afforded, after drying 
under high vacuum, as a diastereomeric mixture (ca.  1:1), as an air-sensitive pale 
yellow foam (0.60 g, 0.67 mmol, 51%).
Rf 0.30 (9:1, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.24, 0.31 (5:95, methanol/acetone + 
0.3% Et3N, A’), 0.17 (acetone + 0.3% Et3N, A’); 
31P NMR (121 MHz, d6-DMSO) d 
149.2, 149.0 (P
III); 
1H NMR (400 MHz, d6-DMSO) d 8.69 (1H, s, NHCONH2), 8.66 
and 8.63 (1H, s, H
4), 7.63 (1H, br s, H
2”), 7.44-7.38 (1H, m, H
4”), 7.42 and 7.40 (2H, d, 
J = 8.0 Hz and J = 8.5 Hz, H
14), 7.34 (1H, t, J = 7.9 Hz, H
5”), 7.34-7.24 (3H, m, 
H
15,H
16), 7.30 and 7.27 (4H, d, J = 8.0 Hz and J = 8.8 Hz, H
10), 7.02 (1H, br d, J = 7.5 
Hz, H
6”), 6.89 and 6.87 (2H, d, J = 8.3 Hz and J = 8.6 Hz, H
11), 6.89 and 6.87 (2H, d, J 
= 8.5 Hz, H
11), 6.31 and 6.27 (1H, app. t, J = 5.8 Hz, H
1’), 5.92 (2H, br s, NH2), 5.63 
and 5.59 (1H, s, H
5), 4.68 and 4.64 (1H, td, J = 5.4, 16.1 Hz and J = 5.9, 17.9 Hz, H
3’), 
4.17 and 4.13 (1H, dd, J = 3.4, 7.7 Hz and J = 3.8, 8.0 Hz, H
4’), 3.81-3.68 (1H, m, H
17), 
3.71, 3.70 and 3.70 (3H, 3H and 6H, s, OCH3), 3.69-3.61 (1H, m, H
17), 3.63-3.49 (2H, 
m, H
19), 3.46 (3H, s, NCH3), 3.49-3.44 and 3.41 (1H, m and dd, J = 3.5, 11.5 Hz, H
5’), 
1923.46-3.41 and 3.37 (1H, m and dd, J = 2.9, 10.8 Hz, H
5’), 2.77 and 2.67 (1H, t, J = 5.9 
Hz, H
18), 2.59 (1H, td, J = 6.7, 13.6 Hz, H
2’), 2.34 (1H, td, J = 6.0, 11.9 Hz, H
2’), 1.15 
(3H, d, J = 7.3 Hz, H
20), 1.13 (3H, d, J = 7.3 Hz, H
20), 1.12 (3H, d, J = 6.8 Hz, H
20), 
1.02 (3H, d, J = 6.8 Hz, H
20); LRMS (ES
+) m/z: 940 ([M + K]
+, 8), 924 ([M + Na]
+, 45), 
902 ([M + H]
+, 78), 303 (DMT
+, 100); HRMS (ES
+): calcd for C49H56N7O8P (M), [M + 
Na]
+ = 924.3820, found 924.3825; [M + H]
+ = 902.4001, found 902.4000. Found also 
DMT
+ (calcd 303.1380, found 303.1381).
5’-O-(4,4’-Dimethoxytrityl)-5-[(3-ureidobenzoyl)methyl]-4N-methyl-2’-
deoxycytidine, 183
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A suspension of nucleoside 160 (0.20 g, 0.29 mmol) in 33 wt% MeNH2/ethanol (2.50 
mL) was stirred under an argon atmosphere, at rt for 1 hour.  The suspension dissolved 
over 25 minutes.  The solvent was removed in vacuo to give a green crystalline solid. 
Following purification by column chromatography (5-20% methanol/ethyl acetate + 
0.5% Et3N), and drying under high vacuum, the desired ring-opened nucleoside 183 was 
afforded as a yellow glassy solid (0.13 g, 0.18 mmol, 61%).
Rf 0.11 (9:1, acetone/ethyl acetate + 0.3% Et3N, A’), 0.25 (1:4, methanol/ethyl acetate + 
0.3% Et3N, A’); LRMS (ES
+) m/z: 758 ([M + K]
+, 10), 742 ([M + Na]
+, 30), 720 ([M + 
H]
+, 5), 303 (DMT
+, 100); (ES
–) m/z: 816 ([M + H3PO4 – H]
–, 100), 718 ([M – H]
–, 41), 
675 ([M – O=C=NH – H]
–, 52); HRMS (ES
+): calcd for C40H41N5O8 (M), [M + H]
+ = 
720.3028, found 720.3024.
1933-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-ureidophenyl)-
(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one, 184
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To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxycytidine  185 
(1.25 g, 1.87 mmol) in anhydrous DMF (6.0 mL), under an argon atmosphere and in 
absence of light, were added distilled Et3N (1.30 mL, 9.33 mmol, 5.0 eq), CuI (0.14 g, 
0.75 mmol, 0.4 eq), then alkyne 156 (0.90 g, 5.61 mmol, 3.0 eq).  The reaction mixture 
was stirred for 15 minutes then tetrakis(triphenylphosphine) palladium (0) (0.53 g, 0.46 
mmol, 0.1 eq) was added and the reaction was stirred at rt for 2¼ hours.  The reaction 
mixture was diluted with methanol/acetone (1:1 v/v, 10 mL), filtered and the residue 
was washed with methanol/acetone (1:1 v/v, 3 ´ 10 mL).  The combined filtrate was 
concentrated in vacuo and under high vacuum, co-evaporating with methanol/toluene to 
give a dark brown foam.   The crude material was partially-purified by column 
chromatography (80-100% acetone/CH2Cl2 + 0.5% Et3N ® 5-20% methanol/acetone + 
0.5% Et3N), to afford, after drying under high vacuum, the product 188 plus alkyne-
dimer impurity, as a pale brown foam (1.49 g).
Rf 0.18 (188), 0.12 (alkyne dimer) (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’), 0.11 (188), 
0.21 (alkyne dimer) (4:1, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.44 (188 + alkyne dimer), 
(1:9, methanol/acetone + 0.3% Et3N, A’).
To a stirred solution of partially-purified product 188 (1.48 g) in anhydrous DMF (10.0 
mL) and distilled Et3N (2.60 mL, 18.7 mmol, 10.0 eq), under an argon atmosphere, in 
absence of light, were added 4Å molecular sieves then CuI (0.39 g, 2.05 mmol, 1.1 eq), 
and the reaction was stirred at 125 °C for 40 minutes.  The mixture was allowed to cool 
and diluted with methanol (20 mL).  The mixture was filtered, the residue was washed 
with methanol (3 ´ 10 mL) and the combined filtrate was concentrated in vacuo and 
under high vacuum to give a green foam/resin.  The compound was twice-purified by 
column chromatography (0-10% methanol/acetone + 0.5% Et3N), then by precipitation 
194from methanol/acetone (1:1 v/v, 8 mL) into diethyl ether (230 ml), to afford, after 
drying under high vacuum, the desired N-methylpyrrolo-dC product 184, as a very pale 
yellow powdery solid (1.03 g, 1.47 mmol, 79% over two steps).
Rf 0.24 (1:9, methanol/acetone + 0.3% Et3N, A’), 0.49 (1:4, methanol/CH2Cl2 + 0.3% 
Et3N, A’); IR (solid): n 3324 (br m, O–H, N–H), 2932, 2836 (w, C–H), 1651 (s, C=O), 
1606 (s, C=C), 1556 (vs, C=N), 1507 (s, Aryl C=C), 1479 (s), 1441 (m), 1402 (s), 1338, 
1303 (m), 1248 (s, O–H), 1176 (s), 1095, 1032 (s, C–O), 904 (m), 828 (s, C–H), 773, 
726 (s), 701 (s, Aryl C–H), 659, 584, 534 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 
8.71 (1H, s, NHCONH2), 8.63 (1H, s, H
4), 7.63 (1H, t, J = 1.8 Hz, H
2”), 7.41 (1H, ddd, 
J = 1.0, 2.0, 7.0 Hz, H
4”), 7.41 (2H, d, J = 7.0 Hz, H
14), 7.34 (1H, t, J = 8.0 Hz, H
5”), 
7.32 (2H, tt, J = 1.5, 7.0 Hz, H
15), 7.29 (2H, d, J = 9.0 Hz, H
10), 7.28 (2H, d, J = 8.5 Hz, 
H
10), 7.28 (1H, t, J = 8.0 Hz, H
16), 7.02 (1H, td, J = 1.3, 7.5 Hz, H
6”), 6.89 (2H, d, J = 
9.0 Hz, H
11), 6.89 (2H, d, J = 9.0 Hz, H
11), 6.26 (1H, dd, J = 5.0, 6.5 Hz, H
1’), 5.92 (2H, 
s, CONH2), 5.59 (1H, s, H
5), 5.40 (1H, d, J = 4.8 Hz, 3’-OH), 4.43 (1H, qn, J = 5.5 Hz, 
H
3’), 4.00 (1H, dd, J = 4.0, 8.0 Hz, H
4’), 3.70 (3H, s, OCH3), 3.69 (3H, s, OCH3), 3.46 
(3H, s, NCH3), 3.40 (1H, dd, J = 4.0, 10.5 Hz, H
5’), 3.29 (1H, dd, J = 2.5, 10.5 Hz, H
5’), 
2.44 (1H, td, J = 6.3, 13.1 Hz, H
2’), 2.18 (1H, ddd, J = 5.0, 6.5, 13.6 Hz, H
2’); 
13C NMR 
(100 MHz, d6-DMSO) d 158.5 (C
7a), 158.1 (C
12–OCH3), 155.9 (CONH2), 153.5 (C
2), 
144.5 (C
13), 142.6 (C
6), 140.9 (C
3”–NHR), 136.2 (C
4), 135.4, 135.1 (C
9), 130.8 (C
1”), 
129.8, 129.7 (C
10), 129.1 (C
5”), 127.9 (C
15), 127.7 (C
14), 126.8 (C
16), 120.9 (C
6”), 118.1 
(C
4”), 117.4 (C
2”), 113.3 (C
11), 107.6 (C
4a), 98.6 (C
5), 86.7 (C
1’), 86.1 (C
8Ar3), 85.7 
(C
4’), 69.0 (C
3’), 62.6 (C
5’), 55.0 (OCH3), 41.5 (C
2’), 29.3 (NCH3); LRMS (ES
+) m/z: 
1425 ([2M + Na]
+, 8), 724 ([M + Na]
+, 100), 702 ([M + H]
+, 50); HRMS (ES
+): calcd 
for C40H39N5O7 (M), [M + Na]
+ = 724.2742, found 724.2733.  Found also DMT
+ (calcd 
303.1380, found 303.1382); Anal. Calcd C40H39N5O7 (701.77), C 68.46%, H 5.60%, N 
9.97%, found C 65.70%, H 5.82%, N 9.35%.
1955’-O-(4,4’-Dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxycytidine, 185
HN
i) POCl3 (3.8 eq), NMI (12.6 eq), dist. pyridine, 0 oC-rt
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ii) 40 wt% MeNH2/H2O, 0 oC-rt
iii) 33 wt% MeNH2/EtOH, rt
C31H32N3O6I
Mol. Wt.: 669.51
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Method 1: To a stirred solution of acetylated nucleoside 187 (1.44 g, 2.07 mmol) and 
N-methylimidazole (2.10 mL, 26.3 mmol, 12.8 eq) in distilled pyridine (50.0 mL), 
under an argon atmosphere, at 0 °C, distilled phosphorous oxychloride (0.73 mL, 7.83 
mmol, 3.8 eq) was added dropwise over 10 minutes.   The yellow suspension of 
intermediate 186 was stirred at rt for 1 hour.  A 40 wt% MeNH2/water solution (10.0 
mL, 116 mmol MeNH2, 55.9 eq MeNH2) was added whilst cooling in ice, and the 
cloudy solution was stirred at rt for 90 minutes.  The pyridine was removed under high 
vacuum, and the mixture was diluted with water (200 mL).  The aqueous solution was 
extracted with CH2Cl2 (4 ´ 100 mL), then the combined organic layer was washed with 
sat. aq KCl (200 mL) and dried (Na2SO4).  Triethylamine (6.0 mL) was added to prevent 
detritylation and the solution was concentrated in vacuo, and dried under high vacuum. 
The viscous brown oil was dissolved in 33 wt% MeNH2/ethanol (10.0 mL, 80.3 mmol 
MeNH2, 38.8 eq MeNH2) and stirred at rt for 40 minutes, then concentrated in vacuo 
and dried under high vacuum.  Following purification by column chromatography (0-
2% methanol/CH2Cl2 + 0.5% Et3N), and drying under high vacuum, the 4N-methyl-dC 
nucleoside 185 was afforded, as a pale yellow foam (1.24 g, 1.86 mmol, 90%).
Method 2: Acetylated nucleoside 187 (6.85 g, 9.80 mmol) was treated with NMI and 
POCl3 in pyridine, then 40 wt% MeNH2/water and worked up, as described in Method 
1.  After treatment with 33 wt% MeNH2/ethanol as described above, the resulting syrup 
was twice-purified by column chromatography (0-3% methanol/CH2Cl2 + 0.5% Et3N, 0-
15% acetone/CH2Cl2 + 0.5% Et3N ® 60% acetone/CH2Cl2 + 0.5% Et3N) to yield a 
syrup containing significant NMI.  Two further purifications (30-100% acetone/toluene 
+ 0.5% Et3N; 10-25% acetone/toluene + 1.0% pyridine) failed to remove NMI, however 
the product was successfully recrystallised from toluene (100 mL), and dried under high 
vacuum over KOH to afford the product 185 as a fluffy white crystalline solid (5.26 g, 
7.86 mmol, 80%).
196Method 3: Acetylated nucleoside 187 (8.27 g, 11.8 mmol) was treated with NMI and 
POCl3  in pyridine, then 40 wt% MeNH2/water and the reaction concentrated as 
described in Method 1.  The resulting syrup was treated with 33 wt% MeNH2/ethanol as 
described   above,   without   an   aqueous   workup,   then   twice-purified   by   column 
chromatography (0-100% acetone/CH2Cl2 + 0.5% Et3N ® 5-15% methanol/acetone + 
1.0% Et3N).   The orange/brown syrup was further purified by a combination of 
precipitation from toluene into diethyl ether, removal of NMI by soaking in diethyl 
ether, and recrystallisation from ethyl acetate to afford the product 185 as a white to off-
white powdery/crystalline solid (3.62 g, 5.40 mmol, 46%).
Rf 0.40 (1:9, methanol/CH2Cl2 + 0.3% Et3N, A’), 0.36 (4:1, acetone/CH2Cl2 + 0.3% 
Et3N, A’), 0.57 (1:9, methanol/acetone + 0.3% Et3N, A’);  Mp  141-144  °C (ethyl 
acetate/diethyl ether); IR (solid): n 3291 (br w, N–H), 3059, 2930, 2835 (w, C–H), 1634 
(s, C=O), 1606 (vs, C=O, C=C), 1547 (s, C=O), 1505 (vs, C=C), 1397 (m, O–H), 1284 
(s, C–O), 1246 (vs, C–N), 1173 (s), 1092, 1030 (m, C–O), 825, 779 (s, Aryl C=C), 700, 
583 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 7.93 (1H, s, H
6), 7.40 (2H, d, J = 7.5 
Hz, H
13), 7.32 (2H, t, J = 7.3 Hz, H
14), 7.29 (4H, d, J = 9.0 Hz, H
9), 7.22 (1H, tt, J = 2.0, 
7.3 Hz, H
15), 7.06 (1H, q, J = 4.5 Hz, NHCH3), 6.89 (4H, d, J = 9.0 Hz, H
10), 6.12 (1H, 
dd, J = 6.2, 7.4 Hz, H
1’), 5.25 (1H, d, J = 4.3 Hz, 3’-OH), 4.20 (1H, dt, J = 3.3, 6.4 Hz, 
H
3’), 3.91 (1H, dd, J = 3.3, 6.5 Hz, H
4’), 3.74 (6H, s, OCH3), 3.20 (1H, dd, J = 3.3, 10.8 
Hz, H
5’), 3.17 (1H, dd, J = 4.5, 10.8 Hz, H
5’), 2.80 (3H, d, J = 4.5 Hz, NHCH3), 2.21 
(1H, ddd, J = 3.0, 6.0, 13.3 Hz, H
2’), 2.09 (1H, td, J = 6.8, 13.6 Hz, H
2’); 
13C NMR (100 
MHz, d6-DMSO) d 163.0 (C
4), 159.8 (C
11–OMe), 155.3 (C
2), 146.8 (C
6), 146.4 (C
12), 
137.2, 137.1 (C
8), 131.4 (C
9), 129.6 (C
14), 129.4 (C
13), 128.4 (C
15), 115.0 (C
10), 87.5 
(C
7Ar3), 87.4 (C
4’), 87.0 (C
1’), 72.4 (C
3’), 65.4 (C
5’), 59.9 (C
5–I), 56.8 (OCH3), 42.4 
(C
2’), 30.4 (NHCH3); LRMS (ES
+) m/z: 692 ([M + Na]
+, 12), 670 ([M + H]
+, 3), 303 
(DMT
+, 100); (ES
–) m/z: 668 ([M – H]
–, 100); HRMS (ES
+): calcd for C31H32N3O6I (M), 
[M + K]
+ = 708.0967, found 708.0962, [M + Na]
+ = 692.1228, found 692.1219, [M + H]
+ = 670.1409, found 670.1414. Found also DMT
+ (calcd 303.1380, found 303.1386); 
Anal. Calcd C31H32N3O6I (669.51), C 55.61%, H 4.82%, N 6.27%, found C 54.80%, H 
4.75%, N 6.05%.
3’-O-Acetyl-5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine, 187
209
197acetic anhydride (1.5 eq)
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To a stirred solution of nucleoside 97 (10.0 g, 15.2 mmol) in distilled pyridine (40.0 
mL), under an argon atmosphere, at 0 °C was added acetic anhydride (7.20 mL, 76.3 
mmol, 5.0 eq) dropwise over 20 minutes.  The reaction was stirred at 0 °C for 15 
minutes then allowed to warm to rt.   After 2¾ hours, the reaction mixture was 
concentrated in vacuo and under high vacuum, co-evaporating with acetone (2 ´ 50 mL) 
and diethyl ether (2 ´ 50 mL), to give white foam/syrup.  The syrup was dissolved in 
ethyl acetate (300 mL) and washed with water (3 ´ 75 mL).  The aqueous was re-
extracted (ethyl acetate, 40 mL) and combined organic fractions were washed with sat. 
aq KCl (120 mL), dried (Na2SO4) and concentrated in vacuo and under high vacuum to 
give   a   white   foam.     Following   purification   by   column   chromatography
(0-2% methanol/CH2Cl2  + 0.5% Et3N), and drying under high vacuum, the desired 
product 187 was afforded as a white foam (10.3 g, 14.7 mmol, 97%).
Rf 0.31 (1:9, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.48 (5:95, methanol/CH2Cl2 + 0.3% 
Et3N, A’), 0.33 (7:3, ethyl acetate/hexane, A’); IR (solid): n 3056 (w, C–H, N–H), 
2933, 2835 (w, C–H), 1683 (br s, C=O), 1606, 1506 (m, Aryl C=C), 1442 (m, C–H), 
1379 (w, CH3), 1244 (vs, C–O), 1174 (s), 11.05 (m), 1073 (s), 1027 (s, C–O), 826, 754, 
700 (s, Aryl C–H), 583 (s), 545 (m) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 11.75 (1H, 
s, NH
3), 8.05 (1H, s, H
6), 7.39 (2H, d, J = 8.0 Hz, H
13), 7.32 (2H, t, J = 7.3 Hz, H
14), 
7.28 (2H, d, J = 9.0 Hz, H
9), 7.28 (2H, d, J = 9.0 Hz, H
9), 7.23 (1H, tt, J = 1.1, 7.2 Hz, 
H
15), 6.89 (4H, d, J = 8.8 Hz, H
10), 6.10 (1H, dd, J = 6.1, 8.2 Hz, H
1’), 5.23 (1H, td, J = 
2.4, 6.4 Hz, H
3’), 4.07 (1H, td, J = 2.9, 4.5 Hz, H
4’), 3.74 (6H, s, OCH3), 3.32 (1H, dd, J 
= 4.9, 10.4 Hz, H
5’), 3.22 (1H, dd, J = 3.1, 10.4 Hz, H
5’), 2.44 (1H, td, J = 7.0, 11.5 Hz, 
H
2’), 2.33 (1H, ddd, J = 2.0, 6.0, 14.3 Hz, H
2’), 2.03 (3H, s, COCH3); 
13C NMR (100 
MHz, d6-DMSO) d 169.9 (COCH3), 160.5 (C
4), 158.1 (C
11–OCH3), 150.1 (C
2), 144.6 
(C
12), 144.1 (C
6), 135.3, 135.2 (C
8), 129.7 (C
9), 127.9 (C
14), 127.6 (C
13), 126.7 (C
15), 
113.3 (C
10), 86.0 (C
7Ar3), 84.7 (C
1’), 83.1 (C
4’), 74.1 (C
3’), 70.2 (C
5–I), 63.4 (C
5’), 55.0 
(OCH3), 36.8 (C
2’), 20.7 (COCH3); LRMS (ES
+) m/z: 721 ([M + Na]
+, 12), 303 (DMT
+, 
100); (ES
–) m/z: 697 ([M – H]
–, 100); HRMS (ES
+): calcd for C32H31N2O8I (M), [M + 
198Et3N + H]
+ = 800.2402, found 800.2369; [M + Na]
+ = 721.1017, found 721.1007. Found 
also DMT
+ (calcd 303.1380, found 303.1383).
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-
acetamidophenyl)-(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one-3’-
O-(2-O-cyanoethyl-N,N-diisopropyl) phosphoramidite, 191
C41H40N4O7
Mol. Wt.: 700.78 C50H57N6O8P
Mol. Wt.: 901.00
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(1.1 eq), dist. DIPEA (2.5 eq) 70
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O CN
dist. THF/anh. DMF (7:9 v/v), ARGON, rt
To a stirred solution of nucleoside 193 (1.37 g, 1.95 mmol) in distilled THF (3.5 mL) 
and anhydrous DMF (4.5 mL), strictly under an argon atmosphere and 
excluding moisture, was added distilled DIPEA (0.86 mL, 4.91 mmol, 2.5 eq) 
followed by chloro-phosphitylating reagent 70 (0.48 mL, 2.15 mmol, 1.1 eq) 
dropwise, and the reaction was stirred at rt for  1¼ hours.   The THF was 
removed  in vacuo  and the residue was dissolved in argon-degassed ethyl 
acetate (60 mL).  The solution was washed with degassed sat. aq KCl (3 ´ 40 
mL), dried (Na2SO4), and concentrated in vacuo and dried under high vacuum 
to give a pale orange foam.  Following purification by column chromatography 
(7:3, acetone/CH2Cl2 + 0.5% Et3N), on silica gel pre-equilibrated with Et3N, 
under argon pressure, the desired phosphoramidite  191  was afforded, after 
drying under high vacuum, as a diastereomeric mixture (ca. 1:1), as an air-
sensitive, pale milky yellow foam (1.51 g, 1.68 mmol, 86%).
Rf 0.33, 0.46 (4:1, acetone/CH2Cl2 + 0.3% Et3N, A’); 
31P NMR (121 MHz, d6-DMSO) d 
149.2, 149.0 (P
III); 
1H NMR (400 MHz, d6-DMSO) d 10.08 (1H, s, NHCOCH3), 8.68 
and 8.65 (1H, s, H
4), 7.79 (1H, br s, H
2”), 7.62 (1H, br d, J = 8.0 Hz, H
4”), 7.42 (1H, t, J 
= 7.8 Hz, H
5”), 7.42 and 7.40 (2H, d, J = 8.0 Hz and J = 8.5 Hz, H
14), 7.34-7.29 (2H, m, 
H
15), 7.30 and 7.28 (4H, d, J = 9.0 Hz, H
10), 7.30-7.23 (1H, m, H
16), 7.16 (1H, br d, J = 
1997.5 Hz, H
6”), 6.89, 6.88 and 6.87 (2H, 2H and 4H, d, J = 9.0 Hz, J = 8.5 Hz and J = 9.0 
Hz, H
11), 6.31 and 6.27 (1H, app. t, J = 5.8 Hz, H
1’), 5.66 and 5.63 (1H, s, H
5), 4.68 and 
4.65 (1H, ddd, J = 5.5, 16.3 Hz and J = 6.0, 16.7 Hz, H
3’), 4.18 and 4.14 (1H, dd, J = 
3.3, 7.8 Hz and J = 3.8, 8.3 Hz, H
4’), 3.82-3.69 (1H, m, H
17), 3.70, 3.70 and 3.69 (3H, 
3H and 6H, s, OCH3), 3.70-3.60 (1H, m, H
17), 3.62-3.48 (2H, m, H
19), 3.47 (3H, s, 
NCH3), 3.47 and 3.43-3.39 (1H, dd and m, J = 4.5, 11.0 Hz, H
5’), 3.44 and 3.38 (1H, dd, 
J = 3.5, 10.5 Hz and J = 3.0, 10.5 Hz, H
5’), 2.77 and 2.67 (1H, t, J = 6.0 Hz, H
18), 2.61 
and 2.59 (1H, td, J = 6.9, 13.4 Hz and J = 6.5, 13.1 Hz, H
2’), 2.35 (1H, td, J = 6.3, 13.1 
Hz, H
2’), 2.08 (3H, s, COCH3), 1.15 (3H, d, J = 7.0 Hz, H
20), 1.13 (3H, d, J = 7.0 Hz, 
H
20), 1.12 (3H, d, J = 7.0 Hz, H
20), 1.02 (3H, d, J = 7.0 Hz, H
20); LRMS (ES
+) m/z: 939 
([M + K]
+, 5), 923 ([M + Na]
+, 100), 901 ([M + H]
+, 9);  HRMS  (ES
+): calcd for 
C50H57N6O8P (M), [M + Et3N + H]
+  = 1002.5253, found 1002.5261; [M + Na]
+  = 
923.3868, found 923.3886; [M + H]
+ = 901.4048, found 901.4033.
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-
acetamidophenyl)-(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one, 
193
Pd(PPh3)4 (0.1 eq)
dist. Et3N (5.0 eq)
dist. Et3N (10.0 eq)
anh. DMF, 4Å sieves CuI (0.4 eq), anh. DMF
argon, dark, rt
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To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxycytidine  185 
(1.69 g, 2.53 mmol) in anhydrous DMF (6.0 mL), under an argon atmosphere and in 
absence of light, were added distilled Et3N (1.77 mL, 12.7 mmol, 5.0 eq), CuI (0.19 g, 
1.01 mmol, 0.4 eq), then alkyne 161 (1.21 g, 7.60 mmol, 3.0 eq).  The reaction mixture 
was stirred for 20 minutes then tetrakis(triphenylphosphine) palladium (0) (0.29 g, 0.25 
mmol, 0.1 eq) was added and the reaction was stirred at rt for 1 hour.  The reaction 
mixture was concentrated under high vacuum, co-evaporating with acetone to give a 
black/brown foam.  The residue was dissolved in CH2Cl2 (100 mL) and washed with 5% 
w/v aq Na2EDTA (pH 9, 3 ´ 70 mL).  The aqueous was re-extracted (CH2Cl2, 2 ´ 50 
mL) and combined organic fractions were washed with sat. aq KCl (100 mL), dried 
200(Na2SO4), and concentrated in vacuo and under high vacuum to give a golden brown 
foam.  The crude material was partially-purified by column chromatography (10-30% 
acetone/CH2Cl2 + 1.0% pyridine ® 50-70% acetone/CH2Cl2 + 1.0% pyridine), to afford, 
after drying under high vacuum, the product  192  plus alkyne-dimer impurity, as a 
yellow glassy foam (1.99 g).
Rf  0.16 (3:2, acetone/CH2Cl2  + 0.3% Et3N, A’), 0.04 (1:4, acetone/CH2Cl2  + 0.5% 
pyridine, A’), 0.28 (4:1, acetone/CH2Cl2 + 0.3% Et3N, A’), 0.32 (4:1, acetone/CH2Cl2 + 
1.0% pyridine, A’); 
1H NMR (400 MHz, d6-DMSO) d 9.97 (1H, s, NHCOCH3), 8.00 
(1H, s, H
6), 7.79 (1H, s, H
2”), 7.46 (1H, ddd, J = 1.0, 2.0, 8.5 Hz, H
4”), 7.43 (1H, q, J = 
5.0 Hz, NHCH3), 7.40 (1H, dd, J = 1.3, 8.3 Hz, H
15), 7.29 (2H, d, J = 9.0 Hz, H
11), 7.29-
7.25 (1H, m, H
5”), 7.28 (2H, d, J = 8.5 Hz, H
11), 7.24 (2H, t, J = 7.8 Hz, H
16), 7.15 (1H, 
tt, J = 1.3, 7.3 Hz, H
17), 6.90 (1H, td, J = 1.3, 7.8 Hz, H
6”), 6.84 (2H, d, J = 9.0 Hz, H
12), 
6.83 (2H, d, J = 9.0 Hz, H
12), 6.16 (1H, t, J = 6.8 Hz, H
1’), 5.28 (1H, d, J = 4.5 Hz, 3’-
OH), 4.26 (1H, dt, J = 3.5, 6.7 Hz, H
3’), 3.97 (1H, td, J = 3.0, 5.0 Hz, H
4’), 3.66 (6H, s, 
OCH3), 3.23 (1H, dd, J = 5.0, 10.5 Hz, H
5’), 3.15 (1H, dd, J = 2.5, 10.5 Hz, H
5’), 2.86 
(3H, d, J = 4.5 Hz, NHCH3), 2.27 (1H, ddd, J = 3.5, 6.3, 13.6 Hz, H
2’), 2.16 (1H, td, J = 
6.7, 13.6 Hz, H
2’), 2.06 (3H, s, COCH3); 
13C NMR (100 MHz, d6-DMSO) d 168.4 
(COCH3), 161.7 (C
4–NHCH3), 158.0, 158.0 (C
13–OCH3), 153.2 (C
2), 144.7 (C
14), 143.0 
(C
6), 139.1 (C
3”), 135.6, 135.3 (C
10), 129.7, 129.6 (C
11), 128.5 (C
5”), 127.8 (C
16), 127.6 
(C
15), 126.6 (C
17), 126.4 (C
6”), 122.5 (C
1”), 121.9 (C
2”), 119.4 (C
4”), 113.2, 113.1 (C
12), 
94.3 (C
8), 90.3 (C
7), 85.9 (C
4’), 85.8 (C
9Ar3), 85.6 (C
1’), 80.4 (C
5), 70.7 (C
3’), 63.8 (C
5’), 
54.9 (OCH3), 40.8 (C
2’), 27.8 (NHCH3), 23.9 (COCH3); LRMS (ES
+) m/z: 723 ([M + 
Na]
+, 100), 303 (DMT
+, 29); (ES
–) m/z: 699 ([M – H]
–, 100); HRMS (ES
+): calcd for 
C41H40N4O7 (M), [M + H]
+ = 701.2970, found 701.2974.  Found also DMT
+  (calcd 
303.1380, found 303.1381).
To a stirred solution of partially-purified alkynylated product 192 (1.92 g) in anhydrous 
DMF (8.5 mL) and distilled Et3N (3.40 mL, 24.4 mmol, 10.0 eq), under an argon 
atmosphere and in absence of light, were added 4Å molecular sieves then CuI (0.51 g, 
2.68 mmol, 1.1 eq), and the reaction was stirred at 125 °C for 35 minutes.  The mixture 
was allowed to cool then filtered and the filtrate was concentrated under high vacuum to 
give a sticky green/brown foam.  The residue was dissolved in CH2Cl2 (150 mL) and 
filtered, and the filtrate was washed with 5% w/v aq Na2EDTA (pH 9, 3 ´ 100 mL), sat. 
aq KCl (100 mL), dried (Na2SO4), and concentrated in vacuo and under high vacuum to 
201give a green/orange foam.  Following purification by column chromatography (0-10% 
methanol/acetone + 0.5% Et3N), and drying under high vacuum, the desired cyclised 
product 193 was afforded, as a yellow powdery solid (1.43 g, 2.04 mmol, 84% over two 
steps).
Rf  0.09 (4:1, acetone/CH2Cl2  + 0.3% Et3N, A’), 0.14 (4:1, acetone/CH2Cl2  + 1.0% 
pyridine, A’); 
1H NMR (400 MHz, d6-DMSO) d 10.08 (NHCOCH3), 8.65 (1H, s, H
4), 
7.79 (1H, br s, H
2”), 7.61 (1H, br d, J = 8.0 Hz, H
4”), 7.42 (1H, t, J = 8.0 Hz, H
5”), 7.40 
(2H, d, J = 7.0 Hz, H
14), 7.32 (2H, t, J = 7.0 Hz, H
15), 7.29 (2H, d, J = 8.5 Hz, H
10), 7.28 
(2H, d, J = 9.0 Hz, H
10), 7.25 (1H, t, J = 7.0 Hz, H
16), 7.16 (1H, br d, J = 8.0 Hz, H
6”), 
6.90 (2H, d, J = 9.0 Hz, H
11), 6.89 (2H, d, J = 9.0 Hz, H
11), 6.26 (1H, dd, J = 5.3, 6.3 
Hz, H
1’), 5.62 (1H, s, H
5), 5.39 (1H, d, J = 5.0 Hz, 3’-OH), 4.43 (1H, td, J = 5.5, 11.0 
Hz, H
3’), 4.01 (1H, dd, J = 4.0, 8.0 Hz, H
4’), 3.70 (3H, s, OCH3), 3.69 (3H, s, OCH3), 
3.47 (3H, s, NCH3), 3.40 (1H, dd, J = 4.0, 11.0 Hz, H
5’), 3.30 (1H, dd, J = 3.0, 11.0 Hz, 
H
5’), 2.45 (1H, td, J = 6.5, 13.6 Hz, H
2’), 2.19 (1H, ddd, J = 5.0, 6.5, 13.6 Hz, H
2’), 2.08 
(3H, s, COCH3); 
13C NMR (100 MHz, d6-DMSO) d 168.5 (COCH3), 158.5 (C
7a), 158.1 
(C
12), 153.4 (C
2), 144.5 (C
13), 142.2 (C
6), 139.6 (C
3”), 136.4 (C
4), 135.4, 135.1 (C
9), 
130.9 (C
1”), 129.8, 129.7 (C
10), 129.2 (C
5”), 127.9 (C
15), 127.7 (C
14), 126.8 (C
16), 122.8 
(C
6”), 119.2 (C
4”), 118.5 (C
2”), 113.3 (C
11), 107.5 (C
4a), 98.9 (C
5), 86.7 (C
1’), 86.1 
(C
8Ar3), 85.7 (C
4’), 69.0 (C
3’), 62.6 (C
5’), 55.0 (OCH3), 41.5 (C
2’), 29.3 (NCH3), 24.0 
(COCH3); LRMS (ES
+) m/z: 803 ([M + Et3N + H]
+, 14), 723 ([M + Na]
+, 100); (ES
–) m/
z: 699 ([M – H]
–, 100); HRMS (ES
+): calcd for C41H40N4O7 (M),[M + H]
+ = 701.2970, 
found 701.2965.  Found also DMT
+ (calcd 303.1380, found 303.1379).
5’-O-(4,4’-Dimethoxytrityl)-5-[(3-aminophenyl)ethynyl]-4N-methyl-2’-
deoxycytidine, 194
H2N (3 eq), dist. Et3N (5.0 eq)
CuI (0.4 eq), (Ph3P)4Pd (0.1 eq)
anh. DMF, dark, argon, rt
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202To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxycytidine  185 
(0.97 g, 1.45 mmol) in anhydrous DMF (4.0 mL), under an argon atmosphere and in 
absence of light, were added distilled Et3N (1.0 mL, 7.25 mmol, 5.0 eq) then CuI (0.11 
g, 0.58 mmol, 0.4 eq) and alkyne 152 (0.49 mL, 4.35 mmol, 3.0 eq).  The reaction 
mixture was stirred for 20 minutes then tetrakis(triphenylphosphine) palladium (0) (0.17 
g, 0.15 mmol, 0.1 eq) was added and the reaction was stirred at rt for 1½ hours.  The 
reaction   mixture   was   concentrated   under   high   vacuum,   co-evaporating   with 
methanol/toluene/acetone to give an orange/brown foam.  The residue was dissolved in 
methanol/acetone   (1:1   v/v,   40   mL)   and   filtered.     The   solid   was   washed   with 
methanol/acetone (1:1 v/v, 2 ´ 20 mL), and the combined filtrate was concentrated in 
vacuo  and dried under high vacuum to give an orange/brown foam.   Following 
purification by column chromatography (0-3% methanol/CH2Cl2  + 0.5% Et3N), and 
drying under high vacuum, the product 194 was afforded, as a pale orange foam (0.91 g, 
1.39 mmol, 95%).
Rf 0.31 (1:9, methanol/CH2Cl2 + 0.3% Et3N); 0.31 (4:1, acetone/CH2Cl2 + 0.3% Et3N, 
A’), 0.03 (1:4, acetone/CH2Cl2 + 0.3% Et3N, A’); IR (solid): n 3337 (br m, O–H, N–H), 
2934, 2835 (w, C–H), 1640 (s, C=O, C=C), 1596 (s, Aryl C–C), 1556 (s), 1505 (vs, 
C=N), 1444 (m, C–H), 1403 (m), 1352 (m, C–H), 1285 (m, O–H), 1246, 1174 (s), 1086 
(br s, C–O), 1029 (br s), 942 (m), 866 (m, C–H), 826 (s, Aryl C–H), 780 (s), 726 (m), 
686 (Aryl-C–H), 583, 537, 518 (s) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 7.94 (1H, s, 
H
6), 7.40 (1H, dd, J = 1.1, 8.4 Hz, H
15), 7.35 (1H, q, J = 4.8 Hz, NHCH3), 7.30-7.25 
(2H, m, H
16), 7.29 (2H, d, J = 8.0 Hz, H
11), 7.29 (2H, d, J = 9.0 Hz, H
11), 7.17 (1H, tt, J 
= 1.0, 7.3 Hz, H
17), 6.96 (1H, t, J = 7.8 Hz, H
5”), 6.86 (2H, d, J = 8.5 Hz, H
12), 6.83 (2H, 
d, J = 8.8 Hz, H
12), 6.61 (1H, t, J = 1.6 Hz, H
2”), 6.57 (1H, ddd, J = 1.1, 2.4, 8.0 Hz, 
H
4”), 6.46 (1H, ddd, J = 1.1, 2.5, 7.5 Hz, H
6”), 6.15 (1H, app. t, J = 6.7 Hz, H
1’), 5.30 
(1H, d, J = 4.3 Hz, 3’-OH), 5.11 (1H, br s, NH2), 4.25 (1H, td, J = 3.1, 9.0 Hz, H
3’), 
3.97 (1H, td, J = 2.4, 4.8 Hz, H
4’), 3.68 (3H, s, OCH3), 3.67 (3H, s, OCH3), 3.23 (1H, 
dd, J = 5.0, 10.5 Hz, H
5’), 3.14 (1H, dd, J = 2.5, 10.3 Hz, H
5’), 2.86 (3H, d, J = 4.8 Hz, 
NHCH3), 2.27 (1H, ddd, J = 3.0, 5.9, 13.4 Hz, H
2’), 2.13 (1H, td, J = 6.8, 13.6 Hz, H
2’); 
13C NMR (100 MHz, d6-DMSO) d 161.7 (C
4–NHCH3), 158.0, 158.0 (C
13–OCH3), 153.2 
(C
2), 148.3 (C
14), 144.6 (C
3”), 142.5 (C
6), 135.6, 135.2 (C
10), 129.7, 129.6 (C
11), 128.7 
(C
5”), 127.8 (C
16), 127.6 (C
15), 126.6 (C
17), 122.4 (C
1”), 119.2 (C
6”), 116.4 (C
2”), 114.5 
(C
4”), 113.2, 113.2 (C
12), 95.3 (C
8), 90.6 (C
7), 85.9 (C
4’), 85.8 (C
9Ar3), 85.6 (C
1’), 79.0 
(C
5), 70.8 (C
3’), 63.7 (C
5’), 54.9 (OCH3), 40.8 (C
2’), 27.9 (NHCH3); LRMS (ES
+) m/z: 
203681 ([M + Na]
+, 100); HRMS (ES
+): calcd for C41H40N4O7 (M), [M + Na]
+ = 681.2684, 
found 681.2671; [M + H]
+  = 659.2864, found 659.2847.   Found also DMT
+  (calcd 
303.1380, found 303.1381).
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-aminophenyl)-
(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one, 195
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Method 1: To a stirred solution of alkynylated product 194 (2.21 g, 3.36 mmol) in 
anhydrous DMF (9.0 mL) and distilled Et3N (4.70 mL, 33.7 mmol, 10.0 eq), under an 
argon atmosphere, in absence of light, were added 4Å molecular sieves then CuI (0.70 
g, 3.70 mmol, 1.1 eq), and the reaction was stirred at 125 °C for 50 minutes.  The 
mixture was allowed to cool, filtered and the filtrate was concentrated under high 
vacuum, co-evaporating with methanol/toluene/acetone to give a dark brown/gold foam. 
The foam was dissolved in DMF (80 mL), filtered, the solid was washed with DMF (3 ´ 
60 mL) and the combined filtrate was concentrated under high vacuum at 35 °C to give 
a sticky, dark brown foam/gum.   The mixture was finally suspended/dissolved in 
CH2Cl2  (100 mL), soaked overnight and filtered.   The solid residue was washed 
(CH2Cl2, 3 ´ 50 mL), and the combined filtrate was concentrated in vacuo to give a 
sticky orange/brown foam.   Following purification by column chromatography (50-
100% acetone/CH2Cl2 + 0.5% Et3N ® 5% methanol/acetone + 0.5% Et3N), and drying 
under high vacuum, the desired product  195  and  bis-tritylated nucleoside  196  were 
isolated, as pale orange foams (195, 0.71 g, 1.07 mmol, 32%; 196, 0.38 g, 0.39 mmol, 
12%).
204Method 2: Cyclised nucleoside 195 was prepared using nucleoside 194 (0.88 g, 1.34 
mmol), by the same procedure as in Method 1, with a reaction time of 30 minutes.  The 
mixture was allowed to cool, filtered, and the filtrate was concentrated  under high 
vacuum to give a viscous brown syrup.  The residue was suspended/dissolved in CH2Cl2 
(50 mL) and filtered.  The solid residue was washed (CH2Cl2, 2 ´ 25 mL) and the 
combined filtrate was concentrated in vacuo and under high vacuum to give a brown 
foam.  Following purification by column chromatography (50-100% acetone/CH2Cl2 + 
0.5% Et3N), and drying under high vacuum, the desired cyclised product  195  was 
afforded, as a pale brown foam (0.71 g, 1.07 mmol, 80%).
Product 195:
Rf 0.08 (5:95, methanol/CH2Cl2 + 0.3% Et3N, A’), 0.14 (4:1, acetone/CH2Cl2 + 0.3% 
Et3N, A’); IR (solid): n 3336 (w, O–H, N–H), 3064, 2930, 2835 (w, C–H), 1699 (w), 
1651 (s, C=O), 1605 (s, C=C), 1553 (s, C=N), 1507 (s, Aryl C–C), 1476 (s, N–H), 
1445, 1398 (s), 1338 (m), 1301 (s), 1246 (vs), 1174 (s), 1095 (s, C–O), 1030 (vs), 969, 
914 (m), 827 (s, C–H), 772, 726 (s), 701 (s, Aryl C–H), 659, 584, 530 (s) cm
-1;
1H NMR (400 MHz, d6-DMSO) d 8.63 (1H, s, H
4), 7.41 (2H, d, J = 7.3 Hz, H
14), 7.32 
(2H, t, J = 7.0 Hz, H
15), 7.29 (4H, d, J = 8.8 Hz, H
10), 7.25 (1H, tt, J = 1.8, 7.3 Hz, H
16), 
7.13 (1H, t, J = 7.8 Hz, H
5”), 6.90 (2H, d, J = 8.8 Hz, H
11), 6.89 (2H, d, J = 9.0 Hz, H
11), 
6.67 (1H, t, J = 1.8 Hz, H
2”), 6.64 (1H, ddd, J = 0.8, 2.2, 8.0 Hz, H
4”), 6.60 (1H, td, J = 
1.3, 8.0 Hz, H
6”), 6.26 (1H, dd, J = 5.0, 6.3 Hz, H
1’), 5.51 (1H, s, H
5), 5.42 (1H, d, J = 
4.8 Hz, 3’-OH), 5.26 (2H, br s, NH2), 4.44 (1H, td, J = 5.3, 10.5 Hz, H
3’), 4.00 (1H, dd, 
J = 3.9, 7.9 Hz, H
4’), 3.71 (3H, s, OCH3), 3.70 (3H, s, OCH3), 3.44 (3H, s, NCH3), 3.39 
(1H, dd, J = 3.9, 10.7 Hz, H
5’), 3.30 (1H, d, J = 2.6, 10.9 Hz, H
5’), 2.44 (1H, td, J = 6.5, 
13.1 Hz, H
2’), 2.19 (1H, ddd, J = 5.1, 6.4, 13.4 Hz, H
2’); 
13C NMR (100 MHz, d6-
DMSO) d 158.5 (C
7a), 158.2 (C
12–OCH3), 153.5 (C
2), 149.0 (C
3”–NHR), 144.5 (C
13), 
143.4 (C
6), 135.9 (C
4), 135.5, 135.2 (C
9), 131.1 (C
1”), 129.8, 129.7 (C
10), 129.3 (C
5”), 
128.0 (C
15), 127.8 (C
14), 126.9 (C
16), 115.6 (C
6”), 114.3 (C
4”), 113.3 (C
11,C
2”), 107.7 
(C
4a), 98.0 (C
5), 86.6 (C
1’), 86.1 (C
8Ar3), 85.6 (C
4’), 69.0 (C
3’), 62.6 (C
5’), 55.0 (OCH3), 
41.5 (C
2’), 29.4 (NCH3); LRMS (ES
+) m/z: 681 ([M + Na]
+, 100); HRMS (ES
+): calcd 
for C39H38N4O6 (M), [M + Na]
+ = 681.2684, found 681.2677.  Found also DMT
+ (calcd 
303.1380, found 303.1381); Anal. Calcd C39H38N4O6 (658.75), C 71.11%, H 5.81%, N 
8.50%, found C 69.90%, H 6.11%, N 8.41%.
Analytical results are consistent with the reported data.
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2053-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-[3-(4,4’-
dimethoxytrityl)aminophenyl]-(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-
one, 196:
Rf 0.33 (4:1, acetone/CH2Cl2 + 0.3% Et3N, A’); 
1H NMR (400 MHz, d6-DMSO) d 8.57 
(1H, s, H
4), 7.40 (2H, d, J = 7.3 Hz, H
14), 7.33-7.26 (4H, m, H
15,H
23), 7.28 (4H, d, J = 
8.8 Hz, H
10), 7.26-7.19 (3H, m, H
16,H
24), 7.22 (4H, d, J = 8.8 Hz, H
19), 7.16 (1H, tt, J = 
1.6, 7.0 Hz, H
25), 6.97 (1H, t, J = 7.9 Hz, H
5”), 6.89 (2H, d, J = 9.0 Hz, H
11), 6.88 (2H, 
d, J = 9.5 Hz, H
11), 6.85 (4H, d, J = 9.0 Hz, H
20), 6.64 (1H, br dd, J = 1.4, 8.2 Hz, H
6”), 
6.54 (1H, d, J = 7.8 Hz, H
4”), 6.51 (1H, t, J = 1.8 Hz, H
2”), 6.22 (1H, dd, J = 5.3, 6.3 Hz, 
H
1’), 5.39 (1H, d, J = 4.5 Hz, 3’-OH), 5.38 (1H, s, NHDMT), 4.40 (1H, qn, J = 5.5 Hz, 
H
3’), 3.98 (1H, dd, J = 3.8, 8.0 Hz, H
4’), 3.69 (6H, s, C
21–OCH3), 3.69 (3H, s, C
12–
OCH3), 3.68 (3H, s, C
12–OCH3), 3.36 (1H, dd, J = 3.8, 10.4 Hz, H
5’), 3.28 (1H, d, J = 
2.8, 10.5 Hz, H
5’), 3.12 (3H, s, NCH3), 2.41 (1H, td, J = 6.4, 12.8 Hz, H
2’), 2.15 (1H, 
ddd, J = 5.3, 6.3, 13.1 Hz, H
2’); 
13C NMR (100 MHz, d6-DMSO) d 158.3 (C
7a), 158.2, 
158.1 (C
12–OCH3), 157.6 (C
21–OCH3), 153.4 (C
2), 147.2 (C
3”–NHR), 145.7 (C
22), 144.4 
(C
13), 143.2 (C
6), 137.2 (C
18), 135.9 (C
4), 135.6, 135.2 (C
9), 129.9 (C
19,C
1”), 129.8, 
129.6 (C
10), 128.7 (C
23), 128.2 (C
5”), 127.9 (C
15), 127.8 (C
14,C
24), 126.8 (C
16), 126.4 
(C
25), 116.8 (C
6”), 116.4 (C
4”), 115.3 (C
2”), 113.3, 113.1 (C
11,C
20), 107.5 (C
4a), 98.0 
(C
5), 86.6 (C
1’), 86.0 (C
8Ar3), 85.6 (C
4’), 69.5 (C
17Ar3), 69.0 (C
3’), 62.6 (C
5’), 55.0 
(OCH3), 41.5 (C
2’), 29.1 (NCH3); LRMS (ES
+) m/z: 1063 ([M + Et3N + H]
+, 16), 983 
([M + Na]
+, 59), 961 ([M + H]
+, 27), 303 (DMT
+, 100).
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-
trifluoroacetamidophenyl)-(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one, 
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206Method 1: To a stirred solution of nucleoside 195 (0.52 g, 0.79 mmol) in distilled 
pyridine (4.0 mL), under an argon atmosphere and excluding moisture, at rt, was added 
TMSCl (0.15 mL, 1.5 eq) slowly.  After stirring for 2 hours, further TMSCl (0.20 mL, 
2.0 eq) was added, and the reaction was stirred for a further 30 minutes.  The reaction 
mixture was cooled to 0 °C, then trifluoroacetic anhydride (0.22 mL, 2.0 eq) was added 
dropwise.  The reaction was stirred at 0 °C for 10 minutes, then allowed to warm to rt 
for 25 minutes.  Water (1.0 mL) was added and the pale yellow solution was stirred for 
25 minutes.  The reaction mixture was reduced to approximately one-third volume, then 
was diluted with CH2Cl2 (150 mL), adding Et3N (1.5 mL) to prevent detritylation.  The 
solution was washed with water (60 mL), the aqueous was re-extracted (CH2Cl2, 2 ´ 50 
mL), and combined CH2Cl2 fractions were washed with sat. aq KCl (140 mL), dried 
(Na2SO4) and concentrated in vacuo and dried under high vacuum to give a yellow gum. 
The compound  was twice-purified  by column  chromatography (50-80% acetone/ 
CH2Cl2 + 0.5% Et3N; 10-60% acetone/CH2Cl2 + 0.5% Et3N ® 5% methanol/acetone + 
0.5% Et3N), from which the product 197 was isolated, after drying under high vacuum, 
as a pale orange foam (0.19 g, 0.25 mmol, 32%).  A mixture containing product 197 and 
bis-trifluoroacetylated compound 198 (ca. 11:2) was also isolated (0.31 g).
Method 2: Product 197 was prepared using nucleoside 195 (0.51 g, 0.78 mmol) as 
described in Method 1, using 5 eq of TMSCl, with a total reaction time of 3½ hours. 
After addition of trifluoroacetic anhydride, white fumes were observed, hence Et3N (2.0 
mL) was added, before water, to prevent detritylation.   Water (2.0 mL) was then added 
and the orange/brown solution was stirred for 2 hours at rt.  The reaction mixture was 
diluted with CH2Cl2 (300 mL) then washed with water (300 mL).  The aqueous was re-
extracted (CH2Cl2, 2 ´ 50 mL), and the combined CH2Cl2 fraction was washed with 
15% aq NH3 (100 mL) and sat. aq KCl (140 mL), dried (Na2SO4) and concentrated in 
vacuo to give a brown gum.  Following purification by column chromatography (5-80% 
acetone/CH2Cl2 + 0.5% Et3N), and drying under high vacuum, the desired product 197 
was afforded, as a pale orange foam (0.31 g, 0.41 mmol, 53%).
Rf  0.31 (197), 0.41 (198) (7:3, acetone/CH2Cl2  + 0.5% Et3N, A’), 0.08 (197) (1:4, 
acetone/CH2Cl2  +   0.5%   Et3N,   A’);  
19F   NMR  (282   MHz,  d6-DMSO)  d  -73.6 
(NHCOCF3); 
1H NMR (400 MHz, d6-DMSO) d 11.36 (NHCOCF3), 8.68 (1H, s, H
4), 
7.83 (1H, br s, H
2”), 7.75 (1H, td, J = 0.9, 8.3 Hz, H
4”), 7.55 (1H, t, J = 8.0 Hz, H
5”), 
7.40 (2H, d, J = 8.0 Hz, H
14), 7.37 (1H, d, J = 8.2 Hz, H
6”), 7.32 (2H, t, J = 7.3 Hz, H
15), 
2077.29 (4H, d, J = 8.3 Hz, H
10), 7.28 (4H, d, J = 9.0 Hz, H
10), 7.24 (1H, t, J = 7.5 Hz, H
16), 
6.89 (2H, d, J = 8.5 Hz, H
11), 6.88 (2H, d, J = 9.0 Hz, H
11), 6.25 (1H, app. t, J = 5.7 Hz, 
H
1’), 5.65 (1H, s, H
5), 5.42 (1H, d, J = 4.3 Hz, 3’-OH), 4.42 (1H, qn, J = 5.0 Hz, H
3’), 
4.00 (1H, dd, J = 3.9, 7.4 Hz, H
4’), 3.69 (3H, s, OCH3), 3.69 (3H, s, OCH3), 3.49 (3H, s, 
NCH3), 3.39 (1H, d, J = 7.3 Hz, H
5’), 3.35 (1H, d, J = 7.3 Hz, H
5’), 2.45 (1H, td, J = 6.5, 
13.1 Hz, H
2’), 2.19 (1H, ddd, J = 5.5, 6.1, 13.2 Hz, H
2’); 
13C NMR (100 MHz, d6-
DMSO) d 158.6 (C
7a), 158.2 (C
12–OCH3), 154.7 (q, 
2JCF = 36.9 Hz, COCF3), 153.4 (C
2), 
144.5 (C
13), 141.6 (C
6), 136.7 (C
4,C
3”), 135.5, 135.2 (C
9), 131.3 (C
1”), 129.8, 129.7 
(C
10), 129.6 (C
5”), 128.0 (C
15), 127.8 (C
14), 126.8 (C
16), 125.4 (C
6”), 121.3 (C
4”), 120.6 
(C
2”), 115.7 (q, 
1JCF = 286.7 Hz, COCF3), 113.3 (C
11), 107.5 (C
4a), 99.3 (C
5), 86.7 (C
1’), 
86.1 (C
8Ar3), 85.7 (C
4’), 68.9 (C
3’), 62.6 (C
5’), 55.0 (OCH3), 41.5 (C
2’), 29.4 (NCH3); 
LRMS (ES
+) m/z: 804 (16), 793 ([M + K]
+, 15), 777 ([M + Na]
+, 99), 303 (DMT
+, 100); 
HRMS (ES
+): calcd for C41H37N4O7F3 (M), [M + Na]
+ = 777.2507, found 777.2509. 
Found also DMT
+ (calcd 303.1380, found 303.1384).
Analytical results are consistent with the reported data.
206
N,N’-Bis-[(2-cyanoethoxy)carbonyl]-S-methyl-isothiourea, 200
41,225,226
NC O O
O
N
O
O
i) (2.0 eq), NaHCO3 (3.0 eq)
201 NC
O N
H
O
N
SMe
O
O
CN
C10H12N4O4S
Mol. Wt.: 284.29
200
H2N NH
SMe
.1/2 H2SO4
C2H7N2O2S1.5
Mol. Wt.: 139.19
205
degassed DCM/H2O (2:1 v/v), argon, rt
NC O O
O
N
O
O
ii) (1.0 eq), dist. DCM, argon, rt
201
1
2
3
4
5
2'
3'
4'
5'
A mixture of S-methylisothiourea hemisulfate 205 (6.03 g, 43.3 mmol) and NaHCO3 
(10.9 g, 130 mmol, 3.0 eq) in argon-degassed, distilled water (50.0 mL) was stirred, 
under an argon atmosphere, at rt, for 30 minutes.  To this was added degassed CH2Cl2 
(150.0 mL) followed by (2-cyanoethyl)-N-succinimidyl carbonate (CEOC-succinimide) 
201 (18.9 g, 86.6 mmol, 2.0 eq) and the mixture was stirred vigorously, under an argon 
atmosphere, at rt for 8 hours.  The mixture was diluted with CH2Cl2 (100 mL) and water 
(100 mL), agitated and separated.  The aqueous layer was re-extracted (CH2Cl2, 3 ´ 100 
mL) and combined CH2Cl2 fractions were dried (Na2SO4) and concentrated in vacuo and 
under high vacuum to give a viscous, cloudy yellow syrup.
208The syrup was redissolved in distilled CH2Cl2 (65.0 mL), to which CEOC-succinimide 
201 (9.47 g, 43.3 mmol, 1.0 eq) was added and the mixture was stirred under an argon 
atmosphere, at rt for 14½ hours.  The yellow solution was diluted with CH2Cl2 (135 mL) 
then washed with sat. aq KCl (80 mL).  The aqueous fraction was re-extracted (CH2Cl2, 
2 ´ 30 mL) and the combined organic fractions were dried (Na2SO4) and concentrated 
in   vacuo  to   give   a   cloudy,   yellow   syrup.     Following   purification   by   column 
chromatography (5:95, ethyl acetate/CH2Cl2), and drying under high vacuum, the 
desired product 200 was afforded as a hard, powdery white solid (11.0 g, 38.7 mmol, 
89%).  A mixture of reagent 201 and product 200 (ca. 7:3) (0.90 g) was also isolated.
Rf  0.46 (1:3, ethyl acetate/CH2Cl2, B’, F’), 0.28 (1:9, ethyl acetate/CH2Cl2, B’);  
1H 
NMR (400 MHz, CDCl3) d 11.77 (1H, s, NH), 4.40 (2H, t, J = 6.3 Hz, H
3), 4.36 (2H, t, 
J = 6.0 Hz, H
3’), 2.78 (4H, t, J = 6.5 Hz, CH2CN), 2.44 (3H, s, SCH3); 
13C NMR (100 
MHz,  CDCl3)  d  173.7 (NHC
1=N), 160.4 (NC
2=O), 150.8 (NHC
2’=O), 116.8 (C
5N), 
116.3 (C
5’N), 61.0 (C
3), 60.6 (C
3’), 18.1 (CH2CN), 14.8 (SCH3); LRMS (ES
+) m/z: 307 
([M + Na]
+, 100), 285 ([M + H]
+, 12), 277 (11), 236 (17).
Analytical results are consistent with the reported data.
225
(2-Cyanoethyl)-N-succinimidyl carbonate, 201
42,226
NC
OH NC
O O
O
N
O
O
DSC 202 (1.3 eq), dist. pyridine (1.4 eq)
anh. MeCN, 4Å molecular sieves, argon, rt C3H5NO
Mol. Wt.: 71.08 C8H8N2O5
Mol. Wt.: 212.16
203
201
A suspension of di-succinimidyl carbonate (DSC) 202 (69.3 g, 271 mmol, 1.3 eq) in 
anhydrous acetonitrile (300 mL), with 4Å molecular sieves, was stirred vigorously at rt, 
under an argon atmosphere for 35 minutes.  Distilled pyridine (23.6 mL, 291 mmol, 1.4 
eq) was added and the mixture was stirred for 15 minutes.  3-Hydroxypropionitrile (3-
HPN) 203 (14.2 mL, 208 mmol) was added dropwise over 35 minutes then the mixture 
was stirred, at rt, for 1½ hours.  The pale yellow mixture was filtered, the residue was 
washed with CH3CN (2 ´ 30 mL) and the combined filtrate was concentrated in vacuo 
and under high vacuum to give a viscous yellow syrup.  The syrup was dissolved in 
argon-degassed CH2Cl2 (500 mL) and washed with degassed sat. aq NaHCO3 (2 ´ 250 
mL).  The combined aqueous fraction was re-extracted (degassed CH2Cl2, 3 ´ 50 mL) 
209and combined CH2Cl2 fractions were washed with degassed sat. aq KCl (2 ´ 200 mL), 
dried (Na2SO4) and concentrated in vacuo and under high vacuum to give a white waxy 
solid.  The solid was co-evaporated with anhydrous CH3CN (2 ´ 50 mL) and dried 
under high vacuum, then triturated with diethyl ether (2 ´ 150 mL) and dried under high 
vacuum, to afford the desired product  201  as a slightly waxy, white solid (42.5 g) 
containing 5.1 mol % N-hydroxysuccinimide (recalculated yield - 195 mmol, 94%).
Rf 0.33 (1:3, ethyl acetate/CH2Cl2, B’, F’), 0.17 (1:9, ethyl acetate/CH2Cl2, B’, F’); IR 
(solid): n 3001, 2968, 2941 (w, C–H), 2262 (w, CºN), 1810, 1781 (s, C=O), 1727 (br 
vs, carbonate C=O), 1474, 1430 (w), 1364 (m), 1263, 1231 (s, C–O), 1196 (vs, C–O), 
1076 (s, C–O), 992, 968 (s), 861, 813 (m), 763, 718 (s), 642 (s, N–O), 575, 460 (m)
cm
-1; 
1H NMR (400 MHz, CDCl3) d 4.52 (2H, t, J = 6.5 Hz, CH2O), 2.85 (4H, s, 
succinimide-CH2), 2.84 (2H, t, J = 6.5 Hz, CH2CN); 
13C NMR (100 MHz, CDCl3) d 
168.4 (succinimide-NCO), 151.3 (OCO2), 115.6 (CN), 64.8 (CH2O), 25.6 (succinimide-
CH2), 18.0 (CH2CN); LRMS (ES
+) m/z: 276 ([M + CH3CN + Na]
+, 30), 235 ([M + Na]
+, 100).
Analytical results are consistent with the reported data.
42
3-N-[2’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-ribofuranosyl]-6-(3-{N,N’-bis-[(2-
cyanoethoxy)carbonyl]guanidinyl}phenyl)-(2,3H)-N-methylpyrrolo[2,3-
d]pyrimidine-2(7H)-one, 207
C39H38N4O6
Mol. Wt.: 658.74
O
OH
O N
N
O
N
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(2.5 eq)
dist. pyridine (5.2 eq), dist. DCM, argon, 35-50 oC
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6
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C48H46N8O10
Mol. Wt.: 894.93
NC O N
H
O
N
S
O
O
CN
200
To a stirred solution of nucleoside 195 (0.39 g, 0.60 mmol) and guanidinylating reagent 
200 (0.19 g, 0.66 mmol, 1.1 eq) in distilled CH2Cl2 (4 mL), under an argon atmosphere, 
was added distilled pyridine (24.1 mL, 0.30 mmol, 0.5 eq) and the solution was stirred at 
35 °C.  Further distilled pyridine (0.05 mL, 0.62 mmol, 1.0 eq) was added at 16½ hours 
210and 19 hours, when distilled CH2Cl2 (1.0 mL) was added and the temperature was raised 
to 50 °C.  Molecular sieves (4Å) and distilled pyridine (0.05 mL, 0.62 mmol, 1.0 eq) 
were added at 20½ hours, distilled CH2Cl2 (2.0 mL) at 22½ hours, and further distilled 
pyridine (0.08 mL, 0.93 mmol, 1.6 eq) and guanidinylating reagent 200 (0.24 g, 0.84 
mmol, 1.4 eq) at 23½ hours.  After a further 17 hours, the reaction mixture was diluted 
with CH2Cl2 (100 mL), filtered and washed with water (50 mL).  The aqueous layer was 
re-extracted (CH2Cl2, 2 ´ 30 mL) and combined organic fractions were washed with sat. 
aq KCl (75 mL), dried (Na2SO4), and concentrated in vacuo and under high vacuum to 
give a golden brown foam.  Following purification by column chromatography (50-
100%   acetone/CH2Cl2),   on   silica   gel   pre-equilibrated   with   pyridine,   the   desired 
guanidinylated product 207 was afforded, as a yellow foam (0.23 g, 0.25 mmol, 42%). 
A mixture of product 207 and starting material 195 (ca. 1:2) (0.03 g) was also isolated.
Rf 0.37 (4:1, acetone/CH2Cl2, A’, E’); IR (solid): n 3271 (br w, O–H, N–H), 2933, 2837 
(w, C–H), 2255 (w, CºN), 1732 (m, C=O), 1650 (s, C=O, C=N), 1622 (s, C=C), 1607, 
1555 (s, C=O), 1507 (s, Aryl C–C), 1424, 1398, 1282, 1229, 1175 (s), 1114, 1083 (s, C–
O), 1057, 1029 (s), 907 (m), 827 (s, Aryl C–H), 791 (s), 770 (s, Aryl C–H), 727 (s, 
CH2), 700 (s, Aryl C–H), 658, 583, 531 (s) cm
-1; 
1H NMR (400 MHz, CDCl3) d 11.57 
(1H, s, CONHCN), 9.91 (1H, s, NHAr), 8.52 (1H, s, H
4), 7.48 (1H, t, J = 1.8 Hz, H
2”), 
7.23 (1H, ddd, J = 1.0, 2.0, 8.0 Hz, H
4”), 7.18-7.15 (1H, m, H
5”), 7.15 (2H, d, J = 7.0 
Hz, H
14), 7.04 (4H, d, J = 9.0 Hz, H
10), 7.04-6.99 (1H, m, H
16), 6.98 (2H, t, J = 9.0 Hz, 
H
15), 6.95 (1H, br d, J = 8.5 Hz, H
6”), 6.54 (2H, d, J = 9.0 Hz, H
11), 6.53 (2H, d, J = 9.0 
Hz, H
11), 6.19 (1H, t, J = 5.5 Hz, H
1’), 5.29 (1H, s, H
5), 4.39 (1H, q, J = 5.5 Hz, H
3’), 
4.19 (2H, br t, J = 5.8 Hz, H
24), 4.00 (2H, br t, J = 5.8 Hz, H
20), 3.90 (1H, td, J = 3.0, 5.0 
Hz, H
4’), 3.46 (3H, s, OCH3), 3.45 (3H, s, OCH3), 3.34 (3H, s, NCH3), 3.26 (1H, dd, J = 
3.0, 11.0 Hz, H
5’), 3.21 (1H, dd, J = 3.3, 10.8 Hz, H
5’), 2.59-2.52 (1H, m, H
2’), 2.53 (2H, 
br t, J = 6.0 Hz, H
23), 2.41 (2H, br t, J = 5.8 Hz, H
19), 2.11 (1H, ddd, J = 5.5, 6.5, 13.6 
Hz, H
2’); 
13C NMR (100 MHz, CDCl3) d 163.5 (C
17=N), 159.3 (C
7a), 159.1, 158.0 (C
12), 
155.3 (NC
18=O), 154.0 (C
2), 153.6 (NHC
22=O), 144.8 (C
13), 142.7 (C
6), 136.8 (C
4), 
136.5 (C
3”–NHR), 136.1, 135.9 (C
9), 132.3 (C
1”), 130.6, 130.5 (C
10), 129.9 (C
5”), 128.6 
(C
15), 128.5 (C
14), 127.5 (C
16), 126.1 (C
6”), 123.3 (C
2”), 123.2 (C
4”), 117.2 (C
21≡N), 
116.4 (C
25≡N), 113.8 (C
11), 109.2 (C
4a), 100.4 (C
5), 88.2 (C
1’), 87.4 (C
8Ar3), 86.6 (C
4’), 
70.9 (C
3’), 63.0 (C
5’), 61.5 (C
19), 60.3 (C
23), 55.6 (OCH3), 43.0 (C
2’), 30.4 (NHCH3), 
18.4 (C
20,C
24); LRMS (ES
+) m/z: 918 ([M + Na]
+, 100), 895 ([M + H]
+, 10); HRMS 
211(ES
+): calcd for C48H46N8O10 (M), [M + Na]
+ = 917.3229, found 917.3234.  Found also 
DMT
+: calcd 303.1380, found 303.1386.
3-Thioureidophenyl acetylene, 209
N
H
H2N
S
209
C9H8N2S
Mol. Wt.: 176.24
H2N
152
C8H7N
Mol. Wt.: 117.15
1 3
7
8 1 3
7
8
NH4SCN (1.1 eq)
15% aq HCl, reflux, dark
Method 1: Ammonium thiocyanate (1.12 g, 14.7 mmol, 1.1 eq) was dissolved, with 
care, in 15% aq HCl (1.5 mL).  This was added to a stirred emulsion of 3-ethynylaniline 
152 (1.50 mL, 13.3 mmol) in 15% aq HCl (1.3 mL), at rt.  The mixture was refluxed, in 
absence of light, for 9¼ hours.  The brown reaction mixture was allowed to cool, then 
diluted with ethyl acetate (180 mL) and washed with water (2 ´ 40 mL) and sat. aq KCl 
(40 mL).  The organic layer (suspension) was removed and concentrated in vacuo to 
give a golden-brown foam/gum.  The gum was dissolved/suspended in acetone (100 
mL), filtered, the residue was washed with acetone (2 ´ 20 mL) and the combined 
filtrate was concentrated in vacuo.  The resulting gum was suspended in diethyl ether 
(50 mL) and allowed to soak overnight.  The mixture was filtered, washed with diethyl 
ether (4 ´ 25 mL) and combined ether fractions were concentrated in vacuo and under 
high vacuum to give a yellow syrup.  Following purification by column chromatography 
(0-8% methanol/CH2Cl2  + 0.5% Et3N), and drying under high vacuum, the desired 
product 209 was afforded as an orange solid (0.14 g, 0.79 mmol, 6%).  Starting material 
152 was also recovered (0.41 g, 3.53 mmol, 27%).
N
H
N
H
S O
211
C16H12N2OS
Mol. Wt.: 280.34
1 3
7
8
9
12
N
H
H2N
S
209
C9H8N2S
Mol. Wt.: 176.24
1 3
7
8
5% aq NaOH, argon, 90 oC
Method 2: Benzoylthiourea 211 (2.54 g, 9.06 mmol) was added, in one portion, to 
stirred 5% aq NaOH (45.0 mL) under argon, at 90 °C.  After stirring for 15 minutes, the 
suspension was filtered hot to remove the benzamide byproduct 212, then cooled and 
acidified to pH 5.0 using 15% aq HCl.  The mixture was then basified to pH 8.0 using 
212conc. aq NH3 and filtered.  The solid was washed with water (3 ´ 10 mL) then dried 
under high vacuum over P2O5 for 2 days, to afford the desired deprotected thiourea 209 
as a pale, cream-coloured powdery solid (1.26 g, 7.15 mmol, 79%).
Rf 0.17 (5:95, acetone/CH2Cl2, A’); Mp 145-148 °C (CH2Cl2); IR (solid): n 3418, 3394 
(m, N–H), 3208 (m), 3160 (br s, water), 3015, 2981 (m, Aryl C–H), 2680 (w), 1618 (s, 
N–H), 1596 (m), 1580 (m, Aryl C–C), 1526, 1514, 1480, 1468 (s), 1423, 1411 (m), 
1297, 1248 (s, N–CS), 1155 (m), 1065 (s, C=S), 999, 888, 831 (m), 786, 711, 688, 667, 
632, 622, 579 (s), 518 (br vs) cm
-1; 
1H NMR (400 MHz, d6-DMSO) d 9.75 (1H, s, NH), 
7.62 (1H, t, J = 1.8 Hz, H
2), 7.54 (2H, extremely br s, NH2), 7.42 (1H, ddd, J = 1.0, 2.0, 
8.0 Hz, H
4), 7.32 (1H, t, J = 8.0 Hz, H
5), 7.07 (1H, td, J = 1.3, 7.7 Hz, H
6), 4.17 (1H, s, 
CºCH
8); 
13C NMR (100 MHz, d6-DMSO) d 181.2 (C=S), 139.5 (C
3), 129.0 (C
5), 127.4 
(C
6), 125.6 (C
2), 123.5 (C
4), 121.8 (C
1), 83.2 (C
7ºCH), 80.8 (CºC
8H); LRMS (ES
+) m/
z: 353 ([2M + H]
+, 100), 199 ([M + Na]
+, 78), 177 ([M + H]
+, 73); HRMS (ES
+): calcd 
for C9H8N2S (M), [3M + Na]
+ = 551.1117, found 551.1121; [2M + Na]
+ = 375.0709, 
found 375.0710; [M + Na]
+ = 199.0300, found 199.0301.
N-Benzoyl-N’-(3-ethynylphenyl) thiourea, 211
N
H
N
H
S O
211
C16H12N2OS
Mol. Wt.: 280.34
H2N
152
C8H7N
Mol. Wt.: 117.15
N
O
CS
210 (1.0 eq)
dry acetone, argon, rt
1
2
3
4
5
6
7
8
9
10
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12
To a stirred solution of 3-ethynylaniline 152 (1.50 mL, 13.3 mmol) in dry acetone (30.0 
mL), under an argon atmosphere, at rt, was added a solution of benzoyl isothiocyanate 
210 (1.82 mL, 13.5 mmol, 1.0 eq) in dry acetone (20.0 mL) dropwise over 12 minutes. 
The solution was stirred at rt for 1 hour, then concentrated in vacuo to give a pale 
yellow papery solid.  Cold dry acetone (15 mL) was added and the mixture was cooled 
at 
–10 °C for 2 hours.  The mixture was filtered cold, then washed with cold, dry acetone 
(2 ´ 5 mL) and diethyl ether (2 ´ 15 mL), then dried under high vacuum over P2O5 to 
afford the desired product 211 as a pale yellow papery solid.  Four further crops were 
obtained from the filtrate. (Combined yield - 2.81 g, 10.0 mmol, 75%).
213Rf 0.69 (5:95, acetone/CH2Cl2, A’); Mp 138-140 °C (acetone); IR (solid): n 3346 (br w, 
N–H), 3259 (s, alkyne C–H), 2991 (br m, Aryl C–H), 1663 (m, C=O), 1600 (s, Aryl C–
C), 1557, 1517 (s, C=O), 1486, 1449 (s), 1338 (s, N–CS), 1299 (s), 1255 (N–CS), 1188, 
1165 (m), 1140 (s, C=S), 1098, 1078 (s), 1024, 1000, 975, 929 (m), 878 (s, Aryl C–H), 
783 (vs, Aryl C–H), 740 (m), 702 (vs, Aryl C–H), 677, 655 (vs), 591, 533, 515 (s) cm
-1; 
1H NMR (300 MHz, CDCl3) d 12.61 (1H, s, CONHCS), 9.09 (1H, s, CSNHAr), 7.90 
(2H, dd, J = 1.3, 6.0 Hz, H
10), 7.86 (1H, t, J = 1.5 Hz, H
2), 7.76 (1H, td, J = 2.2, 7.1 Hz, 
H
4), 7.67 (1H, tt, J = 1.5, 7.3 Hz, H
12), 7.55 (2H, tt, J = 1.7, 7.5 Hz, H
11), 7.41 (1H, td, J 
= 1.8, 7.7 Hz, H
6), 7.37 (1H, t, J = 7.7 Hz, H
5), 3.12 (1H, s, CºCH
8); 
13C NMR (100 
MHz, CDCl3) d 178.6 (C=S), 167.1 (C=O), 137.8 (C
3), 134.0 (C
12), 131.7 (C
9), 130.6 
(C
5), 129.4 (C
11), 129.0 (C
6), 127.6 (C
10), 127.6 (C
2), 124.7 (C
4), 123.1 (C
1), 82.9 
(C
7ºCH), 78.2 (CºC
8H); LRMS (ES
+) m/z: 344 ([M + CH3CN + Na]
+, 50), 330 (49), 
303 ([M + Na]
+, 100), 281 ([M + H]
+, 33); HRMS (ES
+): calcd for C16H12N2OS (M), 
[3M + Cu]
+ = 903.1302, found 903.1038, [2M + Cu]
+ = 623.0631, found 623.0492;
[2M + H]
+ = 561.1413, found 561.1358; [M + H]
+ = 281.0743, found 281.0742.
5’-O-(4,4’-Dimethoxytrityl)-5-[(3-thioureidophenyl)ethynyl]-4N-methyl-2’-
deoxycytidine, 213
(2.5 eq), dist. Et3N (5.0 eq)
CuI (1.1 eq), (Ph3P)4Pd (0.7 eq)
anh. DMF, dark, argon, rt
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C40H39N5O6S
Mol. Wt.: 717.83
To a solution of 5’-O-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-deoxycytidine  185 
(0.31 g, 0.46 mmol) in anhydrous DMF (2.0 mL), under an argon atmosphere and in 
absence of light, were added distilled Et3N (0.33 mL, 2.33 mmol, 5.0 eq), CuI (0.10 g, 
0.51 mmol, 1.1 eq), then alkyne 209 (0.20 g, 1.16 mmol, 2.5 eq).  The mixture was 
stirred for 1 hour then tetrakis(triphenylphosphine) palladium (0) (0.38 g, 0.33 mmol, 
0.7 eq) was added and the reaction was stirred at rt for 1¼ hours.  The reaction mixture 
was concentrated under high vacuum, co-evaporating with methanol/toluene, to give an 
214orange foam/glass.  The residue was dissolved/suspended in methanol/acetone (1:1 v/v, 
40 mL), and filtered.  The solid was washed with methanol/acetone (1:1 v/v, 2 ´ 30 mL) 
and the combined filtrate was concentrated in vacuo and under high vacuum to give a 
golden orange foam/resin.   Following purification by column chromatography (80-
100% acetone/CH2Cl2 + 0.5% Et3N), and drying under high vacuum, the desired product 
213 was afforded as a yellow foam/resin (0.42 g) containing 21.1 mol % Et3N.HI, 22.3 
mol % triethylamine,  and 4.0 mol%  starting material  185, with some Pd-based 
impurities (recalculated yield - 0.47 mmol, quant.).
Rf 0.23 (5:95, methanol/ethyl acetate + 0.5% Et3N, A’), 0.17 (4:1, acetone/CH2Cl2 + 
0.5% Et3N); 
1H NMR (400 MHz, d6-DMSO) d 9.68 (1H, s, NH), 8.01 (1H, s, H
6), 7.49 
(1H, br s, H
2”), 7.44-7.39 (1H, m, NHCH3), 7.42 (2H, d, J = 7.5 Hz, H
15), 7.37 (1H, br 
d, J = 8.3 Hz, H
4”), 7.32-7.27 (1H, m, H
5”), 7.30 (2H, d, J = 9.0 Hz, H
11), 7.30 (2H, d, J 
= 9.0 Hz, H
11), 7.26 (2H, t, J = 8.0 Hz, H
16), 7.17 (1H, t, J = 7.3 Hz, H
17), 6.96 (1H, br 
d, J = 7.5 Hz, H
6”), 6.85 (2H, d, J = 9.0 Hz, H
12), 6.84 (2H, d, J = 9.0 Hz, H
12), 6.16 
(1H, t, J = 6.5 Hz, H
1’), 5.30 (1H, d, J = 4.5 Hz, 3’-OH), 4.28 (1H, td, J = 3.5, 9.5 Hz, 
H
3’), 3.98 (1H, td, J = 3.3, 4.5 Hz, H
4’), 3.67 (3H, s, OCH3), 3.66 (3H, s, OCH3), 3.22 
(1H, dd, J = 5.0, 10.5 Hz, H
5’), 3.16 (1H, dd, J = 2.8, 10.3 Hz, H
5’), 2.87 (3H, d, J = 5.0 
Hz, NHCH3), 2.28 (1H, ddd, J = 3.3, 6.0, 13.3 Hz, H
2’), 2.15 (1H, td, J = 6.7, 13.6 Hz, 
H
2’), 2.08 (2H, s, NH2); 
13C NMR (100 MHz, d6-DMSO) d 181.2 (CSNH2), 161.6 (C
4), 
158.0, 158.0 (C
13), 153.2 (C
2), 144.7 (C
3”), 143.0 (C
6), 139.0 (C
14), 135.6, 135.3 (C
10), 
129.7, 129.6 (C
11), 128.5 (C
5”), 127.9 (C
15), 127.6 (C
16,C
6”), 126.7 (C
17), 126.1 (C
2”), 
123.9 (C
4”), 122.5 (C
1”), 113.2, 113.2 (C
12), 94.1 (C
8), 90.3 (C
7),  85.9 (C
4’), 85.8 
(C
9Ar3), 85.7 (C
1’), 80.8 (C
5), 70.6 (C
3’), 63.7 (C
5’), 55.0, 54.9 (OCH3), 40.9 (C
2’), 27.9 
(NHCH3); LRMS (ES
+) m/z: 740 ([M + Na]
+, 100), 177 ([M + H]
+, 73); HRMS (ES
+): 
calcd for C40H39N5O6S (M), [M + K]
+  = 756.2253, found 756.2260; [M + Na]
+  = 
740.2513, found 740.2550; [M + H]
+ = 718.2694, found 718.2696.
2159.2 Biophysical Studies
9.2.1 Synthesis of Oligonucleotides
Oligonucleotides were synthesised by ATDBio Ltd. and Dr. Bouamaied on an Applied 
Biosystems 394 automated DNA/RNA synthesiser or an ÄKTA™ oligopilot plus DNA/
RNA synthesiser using a standard solid-phase 0.2 or 1.0  mmole phosphoramidite 
synthesis cycle.   The cycle comprises acid-catalysed (TCA) detritylation, coupling, 
capping (Ac2O) and oxidation (iodine/pyridine/THF). Stepwise coupling efficiencies 
and   overall   yields   were   determined   by   an   automated   trityl   cation   conductivity 
monitoring function and in all cases were >96%.
All synthesised phosphoramidite monomers were dissolved in anhydrous DNA grade 
acetonitrile or freshly distilled CH2Cl2  and filtered through a Millipore Millex
®-FH 
syringe filter (0.45mm, 13/25 mm).  After removing the solvent in vacuo, the monomer 
was dissolved in freshly distilled CH2Cl2 and aliquots corresponding to 100-120 mg 
each were transferred in to dry, sealed, argon-flushed ABI reagent bottles.  After drying 
to constant weight, under high vacuum over KOH for 2-3 days, the monomers were 
stored under positive argon pressure at 
–20 °C until required.
All phosphoramidite monomers were dissolved in anhydrous DNA grade acetonitrile 
(or freshly distilled CH2Cl2 if poorly soluble) to a concentration of 0.1 M immediately 
before use.
9.2.2. Deprotection of Oligonucleotides
Oligonucleotides were deprotected/cleaved from solid-support by various conditions. 
Capping was carried out using acetic anhydride.   Washing with 20% diethylamine/ 
acetonitrile was introduced in the latter half of the project.  
OL1, 2, 6-9, 17:  conc. aq ammonia, 55 °C, 5 hours (Capping only).
OL3-5:   30% aq methylamine, rt, 6-18 hours (Capping only), followed by treatment 
with DOWEX-H
+ resin for 15-17 hours.
216OL10-13:  30% aq methylamine, rt, 18 hours (Capping only), followed by treatment 
with DOWEX-H
+ resin for 15-17 hours.
OL14-16:  30% aq methylamine, rt, 6 hours (Capping only), followed by treatment with 
DOWEX-H
+ resin for 15-17 hours.
OL18-25, 32, 33, 35-37, 40, 41, 43-59:  conc. aq ammonia, rt, 24 hours, plus 1 hour at 
50 °C (DEA Wash only).
OL26-31:  conc. aq ammonia, 55 °C, 5 hours (DEA Wash plus Capping).
OL34, 38, 39, 42:  conc. aq ammonia, rt, 12 hours, plus 2 hours at 50 °C (DEA Wash 
only).
OL60-63:  conc. aq ammonia, rt, 12 hours (DEA Wash only).
The deprotection conditions used for oligonucleotides (OL64-70) in the Deprotection 
Study are discussed in Chapter 7.
9.2.3 Purification of Oligonucleotides
Oligonucleotides were purified by reversed-phase HPLC on a Gilson HPLC system 
using an Brownlee Aquapore column (C8, 8 ´ 250 mm, 300Å pore size).  The system 
was controlled by Gilson 7.12 software, and oligonucleotide elution was monitored by 
UV absorption at 297 nm for non-modified and 310 nm for modified oligonucleotides.
The following purification protocol was used: Gradient of acetonitrile in ammonium 
acetate buffer from 0-50% buffer B over 30 minutes (flow rate: 4 mL/min; buffer A: 0.1 
M  ammonium   acetate,  pH  7.0; buffer   B: 0.1  M  ammonium  acetate  with   50% 
acetonitrile, pH 7.0).
9.2.4 Analysis of Oligonucleotides
Mass spectra of oligonucleotides were recorded in cooperation with Dr. Edrees-Abdou, 
using electrospray ionisation (ES) on a Fisons VG platform instrument in HPLC grade 
water, with tripropylamine to aid ionisation; or by Dr. Hong Li, using matrix-assisted 
laser   desorption/ionisation   time-of-flight   (MALDI-TOF)   analysis   on   a 
ThermoBioAnalysis Dynamo MALDI-TOF mass spectrometer in positive ion mode 
217using internal Tn standards.
256   ES MS data was deconvoluted/reprocessed using the 
Maximum Entropy facility in MassLynx software version 2.22.
CE analysis was conducted by Louise Hagon (ATDBio Ltd.), using a Beckman Coulter 
P/ACE™ MDQ Capillary Electrophoresis System, using the 32 Karat Software MDQ 
UV application, at a concentration of ~4 OD/mL.  An ssDNA 100-R gel with Tris-
Borate-7 M Urea system was used.
Analytical HPLC and ion-exchange analysis were conducted by ATDBio Ltd.
9.2.5 UV Melting Studies
UV Melting experiments were performed, partly in cooperation with Dr. Edrees-Abdou, 
on a Varian Cary 400 Scan UV-Visible Spectrophotometer in Hellma® SUPRASIL 
synthetic quartz cuvettes (10 mm pathlength, 1.5 mL sample volume), monitoring at 
260 nm, using Cary WinUV Thermal application software.   Buffers were prepared 
according to the literature procedures,
257 allowed to warm to rt and the pH checked 
before use.
9.2.5.1 Set-Up Procedure
Aqueous solutions of the TFO and duplex strands were mixed in a 5:1 ratio in an 
eppendorf tube and lyophilised.  The residue was redissolved in 1.5 mL of the correct 
buffer, pH 6.1, 6.2, 6.4, 6.6, 7.0 or 7.0 + 2 mM spermine (10 mM sodium phosphate, 
200 mM NaCl, 1 mM Na2EDTA) to afford a 5 mM:1 mM concentration of TFO:duplex. 
The samples were degassed for 1 minute using a sonic-bath, then filtered into the 
cuvettes though Kinesis regenerated cellulose syringe filters (0.45 mm, 15 mm).  The 
samples were subjected to the desired melt programme alongside a matched cell 
reference blank.
2189.2.5.2 UV Melt Programmes
Programme 1
Stage Temp (°C) Rate (°C/min) Hold time (min) Data Interval (°C)
Melt 1 10®80 10.0 5 1.0
Anneal 1 80®10 1.0 2 1.0
Melt 2 10®80 0.5 2 0.25
Anneal 2 80®10 0.5 2 0.25
Melt 3 10®50 0.5 2 0.25
Anneal 3 50®20 0.5 2 0.25
Programme 2
Stage Temp (°C) Rate (°C/min) Hold time (min) Data Interval (°C)
Melt 1 10®80 10.0 2 1.0
Anneal 1 80®10 1.0 2 1.0
Melt 2/3 10®80 0.5 2 0.25
Anneal 2/3 80®10 0.5 2 0.25
Melt 4 10®50 0.5 2 0.25
Anneal 4 50®20 0.5 0 0.25
Programme 3
Stage Temp (°C) Rate (°C/min) Hold time (min) Data Interval (°C)
Melt 1 20®80 10.0 2 1.0
Anneal 1 80®15 0.5 20 0.1
Melt 2/3 15®80 0.5 2 0.1
Anneal 2/3 80®15 0.5 20 0.1
Melt 4/5 15®50 0.25 2 0.1
Anneal 4 50®15 0.25 20 0.1
Anneal 5 50®20 10.0 0 1.0
Following a fast melt/anneal for equilibration of denaturation of the triplex, heat/cool 
cycles up to 80 °C were recorded, followed by cycles up to 50 °C, at a slower rate and 
smaller data interval, for more accurate determination of the triplex Tm and reduction of 
hysteresis.
9.2.5.3 Data Analysis
Tm  values were derived from the derivatives of melting curves for each experiment 
using Cary WinUV Thermal application software or OriginPro 7.5.  
2199.2.6 Fluorescence Melting Studies
Fluorescence melting experiments were conducted, partly in cooperation with Dr. 
Edrees-Abdou, on a Roche LightCycler
® 1.5 instrument in LightCycler glass capilliaries 
(20 mL volume) using Roche LightCycler Software Version 3.5.  The LightCycler has 
one excitation source (488 nm) and change in fluorescence was monitored at 520 nm.
9.2.6.1 Set-Up Procedure
Master solutions (5 mM) of each oligonucleotide involved in each LightCycler run were 
made.  For each experiment within that run, 4.5 mL and 45 mL of the appropriate duplex 
and TFO respectively were lyophilised in 100 mL eppendorf tubes then redissolved in 
90 mL of the correct buffer, pH 6.0 (20 mM NaOAc, 200 mM NaCl), pH 6.2 (10 mM 
sodium phosphate, 200 mM NaCl) or, pH 6.2, 6.6, 7.0 or 7.0 + 2 mM spermine (10 mM 
sodium phosphate, 200 mM NaCl, 1 mM Na2EDTA), to afford a 10:1 ratio of 
TFO:hairpin duplex (5:0.5  mM).  Samples containing only the duplex were used as 
references within each run.  The samples were mixed by vortex then centrifugation, and 
were degassed in a sonic bath for 1 minute.  Aliquots of 20 mL were pipetted into the 
top of two or three LightCycler tubes per sample, which left one or two spare aliquots. 
The tubes were capped and centrifugated gently to avoid breakage, then loaded into the 
carousel and subjected to the desired LC melt programme.
9.2.6.2 LC Melt Programmes
Programme 1
Stage Temp (°C) Step Rate (°C/s) Hold time (s) Rate (°C/min)
Denaturation 30®95 20.0 300 4.0
Hold 95 – 600 –
Annealing 95®30 1.0 300 0.2
Incubation 30 – 3600 –
Melting 30®95 1.0 300 0.2
Hold 95 – 600 –
Cool 95®30 20.0 1, 5, 300 ³4.0
220Programme 2
Stage Temp (°C) Step Rate (°C/s) Hold time (s) Rate (°C/min)
Denaturation 30®95 20.0 300 4.0
Hold 95 – 600 –
Annealing 95®28 1.0 300 0.2
Incubation 28 – 3600 –
Melting 30®28 1.0 300 0.2
Hold 95 – 600 –
Cool 95®30 20.0 5 240
Programme 3
Stage Temp (°C) Step Rate (°C/s) Hold time (s) Rate (°C/min)
Denaturation 30®95 20.0 300 4.0
Hold 95 – 600 –
Annealing 95®27 1.0 300 0.2
Incubation 27 – 3600 –
Slow Melting 27®95 1.0 300 0.2
Hold 2 95 – 600 –
Cool 95®30 20.0 300 4.0
Programme 4
Stage Temp (°C) Step Rate (°C/s) Hold time (s) Rate (°C/min)
Denaturation 30®95 20.0 300 4.0
Hold 95 – 600 –
Annealing 95®30 1.0 240 0.25
Incubation 30 – 3600 –
Slow Melting 30®95 1.0 300 0.2
Hold 2 95 – 600 –
Cool 95®30 20.0 300 0.25
Following fast heating from 30 to 95 °C, and holding at 95 °C for 10 minutes to fully 
denaturate the DNA, a slow stepwise cool/annealing process was recorded (1.0 °C step, 
0.2-0.25  °C/min).   After incubation at low temperature (27-30  °C) for 1 hour to 
equilibrate triplex formation, a slow stepwise heat/melting process was recorded (1.0 °C 
step, 0.2 °C/min).  The samples were held at 95 °C for 10 minutes to equilibrate before 
rapid cooling back to 30 °C.  Approximately ¼ of sample volume (~5 mL) is lost by 
evaporation during the course of the LC programme.
2219.2.6.3 Data Analysis
Tm  values were derived from the negative derivatives of melting curves for each 
experiment using the “Manual Tm” feature in Roche LightCycler Software Version 3.5.
9.2.7 Determining UV/Fluorescence Properties of Fluorescent Nucleosides
9.2.7.1 Deprotection of Nucleosides
DMT-protected nucleosides (143,182,225,226) were treated up to three times with 3% 
TCA/DCM followed by removal of DCM in vacuo and trituration with diethyl ether 
(´3).   The aniline  143, acetamide  225  and urea  182  deprotected nucleosides were 
afforded in this way as pale yellow to orange powders.  The guanidine nucleoside (non-
protonated) was further treated with 20% Et2NH/CH3CN for 24 hours, concentrated in 
vacuo, then treated with a mixture of 40% NH3/H2O and 7N NH3/CH3OH (1:2 v/v) for 
60 hours, before concentration in vacuo and recrystallisation (CH3OH/Et2O).  The fully 
deprotected nucleoside 226 was afforded as a yellow-orange powder.  Treatment with 
20% diethylamine solution cleaved only one 2-cyanoethoxycarbonyl (CEOC) protecting 
group from the guanidine moiety.  Subsequent treatment with ammonia was necessary 
to cleave the second.  Treatment with ammonia only would have resulted in cyclisation 
to form a stable triazine analogue of the guanidine moiety as reported in work by 
Prakash et al.
225 (Section 7.3.2.7).
9.2.7.2 UV Absorption Measurements
Solutions of nucleosides were made in either HPLC grade methanol (
APPp  143, 
AcPPp 
225) or anhydrous DMF (
UPPp 182, 
GPPp 226) up to 0.174 mM (
APPp), 0.109 mM (
AcPPp), 
0.151 mM (
UPPp) and 0.154 mM (
GPPp) concentrations.  The solution being tested was 
filtered through a Millipore Millex
®-FH syringe filter (0.45mm, 13 mm) into a Hellma® 
SUPRASIL synthetic quartz cuvette (10 mm pathlength, 1.5 mL sample volume).  UV 
absorption/excitation spectra were recorded at this and 2-3 lower concentrations by 
successive   dilution   by   factor   of   2,   on   a   Varian   Cary   400   Scan   UV-Visible 
Spectrophotometer   using   Cary   WinUV   Scan   application   software.     Spectra   for 
222compounds run in DMF were dominated by noise below 260 nm, due to loss of solvent 
transparency to UV light below ~270 nm.
Extinction coefficients (e / L mol
-1 cm
-1) were calculated using the Beer-Lambert Law 
(Equation 9.1)
A = e.c.l
Equation 9.1.   Beer-Lambert Law; A = absorbance (dimensionless),  e  = molar extinction 
coefficient (L mol
-1 cm
-1), c = concentration (M), l = pathlength (cm).
For each absorption/excitation maximum, the extinction coefficient was calculated by a 
three-step process:
1. At each concentration measured, the value was calculated using Equation 9.1, 
then the average of those values was taken (ignoring outliers).
2. The value was given as the gradient of a plot of Absorbance  vs  Molar 
Concentration, ignoring significant outliers.
3. The average of the two values was taken to give an extinction coefficient for 
each absorption/excitation maximum.
9.2.7.3 Fluorescence Measurements
Solutions of nucleosides were made in either HPLC grade methanol (
APPp  143, 
AcPPp 
225) or anhydrous DMF (
UPPp 182, 
GPPp 226) up to concentrations of 1-3 mg/mL.  The 
solution being tested was filtered  through a Millipore Millex
®-FH syringe filter 
(0.45mm, 13 mm) into a Hellma® SUPRASIL synthetic quartz cuvette for fluorimetry 
(10 mm pathlength, 1.5 mL sample volume).  An emission spectrum was run for each 
sample, by irradiation at the principal absorption maximum (l  ~360 nm) for that 
sample, on a Varian Cary Eclipse Fluorescence Spectrophotometer using Cary Eclipse 
Scan application software.  Each spectrum was an average of 10 consecutive scans from 
380-600 nm.
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236Appendices
237A:  List of Synthesised Compounds
Cmpd No. Structure Name
65
O
O AcO
AcO
1
2
5
N
1'
2'
O
O
5'
6'
OAc 1,3,5-tri-O-acetyl-2-O-(2-phthalimidoethyl)-D-
ribofuranose
68
O
N
H
F3C N-trifluoroacetyl propargylamine
71 N
ICl2
1
2
3
4
5
6
7
benzyltriethylammonium dichloroiodate
74
1'
2' 3'
4'
5'
2
4 5
6
O
OH O
O
Si
Si
O
N
NH
N
O O
Cl
NMe2
N
1-[1-(3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-b-D-ribofuranosyl)]-(5-chloro-6-oxocytosin-4-
yl)-N,N-dimethylformamidine
75
NH
NH2
O N
O
OAc AcO
AcO O
5
1'
5'
4'
3' 2'
2’,3’,5’-tri-O-acetyl-6-oxocytidine
79
1'
5'
4'
3' 2'
NH
NH2
O N
O
OAc AcO
AcO O
5 Br
5-bromo-2’,3’,5’-tri-O-acetyl-6-oxocytidine
83
1'
5'
4'
3' 2'
NH
NH2
O N
O
OAc AcO
AcO O
5 I
5-iodo-2’,3’,5’-tri-O-acetyl-6-oxocytidine
85
O
OH OH
HO
OMe 1
2 3
4
5
1-O-methyl-D-ribofuranose
86
O
OH O
O
Si
Si
O
OMe 1
2 3
4
5
1-O-methyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl)-D-ribofuranose
87
O
O O
O
Si
Si
O
OMe 1
2
5
O
OMe
1'
2'
1-O-methyl-2-O-methylethanoyl-3,5-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-D-ribofuranose
88
O
O O
O
Si
Si
O
OMe 1
2
5
OH
1'
2'
1-O-methyl-2-O-(2-hydroxyethyl)-3,5-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-D-ribofuranose
23889
O
O O
O
Si
Si
O
1a
2
5
N
1'
2'
O
O
OMe
3' 4' 5'
6'
1-O-methyl-2-O-(2-phthalimidoethyl)-3,5-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-a-D-ribofuranose
91
OAc
O
OAc AcO
AcO
1
5
1,2,3,5-tetra-O-acetyl-b-D-ribofuranose
97
NH
O
O N
O
OH
O
I MeO
MeO
2'
5'
5
7
8
9
10
11
12
13
14 15
11
5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-deoxyuridine
99
NH
NH2
O N
O
OH OH
HO O
5 Br
5-bromo-6-oxocytidine
100
NH
NH2
O N
O
OH OH
HO O
5 I
5-iodo-6-oxocytidine
101
NH
NH2
O N
O
OH OH
HO O
5
6-oxocytidine
108
NH
NH2
O N
O
OH OH
HO O
5 Cl
5-chloro-6-oxocytidine
109
NH
NH2
O N
O
OAc AcO
AcO O
5 Cl
5-chloro-2’,3’,5’-tri-O-acetyl-6-oxocytidine
110
F3C N
H
N
N
H
CF3
NH2
O O
1 2
3
4 4
3
5 5
6 6
N-(2-aminoethyl)-bis-N,N-[2-
(trifluoroacetamido)ethyl]amine
111 F3C N
H
H2
+
N
N
H
CF3
O O
1
2
3
4
CF3CO2
-
4 bis-N,N-[2-(trifluoroacetamido)ethyl]ammonium 
trifluoroacetate
116
F3C N
H
N
NH
HN
O
O
CF3 O
1
2
3
5
4
6
7
8
9
10
11
8
11
12
13
14
15
N-[2-N’-(4-methoxytritylamino)ethyl]-bis-N,N-(2-ethyl 
trifluoroacetamide)
128 F3C N
H
H
N
N
H
CF3
O O
1
2 2
3 3
4 1 4
bis-N,N-[2-(trifluoroacetamido)ethyl]amine
239141
N
NH2
O N O
OH
HO O
2'
5'
1'
5
2
2,2’-anhydro-6-oxocytidine
142
NH
NH
O N O
OH
HO O
2'
5'
1'
5
6
6,2’-anhydro-6-oxocytidine
143
O
OH
HO N
N
O
N
H2N
4
5
6
4a
7a
5'
2'
3''
3-N-[2’-deoxy-b-D-ribofuranosyl]-6-(3-aminophenyl)-
(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
145
N
O N
O
O
O
MeO
MeO
O
HN
P
N
O
CN
4
5
6
2'
5'
8
9
12
13
16
12
1''
3''
17
18
19 20
F3C
O 3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-[3-(trifluoroacetamido)phenyl]}-
(2,3H)-furano[2,3-d]pyrimidine-2-one-3’-O-(2-O-
cyanoethyl-N,N-diisopropyl) phosphoramidite
146
N
O N
O
O
O
MeO
MeO
O
HN
P
N
O
CN
2 4
5
6
2'
5'
8 9
12
13
16
12
1''
3''
17
18
19
20
H2N
O 3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-ureidophenyl)-(2,3H)-furano[2,3-
d]pyrimidine-2-one-3’-O-(2-O-cyanoethyl-N,N-
diisopropyl) phosphoramidite
147
N
O N
O
O
O
MeO
MeO
O
HN
P
N
O
CN
2 4
5
6
2'
5'
8 9
12
13
16
12
1''
3''
17
18
19
20
O 3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-acetamidophenyl)-(2,3H)-
furano[2,3-d]pyrimidine-2-one-3’-O-(2-O-cyanoethyl-
N,N-diisopropyl) phosphoramidite
151
NH2
OH
7
8
9
10 1
2
3
4
5
6
4-(3-aminophenyl)-2-methyl-but-3-yn-2-ol
152
NH2
7
8
1
3
3-aminophenyl acetylene, 3-ethynylaniline
240153
NH
O
O N
O
OH
O
MeO
MeO
NH2
2'
5'
5
7
8 1''
3''
9
10
13
14
17
13
6
5-[(3-aminophenyl)ethynyl]-5’-O-(4,4’-
dimethoxytrityl)-2’-deoxyuridine
154
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O N
O
OH
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MeO
MeO
O
H2N
2 4
4a
5
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7a
2'
5'
8
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11
12
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14
15 16
12
1''
3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-aminophenyl)-(2,3H)-furano[2,3-
d]pyrimidine-2-one
155
N
O N
O
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MeO
MeO
O
HN
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5' 8 9
12
13
16
12
1''
3''
O
F3C
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-[3-(trifluoroacetamido)phenyl]}-
(2,3H)-furano[2,3-d]pyrimidine-2-one
156 N
H
H2N
O
1 3
7 8
3-ureidophenyl acetylene
159 NH
O
O N
O
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MeO
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O
H2N
5-[(3-ureidophenyl)ethynyl]-5’-O-(4,4’-
dimethoxytrityl)-2’-deoxyuridine
160
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MeO
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15 16
12
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3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-ureidophenyl)-(2,3H)-furano[2,3-
d]pyrimidine-2-one
161 N
H
O
1 3
7
8 3-acetamidophenyl acetylene
162 NH
O
O N
O
OH
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MeO
MeO
NH
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5
7
8 1''
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13
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17
13
6
O
5-[(3-acetamidophenyl)ethynyl]-5’-O-(4,4’-
dimethoxytrityl)-2’-deoxyuridine
241163
N
O N
O
OH
O
MeO
MeO
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15 16
12
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3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-acetamidophenyl)-(2,3H)-
furano[2,3-d]pyrimidine-2-one
164
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O
O N
NH
O 5'
5
NH F3C
O
P
N
O
CN
MeO
MeO
11
14
15
18
6
7
8 9
19
20
21
22
5’-O-(4,4’-dimethoxytrityl)-5-(3-
trifluoroacetamidopropynyl)-2’-deoxyuridine-3’-O-(2-
O-cyanoethyl-N,N-diisopropyl) phosphoramidite
165
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O
OH
O N
NH
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2'
5
NH F3C
O
MeO
MeO
10
14
18
6
7
8 9
14
5’-O-(4,4’-dimethoxytrityl)-5-(3-
trifluoroacetamidopropynyl)-2’-deoxyuridine
178
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O N
N
O
N
4
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MeO
MeO
12
16
5'
2'
8
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P
N
O
CN 17
18
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HN
F3C
O
12
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-trifluoroacetamidophenyl)-(2,3H)-
N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one-3’-O-(2-
O-cyanoethyl-N,N-diisopropyl) phosphoramidite
179 O
O
O N
N
O
N
HN
H2N
O
P
N
O
CN
MeO
MeO
8
12
16
2'
5'
4
5
3''
17
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20
12
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-ureidophenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one-3’-O-(2-O-
cyanoethyl-N,N-diisopropyl) phosphoramidite
182
O
OH
HO N
N
O
N
HN
H2N
O
2'
5'
4
5
3''
3-N-[2’-deoxy-b-D-ribofuranosyl]-6-(3-ureidophenyl)-
(2,3H)-N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
242183
O
OH
O N
N
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MeO
MeO
HN
O
8
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2'
5
6
7
NH
O
H2N
3''
9
13
13
17
5’-O-(4,4’-dimethoxytrityl)-5-[(3-
ureidobenzoyl)methyl]-4N-methyl-2’-deoxycytidine
184
O
OH
O N
N
O
N
HN
H2N
O
4
5
6
MeO
MeO
12
16
4a
7a
5'
2'
8
3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-ureidophenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
185
HN
O
OH
O N
N
O
MeO
MeO
I
5'
2'
5
7
11
15
11
5’-O-(4,4’-dimethoxytrityl)-5-iodo-4N-methyl-2’-
deoxycytidine
187
O
O
OAc
O N
NH
O
MeO
MeO
I
5'
2'
5
7
11
15
11
3’-O-acetyl-5’-O-(4,4’-dimethoxytrityl)-5-iodo-2’-
deoxyuridine
188
O
OH
O N
N
O
HN
NH H2N
O
6
4
2'
5'
MeO
MeO
7 8
11
12
15
1''
3''
7
8
5’-O-(4,4’-dimethoxytrityl)-5-[(3-
ureidophenyl)ethynyl]-4N-methyl-2’-deoxycytidine
191
O
O
O N
N
O
N
HN
O
P
N
O
CN
MeO
MeO
8
12
16
2'
5'
4
5
3''
17
18
19
20
12
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-acetamidophenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one-3’-O-(2-O-
cyanoethyl-N,N-diisopropyl) phosphoramidite
192
O
OH
O N
N
O
HN
NH
O
6
4
2'
5'
MeO
MeO
7 8
11
12
15
1''
3''
7
8 5’-O-(4,4’-dimethoxytrityl)-5-[(3-
acetamidophenyl)ethynyl]-4N-methyl-2’-
deoxycytidine
243193
O
OH
O N
N
O
N
HN
O
4
5
6
MeO
MeO
12
16
4a
7a
5'
2'
8
3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-acetamidophenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
194
O
OH
O N
N
HN
6
2'
5'
MeO
MeO
9 10
13
14
17
1''
3''
7
8
O
NH2
5 5’-O-(4,4’-dimethoxytrityl)-5-[(3-
aminophenyl)ethynyl]-4N-methyl-2’-deoxycytidine
195
O
OH
O N
N
O
N
H2N
4
5
6
MeO
MeO
12
16
4a
7a
5'
2'
8
3''
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-aminophenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
196
O
OH
O N
N
O
N
HN
4
5
6 MeO
MeO
16
4a
7a
5'
3''
8
12
17
25
OMe
OMe 21
21
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-[3-(4,4’-
dimethoxytrityl)aminophenyl]-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
197
O
OH
O N
N
O
N
4
5
6
MeO
MeO
12
16
5'
2'
8
3''
HN
F3C
O
12
3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-trifluoroacetamidophenyl)-(2,3H)-
N-methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
200 NC
O N
H
O
N
SMe
O
O
CN 1
2
3
4
5
2'
3'
4'
5' N,N’-bis-[(2-cyanoethoxy)carbonyl]-S-methyl-
isothiourea
201 NC
O O
O
N
O
O
(2-cyanoethyl)-N-succinimidyl carbonate
207
O
OH
O N
N
O
N
4
5
6
MeO
MeO
12
16
5'
2'
8
3''
N
H
12
N
HN
O O
NC
O
O
NC
17
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20
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22
23
24
25 3-N-[2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-b-D-
ribofuranosyl]-6-(3-{N,N’-bis-[(2-
cyanoethoxy)carbonyl]guanidinyl}phenyl)-(2,3H)-N-
methylpyrrolo[2,3-d]pyrimidine-2(7H)-one
244209 N
H
H2N
S
1 3
7
8 3-thioureidophenyl acetylene
211
N
H
N
H
S O
1
2
3
4
5
6
7
8
9
10
11
12
N-benzoyl-N’-(3-ethynylphenyl)-thiourea
213
O
OH
O N
N
HN
6
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5'
MeO
MeO
9 10
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7
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5
H2N
S
5’-O-(4,4’-dimethoxytrityl)-5-[(3-
thioureidophenyl)ethynyl]-4N-methyl-2’-
deoxycytidine
225
O
OH
HO N
N
O
N
4
5
6
5'
2'
3''
HN
O 3-N-[2’-deoxy-b-D-ribofuranosyl]-6-(3-
acetamidophenyl)-(2,3H)-N-methylpyrrolo[2,3-
d]pyrimidine-2(7H)-one
226
O
OH
HO N
N
O
N
4
5
6
5'
2'
3''
HN
H2N
NH 3-N-[2’-deoxy-b-D-ribofuranosyl]-6-(3-
guanidinylphenyl)-(2,3H)-N-methylpyrrolo[2,3-
d]pyrimidine-2(7H)-one
245B:  Oligonucleotide List
ODN 
No. Sequence Expected 
Mass
Expected 
[M+H]
+
Observed 
Mass Notes
1 GCT AAA AAG ACA GAG AGA TCG 6521.34 - *
2 CGA TCT CTC TGT CTT TTT AGC 6329.17 - *
3 TTT TTM T
MPfT MTM TMT 4535.04 4536.05 4535.16
4 TTT TTM T
APPfT MTM TMT 4612.13 4613.13 4611.98
5 TTT TTM T
UPPfT MTM TMT 4655.15 4656.16 4654.83 / 
4697.25
partial 
acetylation
6
F GTG TTA GGA AGA CAA AAA AGA 
ACT GGT HHA CCA GTT CTT TTT 
TGT CTT CCT AAC AC
17843.96 - * CG hd
7
F GTG TTA GGA AGA GAA AAA AGA 
ACT GGT HHA CCA GTT CTT TTT 
TCT CTT CCT AAC AC
17843.96 - * GC hd
8
F GTG TTA GGA AGA AAA AAA AGA 
ACT GGT HHA CCA GTT CTT TTT 
TTT CTT CCT AAC AC
17842.97 - * AT hd
9
F GTG TTA GGA AGA TAA AAA AGA 
ACT GGT HHA CCA GTT CTT TTT 
TAT CTT CCT AAC AC
17842.97 - * TA hd
10 Q PMM TPM T
MPfP TPT PTM PT 5807.10 5808.10 5807.41 / 
5827.63
partially 
uncyclised
11 Q PMM TPM T
APPfP TPT PTM PT 5884.18 5885.19 5884.66 / 
5902.71
partially 
uncyclised
12 Q PMM TPM T
AcPPfP TPT PTM PT 5926.22 5927.23 5926.67 / 
5943.79
partially 
uncyclised
13 Q PMM TPM T
UPPfP TPT PTM PT 5927.21 5928.21 5927.31 / 
5945.78
partially 
uncyclised
14 Q PMM TPM T
APPfT TPT PTM PT 5845.14 - 5846.7
15 Q PMM TPM P
APPfT TPT PTM PT 5884.18 - 5882.5
16 Q PMM TPM P
APPfP TPT PTM PT 5923.17 - 5963.6  [M+2Na-2H]
17
F GTG TTA GGA AGA CAA AAA AGA 
ACT GGT HHA CCA GTT CTT TTT 
TCT CTT CCT AAC AC
17803.93 - * CC hd
18 Q PMM TPM T
AcPPpT TPT PTM PT 5887.04 - 5889.1
19 Q PMM TPM P
AcPPpT TPT PTM PT 5926.11 - 5929.6
20 Q PMM TPM T
AcPPpP TPT PTM PT 5926.11 - 5929.9
21 Q PMM TPM P
AcPPpP TPT PTM PT 5965.14 - 5966.1
22 Q PMM TPM T
UPPpT TPT PTM PT 5888.07 - 5890.5
23 Q PMM TPM P
UPPpT TPT PTM PT 5927.10 - 5929.3  (+ 5875.4)
24 Q PMM TPM T
UPPpP TPT PTM PT 5927.10 - 5928.8
25 Q PMM TPM P
UPPpP TPT PTM PT 5966.13 - 5968.3
26 GCT AAA AAG AGA GAG AGA TCG 6561.37 - *
27 GCT AAA AAG AAA GAG AGA TCG 6545.37 - *
28 GCT AAA AAG ATA GAG AGA TCG 6536.36 - *
29 CGA TCT CTC TCT CTT TTT AGC 6289.14 - *
30 CGA TCT CTC TTT CTT TTT AGC 6304.15 - *
31 CGA TCT CTC TAT CTT TTT AGC 6313.17 - *
32 TTT TTM TTT MTM TMT 4496.99 - 4499.2
24633 TTT TTM TTP MTM TMT 4536.03 - 4541.0  (+ 4236.8)
34 TTT TTM PTT MTM TMT 4536.03 - 4537.4
35 TTT TTM PTP MTM TMT 4575.07 - 4578.0
36 TTT TTM T
APPpT MTM TMT 4611.14 - 4611.9
37 TTT TTM T
APPpP MTM TMT 4650.18 - 4652.6
38 TTT TTM P
APPpT MTM TMT 4650.18 - 4651.8
39 TTT TTM P
APPpP MTM TMT 4689.21 - 4690.0
40 TTT TTM T
AcPPpT MTM TMT 4653.18 - 4653.8
41 TTT TTM T
AcPPpP MTM TMT 4692.21 - 4696.4
42 TTT TTM P
AcPPpT MTM TMT 4692.21 - 4693.2
43 TTT TTM P
AcPPpP MTM TMT 4731.25 - 4733.1
44 TTT TTM T
UPPpT MTM TMT 4654.17 - 4655.3
45 TTT TTM T
UPPpP MTM TMT 4693.20 - 4696.6
46 TTT TTM P
UPPpT MTM TMT 4693.20 - 4697.0
47 TTT TTM P
UPPpP MTM TMT 4732.24 - 4734.1
48 TTT TTM T
GPPpT MTM TMT 4653.18 - 4653.9
49 TTT TTM T
GPPpP MTM TMT 4692.22 - 4694.4
50 TTT TTM P
GPPpT MTM TMT 4692.22 - 4694.1
51 TTT TTM P
GPPpP MTM TMT 4731.25 - 4732.2
52 Q PMM TPM T
APPpT TPT PTM PT 5845.17 - 5849.2
53 Q PMM TPM P
APPpT TPT PTM PT 5884.21 - 5884.8
54 Q PMM TPM T
APPpP TPT PTM PT 5884.21 - 5886.0
55 Q PMM TPM P
APPpP TPT PTM PT 5923.24 - 5924.2
56 Q PMM TPM T
GPPpT TPT PTM PT 5887.21 - 5887.8
57 Q PMM TPM P
GPPpT TPT PTM PT 5926.25 - 5928.6
58 Q PMM TPM T
GPPpP TPT PTM PT 5926.25 - 5926.1
59 Q PMM TPM P
GPPpP TPT PTM PT 5965.28 - 5967.5
60 Q PMM TPM TTT TPT PTM PT 5731.00 - 5730.4
61 Q PMM TPM PTT TPT PTM PT 5770.03 - 5771.0
62 Q PMM TPM TTP TPT PTM PT 5770.03 - 5770.5
63 Q PMM TPM PTP TPT PTM PT 5809.07 - 5809.7
64 TTT TTT TTT TTT 3588.35 -
Oligonucleotides for 
Deprotection Study 
(Chapter 7)
65 TTT TTT TTP TTT 3627.39 -
66 TTT TPT PTP TTT 3705.46 -
67 TPP PTP PTP TPT 3861.61 -
68 TTT TTT TT
BAU TTT 3686.46 -
69 TTT TTT TT
AcPPp TTT 3744.54 -
70 TTT TTT TTS TTT 3737.57 -
71 TTT TTT TT
MOEpU TTT 3701.47 -
72 TTT TTT TT
AET TTT 3647.42 -
73 TTT T
AETT 
AETT
AET TTT 3765.56 -
74 TTT TTT TT
GP TTT 3669.43 -
Table.   ES MS (1 dp), MALDI-TOF MS (2 dp),  Q  = DABCYL (quencher),  F  = FAM 
(fluorophore),  H  = HEG.   Key nucleotides marked in bold.   * No MS analysis 
necessary.
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